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vFore word
“STDs are hid den ep i dem ics of enor mous
health and eco nomic con se quence in the
United States. They are hid den be cause
many Amer i cans are re luc tant to ad dress
sex ual health is sues in an open way and
be cause of the bi o logic and so cial
char ac ter is tics of these dis eases. All
Amer i cans have an in ter est in STD
pre ven tion be cause all com mu ni ties are
im pacted by STDs and all in di vid u als
di rectly or in di rectly pay for the costs of
these dis eases. STDs are pub lic health
prob lems that lack easy so lu tions be cause
they are rooted in hu man be hav ior and
fun da men tal so ci etal prob lems. In deed,
there are many ob sta cles to ef fec tive
pre ven tion ef forts. The first hur dle will be to 
con front the re luc tance of Amer i can so ci ety 
to openly con front is sues sur round ing
sex u al ity and STDs. De spite the bar ri ers,
there are ex ist ing in di vid ual- and
com mu nity-based in ter ven tions that are
ef fec tive and can be im ple mented
im me di ately. That is why a multifaceted
approach is necessary to both the
individual and community levels.
To suc cess fully pre vent STDs, many
stakeholders need to re de fine their
mis sion, re fo cus their ef forts, mod ify
how they de liver ser vices, and ac cept
new re spon si bil i ties. In this pro cess,
strong lead er ship, in no va tive think ing,
part ner ships, and ad e quate re sources
will be re quired. The ad di tional
in vest ment re quired to ef fec tively
pre vent STDs may be con sid er able, but
it is neg li gi ble when com pared with the
likely re turn on the in vest ment. The
pro cess of pre vent ing STDs must be a
col lab o ra tive one. No one agency,
or ga ni za tion, or sec tor can ef fec tively do 
it alone; all mem bers of the com mu nity
must do their part. A suc cess ful na tional
ini tia tive to con front and pre vent STDs
re quires wide spread pub lic aware ness
and par tic i pa tion and bold na tional
lead er ship from the high est lev els.”1
1Con clud ing state ment from the In sti tute of
Med i cine’s Sum mary Re port, The Hid den
Ep i demic: Con front ing Sex u ally Trans mit ted
Dis eases, Na tional Acad emy Press, Wash ing ton,
DC, 1997, p.43.
Pref ace
Sex u ally Trans mit ted Dis ease Sur veil lance,
2007 pres ents sta tis tics and trends for
sex u ally trans mit ted dis eases (STDs) in the
United States through 2007. This an nual
pub li ca tion is in tended as a ref er ence
doc u ment for pol icy mak ers, pro gram
man ag ers, health plan ners, re search ers,
and oth ers who are con cerned with the
pub lic health im pli ca tions of these dis eases. 
The fig ures and ta bles in this edi tion
su per sede those in ear lier
pub li ca tions of these data.
The sur veil lance in for ma tion in this re port
is based on the fol low ing sources of data:
(1) case re ports from state and lo cal STD
pro grams; (2) the Re gional In fer til ity
Pre ven tion Pro jects, the Na tional Job
Train ing Pro gram, the Cor rec tions STD
Prev a lence Mon i tor ing Pro ject, the Indian
Health Service, and the Men Who Have
Sex With Men (MSM) Prev a lence
Mon i tor ing Pro ject; (3) the Gono coc cal
Iso late Sur veil lance Pro ject (GISP); and (4)
na tional sur veys im ple mented by fed eral
and pri vate or ga ni za tions.
The STD sur veil lance sys tems op er ated by
state and lo cal STD con trol pro grams,
which pro vide the case re port data for
chlamydia, gon or rhea, syph i lis, and
chancroid are the data sources of many of
the fig ures and most of the sta tis ti cal ta bles
in this pub li ca tion. These sys tems are an
in te gral part of pro gram man age ment at all
lev els of STD pre ven tion and con trol in the
United States. Be cause of in com plete
di ag no sis and re port ing, the num ber of
STD cases re ported to CDC is less than the
ac tual num ber of cases oc cur ring in the
United States pop u la tion. Case re port data
for other STDs are not avail able be cause
they are not na tion ally no ti fi able dis eases.
Sex u ally Trans mit ted Dis ease Sur veil lance, 
2007 con sists of four parts. The Na tional
Pro file con tains fig ures that pro vide an
over view of STD mor bid ity in the United
States. The ac com pa ny ing text iden ti fies
ma jor find ings and trends for se lected
STDs. The Spe cial Fo cus Pro files
con tain fig ures and text de scrib ing STDs in 
se lected sub groups and pop u la tions that
are a fo cus of na tional and state
pre ven tion ef forts. The De tailed Ta bles
pro vide sta tis ti cal in for ma tion about STDs
at the county, met ro pol i tan sta tis ti cal area
(MSA), re gional, state, and na tional lev els. 
The Ap pen dix in cludes in for ma tion on
in ter pret ing the STD sur veil lance data
used to pro duce this re port, Healthy
Peo ple 2010 STD ob jec tives, Gov ern ment
Per for mance and Re sults Act (GPRA)
goals, and STD sur veil lance case
def i ni tions.
Se lected fig ures and ta bles in this doc u ment 
iden tify goals that re flect prog ress to wards
some of the Healthy Peo ple 2010
(HP2010) na tional health sta tus ob jec tives
for STDs.1 Ap pen dix Ta ble A3 dis plays
prog ress made to wards the HP2010 tar gets
for STDs. These tar gets are used as
ref er ence points through out this edi tion of
Sex u ally Trans mit ted Dis ease Sur veil lance
2007.
vi   
Any com ments and sug ges tions that
would im prove the use ful ness of fu ture
pub li ca tions are ap pre ci ated and should
be sent to Di rec tor, Di vi sion of STD
Pre ven tion, Na tional Cen ter for
HIV/AIDS, Viral Hepatitis, STD, and TB
Pre ven tion, Cen ters for Dis ease Con trol
and Pre ven tion, 1600 Clifton Road,
Mailstop E-02, At lanta, Geor gia, 30333.
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1 U.S. De part ment of Health and Hu man Ser vices.
Healthy Peo ple 2010. 2nd ed. With Un der stand ing
and Im prov ing Health and Ob jec tives for Im prov ing 
Health. 2 vols. Wash ing ton, DC: U.S. Gov ern ment
Print ing Of fice, November 2000.
Ac knowl edg ments
Publication of this re port would not have been pos si ble with out the con tri bu tions of the
State and Ter ri to rial Health De part ments and the Sex u ally Trans mit ted Dis ease Con trol
Pro grams and the Re gional In fer til ity Pre ven tion Pro jects, which pro vided sur veil lance
data to the Cen ters for Dis ease Con trol and Pre ven tion.
This re port was pre pared by the fol low ing staff and con trac tors of the Di vi sion of STD
Pre ven tion, Na tional Cen ter for HIV/AIDS, Viral Hepatitis, STD, and TB Pre ven tion, Cen ters for 
Dis ease Con trol and Pre ven tion:
Office of the Director
Keith Da vis
John Douglas
Melinda Flock
Su zanne Haecker
Amy Pulver
Jill Wasserman
Ra chel Wynn
Epidemiology and Surveillance Branch
Stu art Berman
Deblina Datta
Kristen Mahle
Lori Newman
Catherine Lindsey Satterwhite
John Su
Hillard Weinstock
Eileen Yee
Statistics and Data Management Branch
 Su san Bradley
Jim Braxton
Delicia Carey
Sharon Clanton
Darlene Da vis
LaZetta Grier
Sam uel Groseclose
Alesia Harvey
Rose Hors ley
Kathleen Hutchins
Rob Nel son
Maya Stern berg
Akbar Zaidi
viii
ix
Con tents
Fore word . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
Pref ace . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
Ac knowl edg ments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Fig ures in the Na tional Pro file . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
Fig ures in the Spe cial Fo cus Pro files . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
Ta bles in the Na tional Pro file. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiv
Geo graphic Di vi sions of the United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvii
Na tional Over view of Sex u ally Trans mit ted Dis eases, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . 1
Na tional Pro file
In tro duc tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Chlamydia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Gon or rhea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Syph i lis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Other Sex u ally Trans mit ted Dis eases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Spe cial Fo cus Profiles
In tro duc tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
STDs in Women and In fants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
STDs in Ad o les cents and Young Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
STDs in Ra cial and Eth nic Mi nor i ties  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
STDs in Men Who Have Sex with Men  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
STDs in Per sons En ter ing Cor rec tions Fa cil i ties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Ta bles
Na tional Sum mary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Chlamydia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Gon or rhea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Syph i lis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Chancroid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Se lected STDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Ap pen dix
In ter pret ing STD Sur veil lance Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Ta ble A1. Se lected STDs — Per cent age of un known, miss ing, or in valid val ues
for se lected de mo graphic vari ables by state, 2007 . . . . . . . . . . . . . . . . . . . . . 155
Ta ble A2. Re ported cases of sex u ally trans mit ted dis ease by sex and re port ing source:
United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Ta ble A3. Healthy Peo ple 2010 Sex u ally Trans mit ted Dis eases Ob jec tive Sta tus . . . . . . 157
Ta ble A4. Gov ern ment Per for mance Re sults Act (GPRA) Sex u ally Trans mit ted
Dis eases Goals and Mea sures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
STD Sur veil lance Case Def i ni tions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Con tri bu tors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Fig ures in the Na tional Pro file
Chlamydia
Fig ure  1. Chlamydia — Rates: To tal and by sex: United States, 1988–2007 . . . . . . . . . . 11
Fig ure  2. Chlamydia — Rates by re gion: United States, 1998–2007 . . . . . . . . . . . . . . . . 11
Fig ure  3. Chlamydia — Rates by state: United States and out ly ing ar eas, 2007 . . . . . . . 12
Fig ure  4. Chlamydia — Rates by county: United States, 2007 . . . . . . . . . . . . . . . . . . . . 12
Fig ure  5. Chlamydia — Age- and sex-spe cific rates: United States, 2007 . . . . . . . . . . . . 13
Fig ure  6. Chlamydia — Rates by race/eth nic ity: United States, 1998–2007 . . . . . . . . . . 13
Fig ure  7. Chlamydia — Cases by re port ing source and sex: United States,
1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Fig ure  8. Chlamydia — Prev a lence by age group and race/eth nic ity re ported
from a na tional sur vey, 1999–2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Fig ure  9. Chlamydia — Me dian state-spe cific positivity among 15- to 24-year-old
women tested in fam ily plan ning clin ics: United States, 1997–2007 . . . . . . . . . 15
Fig ure 10. Chlamydia — Positivity among 15- to 24-year-old women tested in fam ily
plan ning clin ics by state: United States and out ly ing ar eas, 2007 . . . . . . . . . . . 15
Fig ure 11. Chlamydia — Trends in positivity among 15- to 24-year-old women
tested in fam ily plan ning clin ics by HHS re gion, 2003–2007 . . . . . . . . . . . . . . 16
Fig ure 12. Chlamydia — Per cent of nu cleic acid am pli fi ca tion tests (NAATs)
used in fam ily plan ning clin ics among 15- to 24-year-old women by
HHS re gion, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Gon or rhea 
Fig ure 13. Gon or rhea — Rates: United States, 1941–2007 and the Healthy
Peo ple 2010 tar get . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Fig ure 14. Gon or rhea — Rates: To tal and by sex: United States, 1988–2007 and
the Healthy Peo ple 2010 tar get . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Fig ure 15. Gon or rhea — Rates by re gion: United States, 1998–2007 and the
Healthy Peo ple 2010 tar get . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Fig ure 16. Gon or rhea — Rates by state: United States and out ly ing ar eas, 2007 . . . . . . . 25
Fig ure 17. Gon or rhea — Rates by county: United States, 2007 . . . . . . . . . . . . . . . . . . . . 26
Fig ure 18. Gon or rhea — Age- and sex-spe cific rates: United States, 2007 . . . . . . . . . . . . 26
Fig ure 19. Gon or rhea — Age-spe cific rates among women 15 to 44 years of age: 
United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Fig ure 20. Gon or rhea — Age-spe cific rates among men 15 to 44 years of age: 
United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Fig ure 21. Gon or rhea — Rates by race/eth nic ity: United States, 1998–2007 . . . . . . . . . . 28
Fig ure 22. Gon or rhea — Cases by re port ing source and sex: United States,
1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Fig ure 23. Gon or rhea — Positivity among 15- to 24-year-old women tested
in fam ily plan ning clin ics by state: United States and out ly ing
ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Fig ure 24. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Prev a lence of
ciprofloxacin re sis tant Neisseria gonorrhoeae by GISP site, 2004–2007 . . . . . . 29
Fig ure 25. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Pen i cil lin, tet ra cy cline,
and ciprofloxacin re sis tance among GISP iso lates, 2007 . . . . . . . . . . . . . . . . . 30
x
Fig ure 26. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Per cent of Neisseria
gonorrhoeae iso lates with re sis tance or in ter me di ate re sis tance to
ciprofloxacin, 1990–2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Fig ure 27. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Per cent of Neisseria
gonorrhoeae iso lates with re sis tance to ciprofloxacin by sex ual be hav ior,
2001–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Syph i lis 
Fig ure 28. Syph i lis — Re ported cases by stage of in fec tion: United States, 1941–2007. . . 37
Fig ure 29. Pri mary and sec ond ary syph i lis — Rates: To tal and by sex: United States,
1988–2007 and the Healthy Peo ple 2010 tar get . . . . . . . . . . . . . . . . . . . . . . . 37
Fig ure 30. Pri mary and sec ond ary syph i lis — Rates by re gion: United States,
1998–2007 and the Healthy Peo ple 2010 tar get . . . . . . . . . . . . . . . . . . . . . . . 38
Fig ure 31. Pri mary and sec ond ary syph i lis — Rates by state: United States and
out ly ing  ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Fig ure 32. Pri mary and sec ond ary syph i lis — Rates by county: United States, 2007 . . . . . 39
Fig ure 33. Pri mary and sec ond ary syph i lis — Age- and sex-spe cific rates:
United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Fig ure 34. Pri mary and sec ond ary syph i lis — Age-spe cific rates among women
15 to 44 years of age: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . 40
Fig ure 35. Pri mary and sec ond ary syph i lis — Age-spe cific rates among men
15 to 44 years of age: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . 40
Fig ure 36. Primary and sec ond ary syph i lis — Rates by race/eth nic ity: United States,
1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Fig ure 37. Pri mary and sec ond ary syph i lis — Re ported cases by stage and sex ual
ori en ta tion, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Fig ure 38. Pri mary and sec ond ary syph i lis — Re ported cases by sex ual ori en ta tion
and race/eth nic ity, 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Fig ure 39. Pri mary and sec ond ary syph i lis — Re ported cases by re port ing source
and sex: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Fig ure 40. Pri mary and sec ond ary syph i lis — Per cent age of re ported cases by
sex ual ori en ta tion and se lected re port ing sources, 2007 . . . . . . . . . . . . . . . . . . 43
Fig ure 41. Con gen i tal syph i lis (CS) — Re ported cases for in fants < 1 year of age
and rates of pri mary and sec ond ary syph i lis among women:
United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Other Sex u ally Trans mit ted Dis eases
Fig ure 42. Chancroid — Re ported cases: United States, 1981–2007. . . . . . . . . . . . . . . . . 48
Fig ure 43. Hu man papillomavirus (HPV) — Prev a lence of high-risk and low-risk
types among fe males 14 to 59 years of age re ported from a na tional
sur vey, 2003–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Fig ure 44.  Gen i tal warts — Ini tial vis its to phy si cians’ of fices: United States,
1966–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Fig ure 45. Gen i tal her pes — Ini tial vis its to phy si cians’ of fices: United States,
1966–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Fig ure 46. Gen i tal her pes — Her pes sim plex vi rus, type 2, seroprevalence in
non-His panic whites and non-His panic blacks by age group re ported
from a na tional sur vey, 1976–1980, 1988–1994, 1999–2004 . . . . . . . . . . . . . 50
Fig ure 47. Trichomoniasis and other vag i nal in fec tions in women — Ini tial vis its
to phy si cians’ of fices: United States, 1966–2007 . . . . . . . . . . . . . . . . . . . . . . . 51
xi
Fig ures in the Spe cial Fo cus Pro files
STDs in Women and In fants
Fig ure  A. Chlamydia — Rates among women by state: United States and
out ly ing ar eas, 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Fig ure  B. Chlamydia — Positivity in 15- to 24-year-old women tested in pre na tal
clin ics by state: United States and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . 59
Fig ure  C. Gon or rhea — Rates among women by state: United States and
out ly ing ar eas, 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Fig ure  D. Gon or rhea — Positivity in 15- to 24-year-old women tested in pre na tal
clin ics by state: United States and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . 60
Fig ure  E. Pri mary and sec ond ary syph i lis — Rates among women by state:
United States and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Fig ure  F. Con gen i tal syph i lis — Rates for in fants < 1 year of age by state:
United States and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Fig ure  G. Ectopic preg nancy — Hos pi tal iza tions of women 15 to 44 years of age:
United States, 1997–2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Fig ure  H. Pel vic in flam ma tory dis ease — Hos pi tal iza tions of women 15 to 44 years
of age: United States, 1997–2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Fig ure  I. Pel vic in flam ma tory dis ease — Ini tial vis its to phy si cians’ of fices by women
15 to 44 years of age: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . 63
STDs in Ad o les cents and Young Adults 
Fig ure  J. Chlamydia — Trends in positivity among 15- to 19-year-old women
tested in fam ily plan ning clin ics by HHS re gion, 2003–2007 . . . . . . . . . . . . . . 68
Fig ure  K. Chlamydia — Prev a lence among 16- to 24-year-old women en ter ing
the Na tional Job Train ing Pro gram by state of res i dence: United States
and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Fig ure  L. Chlamydia — Prev a lence among 16- to 24-year-old men en ter ing
the Na tional Job Train ing Pro gram by state of res i dence: United States
and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Fig ure  M. Gon or rhea — Prev a lence among 16- to 24-year-old women en ter ing
the Na tional Job Train ing Pro gram by state of res i dence: United States
and out ly ing ar eas, 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Fig ure  N. Gon or rhea — Prev a lence among 16- to 24-year-old men en ter ing
the Na tional Job Train ing Pro gram by state of res i dence: United States
and out ly ing ar eas, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
STDs in Ra cial and Eth nic Mi nor i ties  
Fig ure  O. Chlamydia — Rates by race/eth nic ity and sex: United States, 2007 . . . . . . . . . 75
Fig ure  P. Chlamydia — Positivity among 15- to 24-year-old women screened
in In dian Health Ser vice (IHS) clin ics by HHS re gion, 2007. . . . . . . . . . . . . . . 75
Fig ure  Q. Gon or rhea — Rate ra tios by race/eth nic ity: United States, 1998–2007 . . . . . . 76
Fig ure  R. Gon or rhea — Rates by race/eth nic ity and sex: United States, 2007 . . . . . . . . . 76
Fig ure  S. Gon or rhea — Rate ra tios by race/eth nic ity and re gion: United States, 2007 . . 77
Fig ure  T. Pri mary and sec ond ary syph i lis — Rates by race/eth nic ity and sex:
United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
xii
Fig ure  U. Pri mary and sec ond ary syph i lis — Rates among 15- to 19-year-old
fe males by race/eth nic ity: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . 78
Fig ure  V. Pri mary and sec ond ary syph i lis — Rates among 15- to 19-year-old
 males by race/eth nic ity: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . 78
Fig ure  W. Con gen i tal syph i lis — Rates among in fants < 1 year of age by mother’s
race/eth nic ity: United States, 1998–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
STDs in Men Who Have Sex with Men  
Fig ure  X. MSM Prev a lence Mon i tor ing Pro ject — Num ber of gon or rhea tests
and num ber of pos i tive tests in men who have sex with men, STD clin ics,
1999–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Fig ure  Y. MSM Prev a lence Mon i tor ing Pro ject — Syph i lis se ro logic re ac tiv ity
among men who have sex with men, STD clin ics, 1999–2007. . . . . . . . . . . . . 85
Fig ure  Z. MSM Prev a lence Mon i tor ing Pro ject — City-spe cific me dian num ber
of HIV tests and positivity among men who have sex with men,
STD clin ics, 1999–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Fig ure AA. MSM Prev a lence Mon i tor ing Pro ject — Test positivity for gon or rhea,
chlamydia, and HIV and seroreactivity to syph i lis among men who
have sex with men, by race/eth nic ity, STD clin ics, 2007. . . . . . . . . . . . . . . . . . 87
Fig ure BB. Gono coc cal Iso late Sur veil lance Pro ject (GISP)  — Per cent of ure thral
 Neisseria gonorrhoeae iso lates ob tained from men who have sex with
men at tend ing STD clin ics, 1988–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Fig ure CC. Gono coc cal Iso late Sur veil lance Pro ject (GISP)  — Per cent of ure thral
 Neisseria gonorrhoeae iso lates ob tained from men who have sex with
men at tend ing STD clin ics by GISP site, 2004–2007 . . . . . . . . . . . . . . . . . . . . 88
STDs in Per sons En ter ing Cor rec tions Fa cil i ties 
Fig ure DD. Chlamydia — Positivity by age and sex, ju ve nile cor rec tions
fa cil i ties, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Fig ure EE. Chlamydia — Positivity by age group and sex, adult cor rec tions
fa cil i ties, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Fig ure FF. Gon or rhea — Positivity by age and sex, ju ve nile cor rec tions
fa cil i ties, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Fig ure GG. Gon or rhea — Positivity by age group and sex, adult cor rec tions
fa cil i ties, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
xiii
Ta bles in the Na tional Pro file
Na tional Sum mary
Ta ble 1. Cases of sex u ally trans mit ted dis eases re ported by state health
de part ments and rates per 100,000 pop u la tion: United  States,
1941–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 
Chlamydia
Ta ble 2. Chlamydia — Re ported cases and rates by state, ranked by rates:
United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Ta ble 3. Chlamydia — Re ported cases and rates by state/area and re gion
 listed in al pha bet i cal or der: United States and out ly ing ar eas, 2003–2007. . . 102
Ta ble 4. Chlamydia — Women – Re ported cases and rates by state/area
and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Ta ble 5. Chlamydia — Men – Re ported cases and rates by state/area
 and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Ta ble 6. Chlamydia — Re ported cases and rates in se lected met ro pol i tan
 sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der: United States,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Ta ble 7. Chlamydia — Women – Re ported cases and rates in se lected
met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Ta ble 8. Chlamydia — Men – Re ported cases and rates in se lected
met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Ta ble 9. Chlamydia — Coun ties and in de pend ent cit ies ranked by num ber
of re ported cases: United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Ta ble 10. Chlamydia — Re ported cases and rates per 100,000 pop u la tion
by age group and sex: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . 109
Ta ble 11A. Chlamydia — Re ported cases by race/eth nic ity, age group and sex:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Ta ble 11B. Chlamydia — Rates per 100,000 pop u la tion by race/eth nic ity,
age group and sex: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . 111
Gon or rhea
Ta ble 12. Gon or rhea — Re ported cases and rates by state, ranked by rates:
 United States, 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Ta ble 13. Gon or rhea —  Re ported cases and rates by state/area and re gion
listed in al pha bet i cal or der: United States and out ly ing ar eas, 2003–2007 . . . 113
Ta ble 14. Gon or rhea —  Women –  Re ported cases and rates by state/area
and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Ta ble 15. Gon or rhea — Men – Re ported cases and rates by state/area
and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
xiv
Ta ble 16. Gon or rhea —  Re ported cases and rates in se lected met ro pol i tan
 sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Ta ble 17. Gon or rhea — Women – Re ported cases and rates in se lected
met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Ta ble 18. Gon or rhea — Men – Re ported cases and rates in se lected met ro pol i tan
sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der: United States,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Ta ble 19. Gon or rhea — Coun ties and in de pend ent cit ies ranked by num ber
of re ported cases: United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Ta ble 20. Gon or rhea — Re ported cases and rates per 100,000 pop u la tion
by age group and sex: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . 120
Ta ble 21A. Gon or rhea — Re ported cases by race/eth nic ity, age group and sex:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Ta ble 21B. Gon or rhea — Rates per 100,000 pop u la tion by race/eth nic ity,
age group and sex: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . 123
Syph i lis
Ta ble 22. All stages of syph i lis  — Re ported cases and rates by state/area
and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Ta ble 23. All stages of syph i lis — Re ported cases and rates in se lected
met ro pol i tan sta tis ti cal ar eas† (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Ta ble 24. Pri mary and sec ond ary syph i lis — Re ported cases and rates by state,
ranked by rates: United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Ta ble 25. Pri mary and sec ond ary syph i lis — Re ported cases and rates by
state/area and re gion listed in al pha bet i cal or der: United States and
out ly ing ar eas, 2003–2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Ta ble 26. Pri mary and sec ond ary syph i lis — Women – Re ported cases and
rates by state/area and re gion listed in al pha bet i cal or der: United States
and out ly ing ar eas, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Ta ble 27. Pri mary and sec ond ary syph i lis — Men – Re ported cases and rates
by state/area and re gion listed in al pha bet i cal or der: United States
and out ly ing ar eas, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Ta ble 28. Pri mary and sec ond ary syph i lis — Re ported cases and rates in
se lected met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal
or der: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Ta ble 29. Pri mary and sec ond ary syph i lis — Women – Re ported cases and
rates in se lected met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal
or der: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Ta ble 30. Pri mary and sec ond ary syph i lis — Men – Re ported cases and rates
in se lected met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal
or der: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Ta ble 31. Pri mary and sec ond ary syph i lis — Coun ties and in de pend ent cit ies
ranked by num ber of re ported cases: United States, 2007 . . . . . . . . . . . . . . . 133
Ta ble 32. Pri mary and sec ond ary syph i lis — Re ported cases and rates per 100,000
pop u la tion by age group and sex: United States, 2003–2007. . . . . . . . . . . . . 134
Ta ble 33A. Pri mary and sec ond ary syph i lis — Re ported cases by race/eth nic ity,
age group and sex: United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . 136
xv
Ta ble 33B. Pri mary and sec ond ary syph i lis — Rates per 100,000 pop u la tion by
race/eth nic ity, age group and sex: United States, 2003–2007. . . . . . . . . . . . . 137
Ta ble 34. Early la tent syph i lis — Re ported cases and rates by state/area and
re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Ta ble 35. Early la tent syph i lis — Re ported cases and rates in se lected met ro pol i tan
sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der: United States,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Ta ble 36. Late and late la tent syph i lis — Re ported cases and rates by state/area
and re gion listed in al pha bet i cal or der: United States and out ly ing ar eas,
2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Ta ble 37. Late and late la tent syph i lis — Re ported cases and rates in se lected
met ro pol i tan sta tis ti cal ar eas (MSAs) listed in al pha bet i cal or der:
United States, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Ta ble 38. Con gen i tal syph i lis — Re ported cases and rates in in fants < 1 year of age
by state, ranked by rates: United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . 142
Ta ble 39. Con gen i tal syph i lis — Re ported cases and rates in in fants < 1 year of age
by state/area and re gion listed in al pha bet i cal or der: United States
and out ly ing ar eas, 2003–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
Ta ble 40. Con gen i tal syph i lis — Re ported cases and rates in in fants < 1 year of age
by race/eth nic ity of mother: United States, 2003–2007 . . . . . . . . . . . . . . . . . 144
Chancroid
Ta ble 41. Chancroid — Re ported cases and rates by state/area listed in al pha bet i cal
or der: United States and out ly ing ar eas, 2003–2007 . . . . . . . . . . . . . . . . . . . 145
Se lected STDs
Ta ble 42. Se lected STDs and com pli ca tions — Ini tial vis its to phy si cians' of fices,
Na tional Dis ease and Ther a peu tic In dex: United States, 1966–2007 . . . . . . . 146
In ter pret ing STD Sur veil lance Data 
Ta ble A1. Se lected STDs — Per cent age of un known, miss ing, or in valid val ues
for se lected vari ables by state and by na tion ally no ti fi able STD, 2007 . . . . . . 155
Ta ble A2. Re ported cases of sex u ally trans mit ted dis ease by re port ing source
and sex: United States, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Ta ble A3. Healthy Peo ple 2010 Sex u ally Trans mit ted Dis eases Ob jec tive Sta tus . . . . . . 157
Ta ble A4. Gov ern ment Per for mance Re sults Act (GPRA) Sex u ally Trans mit ted
Dis eases Goals and Mea sures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
xvi
xvii
MidwestWest Northeast
South
Geographic Divisions of the United States
West Midwest South Northeast
Alaska Il li nois Al a bama Con nect i cut
Ar i zona In di ana Ar kan sas Maine
Cal i for nia Iowa Del a ware Mas sa chu setts
Col o rado Kan sas Dis trict of Co lum bia New Hamp shire
Ha waii Mich i gan Florida New Jer sey
Idaho Min ne sota Geor gia New York
Montana Mis souri Ken tucky Penn syl va nia
Ne vada Ne braska Lou i si ana Rhode Is land
New Mex ico North Da kota Mary land Ver mont
Or e gon Ohio Mis sis sippi
Utah South Da kota North Carolina
Wash ing ton Wis con sin Oklahoma
Wy o ming South Carolina
Ten nes see
Texas
Vir ginia
West Vir ginia

National Overview of Sexually
Transmitted Diseases, 2007
The logo on the cover of Sexually
Transmitted Disease Surveillance, 2007 is a 
reminder of the multifaceted, national
dimensions of the morbidity, mortality, and
costs that result from sexually transmitted
diseases (STDs) in the United States. It
highlights the central role of STD
prevention in improving health among
women and infants and in promoting HIV
prevention. Organized collaboration among 
interested, committed public and private
organizations and communities is the key to 
reducing STDs and their related health
burdens. As noted in the report of the
Institute of Medicine, The Hidden
Epidemic: Confronting Sexually
Transmitted Diseases,1 surveillance is a key
component of our efforts to prevent and
control these diseases.
This overview summarizes national
surveillance data on the three notifiable
diseases for which there are federally-
funded control programs: chlamydia,
gonorrhea, and syphilis. Several
observations for 2007 are worthy of note.
Chlamydia
In 2007, 1,108,374 cases of sexually
transmitted Chlamydia trachomatis
infection were reported to CDC (Table 1).
This is the largest number of cases ever
reported to CDC for any condition. This
case count corresponds to a rate of 370.2
cases per 100,000 population, an increase
of 7.5% compared with the rate in 2006.
Rates of reported chlamydial infections
among women have been increasing
annually since the late 1980s when public
programs for screening and treatment of
women were first established to avert pelvic 
inflammatory disease and related
complications. The continued increase in
chlamydia case reports in 2007 most likely
represents a continued increase in screening 
for this infection, more sensitive tests, and
more complete national reporting, but it
may also reflect a true increase in
morbidity.
In 2007, the overall rate of chlamydial
infection in the United States among
women (543.6 cases per 100,000 females)
was almost three times the rate among men 
(190.0 cases per 100,000 males), reflecting
the large number of women screened for
this disease (Tables 4 and 5). However, with 
the increased availability of urine testing,
men are increasingly being tested for
chlamydial infection. From 2003 through
2007, the chlamydia rate in men increased
by 43% (compared with a 17% increase in
women over this period).
Data from multiple sources on prevalence
of chlamydial infection in defined
populations have been useful in monitoring 
disease burden and guiding chlamydia
screening programs.
In 2007, the median state-specific
chlamydia test positivity among women 15
to 24 years of age who were screened at
selected family planning clinics in all states,
the District of Columbia, Puerto Rico, and
the Virgin Islands was 6.9% (range: 2.9% to 
16.8%) (Figures 9 and 10).
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At selected prenatal clinics in 22 states,
Puerto Rico, and the Virgin Islands the
median state-specific chlamydia
prevalence was 7.4% (range: 2.0% to
20.7%) (Figure B).
The prevalence of infection is greater
among economically-disadvantaged
women 16 to 24 years of age who entered
the National Job Training Program in 2007
from 40 states, the District of Columbia,
and Puerto Rico. The median state-specific
prevalence was 13.2% (range: 3.8% to
23.5%) (Figure K). Among men entering the
program in 2007 from 47 states, the District
of Columbia, and Puerto Rico the median
state-specific chlamydia prevalence was
7.2% (range: 2.0% to 14.5%) (Figure L).
The prevalence is also high among
adolescent women entering juvenile
detention centers. In 73 centers the median
chlamydia positivity by facility was 14.3%
(range: 2.5% to 32.1%) (Table A).
Among adolescent men entering 109
juvenile detention centers, the median
chlamydia positivity by facility was 5.7% 
(range: 0.0% to 14.2%) (Table A).
Although these data on prevalence are not
entirely comparable because of differences
in the populations screened, in the
performance characteristics of the screening 
tests, and variations in screening criteria,
they provide important information on the
continuing high burden of disease in the
United States.
Gonorrhea
Following a 74% decline in the rate of
reported gonorrhea from 1975 to 1997,
overall gonorrhea rates appeared to
plateau. In 2007, 355,991 cases of
gonorrhea were reported in the United
States, corresponding to a rate of 118.9
cases per 100,000 population, little change
from the rate in 2006 of 119.7 cases 
(Figure 13 and Table 1). This rate
considerably exceeds the Healthy People
2010 (HP2010) target of 19 cases per
100,000 population.
As in previous years, in 2007 the South had 
the highest gonorrhea rate among the four
regions of the country (Table 13). Although
the gonorrhea rate in the South declined
for many years, it increased by 5.3%
between 2003 and 2006. In 2007, the rate
remained essentially unchanged from 2006. 
The rate in the West decreased slightly in
2007 after a 29% increase between 2003
and 2006. While rates increased slightly in
the Northeast and Midwest from 2006 to
2007, they have remained relatively stable
over the past five years.
For the sixth consecutive year, the
gonorrhea rate in women in 2007 was
higher (123.5 per 100,000 population) than 
the rate among men (113.7 per 100,000
population) (Figure 14). As with chlamydia, 
gonorrhea rates in women 15 to 24 years
of age are particularly high. In men, they
are highest among men 20 to 29 years of
age (Figure 18). In 2007, the gonorrhea
rate among black men was 26 times higher
than that in white men; the gonorrhea rate
for black women was 15 times higher than
that in white women.
In 2007, data on gonorrhea prevalence in
defined populations were available from
several sources. These data showed a
continuing high burden of disease in
adolescents and young adults in parts of
the United States.
For 16- to 24-year-old women entering the
National Job Training Program in 36 states, 
and Puerto Rico in 2007, the median
state-specific gonorrhea prevalence was
3.0% (range: 0.0% to 7.2%) (Figure M).
Among men entering the program from 32
states and Puerto Rico, the median
state-specific gonorrhea prevalence was
1.1% (range: 0.0% to 4.4%) (Figure N).
Among women entering juvenile
corrections facilities the median gonorrhea
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positivity was 5.3% (range: 0.0% to
13.9%); the median gonorrhea positivity
for men entering juvenile corrections
facilities was 1.0% (range: 0.0% to 4.5%).
Among men who have sex with men
(MSM) attending eight STD clinics, the
median clinic urethral gonorrhea positivity
was 8.0% (range: 5% to 15%).
In the Gonococcal Isolate Surveillance
Project (GISP), a sentinel surveillance
project in 30 STD clinics throughout the
United States, 36% of the isolates from
MSM were resistant to ciprofloxacin in
2007. The overall proportion of resistant
isolates among heterosexuals was 8.7%. As
a result of the high prevalence of quinolone 
resistant N. gonorrhoeae among MSM and
heterosexuals, CDC revised the STD
Treatment Guidelines in 2007.
Fluoroquinolones are no longer
recommended for the treatment of
gonorrhea and associated conditions such
as pelvic inflammatory disease.2
Syphilis
The rate of primary and secondary (P&S)
syphilis reported in the United States
decreased during the 1990s and in 2000
was the lowest since reporting began in
1941. The low rate of syphilis and the
concentration of the majority of syphilis
cases in a small number of geographic
areas led to the development of the
National Plan to Eliminate Syphilis, which
was announced by the Surgeon General in
1999 and updated in 2006.3 The rate of
P&S syphilis in the United States declined
by 89.7% from 1990 through 2000.
However, the rate of P&S syphilis has
increased each year since 2001, mostly in
men, but also in women for the past three
years. In 2007, 11,466 cases of P&S
syphilis were reported to CDC,
corresponding to a rate of 3.8 cases per
100,000 population, a 15% increase from
2006. Since 2001, the rate of P&S syphilis
has increased 81%. After 14 years of
decline, the rate of congenital syphilis
increased in 2006 and again in 2007, a
28% increase since 2005. There were 430
cases of congenital syphilis reported in
2007 compared to 373 reported cases in
2006 and 339 in 2005.
Although wide disparities exist in the rates
of STDs among racial and ethnic groups,
there has been a reduction in these
differences for syphilis over the past eight
years. The P&S syphilis rate for 2007 in
blacks was 7 times the rate in whites, which 
is substantially lower than the disparity
observed in 1999, when the rate among
blacks was 29 times greater than that
among whites (Table 33B). However, with
increases in syphilis among blacks occurring 
since 2003 at a greater rate than those
among whites, we are no longer seeing
declines in this health disparity. In 2007,
increases were observed among both black
men (23.2 cases per 100,000 population,
up from 18.1 in 2006) and black women
(5.6 cases per 100,000 population, up from 
4.9 in 2006). Smaller increases were
observed among white men (3.7 cases per
100,000 population, up from 3.5 in 2006)
and white women (0.4 per 100,000
population, up from 0.3 per 100,000 in
2006).
While syphilis elimination efforts have
successfully focused on heterosexual
minority populations at risk for syphilis,
increases in syphilis among MSM since
2001 and more recent increases among
women and blacks highlight the importance 
of continually reassessing and refining
surveillance, prevention, and control
strategies.
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Academy Press, Washington, DC, 1997.
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Na tional Pro file
The Na tional Pro file sec tion con tains fig ures show ing trends and the dis tri bu tion of
na tion ally re port able sex u ally trans mit ted dis eases (chlamydia, gon or rhea, syph i lis and
chancroid) by age, sex, race/eth nic ity, and lo ca tion for the United States. Where rel e vant, the
fig ures il lus trate prog ress to wards spe cific Healthy Peo ple 2010 tar gets* for the na tion.1
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* See the Ap pen dix for a list ing of the Healthy
Peo ple 2010 ob jec tives for the dis eases
ad dressed in this re port.
1 U.S. De part ment of Health and Hu man
Ser vices. Healthy Peo ple 2010. 2nd ed. With
Un der stand ing and Im prov ing Health and
Ob jec tives for Im prov ing Health. 2 vols.
Wash ing ton, DC: U.S. Gov ern ment Print ing
Of fice, No vem ber 2000.

Chlamydia
Background
Chlamydia trachomatis infections are the
most commonly reported notifiable disease
in the United States. They are among the
most prevalent of all STDs and, since 1994, 
have comprised the largest proportion of all 
STDs reported to CDC (Table 1). Recent
studies also demonstrate the high
prevalence of chlamydial infections in the
general U.S. population. Among young
adults (18–26 years of age) participating in
the nationally-representative National
Longitudinal Study of Adolescent Health
from 2001 to 2002, chlamydia prevalence
was 4.2%.1 
In women, chlamydial infections, which are 
usually asymptomatic, may result in pelvic
inflammatory disease (PID), which is a
major cause of infertility, ectopic pregnancy, 
and chronic pelvic pain. Data from a
randomized controlled trial of chlamydia
screening in a managed care setting
suggested that screening programs can lead 
to a reduction in the incidence of PID by as 
much as 60%.2 As with other inflammatory
STDs, chlamydial infection can facilitate the 
transmission of HIV infection.3 In addition,
pregnant women infected with chlamydia
can pass the infection to their infants during 
delivery, potentially resulting in neonatal
ophthalmia and pneumonia. Due to the
large burden of disease and risks associated 
with infection, CDC recommends screening 
all sexually active women younger than 26
years of age for chlamydia annually.4 
The increase in reported chlamydial
infections during the last 10 years reflects
the expansion of chlamydia screening
activities, use of increasingly sensitive
diagnostic tests, an increased emphasis on
case reporting from providers and
laboratories, improvements in the
information systems for reporting, and,
possibly, true increases in disease.
However, many women who are at risk are
still not being tested, reflecting, in part, lack
of awareness among some health care
providers and limited resources available to 
support screening. Chlamydia screening
and reporting are likely to continue to
expand further in response to the
Healthcare Effectiveness Data and
Information Set (HEDIS) annual measure
assessing chlamydia screening coverage of
sexually active women 16 through 25 years 
of age who receive medical care through
commercial or Medicaid managed care
organizations.5 In 2007, 36.4% of women
aged 16–20 years were screened in
commercial care settings; in Medicaid
populations, 48.8% of women aged 16–20
years were screened.6
To better monitor trends in disease burden
in defined populations during the
expansion of chlamydia screening activities, 
data on chlamydia positivity and
prevalence among persons screened in a
variety of settings are used. In most
instances, test positivity serves as a
reasonable approximation of prevalence.7 
Chlamydia — United States 
In 2000, for the first time, all 50 states and
the District of Columbia had regulations
requiring the reporting of chlamydia cases. 
In 2007, 1,108,374 chlamydial infections
were reported to CDC from 50 states and
the District of Columbia (Table 1). This case 
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count corresponds to a rate of 370.2 cases
per 100,000 population, an increase of
7.5% compared with the rate of 344.3 in
2006. The reported number of chlamydial
infections was over three times the number
of reported cases of gonorrhea (355,991
gonorrhea cases were reported in 2007)
(Table 1). 
From 1988 through 2007, the rate of
reported chlamydial infection increased
from 87.1 to 370.2 cases per 100,000
population (Figure 1, Table 1).
Chlamydia by Region 
For the years 1998 to 2007, overall rates
were similar in the Midwest, West, and
South (Figure 2). Rates have consistently
remained lowest in the Northeast. In
2007, reported cases continued to
increase in all regions (Table 3).
Chlamydia by State 
In 2007, chlamydia rates per 100,000
population by state ranged from 156.3
cases in New Hampshire to 745.1 cases in
Mississippi (Figure 3, Table 2). Fifteen
states, the District of Columbia, and Guam
had chlamydia case rates higher than 400
cases per 100,000 population. 
Chlamydia by Metropolitan Statistical
Area (MSA) 
In 2007, the chlamydia case rate per
100,000 population in the 50 most
populous MSAs increased overall, among
both women and men (Table 6). Among
women, the 2007 case rate of 568.7 was a
7.7% increase over the 2006 case rate of
528.1 (Table 7). The 2007 case rate among 
men (211.8 per 100,000 population)
increased 11.9% from the 2006 case rate
(189.2) (Table 8). In 2007, 57.3% of
chlamydia cases were reported by these
MSAs. 
Chlamydia by County 
Counties in the United States with the
highest chlamydia case rates per 100,000
population were located primarily in the
Southeast and West, including Alaska
(Figure 4). In 2007, 597 (19.0%) of 3,140
counties had rates greater than 400.0 cases
per 100,000 population. Rates per 100,000 
population were 300.0 or less in 2,228
counties (71.0%) and between 300.1 and 
400.0 in 315 counties (10.0%). Fifty-three 
counties and independent cities reported
40% of all chlamydia cases in 2007
(Table 9). Case rates ranged from 247.9
(Miami-Dade County, Florida) to 1,265.0
(St. Louis (City), Missouri) per 100,000
population.
Chlamydia by Sex 
In 2007, the overall rate of reported
chlamydial infection among women in all
50 states and the District of Columbia
(543.6 cases per 100,000 females) was
almost three times higher than the rate
among men (190.0 cases per 100,000
males), likely reflecting a greater number of
women screened for this infection (Figure 1, 
Tables 4 and 5). The lower rates among
men also suggest that many of the sex
partners of women with chlamydia are not
being diagnosed or reported as having
chlamydia. However, with the advent of
highly sensitive nucleic acid amplification
tests (NAATs) that can be performed on
urine, symptomatic and asymptomatic men 
are increasingly being diagnosed with
chlamydial infection. From 2003 through
2007, the chlamydial infection rate in men
increased by 42.9% (from 133.0 to 190.0
cases per 100,000 males) compared with a
17.3% increase in women during the same
period (from 463.6 to 543.6 cases per
100,000 females).
Chlamydia by Age
Among women, the highest age-specific
rates of reported chlamydia in 2007 were
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among those 15 to 19 years of age
(3,004.7 cases per 100,000 females) and
20 to 24 years of age (2,948.8 cases per
100,000 females) (Figure 5, Table 10).
When compared to 2003, case rates per
100,000 women have increased in these
two age groups by 12.4% and 17.3%,
respectively. These increased rates in
women may, in part, reflect increased
screening in this group. Age-specific rates
among men, while substantially lower
than the rates among women, were
highest in the 20- to 24-year-old age
group (932.9 cases per 100,000 males)
(Figure 5, Table 10). Chlamydia case
rates among men have increased in most
age groups since 2003.
Chlamydia by Race/Ethnicity
In 2007, chlamydia rates increased for all
racial and ethnic groups except American
Indian/Alaska Natives. (Figure 6, Table 11B). 
The rate of chlamydia among blacks was
over eight times higher than that of whites
(1,398.7 and 162.3 cases per 100,000,
respectively). The rates among American
Indian/Alaska Natives (732.9) and Hispanics 
(473.2) were also higher than that of whites 
(4.5 and 2.9 times higher, respectively). In
2007, the chlamydia case rate per 100,000
population among Asian/Pacific Islanders
was 139.5.
Chlamydia by Reporting Source
The majority of chlamydia cases reported in
2007 were from venues outside of STD
clinics (Table A2). Over time, the proportion
of cases reported from non-STD clinic sites
has continued to increase (Figure 7). In
2007, among women, only 11.9% of
chlamydia cases were reported through an
STD clinic (98,382 of 825,660 total cases).
In contrast, among men, 33.1% of
chlamydia cases were reported through an
STD clinic in 2007 (92,906 of 280,337 total 
cases).
Chlamydia Prev a lence in the
Pop u la tion
The National Health and Nutrition
Examination Survey (NHANES) is a
nationally-representative survey of the U.S.
civilian, non-institutionalized 14- to 39-year 
old population and provides an important
measure of chlamydia disease burden.
From 1999 to 2002, the overall prevalence
of chlamydia infection was 2.2% and was
similar between males and females (2.0%
and 2.5%, respectively).8 Prevalence was
higher among non-Hispanic blacks than
non-Hispanic whites in all age groups
(Figure 8).
Chlamydia Prevalence Monitoring
Project
Chlamydia screening and prevalence
monitoring activities were initiated in
Health and Human Services (HHS) Region
X (Alaska, Idaho, Oregon, Washington) in
1988 as a CDC-supported demonstration
project. In 1993, chlamydia screening
services for women were expanded to three 
additional HHS regions (III, VII, and VIII)
and, in 1995, to the remaining HHS
regions (I, II, IV, V, VI, and IX). In some
regions, federally-funded chlamydia
screening supplements local-and
state-funded screening programs. Screening 
criteria and practices vary by region and
state.
Fam ily Plan ning Clin ics
In 2007, the median state-specific
chlamydia test positivity among 15- to
24-year-old women who were screened
during visits to selected family planning
clinics in all 50 states, Puerto Rico, and the
Virgin Islands was 6.9% (range: 2.9% to
16.8%) (Figures 9 and 10). Since 1997, the 
median chlamydia positivity rate has
slightly increased over time. This increase is 
likely due primarily to increasing usage of
more sensitive test technology. See
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Appendix (Chlamydia, Gonorrhea, and
Syphilis Prevalence Monitoring) for details.
Chlamydia test positivity among
15–24-year-old women screened in family
planning clinics fluctuated in all 10 HHS
regions between 2003 and 2007 (Figure 11). 
Positivity has remained fairly stable in four
regions (I, III, V, X). From 2003 to 2006,
slight decreases in positivity occurred in one
region (II), followed by a small increase in
2007. In the remaining five regions (IV, VI,
VII, VIII, IX), positivity rates increased slightly 
over the five-year time frame from 2003 to
2007. The positivity rates presented in
Figure 11 are not adjusted for changes in
laboratory test methods and associated
increases in test sensitivity. Utilization of
more sensitive tests has been shown to
impact positivity rates.9 Usage of NAAT
technology in family planning clinics to
screen women aged 15–24 years for
chlamydia is widespread (Figure 12). In
four regions, NAATs were used nearly
exclusively from 2003 to 2007 (I, V, VII,
VIII). By 2007, five additional regions used
NAATs over 50% of the time (II, III, IV, IX,
X). Only one region (VI) reported a low
NAAT-usage rate in 2007; however, usage
increased from 2003 to 2007.
Chlamydia Among Special
Populations
Additional information on chlamydia
screening programs for women of
reproductive age and chlamydia among
adolescents, minority populations, and in
corrections facilities can be found in the
Special Focus Profiles.
Chlamydia Summary
Both prevalence and reported cases of
genital Chlamydia trachomatis infections
remain high across age groups, racial/ethnic 
groups, geographic locales, and both sexes. 
The burden of chlamydia appears higher
among women, especially those of younger 
age (15 to 19 and 20 to 24 years of age),
but this may be a reflection of persons
recommended for screening. Racial
differences also persist; case rates among
blacks continue to be substantially higher
than rates among other racial/ethnic
groups.
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Fig ure  1. Chlamydia — Rates: Total and by sex: United States, 1988–2007
Note: As of January 2000, all 50 states and the District of Columbia had regulations requiring the
reporting of chlamydia cases.
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Fig ure  2. Chlamydia — Rates by re gion: United States, 1998–2007
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Fig ure  3. Chlamydia — Rates by state: United States and outlying areas, 2007
Note: The to tal rate of chlamydia for the United States and out ly ing ar eas (Guam, Puerto Rico and
Virgin Islands) was 368.1 per 100,000 population. For further information on chlamydia
reporting, see Appendix (Chlamydia Morbidity Reporting).
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Fig ure  4. Chlamydia — Rates by county: United States, 2007
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Fig ure  5. Chlamydia — Age- and sex-specific rates: United States, 2007
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Fig ure  6. Chlamydia — Rates by race/ethnicity: United States, 1998–2007
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Note: Error bars indicate 95% confidence intervals.
SOURCE: National Health and Nutrition Examination Survey
Ann Intern Med. 2007 Jul 17;147(2):89–96.
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Fig ure  9. Chlamydia — Median state-specific positivity among 15- to 24-year-old women
tested in family planning clinics: United States, 1997–2007
Note: As of 1997, all 10 Health and Human Services (HHS) regions, representing all 50 states,
the District of Columbia, and outlying areas, reported chlamydia positivity data. See
Appendix for definitions of HHS regions.
SOURCE: Chlamydia Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
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Fig ure 10. Chlamydia — Positivity among 15- to 24-year-old women tested in fam ily plan ning
clin ics by state: United States and outlying areas, 2007
*Data not available in 2007.
Note: Includes states and outlying areas that re ported chlamydia positivity data on at least 500
women aged 15–24 years screened during 2007.
SOURCE: Chlamydia Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
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Fig ure 11. Chlamydia — Trends in positivity among 15- to 24-year-old women tested in fam ily
plan ning clin ics by HHS re gion, 2003–2007
Note: See Appendix for definitions of HHS Regions.
SOURCE: Chlamydia Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
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Figure 12. Chlamydia — Percent of tests that were nucleic acid amplification tests
(NAATs) in family planning clinics among 15- to 24-year-old women by HHS
region, 2003–2007
Note: See Appendix for definitions of HHS Regions.
SOURCE: Chlamydia Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
Gonorrhea 
Background
Gonorrhea is the second most
commonly-reported notifiable disease in
the United States. Infections due to
Neisseria gonorrhoeae, like those resulting
from Chlamydia trachomatis, are a major
cause of PID in the United States. PID can
lead to serious outcomes in women such as 
tubal infertility, ectopic pregnancy, and
chronic pelvic pain. In addition,
epidemiologic and biologic studies provide
strong evidence that gonococcal infections
facilitate the transmission of HIV infection.1 
From 1975 through 1997, the national
gonorrhea rate declined 74% following
implementation of the national gonorrhea 
control program in the mid-1970s
(Figure 13). For the past ten years,
however, gonorrhea rates appear to
have reached a plateau, unfortunately
still far from the Healthy People 2010
target of 19 cases per 100,000
population (Figure 14 and Table 1).
Increases in gonorrhea rates in eight
western states from 2000 to 2005 have
been described among a wide variety of
populations in the affected states.2 Increases 
in quinolone-resistant Neisseria
gonorrhoeae (QRNG) in 2006 led to
changes in national guidelines that now
limit the recommended treatment of
gonorrhea to a single class of drug, the
cephalosporins.3 The combination of
increases in gonorrhea morbidity in some
populations with increases in resistance and 
decreased treatment options have  
reinforced the need for better understanding
of the epidemiology of gonorrhea.
Although gonorrhea case reporting is useful 
for monitoring trends in gonorrhea, true
increases or decreases in disease burden
may be masked by changes in screening
practices (affected by concomitant testing
for chlamydia and broader use of
urine-based testing), use of diagnostic tests
with differing test performance, and
changes in reporting practices.4 
For most areas, the number of gonorrhea
cases reported to CDC is affected by many
factors, in addition to the occurrence of the
infection within the population. As with
reporting of other STDs, reporting of
gonorrhea cases to CDC is incomplete.5 For 
these reasons, supplemental data on
gonorrhea prevalence in persons screened
in a variety of different settings are useful in 
assessing disease burden in selected
populations.
Gonorrhea — United States 
In 2007, 355,991 cases of gonorrhea were
reported in the United States. The rate of
reported gonorrhea in the United States
was 118.9 cases per 100,000 population in
2007 (Figure 13 and Table 1), a decrease of 
0.7% since 2006. Gonorrhea rates have
remained relatively stable for over 10 years.
Gonorrhea by Region 
As in previous years, in 2007 the South had 
the highest gonorrhea rate among the four
regions of the country (156.0 cases per
100,000 population). Rates in the South
and Midwest have remained substantially
higher than rates in the Northeast and
West. Rates in all regions over the last year
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have shown little change (Figure 15 and
Table 13).
An evaluation of increases in gonorrhea in
eight western states from 2000 to 2005
suggested that increases were likely due to
a variety of factors such as changes in
testing practices (increased volume and use
of more sensitive tests) as well as real
increases in disease.2
Gonorrhea by State
In 2007, only seven states and Puerto Rico
had gonorrhea rates below the HP2010
national target of 19 cases per 100,000
population (Figure 16 and Tables 12 and
13).6 This is an increase from 2006 of three
states (Montana, North Dakota, and
Wyoming) that now meet the HP2010
target.
Gonorrhea by Metropolitan Statistical
Area (MSA)
The overall gonorrhea rate in the 50 most
populous MSAs was 129.4 cases per
100,000 population in 2007. This is
essentially unchanged from 2006. All of
these MSAs had rates higher than the
HP2010 target of 19 cases per 100,000
population. In 2007, 58.6% of
gonorrhea cases were reported by these
MSAs (Table 16). Similar to previous
years, in 2007 the total gonorrhea rate
among females in these MSAs (128.4)
remained similar to that among males
(129.9) (Tables 17 and 18).
Gonorrhea by County 
In 2007, 1,305 (41.6%) of 3,140 counties
in the United States had gonorrhea rates at
or below the HP2010 national target of 19
cases per 100,000 population. Rates per
100,000 population were between 19 and
100 in 1,099 counties (35.0%), and greater
than 100 in 736 counties (23.4%). The
majority of counties with greater than 100
cases per 100,000 population were located
in the South (Figure 17). 
In 2007, 50% of reported gonorrhea cases
occurred in just 69 counties or independent 
cities (Table 19).
Gonorrhea by Sex
Prior to 1996, rates of gonorrhea among
men were higher than rates among women. 
For the seventh consecutive year, however,
gonorrhea rates among women and men
were similar with rates among women
being slightly higher (Figure 14). In 2007,
the gonorrhea rate among women was
123.5 and the rate among men was 113.7
cases per 100,000 population (Tables 14
and 15).
Gonorrhea by Age
In 2007, gonorrhea rates continued to be
highest among adolescents and young
adults. Among females in 2007, 15- to 19
and 20- to 24-year-old women had the
highest rates of gonorrhea (647.9 and
614.5, respectively). Among males, the rate 
was highest in those 20 to 24 years of age 
(450.1) (Figure 18 and Table 20). 
From 2003 to 2007, slight increases were
seen among the age groups under 35 years
(4.8% among those 15 to 19 years of age,
2.6% among those 20 to 24 years of age,
5.8% among those 25 to 29 years of age,
and 4.3% among those 30 to 34 years of
age) (Table 20). Slight decreases were seen
among those 35 to 39 years of age (4.6%),
and those 40 to 44 years of age (2.0%).
Among females between 15 and 44 years
of age (from 2003 to 2007) increases were
greatest in those 25 to 29 years of age
(10.9%) and those 30 to 34 years of age
(11.4%). Among males between 15 and 44
years of age, increases over that time
period were seen among those 15 to 19
years of age (9.5%) and those 25 to 29
years of age (1.5%) (Figures 19 and 20,
and Table 20).
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Gonorrhea by Race/Ethnicity 
In 2007, gonorrhea rates remained highest
among blacks (662.9 cases per 100,000
population, Table 21B and Figure 21).
Similar to recent years, the rate among
blacks was 19.1 times greater than the rate
among whites (34.7 cases per 100,000
population). Gonorrhea rates were 3.1
times greater among American
Indian/Alaska Natives (107.1 cases per
100,000 population), and 2.0 times greater
among Hispanics (69.2 cases per 100,000
population) than among whites in 2007.
Rates among whites were 1.8 times higher
than those among Asian Pacific Islanders
(18.8 cases per 100,000 population in
2007 (Figure 21).
Between 2003 and 2007, gonorrhea rates
showed no marked changes for any racial
or ethnic group, except for a 14.9% decline 
among Asian Pacific Islanders. There was a   
21.8% decline among American Indian/
Alaska Natives from 2006 to 2007 (Figure
21 and Table 21B). Additional information
on gonorrhea among minority populations
can be found in the Special Focus
Profiles.
Gonorrhea by Region and Sex 
Between 2003 and 2007, gonorrhea rates
among women increased 19.1% in the
West, 8.7% in the South, and 5.5% in the
Midwest. Gonorrhea rates among women
decreased 19.7% in the Northeast during
the same time period.
Between 2003 and 2007, gonorrhea rates
among men increased 15.1% in the West
and 1.7% in the South, and decreased
9.4% in the Northeast and 0.5% in the
Midwest (Tables 14 and 15).
Gonorrhea by Race/Ethnicity and Sex
From 2003 to 2007, overall rates among 
white, Hispanic, American Indian/Alaska 
Native, and black men increased (2.7%,
2.6%, 1.0%, and 0.4% respectively).
Gonorrhea rates decreased only among
Asian/Pacific Islander males (5.3%)
(Table 21B). 
Between 2003 and 2007 the overall rate
among white, American Indian/Alaska
Native, and black women increased (9.0%,
6.1%, and 3.8% respectively). However,
decreases were seen among Asian/Pacific
Islander and Hispanic women (21.8% and
3.4% respectively) (Table 21 B). 
Currently, 15- to 19-year-old black women
still have the highest gonorrhea rate of any
group (2,955.7 per 100,000 population),
closely followed by 20- to 24 year-old black 
women (2,789.2), and 20- to 24-year-old
black men (2,451.3).
Gonorrhea by Reporting Source 
In 2007, 26.7% of gonorrhea cases were
reported by STD clinics (Table A2). This
is a slight change from 2003, when
29.9% of gonorrhea cases were reported
by STD clinics. In 2007, a higher
proportion of male gonorrhea cases were
reported from STD clinics than female
cases (37.2% and 17.3% respectively)
(Figure 22 and Table A2).
Gonorrhea Prevalence Monitoring
Project
Gonorrhea test positivity data are available
from a variety of settings. Screening criteria
and practices may vary by state and over
time.
Fam ily Plan ning Clin ics
In 2007, the median state-specific
gonorrhea test positivity among 15- to
24-year-old women screened in selected
family planning clinics in 43 states, Puerto
Rico, and the Virgin Islands was 0.9%
(range: 0.1% to 4.9%) (Figure 23). Median
gonorrhea positivity in family planning
clinics has shown minimal change in recent
years (range: 0.8% to 1.1% between 2003
and 2007).
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Pre na tal Clin ics
For women attending selected prenatal
clinics in 19 states, Puerto Rico, and the
Virgin Islands, the median positivity was
0.8% (range: 0.0% to 3.9%) (Figure D).
Median gonorrhea positivity in prenatal
clinics has shown minimal change in recent
years (range: 0.8% to1.0% between 2003
and 2007).
Na tional Job Train ing Pro gram
Among 16- to 24-year-old women entering
the National Job Training Program in 36
states and Puerto Rico in 2007, the median 
state-specific gonorrhea prevalence was
3.0% (range: 0.0% to 7.2%) (Figure M).
Among men entering the program from 32
states and Puerto Rico in 2007, the median 
state-specific gonorrhea positivity was 1.1% 
(range: 0.0% to 4.4%) (Figure N).
Ju ve nile Cor rec tions
In 2007, the median positivity for
gonorrhea by facility in women entering 52
juvenile corrections facilities was 5.3%
(range: 0.0% to 13.9%). In men entering
90 juvenile corrections facilities in 2007, the 
median was 1.0% (range: 0.0% to 4.5%)
(Table C).
Gonococcal Isolate Surveillance
Project (GISP) 
Antimicrobial resistance remains an
important consideration in the treatment of
gonorrhea.3,7,8,9,101112,3,14 In 1986, the Gonococcal
Isolate Surveillance Project (GISP), a
national sentinel surveillance system, was
established to monitor trends in
antimicrobial susceptibilities of strains of
Neisseria gonorrhoeae in the United States
among selected STD clinics in
approximately 25–30 GISP sentinel sites14
(Figure 24). 
Overall in 2007, 27% of isolates collected
from 29 of 30 GISP sites were resistant to
penicillin, tetracycline, ciprofloxacin, or
some combination of those antibiotics
(Figure 25).
Quinolone-re sis tant N. Gonorrhoeae (QRNG)
Resistance to ciprofloxacin (a fluoroquinolone 
in the quinolone family of antimicrobials) was 
first identified in GISP sites in 1991. From
1991 through 1998, fewer than nine
quinolone-resistant N. gonorrhoeae (QRNG)
isolates were identified each year, and such
isolates were identified in only a few GISP
clinics. However since 1999 QRNG
prevalence has steadily increased, first in
Hawaii and the Pacific Islands, then in the
Western states, and then among MSM.7,9,10
In 2007, 891 (14.8%) of 6,009 GISP
isolates collected were identified as QRNG,
an increase from 2006, when 843/6,089
(13.8%) isolates were identified as QRNG
(Figure 26). QRNG isolates were identified
from all 29 GISP sites that submitted
isolates in 2007. GISP did not receive any
isolates from Tripler in 2007.
QRNG by Re gion
In 2007, QRNG increased most markedly
in those regions where prevalence had
been relatively low.
In 2007, 20 (28.6%) of 70 isolates
submitted from Honolulu demonstrated
ciprofloxacin-resistance, a decrease from 
34 (35.8%) of 95 isolates in 2006.
From 2006 to 2007, several western sites
demonstrated an increase in the number of
isolates resistant to ciprofloxacin. In
Albuquerque, the prevalence of QRNG
more than doubled to 16.7% of isolates
collected in 2007 from 7.3% in 2006; in
Denver, 17% were resistant to
fluoroquinolones in 2007 compared with
15.7% in 2006; in Las Vegas, the
prevalence also doubled to 18.7% in 2007
from 8.7% in 2006; in Long Beach, 30.4%
were resistant in 2007 compared to 28.4%
in 2006; in Orange County, 41% were
resistant in 2007 compared with 34.6% in
2006; in Portland, 28.6% were resistant in
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3,7-14
2007 compared with 27.2% in 2006; and
in San Diego, 36.3% were resistant in 2007
compared with 35.1% in 2006. The
prevalence in Los Angeles was relatively the 
same at 22.4% in 2007. In other western
sites such as Phoenix, San Francisco, and
Seattle, the prevalence of QRNG decreased 
slightly during the same time period. In
Phoenix, 8.7% of isolates were QRNG
when compared with 11.9% in 2006; in
San Francisco, the prevalence of QRNG
decreased to 31.3% in 2007 from 44.5% in 
2006; and in Seattle to 29.3% in 2007 from 
31.8% in 2006.
In the South from 2006 to 2007, most of
the sites continued to observe increases in
the prevalence of QRNG. In Baltimore,
QRNG resistance increased to 2% in 2007
from 1.4% in 2006; in Birmingham, the
prevalence increased about eight fold to
9.4% in 2007 from 1.1% in 2006; in Dallas, 
the prevalence increased to 7.5% from
6.1%; in Greensboro, it tripled to 5.3%
from 1.7%; in New Orleans it increased to
18.1% from 10.2%; and in Oklahoma City,
it increased to 6% from 4.3%. However, in
Atlanta, where isolates were submitted from 
January—April 2007 only, the prevalence
of QRNG decreased to 2.6% in 2007 from
5.7% in 2006. In Miami, the prevalence of
QRNG  remained about the same in 2007
at 19.6%.
In the Midwest and Northeast there were 
dramatic increases in prevalence of QRNG
from 2006 to 2007 among several sites. In
Chicago, the prevalence of isolates that
were resistant to ciprofloxacin doubled to
8.6% in 2007 from 4.1% in 2006; in
Cincinnati, the prevalence almost doubled
to 1.2% in 2007 from 0.7% in 2006; in
Detroit, it increased by five fold to 1.7% in
2007 from 0.3% in 2006; in Minneapolis, it 
doubled to 10.7% in 2007 from 5.7% in
2006; and in New York City, it also almost
doubled to 14.9% in 2007 from 7.6% in
2006. There was a decrease in QRNG
prevalence in Cleveland to 0.7% in 2007
from 3.1% in 2006 and in Philadelphia to
29.1% from 30.3%, respectively.
New sites in GISP that identified
ciprofloxacin-resistant isolates included
Kansas City and Richmond. Kansas City
rejoined GISP in September 2007 and
observed a QRNG prevalence of 16.4% in
2007. Richmond started collection in
November 2007 and QRNG was identified
in 17.9% of isolates.
QRNG by Sex ual Be hav ior
The prevalence of QRNG in isolates from
MSM slightly decreased from 39% in 2006
to 36% in 2007. During the same time
period, the prevalence of QRNG in isolates
from heterosexuals increased from 7% to
9% (Figure 27).
As a result of high and continued
widespread prevalence of QRNG among
MSM and then more recently, among
heterosexuals, CDC revised the 2006 CDC
STD Treatment Guidelines in April 2007.3
Therefore, CDC states that
fluoroquinolones are no longer
recommended for use in the United States
for the treatment of gonococcal infections
and associated conditions such as pelvic
inflammatory disease.3
Other Antimicrobial Sus cep ti bil ity Test ing 
The proportion of GISP isolates
demonstrating decreased susceptibility to
ceftriaxone or cefixime has remained very
low over time. Overall in GISP, from 1987
to 2007, there have been a total of four
isolates with decreased susceptibility to
ceftriaxone (all four had minimum
inhibitory concentrations (MICs) of 0.5
µg/ml) and 48 isolates with decreased
susceptibility to cefixime (MIC range from
0.5–2.0 µg/ml) in GISP. In 2007, there were 
no isolates identified with decreased
susceptibility to ceftriaxone. (Note:
Cefixime was discontinued in 2007 from
the GISP antibiotic susceptibility panel.)
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The proportion of GISP isolates
demonstrating elevated MICs to
azithromycin has been increasing since
GISP began monitoring azithromycin
susceptibility in 1992. In 2005, there was a
change in the media used for antimicrobial
susceptibility testing which resulted in an
observational shift of the MIC curve for
azithromycin. Thus, the azithromycin MIC
for decreased susceptibility was changed
from ≥ 1.0 µg/ml to ≥ 2.0 µg/ml in 2005
and thereafter. In 2007, 0.5% (27/6,009)
isolates had azithromycin MIC ≥  2.0 µg/ml
compared to 0.2% (14/6,089) in 2006.
Additional information on antimicrobial
susceptibility data and on GISP may be
found in the 2007 GISP report8 or the GISP 
website: http://www.cdc.gov/std/GISP 
Gonorrhea Among Special Populations
Additional information about gonorrhea in
racial and ethnic minority populations,
adolescents, MSM, and other at risk
populations can be found in the Special
Focus Profiles.
Gonorrhea Summary
In summary, the national gonorrhea rate
has remained relatively unchanged for
approximately ten years. Unfortunately the
2007 rate of 118.9 cases per 100,000
population is still greater than the Healthy
People 2010 goal of 19 cases per 100,000
population. Of particular concern are the
persistent high rates in some geographic
areas, adolescents and young adults, and
some racial/ethnic groups.
Although fluoroquinolones are no longer
recommended for treatment of gonococcal
infections in the U.S., GISP data continues
to show widespread increases in QRNG
prevalence throughout the country. With
only one class of antibiotics recommended
for treating gonorrhea, continued
monitoring for the emergence of decreased
susceptibility and resistance to
cephalosporins is critical.
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Figure 13. Gon or rhea — Rates: United States, 1941–2007 and the Healthy Peo ple 2010
target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
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Figure 14. Gon or rhea — Rates: Total and by sex: United States, 1988–2007 and the
Healthy People 2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
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Figure 15. Gon or rhea — Rates by region: United States, 1998–2007 and the Healthy People 
2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
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Figure 16. Gon or rhea — Rates by state: United States and outlying areas, 2007 
Note: The to tal rate of gon or rhea for the United States and out ly ing ar eas (Guam, Puerto Rico and
Vir gin Is lands) was 117.4 per 100,000 pop u la tion. The Healthy People 2010 target is 19.0
cases per 100,000 population. 
26  Gonorrhea National Profile STD Surveillance 2007
Rate per 100,000
population
<=19.0 (n= 1,305)
19.1-100.0 (n= 1,099)
>100.0 (n=   736)
Figure 17. Gon or rhea — Rates by county: United States, 2007
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
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Figure 18. Gon or rhea — Age- and sex-specific rates: United States, 2007
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Figure 19. Gon or rhea — Age-specific rates among women 15 to 44 years of age: 
United States, 1998–2007
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Figure 20. Gon or rhea — Age-specific rates among men 15 to 44 years of age: 
United States, 1998–2007
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Figure 21. Gon or rhea — Rates by race/ethnicity: United States, 1998–2007
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Figure 22. Gon or rhea — Cases by reporting source and sex: United States, 1998–2007
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Figure 23. Gon or rhea — Positivity among 15- to 24-year-old women tested in family planning
clinics by state: United States and outlying areas, 2007
*States/areas not meeting minimum inclusion criteria.
Note: Includes states and outlying areas that reported positivity data on at least 500 women aged
15–24 years screened during 2007.
SOURCE: Gonorrhea Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
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Figure 24. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Prevalence of ciprofloxacin
resistant Neisseria gonorrhoeae by GISP site, 2004–2007
Note: Not all sites participated in GISP for the last 4 years. Sites include: ALB=Albuquerque, NM;  ATL=Atlanta, GA; BAL=Baltimore, MD;
BHM=Birmingham, AL; CHI=Chicago, IL; CIN=Cincinnati, OH; CLE=Cleveland, OH; DAL=Dallas, TX; DEN=Denver, CO; DTR=Detroit,
MI; GRB=Greensboro, NC; HON=Honolulu, HI; KCY=Kansas City, MO; LAX=Los Angeles, CA; LBC=Long Beach, CA; LVG=Las Vegas, 
NV; MIA=Miami, FL; MIN=Minneapolis, MN;  NOR=New Orleans, LA; NYC=New York City, NY; OKC=Oklahoma City, OK; ORA=Orange 
County, CA; PHI=Philadelphia, PA; PHX=Phoenix, AZ; POR=Portland, OR; RIC=Richmond, VA; SDG=San Diego, CA; SEA=Seattle,
WA; SFO=San Francisco, CA; and TRP=Tripler Army Medical Center, HI
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Figure 25. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Penicillin, tetracycline, and
ciprofloxacin resistance among GISP isolates, 2007
Note: PenR=penicillinase producing N. gonorrhoeae and chro mo som ally me di ated
pen i cil lin-resistant  N. gonorrhoeae; TetR=chromosomally and plasmid mediated
tetracycline-resistant N. gonorrhoeae; QRNG=ciprofloxacin resistant N. gonorrhoeae.
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Figure 26. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Percent of Neisseria
gonorrhoeae isolates with re sis tance or intermediate resistance to
ciprofloxacin, 1990–2007
Note: Re sis tant iso lates have ciprofloxacin MICs ≥ 1 µg/ml. Iso lates with intermediate resistance
 have ciprofloxacin MICs of 0.125 – 0.5 µg/ml. Susceptibility to ciprofloxacin was first
measured in GISP in 1990.
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Figure 27. Gono coc cal Iso late Sur veil lance Pro ject (GISP) — Percent of Neisseria
gonorrhoeae isolates with resistance to ciprofloxacin by sexual behavior,
2001–2007

Syphilis 
Background 
Syphilis, a genital ulcerative disease, causes 
significant complications if untreated and
facilitates the transmission of HIV.
Untreated early syphilis in pregnant women 
results in perinatal death in up to 40% of
cases and, if acquired during the four years
preceding pregnancy, may lead to infection
of the fetus in 80% of cases.1 
The rate of primary and secondary (P&S)
syphilis reported in the United States
decreased during the 1990s; in 2000, the
rate was the lowest since reporting began in 
1941 (Figure 28). The low rate of infectious 
syphilis and the concentration of the
majority of syphilis cases in a small number
of geographic areas in the United States led 
to the development of the CDC’s National
Plan to Eliminate Syphilis, which was
announced by Surgeon General David
Satcher in October 1999 and revised in
May 2006.2 
Although the rate of P&S syphilis in the
United States declined 89.7% between
1990 and 2000, the rate of P&S syphilis
increased annually between 2001 and
2007. Overall increases in rates between
2001 and 2007 were observed primarily
among men (from 3.0 cases per 100,000
population to 6.6 cases per 100,000
population). After persistent declines from
1992 to 2003, the rate of P&S syphilis
among women increased from 0.8 cases
per 100,000 population in 2004 to 0.9
cases per 100,000 population in 2005 to
1.0 case per 100,000 population in 2006,
to 1.1 case per 100,000 population in
2007. 
Syphilis remains an important problem in
the South and in urban areas in other
regions of the country. Increases in cases 
among MSM have occurred and have
been characterized by high rates of HIV
co-infection and high-risk sexual
behavior.3,4,5,6,7The estimated proportion of
P&S syphilis cases attributable to MSM
increased from 4% in 2000 to 62% in
2004.8,9 In 2005, CDC requested that all
state health departments report sex of sex
partners for persons with syphilis. In 2007, 
65% of those P&S syphilis cases in 44
states and Washington D.C. with available
information were among MSM. Of
reported male cases with P&S syphilis, sex 
of partner information in 2007 was
available for 79%.
Syphilis — All Stages (P&S, Early
Latent, Late, Late Latent,
Congenital) 
Between 2006 and 2007, the number of
cases of early latent syphilis reported to
CDC increased 17.2% (from 9,186 to
10,768), while the number of cases of late
and late latent syphilis increased 3.5%
(from 17,644 to 18,256) (Table 1). The
total number of cases of syphilis (all stages:
P&S, early latent, late, late latent, and
congenital syphilis) reported to CDC
increased 10.7% (from 36,959 to 40,920)
between 2006 and 2007 (Table 1). 
P&S Syphilis — United States
In 2007, P&S syphilis cases reported to
CDC increased to 11,466 from 9,756 in
2006, an increase of 17.5%. The rate of
P&S syphilis in the United States in 2007
(3.8 cases per 100,000 population) was
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15.2% higher than the rate in 2006 (3.3
cases per 100,000 population), and it is
greater than the HP 2010 target of 0.2
case per 100,000 population (Figure 29,
Table 1).10
P&S Syphilis by Region 
The South accounted for 48.8% of the P&S 
syphilis cases in 2007 and 47.1% in 2006.
Between 2006 and 2007, rates increased
21.4% in the South (from 4.2 to 5.1 cases
per 100,000 population), 30.8% in the
Northeast (from 2.6 to 3.4), 8.1% in the
West (from 3.7 to 4.0) and 5.6% in the
Midwest (from 1.8 to 1.9). The 2007 rates
in all regions were greater than the HP
2010 target of 0.2 cases per 100,000
population (Figure 30, Table 25).
P&S Syphilis by State 
In 2007, P&S syphilis rates in three states
were less than or equal to the HP 2010
target of 0.2 case per 100,000 population
(Figure 31, Table 24). Four states and one
outlying area reported five or fewer cases of 
P&S syphilis in 2007 (Table 24).
P&S Syphilis by Metropolitan
Statistical Area (MSA) 
The rate of P&S syphilis in 2007 for the 50
most populous MSAs (5.7) exceeded the
HP 2010 target of 0.2 cases per 100,000
population (Table 28).
P&S Syphilis by County 
In 2007, 2,275 of 3,140 counties (72.4%)
in the United States reported no cases of
P&S syphilis compared with 2,360 (75.2%) 
in 2006. Of 865 counties reporting at least
one case of P&S syphilis in 2007, five
(0.6%) had rates at or below the HP2010
target of 0.2 cases per 100,000 population.
Rates of P&S syphilis were above the
HP2010 target for 860 counties in 2007
(Figure 32). These 860 counties (27.4% of
the total number of counties in the United
States) accounted for 99.9% of the total
P&S syphilis cases reported in 2007. In
2007, half of the total number of P&S
syphilis cases were reported from 23
counties and two cities (Table 31).
P&S Syphilis by Sex
The rate of P&S syphilis increased 17.9%
among men (from 5.6 cases to 6.6 cases
per 100,000 men) between 2006 and 2007 
(Figure 29, Table 27). During this time, the
rate increased 10.0% among women from
1.0 to 1.1 cases per 100,000 women
(Figure 29, Table 26).
P&S Syphilis by Age
In 2007, the rate of P&S syphilis was
highest in persons in the 25- to 29-year-old
age group (8.9 cases per 100,000
population) (Figure 33 and Table 32).
Between 2006 and 2007, P&S syphilis
rates in most age groups among men and
women increased (Table 32 and Figures 34
and 35).
P&S Syphilis by Race/Ethnicity
From 2006 to 2007, the rate of P&S
syphilis increased in all racial and ethnic
groups except Asian/Pacific Islanders
(Figure 36). The rate increased 5.3%
among non-Hispanic whites (from 1.9 to
2.0), 25% among blacks (from 11.2 to
14.0), 22.9% among Hispanics (from 3.5 to 
4.3), and 6.3% among American
Indian/Alaska Natives (from 3.2 to 3.4). 
The rate remained the same at 1.2 cases
per 100,000 population among
Asian/Pacific Islanders (Table 33B).
P&S Syphilis by Sex and Sex
Behavior
The male to female rate ratio for P&S
syphilis has risen steadily since 1996 when
it was 1.2, suggesting an increase among
MSM. In 2007, the rate of P&S syphilis in
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males was 6.0 times that in females, an
increase from 5.7 in 2006.
In 2005, CDC began collecting information
on the sexual orientation of patients with
P&S syphilis. In 2007, this information was
available for 79% of male cases.
In 2007, the stage of disease was reported
as follows: among heterosexual men with
P&S syphilis, 43.0% had primary syphilis
and 57% had secondary syphilis. Among
female patients, 17.9% had primary syphilis 
and 82.1% had secondary syphilis. Among
men who had sex with men with P&S
syphilis, 24.3% had primary syphilis and
75.7% had secondary syphilis (Figure 37).
Of females with P&S syphilis, 21.9% were
white, 63.5% were black, 9.6% were
Hispanic, and 5.0% were of other
races/ethnicities. Of heterosexual men,
19.3% were white, 59.8% were black,
16.1% were Hispanic, and 4.8% were of
other race/ethnicities. Of men who had sex
with men, 40.8% were white, 33.2% were
black, 19.3% were Hispanic, and 6.7%
were of other races/ethnicities (Figure 38).
P&S Syphilis by Race/Ethnicity and
Sex
From 2006 to 2007, the P&S syphilis rate
among non-Hispanic white males increased 
5.7% (from 3.5 to 3.7), and increased
among non-Hispanic white females as well
(from 0.3 to 0.4). The rate increased 28.2% 
among black males (from 18.1 to 23.2) and 
14.3% among black females (from 4.9 to
5.6). The rate increased 25.0% among
Hispanic males (from 6.0 to 7.5), but
remained unchanged among Hispanic
females (0.8). The rate remained
unchanged for both Asian/Pacific Island
males (2.4), and Asian/Pacific Island
females (0.1). The rate increased 36.8%
among American Indian/Alaska Native
females (from 1.9 to 2.6), but decreased
8.5% among American Indian/Alaska
Native males (from 4.7 to 4.3) (Table 33B).
P&S Syphilis by Race/Ethnicity, Age,
and Sex 
In 2007, the rate of P&S syphilis among
blacks was highest among women aged 20
to 24 years (16.0) and among men aged 20 
to 24 years (57.5) and 25 to 29 years
(57.4). For non-Hispanic whites, the rate
was highest among women aged 20 to 24
years (1.1) and among men aged 40 to 44
years (10.4). For Hispanics, the rate was
highest among women aged 20 to 24 years 
(2.3) and among men aged 40 to 44 years
(15.5). For Asian/Pacific Islanders, the rate
was highest among women aged 20 to 24
years and 30 to 34 years (both 0.4) and
among men aged 25 to 29 years (5.8). For
American Indian/Alaska Natives, the rate
was highest among women aged 25 to 29
years (7.8) and among men aged 30 to 34
years (18.2) (Table 33B).
P&S Syphilis by Reporting Source
In 1990, 25.6% of P&S syphilis cases were
reported from sources other than STD
clinics; this figure increased to 39.2% in
1998. Between 1998 and 2007, the
proportion of P&S syphilis cases reported
from sources other than STD clinics
increased from 39.2% to 68.7% (Figure 39
and Table A2). Between 2001 and 2007,
the number of cases among males reported 
from non-STD clinic sources increased
sharply while the number from STD clinics
increased slightly (Figure 39).
During 2007, patients with P&S syphilis
primarily sought care with private
physicians or STD clinics. Men who have
sex with men were more frequently
reported from private physicians (36.7%)
than STD clinics (27.1%) (Figure 40). More
cases among women and heterosexual men 
were reported from STD clinics than private 
physicians.
STD Sur veil lance 2007 National Profile Syphilis   35
Congenital Syphilis — United States
After 14 years of decline in the United
States, the rate of congenital syphilis
increased 15.4% between 2006 and 2007
(from 9.1 to 10.5 cases per 100,000 live
births) (Table 39). In 2007, 430 cases were
reported, an increase from 373 in 2006.
This increase in the rate of congenital
syphilis may relate to the increase in the
rate of P&S syphilis among women that has 
occurred in recent years (Figure 41).
Congenital Syphilis by State
In 2007, 29 states, the District of Columbia, 
and two outlying area had rates of
congenital syphilis that exceeded the HP
2010 target of one case per 100,000 live
births (Tables 38 and 39).
Syphilis Among Special Populations
Additional information about syphilis and
congenital syphilis in racial and ethnic
minority populations, adolescents, MSM,
and other at-risk populations can be found
in the Special Focus Profiles.
Syphilis Summary
In recent years, MSM have accounted for
an increasing number of estimated syphilis
cases in the United States9 and now
account for 65% of syphilis cases in the
United States based on information from
44 states and Washington, D.C. Despite the 
majority of U.S. syphilis cases occurring
among MSM, syphilis cases among
heterosexuals is an emerging problem given 
the recent increases among women and
infants. 
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Figure 28. Syph i lis — Re ported cases by stage of infection: United States, 1941–2007
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Figure 29. Primary and secondary syph i lis — Rates: Total and by sex: United States,
1988–2007 and the Healthy Peo ple 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
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Figure 30. Pri mary and sec ond ary syph i lis — Rates by re gion: United States, 1998–2007 
and the Healthy Peo ple 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
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Figure 31. Pri mary and sec ond ary syph i lis — Rates by state: United States and out ly ing 
areas, 2007
Note: The total rate of P&S syphilis for the United States and outlying areas (Guam, Puerto Rico and
Virgin Islands) was 3.8 per 100,000 population. The Healthy People 2010 target is 0.2 case per 
100,000 population.
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Figure 32. Pri mary and sec ond ary syph i lis — Rates by county: United States, 2007
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population. In 2007,
2,274 (72.4%) of 3,140 counties in the U.S. reported no cases of P&S syphilis.
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Figure 33. Primary and secondary syph i lis — Age- and sex-specific rates: United States,
2007
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Figure 34. Pri mary and sec ond ary syph i lis — Age-specific rates among women 15 to 44
years of age: United States, 1998–2007
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Figure 35. Pri mary and sec ond ary syph i lis — Age-specific rates among men 15 to 44 years 
of age: United States, 1998–2007
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Figure 36. Pri mary and sec ond ary syph i lis — Rates by race/eth nic ity: United States,
1998–2007
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Figure 37. Pri mary and sec ond ary syph i lis — Re ported cases* by stage and sexual
orientation, 2007
*21% of reported male cases with P&S syphilis were missing sex of sex partner information.
 
†MSM denotes men who have sex with men.
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Fig ure 38.     Pri mary and sec ond ary syph i lis — Re ported cases* by sexual orientation and
race/ethnicity†, 2007
*21% of reported male cases with P&S syphilis were missing sex of sex partner information; 3%
of reported males cases with sex of partner data were missing race/ethnicity data.
  †No imputation was done for race/ethnicity.
 ‡MSM denotes men who have sex with men.
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Figure 39. Primary and secondary syph i lis — Reported cases by reporting source and sex:
United States, 1998–2007
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Figure 40. Primary and secondary syph i lis — Percentage of reported cases* by sexual
orientation and selected reporting sources, 2007
*21% of reported male cases with P&S syphilis were missing sex of sex partner information; 3.3% 
of reported male cases with sex of partner data were missing source of information data.
†MSM denotes men who have sex with men.
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Figure 41. Con gen i tal syph i lis (CS) — Re ported cases for in fants < 1 year of age and rates
of pri mary and sec ond ary syph i lis among women: United States, 1998–2007

Other Sexually Transmitted
Diseases
Chancroid 
Since 1987, reported cases of chancroid
declined steadily until 2001. Since then, the
number of cases reported has fluctuated
(Figure 42, Table 1). In 2007, 23 cases of
chancroid were reported in the United
States. Only eight states reported one or
more cases of chancroid in 2007 (Table 41).
Although the overall decline in reported
chancroid cases most likely reflects a decline
in the incidence of this disease, these data
should be interpreted with caution since
Haemophilus ducreyi, the causative
organism of chancroid, is difficult to culture
and, as a result, this condition may be
substantially under-diagnosed.1,2
Human Papillomavirus 
Persistent infection with high risk human
papillomavirus (HR-HPV) can lead to
development of anogenital cancers (i.e.,
cervical cancer). In June 2006, a
quadrivalent HPV vaccine was licensed for
use in the United States. The vaccine
provides protection against types 6, 11, 16,
and 18. Types 6 and 11 are associated with 
genital warts while types 16 and 18 are
oncogenic types associated with anogenital
cancers.
Sentinel surveillance for cervical infection
with high-risk human papillomavirus types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, or 68 was conducted in 26 STD, family
planning and primary care clinics in six
locations (Boston, Baltimore, New Orleans,
Denver, Seattle and Los Angeles) as part of
an effort to estimate national burden of
disease and inform prevention programs
such as vaccine programs in the U.S.
Testing was performed using a
commercially available test for HR-HPV
DNA (Hybrid Capture 2, Qiagen,
Gaithersburg, MD). Results from
2003–2005 document an overall HR-HPV
prevalence of 23%. Prevalence in STD
clinics was 27%, 26% in family planning
clinics, and 15% in primary care clinics.
Prevalence by age group was: 14 to 19
years 35%; 20 to 29 years 29%; 30 to 39
years 13%; 40 to 49 years 11%; and 50 to
65 years 6%.3
Preliminary results from the sentinel
surveillance project from 2003–2004 also
report PCR-based HPV type-specific
prevalence estimates for types 16 and 18.
Overall prevalence of infection with HPV
types 16 or 18 was 8%. Prevalence of HPV
16 or 18 by age group was: 16% in 14 to
19 year olds; 10% in 20 to 29 year olds;
3% in 30 to 39 year olds; 2% in 40 to 49
year olds and 1% in 50 to 65 year olds.4
National population-based data were also
obtained from the National Health and
Nutrition Examination Survey (NHANES)
identifying prevalence of both HR-HPV and 
low-risk HPV (LR-HPV, which is associated
with development of anogenital warts) in
the civilian, non-institutionalized female
population of the U.S., 2003–2004 (Figure
43). The overall HPV prevalence including
high- and low-risk types, was 26.8% (95%
confidence interval (CI): 23.3–30.9) among 
U.S. females aged 14 to 59 years. HPV
vaccine preventable types 6 or 11 (low-risk
types) or 16 or 18 (high-risk types) were
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detected in 3.4% of female participants;
HPV-6 was detected in 1.3% (95% CI:
0.8–2.3), HPV-11 in 0.1% (95% CI:
0.03–0.3), HPV-16 in 1.5% (95% CI:
0.9–2.6), and HPV-18 in 0.8% (95% CI:
0.4–1.5) of female participants.5
Data from the National Disease and
Therapeutic Index (NDTI) suggest that
genital warts (Figure 44) as measured by
initial visits to physicians’ offices, may be
increasing. The NHANES 1999–2004
survey years demonstrated that 5.6% (95% 
CI: 4.9–6.4) of sexually active 18–59 year
olds self-reported a history of a genital wart 
diagnosis.6
Pelvic Inflammatory Disease 
For data on Pelvic Inflammatory Disease
(PID), see the Special Focus Profile on
Women and Infants. 
Herpes Simplex Virus (HSV)
Case reporting data for genital herpes
simplex virus are not available. Trend data
are based on estimates of the initial office
visits in physicians’ office practices for these 
conditions from the National Disease and
Therapeutic Index (NDTI) (Figure 45 and
Table 42).
National trend data on the seroprevalence
of HSV-2 among those aged 14 to 49 years 
from the NHANES survey years
1999–2004 were compared with survey
years 1988–1994. Seroprevelance
decreased from 21% (95% CI: 19.1–23.1)
in 1988–1994 to 17.0% (95% CI:
15.8–18.3) in 1999–2004. When including
data on blacks and whites from NHANES
survey years 1976–1980, blacks had higher 
seroprevalence than whites for each survey
period and age group7 (Figure 46). In
1999–2004, the overall percentage of
survey participants who reported having
been diagnosed with genital herpes was
3.8%.7
While HSV-2 seroprevalence is decreasing,
most persons with HSV-2 have not been
diagnosed. Increasing visits for genital
herpes, as suggested by NDTI data, may
indicate increased recognition of infection.
Trichomoniasis
Case reporting data are not available for
trichomoniasis and trend data for this
infection is limited to estimates of initial
physician office visits from NDTI (Figure 47 
and Table 42). NHANES data from
2001–2004 demonstrated an overall
prevalence of 3.1% (95% CI: 2.3–4.3), with 
highest prevalence observed among blacks
13.3% (95% CI: 10.0–17.7).8
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Figure 42. Chancroid — Re ported cases: United States, 1981–2007
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Figure 43. Human papillomavirus (HPV) — Prevalence of high-risk and low-risk types
among females 14 to 59 years of age reported from a national survey,
2003–2004
Note: Error bars indicate 95% confidence intervals. Both high-risk and low-risk HPV types were
detected in some females.
SOURCE: National Health and Nutrition Examination Survey
JAMA, 2007, 297;813–819 Copyright © 2007, American Medical Association. All Rights reserved.
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Figure 44.  Gen i tal warts — Ini tial vis its to phy si cians’ of fices: United States, 1966–2007 
Note: See Appendix (Other Data Sources) and Table 42. The relative standard error for genital
warts estimates range from 17% to 29.3%.
SOURCE: National Disease and Therapeutic Index (IMS Health)
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Fig ure 45. Gen i tal her pes — Initial vis its to phy si cians’ of fices: United States, 1966–2007
Note: See Appendix (Other Data Sources) and Table 42. The relative standard error for genital
herpes estimates range from 17% to 29.3%.
SOURCE: National Disease and Therapeutic Index (IMS Health)
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Fig ure 46. Gen i tal her pes — Herpes simplex virus, type 2, seroprevalence in non-Hispanic
whites and non-Hispanic blacks by age group reported from national surveys,
1976–1980, 1988–1994, 1999–2004 
Note: Error bars indicate 95% confidence intervals.
SOURCE: National Health and Nutrition Examination Survey
JAMA, 2006, 296:964–973. Copyright © 2006, American Medical Association. All Rights reserved. 
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Fig ure 47. Trichomoniasis and other vag i nal in fec tions in women — Ini tial vis its to
phy si cians’ of fices: United States, 1966–2007
Note: See Appendix (Other Data Sources) and Table 42. The relative standard error for
trichomoniasis estimates range from 16% to 29.3% and for other vaginitis estimates range
from 8% to 13%.
SOURCE: National Disease and Therapeutic Index (IMS Health)
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Spe cial Fo cus Pro files
The Spe cial Fo cus Pro files high light trends and dis tri bu tion of STDs in pop u la tions of
par tic u lar in ter est for STD and HIV pre ven tion pro grams in state and lo cal health
de part ments. These pop u la tions are most vul ner a ble to STDs and their con se quences:
women and in fants, ad o les cents and young adults, racial and ethnic mi nor i ties, MSM, and
per sons en ter ing cor rec tions fa cil i ties. The Spe cial Fo cus Pro files re fer to fig ures lo cated
in dis ease-spe cific sec tions in the Na tional Pro file and ad di tional fig ures and ta bles
(Fig ures A-EE and Ta bles A-F) that high light spe cific points made in the text.
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STDs in Women and Infants
Public Health Impact
Women and infants disproportionately bear 
the long term consequences of STDs.
Women infected with Neisseria
gonorrhoeae or Chlamydia trachomatis can 
develop PID, which, in turn, may lead to
reproductive system morbidity such as
ectopic pregnancy and tubal factor
infertility. If not adequately treated, up to
40% of women infected with chlamydia or
gonorrhea may develop PID.1,2 Among
women with PID, tubal scarring can cause
involuntary infertility in 20%, ectopic
pregnancy in 9%, and chronic pelvic pain
in 18%.3 Approximately 70% of chlamydial 
infections and 50% of gonococcal
infections in women are asymptomatic.4,5,6
These infections are detected primarily
through screening programs. The vague
symptoms associated with chlamydial and
gonococcal PID cause 85% of women to
delay seeking medical care, thereby
increasing the risk of infertility and ectopic
pregnancy.7 Data from a randomized
controlled trial of chlamydia screening in a
managed care setting suggest that such
screening programs can reduce the
incidence of PID by as much as 60%.8 
Human papillomavirus (HPV) infections are
highly prevalent, especially among young
sexually-active women. While the great
majority of HPV infections in women
resolve within one year, they are a major
concern because persistent infection with
specific types are causally related to cervical
cancer; these types also cause Pap smear
abnormalities. Other types cause genital
warts, low grade Pap smear abnormalities
and, rarely, recurrent respiratory
papillomatosis in infants born to infected
mothers.9
Direct Impact on Pregnancy
Gonorrhea and chlamydia can result in
adverse outcomes of pregnancy, including
neonatal ophthalmia and, in the case of
chlamydia, neonatal pneumonia. Although 
topical prophylaxis of infants at delivery is
effective for prevention of gonococcal
ophthalmia neonatorum, prevention of
neonatal pneumonia requires prenatal
detection and treatment.
Genital infections with herpes simplex virus 
are extremely common, may cause painful
outbreaks, and may have serious
consequences for pregnant women.10 
When a woman has a syphilis infection
during pregnancy, she may transmit the
infection to the fetus in utero. This may
result in fetal death or an infant born with
physical and mental developmental
disabilities. Most cases of congenital
syphilis are easily preventable if women
are screened for syphilis and treated early
during prenatal care.11
Observations
Chlamydia — United States 
Between 2006 and 2007, the rate of
chlamydial infections in women
increased from 510.8 to 543.6 per
100,000 females (Figure 1, Table 4).
Chlamydia rates exceed gonorrhea rates
among women in all states (Figures A
and C, Tables 4 and 14).
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Chlamydia Prevalence Monitoring
Project
Prenatal Clinics — In 2007, the median
state-specific chlamydia test positivity
among 15- to 24-year-old women screened
in selected prenatal clinics in 22 states,
Puerto Rico, and the Virgin Islands was
7.4% (range: 2.0% to 20.7%) (Figure B). 
Family Planning Clinics — In 2007, the
median state-specific chlamydia test
positivity among 15- to 24-year-old women 
who were screened during visits to selected
family planning clinics in all 50 states,
Puerto Rico, and the Virgin Islands was
6.9% (range: 2.9% to 16.8%) (Figures 9
and 10).
Gonorrhea — United States
Gonorrhea rates among women were higher 
than the overall HP 2010 target of 19.0
cases per 100,000 population12 in 45 states,
Washington D.C., Guam, and the Virgin
Islands in 2007 (Figure C, Table 14).
Like chlamydia, gonorrhea is often
asymptomatic in women. Gonorrhea
screening, therefore, is an important strategy 
for the identification of gonorrhea among
women. Large-scale screening programs for
gonorrhea in women began in the 1970s.
After an initial increase in cases detected
through screening, gonorrhea rates for both
women and men declined steadily
throughout the 1980s and early 1990s, and
then reached a plateau (Figure 13). The
gonorrhea rate for women (123.5 per
100,000 females) increased slightly in 2007
for the third consecutive year (Figure 14).
Although the gonorrhea rate in men has
historically been higher than the rate in
women, the gonorrhea rate among women
has been comparable to the rate among
men for seven consecutive years (Figure 14
and Tables 14 and 15).
Gonorrhea Prevalence Monitoring
Project
Prenatal Clinics — In 2007, the
median state-specific gonorrhea test
positivity among 15- to 24-year-old
women screened in selected prenatal
clinics in 19 states, Puerto Rico, and the
Virgin Islands was 0.8% (range: 0.0% to
3.9%) (Figure D). Median gonorrhea
positivity in prenatal clinics has shown
minimal change in recent years.
Family Planning Clinics — In 2007, the 
median state-specific gonorrhea test
positivity among 15- to 24-year-old
women screened in selected family
planning clinics in 43 states, Puerto Rico,
and the Virgin Islands was 0.9% (range:
0.1% to 4.9%) (Figure 23). Median
gonorrhea positivity in family planning
clinics has shown minimal change in recent 
years.
Primary and Secondary Syphilis by
State
The HP 2010 target for primary and
secondary (P&S) syphilis is 0.2 case per
100,000 population. In 2007, 32 states
and the District of Columbia had rates of
P&S syphilis for women that were greater
than 0.2 case per 100,000 population
(Table 26).
Congenital Syphilis
The HP 2010 target for congenital syphilis
is 1.0 case per 100,000 live births. In
2007, 29 states, the District of Columbia,
Guam, and Puerto Rico had rates higher
than this target (Table 38). 
Trends in congenital syphilis usually follow
trends in P&S syphilis among women, with 
a lag of one to two years (Figure 41). The
congenital syphilis rate peaked in 1991 at
107.3 cases per 100,000 live births, and
declined by 92.4% to 8.2 cases per
100,000 live births in 2005 (Table 39).
The rate of P&S syphilis among women
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declined 94.8% (from 17.3 to 0.9 cases per 
100,000 females) during 1990–2005
(Figure 29).
After 14 years of decline in the United
States, the rate of congenital syphilis
increased 11.0% between 2005 and 2006
(from 8.2 to 9.1 cases per 100,000 live
births) (Table 39). Rates increased again
between 2006 and 2007 by 15.4% (from
9.1 to 10.5 cases per 100,000 live births)
(Table 39).
The 2007 rate of congenital syphilis for the
United States is currently 10.5 times higher
than the HP 2010 target of 1.0 case per
100,000 live births (Table 38).
While most cases of congenital syphilis
occur among infants whose mothers have
had some prenatal care, late or limited
prenatal care has been associated with
congenital syphilis. Failure of health care
providers to adhere to maternal syphilis
screening recommendations also contributes 
to the occurrence of congenital syphilis.13
Pelvic Inflammatory Disease 
Accurate estimates of pelvic inflammatory
disease (PID) and tubal factor infertility
resulting from gonococcal and chlamydial
infections are difficult to obtain. Definitive
diagnoses of these conditions can be
complex. Hospitalizations for PID have
declined steadily throughout the 1980s and
early 1990s,14,15 but have remained
relatively constant between 2000 and 2006
(Figure H).
The estimated number of initial visits to
physicians’ offices for PID from the National 
Disease and Therapeutic Index (NDTI) has 
generally declined from 2000 through
2007 (Figure I and Table 42).
Since 2000, the number of cases of PID
diagnosed in emergency departments
among women 15 to 44 years of age has
generally declined though cases increased
from 2005–2006.
Racial disparities in diagnosed PID have
been observed in both ambulatory and
hospitalized settings. Black women had
rates of disease that were two to three
times those in white women. These
disparities are consistent with the marked
racial disparities observed for chlamydia
and gonorrhea; however, because of the
subjective methods by which PID is
diagnosed, racial disparity data should be
interpreted with caution.15
Ectopic Pregnancy
Evidence suggests that health care
practices associated with clinical
management of ectopic pregnancy
changed in the late 1980s and early 1990s. 
Before that time, treatment of ectopic
pregnancy usually required admission to a
hospital. Hospitalization statistics were
therefore useful for monitoring trends in
ectopic pregnancy. From 1997 to 2006,
hospitalizations for ectopic pregnancy have 
remained generally stable (Figure G). As of 
the date of publication of this report, 2007
data are not available. Data suggest that
nearly half of all ectopic pregnancies are
treated on an outpatient basis.16
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Fig ure  A. Chlamydia — Rates among women by state: United States and out ly ing ar eas, 2007
Note: The total chlamydial infection rate among women in the United States and outlying areas
(Guam, Puerto Rico and Virgin Islands) was 540.9 per 100,000 female population.
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Fig ure  B. Chlamydia — Positivity in 15- to 24-year-old women tested in pre na tal
clin ics by state: United States and outlying areas, 2007
*States/areas not meeting minimum inclusion criteria in prenatal clinics.
Note: Includes states and outlying areas that reported chlamydia positivity data on at least 100
women aged 15 to 24 years during 2007.
SOURCE: Chlamydia Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
60  STDs in Women and Infants Special Focus Profiles STD Surveillance 2007
Rate per 100,000
population
Guam 78.7   
Puerto Rico 8.1    
Virgin Is. 89.8   
<=19.0
19.1-100.0
>100.0
(n=  6)
(n= 25)
(n= 23)
VT     9.5
NH     9.5
MA    38.6
RI    30.6
CT    76.3
NJ    68.6
DE   159.1
MD   121.7
DC   348.7
257.2
100.7
76.0 158.7
79.7 76.6
128.1
196.4
45.9
20.9
173.6 152.5
74.3
100.6 88.0
264.4
6.7
175.3
74.3
326.5
183.4
15.9
95.086.9
98.4
83.6
198.0
20.9
200.2
143.6
30.3
108.6
254.3
39.1
169.9
137.3
27.2
86.7
58.0
54.3
145.4
16.1
Fig ure  C. Gon or rhea — Rates among women by state: United States and out ly ing ar eas, 2007
Note: The total gonorrhea infection rate among women in the United States and outlying areas
(Guam, Puerto Rico and Virgin Islands) was 121.9 per 100,000 female population.
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Fig ure  D. Gon or rhea — Positivity in 15- to 24-year-old women tested in prenatal
clin ics by state: United States and outlying areas, 2007
*States/areas not meeting minimum inclusion criteria in prenatal clinics.
Note: Includes states and outlying areas that reported gonorrhea positivity data on at least 100
women aged 15 to 24 years during 2007.
SOURCE: Gonorrhea Prevalence Monitoring Project (Re gional In fer til ity Prevention Pro jects); Of fice of Pop u la tion Af fairs;
Lo cal and State STD Con trol Pro grams; Cen ters for Dis ease Con trol and Pre ven tion
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Fig ure  E. Pri mary and sec ond ary syph i lis — Rates among women by state: United States and
out ly ing ar eas, 2007
Note: The total rate of P&S syphilis among women in the United States and outlying areas (Guam,
Puerto Rico, and Virgin Islands) was 1.1 per 100,000 female population.
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Fig ure  F. Con gen i tal syph i lis — Rates for in fants < 1 year of age by state: United States and
out ly ing ar eas, 2007
Note: The total rate of congenital syphilis for infants < 1 year of age for the United States and outlying 
areas (Guam, Puerto Rico, and Virgin Islands) was 10.5 per 100,000 live births. The Healthy
People 2010 target is 1.0 case per 100,000 live births.
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Fig ure  G. Ectopic preg nancy — Hos pi tal iza tions of women 15 to 44 years of age: United
States, 1997–2006
Note: The relative standard error for these estimates is 14.2%. Data only available through 2006.
SOURCE: National Hospital Discharge Survey (National Center for Health Statistics, CDC)
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Fig ure  H. Pel vic in flam ma tory dis ease — Hos pi tal iza tions of women 15 to 44 years
of age: United States, 1997–2006
Note: The relative standard error for these estimates of the total number of acute unspecified PID 
cases ranges from 11.9% to 17.2%. The relative standard error for these estimates of the
total number of chronic PID cases ranges from 11% to 18%. Data only available through
2006.
SOURCE: National Hospital Discharge Survey (National Center for Health Statistics, CDC)
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Fig ure  I. Pel vic in flam ma tory dis ease — Ini tial vis its to phy si cians’ of fices by women
15 to 44 years of age: United States, 1998–2007
Note: The relative standard error for these estimates range from 21.6% to 29.3%. See Ap pen dix
(Other Data Sources) and Table 42.
SOURCE: National Disease and Therapeutic Index (IMS Health)

STDs in Adolescents and Young
Adults
Public Health Impact
Compared to older adults, sexually-active
adolescents 15 to 19 years of age and
young adults 20 to 24 years of age are at
higher risk for acquiring STDs for a
combination of behavioral, biological, and
cultural reasons. For some STDs, for
example, Chlamydia trachomatis,
adolescent women may have a
physiologically increased susceptibility to
infection due to increased cervical ectopy.
The higher prevalence of STDs among
adolescents also reflects multiple barriers to
accessing quality STD prevention services,
including lack of insurance or other ability to 
pay, lack of transportation, discomfort with
facilities and services designed for adults,
and concerns about confidentiality. Recent
estimates suggest that while representing
25% of the ever sexually active population,
15 to 24 year-olds acquire nearly half of all
new STDs.1
Observations
Chlamydia
Chlamydia rates for persons 15 to 19 and
20 to 24 years of age continue to increase as 
they have for all age groups. Between 2006
and 2007, the increase for those 15 to 19
years of age was 7.7%, and for those 20 to
24 years of age was 6.6% (Table 10).
15- to 19-Year-Old Women — As in
previous years, in 2007 15- to 19-year-old
women had the highest rate of chlamydia
(3,004.7 per 100,000 population) compared 
to any other age/sex group (Figure 5 and
Table 10). Chlamydia rates for 15- to
19-year-old women increased 6.4%
from 2,824 per 100,000 population in
2006 to 3,004.7 per 100,000 population
in 2007.
20- to 24-Year-Old Women — In 2007,
as in previous years, 20- to 24-year-old
women had the second highest rate of
chlamydia (2,948.8 per 100,000
population) compared to any other age/sex 
group. Chlamydia rates in women of this
age group increased 5.6% from 2006 to
2007.
15- to 19-Year-Old Men — Chlamydia
rates for 15- to 19-year-old men increased
14.3% from 537.9 per 100,000 population 
in 2006 to 615.0 per 100,000 population
in 2007.
20- to 24-Year-Old Men — As in
previous years, in 2007, 20- to 24-year old 
men had the highest rate of chlamydia
among men (932.9 per 100,000
population). Chlamydia rates in men of
this age group increased 9.4% from 2006
to 2007.
Gonorrhea
For the third consecutive year, gonorrhea
rates for persons 15 to 19 and 20 to 24
years of age increased. Between 2006 and
2007, the increase for those 15 to 19 years 
of age was 2.1%, and for those 20 to 24
years of age was 0.7% (Table 20).
15- to 19-Year-Old Women — As in
previous years, in 2007 15- to 19-year-old
women had the highest rate of gonorrhea
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(647.9 per 100,000 population) compared
to any other age/sex group (Figure 19 and
Table 20). Gonorrhea rates in women of this 
age group have increased for the past three
years.
20- to 24-Year-Old Women — In 2007,
as in previous years, 20- to 24-year-old
women had the second highest rate of
gonorrhea (614.5 per 100,000 population)
compared to any other age/sex group.
Gonorrhea rates in women of this age group 
have also increased for the past three years.
15- to 19-Year-Old Men — Gonorrhea
rates for 15- to 19-year-old men increased
3.8% from 275.4 per 100,000 population in 
2006 to 286.0 per 100,000 population in
2007. Gonorrhea rates in men of this age
group have increased for the past three
years. (Figure 20, Table 20).
20- to 24-Year-Old Men — As in previous 
years, in 2007, 20- to 24-year old men had
the highest rate of gonorrhea among men
(450.1 per 100,000 population). Gonorrhea 
rates in men of this age group declined
0.4% from 2006 to 2007.
Primary and Secondary Syphilis 
Syphilis rates among 15- to 19-year old
women have increased annually since 2004
from 1.5 cases per 100,000 population to
2.4 per 100,000 population in 2007. Rates
in women have been the highest each year
in the 20 to 24 year age group. In this age
group there were 3.5 cases per 100,000
population in 2007 (Figure 33, Table 32).
Syphilis rates for women in these younger
age groups are comparable to rates in older
age groups.
In contrast, in men, rates among 15- to
19-years olds are much lower than those in
men in older age groups. However, these
rates have increased since 2002 from 1.3
cases per 100,000 population in 2002 to 3.0 
in 2006 and 3.8 in 2007. During 2003 to
2006, rates in men had been the highest
each year in the 35 to 39 year old age
group. In 2007, rates in men were highest
in the 25 to 29 year old age group, with
14.9 cases per 100,000 population, and
14.4 cases per 100,000 population in the
35 to 39 year old age group (Figure 33,
Table 32).
Chlamydia Prevalence Monitoring
Project
Chlamydia test positivity among 15- to
19-year-old women screened in family
planning clinics fluctuated in all 10 HHS
regions between 2003 and 2007 (Figure
J). Positivity has remained fairly stable in
four regions (I, III, V, X). From 2003 to
2006, slight decreases in positivity
occurred in one region (II), followed by a
small increase in 2007. In the remaining
five regions (IV, VI, VII, VIII, IX), positivity
rates increased slightly over the five-year
time frame from 2003 to 2007. The
positivity rates presented in Figure J are
not adjusted for changes in laboratory test
methods and associated increases in test
sensitivity.
National Job Training Program 
Since 1990, approximately 20,000 female
National Job Training Program entrants
have been screened each year for
chlamydia. Since 2004, approximately
35,000 male entrants have been screened
annually. This program, administered by
the National Job Training Program at
more than 100 sites throughout the
country, is a job training program for
socioeconomically-disadvantaged youth
aged 16 to 24 years of age.
Chlamydial infection is widespread
geographically and highly prevalent
among socioeconomically-disadvantaged
young women and men entering the
National Job Training Program.2,3,4
Specimens from at least 100 students from 
each state and outlying area were tested by 
a single national contract laboratory.*
Among women entering the program from
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2–4
40 states, the District of Columbia, and
Puerto Rico in 2007, based on their place of 
residence before program entry, the median
state-specific chlamydia prevalence was
13.2% (range: 3.8% to 23.5%) (Figure K).
Among men entering the program from 47
states, the District of Columbia, and Puerto
Rico in 2007, the median state-specific
chlamydia prevalence was 7.2% (range:
2.0% to 14.5%) (Figure L).
Data from National Job Training Program
centers that submit gonorrhea specimens
from female students aged 16 to 24 years to
the national contract laboratory indicated a
high prevalence of gonococcal infection in
this population. Specimens from at least 100 
students from each state and outlying area
were tested by the contract laboratory.
Among women entering the program from
36 states and Puerto Rico, the median
state-specific gonorrhea prevalence was 3.0% 
(range: 0.0% to 7.2%) in 2007 (Figure M).
Among men entering the program from 32
states and Puerto Rico in 2007, the median
state-specific gonorrhea prevalence was 1.1% 
(range: 0.0% to 4.4%) (Figure N).
Juvenile Corrections Facilities
Among adolescent women entering
juvenile corrections facilities, the
Corrections STD Prevalence Monitoring
Project identified a median facility-specific
chlamydia positivity rate of 14.3% (range:
2.5% to 32.1%) (Table A) and a median
gonorrhea positivity rate of 5.3% (range:
0.0% to 13.9%) (Table C). Among
adolescent men entering juvenile
corrections facilities, the median
facility-specific chlamydia positivity rate
was 5.7% (range: 0.0% to 14.2%) and the
median gonorrhea positivity rate was 1.0% 
(range: 0.0% to 4.5%). See Special
Focus Profiles (STDs in Persons Entering 
Corrections Facilities) for additional details.
*Laboratory data are provided by the
Center for Disease Detection, San Antonio, 
Texas. 
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Fig ure  J. Chlamydia — Trends in positivity among 15- to 19-year-old women tested in fam ily
plan ning clin ics by HHS region, 2003–2007
Note: See Appendix for definitions of HHS Regions.
SOURCE: Re gional In fer til ity Pre ven tion Pro jects; Of fice of Pop u la tion Af fairs; Lo cal and State STD Con trol Pro grams; Cen ters 
for Dis ease Con trol and Pre ven tion
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Fig ure  K. Chlamydia — Prev a lence among 16- to 24-year-old women en ter ing the National Job
Training Program by state of res i dence: United States and outlying areas, 2007
*Fewer than 100 women residing in these states/areas and entering the National Job Training
Program were screened for chlamydia in 2007.
SOURCE: National Job Training Program; Department of Labor (in collaboration with the Center for Disease Detection, San
Antonio, Texas)
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Fig ure  L. Chlamydia — Prev a lence among 16- to 24-year-old men en ter ing the National Job
Training Program by state of res i dence: United States and outlying areas, 2007
*Fewer than 100 men residing in these states/areas and entering the National Job Training
Program were screened for chlamydia in 2007.
SOURCE: National Job Training Program; Department of Labor (in collaboration with the Center for Disease Detection, San
Antonio, Texas)
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Fig ure  M. Gon or rhea — Prev a lence among 16- to 24-year-old women en ter ing the National Job
Training Program by state of res i dence: United States and outlying areas, 2007
*Fewer than 100 women residing in these states/areas and entering the National Job Training
Program were screened for gonorrhea by the national contract laboratory in 2007.
Note: Many training centers test female students for gonorrhea using local laboratories; these
results are not available to CDC. For this map, gonorrhea test results for students at centers
submitting specimens to the national contract laboratory were included if the number of
gonorrhea tests submitted was greater than 90% of the number of chlamydia tests submitted.
SOURCE: National Job Training Program; Department of Labor (in collaboration with the Center for Disease Detection, San
Antonio, Texas)
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Fig ure  N. Gon or rhea — Prev a lence among 16- to 24-year-old men en ter ing the National Job
Training Program by state of res i dence: United States and outlying areas, 2007
*Fewer than 100 men residing in these states/areas and entering the National Job Training Program
were screened for gonorrhea by the national contract laboratory in 2007.
Note: Many training centers test male students for gonorrhea using local laboratories; these results
are not available to CDC. For this map, gonorrhea test results for students at centers submitting 
specimens to the national contract laboratory were included if the number of gonorrhea tests
submitted was greater than 90% of the number of chlamydia tests submitted.
SOURCE: National Job Training Program; Department of Labor (in collaboration with the Center for Disease Detection, San
Antonio, Texas)
STDs in Racial and Ethnic
Minorities
Public Health Impact
Surveillance data show higher rates of
reported STDs among some minority racial
or ethnic groups when compared with rates
among whites. Race and ethnicity in the
United States are risk markers that correlate
with other more fundamental determinants
of health status such as poverty, access to
quality health care, health care seeking
behavior, illicit drug use, and living in
communities with high prevalence of STDs.
Acknowledging the disparity in STD rates by 
race or ethnicity is one of the first steps in
empowering affected communities to
organize and focus on this problem.
STD Reporting Practices
Surveillance data are based on cases of
STDs reported to state and local health
departments (see Appendix). In many
areas, reporting from public sources, (for
example, STD clinics) is thought to be more
complete than reporting from private
sources. Since minority populations may
utilize public clinics more than whites,
differences in rates between minorities and
whites may be increased by this reporting
bias. However, prevalence data from
population-based surveys such as the
National Health and Nutrition Examination
Survey (NHANES) and the National
Longitudinal Study of Adolescent Health
(Add Health) confirm the existence of
marked STD disparities.1,2
Completeness of Race/Ethnicity Data
To adjust for missing case report data,
cases for which information is unknown
are redistributed according to the
distribution of cases in which race or
ethnicity is known. This process may
exacerbate any reporting bias.
Chlamydia — In 2007, 25.7% of reports
on chlamydia cases were missing race or
ethnicity (ranging by state from 0.0% to
55.5%) (Table A1).
Gonorrhea — In 2007, 20.3% of reports
on gonorrhea cases were missing
information on race or ethnicity (ranging
by state from 0.0% to 40.2%).
Syphilis — In 2007, only 4.1% of reports 
on syphilis cases were missing information
on race or ethnicity (ranging from 0.0% to
22.6% among states with 10 or more cases 
of P&S syphilis).
Observations
Chlamydia
All racial and ethnic groups except
American Indian/Alaska Natives reported
increases in chlamydia rates from 2006 to
2007 (Table 11B). From 2003 to 2007,
chlamydia rates increased by 24.6%
among blacks; 9.0% among American
Indian/Alaska Natives; 10.5% among
Hispanics; and 18.7% among whites. Over 
the same time period, rates decreased by
1.5% among Asian/Pacific Islanders.
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Blacks — In 2007, approximately 48% of
all chlamydia cases occurred among blacks
(Table 11A). Overall, the rate of chlamydia
among blacks in the United States was more 
than eight times that among whites. The rate 
of chlamydia among black women was
more than seven times higher than the rate
among white women (1,906.0 and 249.3
per 100,000 women, respectively) (Figure O,
Table 11B). The chlamydia rate among black
men was more than 11 times higher than that 
among white men (841.3 and 71.9 per
100,000 men, respectively).
American Indian/Alaska Natives — In
2007, the chlamydia rate among American
Indian/Alaska Natives was 732.9 cases per
100,000 population, a decrease of 7.2%
from the 2006 rate of 790.1. The chlamydia 
positivity rate among females aged 15–24
years screened in Indian Health Service
(IHS) clinics ranged from 8.1% in HHS
region V to 11.6% in region VIII (Figure P).
Asian/Pacific Islanders — In 2007, the
chlamydia rate among Asian/Pacific
Islanders was 139.5 cases per 100,000
population, a slight increase from the 2006
rate of 127.2.
Hispanics — In 2007, the chlamydia rate
among Hispanics was 473.2 cases per
100,000 population, nearly three times
higher than the rate among whites (162.3).
Gonorrhea
All racial and ethnic groups except blacks
saw declines in gonorrhea rates from 2006
to 2007. In contrast, the gonorrhea rate
among blacks increased by 1.8% from 2006 
to 2007 (Table 21B and Figure 21).
Blacks — In 2007, approximately 70% of
the total number of reported cases of
gonorrhea occurred among blacks (Table
21A). In 2007, the rate of gonorrhea among 
blacks was 662.9 cases per 100,000
population. Overall, the rate of gonorrhea
among blacks in the United States was 19
times greater than that among whites This
disparity is unchanged from recent years
(20 times higher in 2003) (Figure Q, Table
21B). This disparity was higher for black
men (26.1 times higher) than for black
women (14.9 times higher) (Figure R). The 
disparity in gonorrhea rates for blacks was
higher in the Midwest and Northeast (27.2
and 24.8 times higher, respectively) than in 
the South or the West (15.6 and 12.4
times higher, respectively) (Figure S).
In 2007, gonorrhea rates were highest for
blacks aged 15 to 19 and 20 to 24 years
among all racial, ethnic, and age
categories. Black women aged 15 to 19
years had a gonorrhea rate of 2,955.7
cases per 100,000 women. This rate was
14.7 times greater than the 2007 rate
among white women of similar age
(200.6). Black men in the 15- to
19-year-old age category had a 2007
gonorrhea rate of 1,537.8 cases per
100,000 men, which was 38.7 times
higher than the rate among 15- to
19-year-old white men of 39.7 per
100,000 men. Among those aged 20 to
24 years, the gonorrhea rate among
blacks was 16.5 times greater than that
among whites (2,618.3 and 158.8 cases
per 100,000 population, respectively)
(Table 21B).
American Indian/Alaska Natives — In
2007 the gonorrhea rate among American
Indian/Alaska Natives was 107.1 which
was 3.1 times higher than the rate among
whites. This disparity is similar to recent
years (3.1 times higher in 2003) (Figure Q, 
Table 21B). This disparity was higher for
American Indian/Alaska Native women
(3.4 times higher) than for American
Indian/Alaska Native men (2.6 times
higher) (Figure R). The disparity in
gonorrhea rates for American
Indian/Alaska Natives was higher in the
Northeast and the Midwest (3.9 and 3.3
times higher, respectively) than in the West 
or the South (2.9 and 2.6 times,
respectively) (Figure S).
72   STDs in Racial and Ethnic Minorities        Special Focus Profiles STD Sur veil lance 2007
Asian/Pacific Islanders — In 2007 the
gonorrhea rate among Asian/Pacific
Islanders was 18.8 cases per 100,000
population which was lower than the rate
among whites (Figure Q, Table 21B). This
difference is greater for Asian/Pacific
Islander women than for Asian/Pacific
Islander men (Figure R). Rates among
Asian/Pacific Islanders are consistently
lower than among whites in all four regions 
of the U.S. (Figure S).
Hispanics — In 2007, the gonorrhea rate
among Hispanics was 69.2 which was
higher than the rate among whites. This
disparity is similar to that in recent years
(Figure Q, Table 21B). This disparity was
higher for Hispanic men than for Hispanic
women (Figure R). The disparity in
gonorrhea rates for Hispanics was higher in
the Northeast than in the West, the Midwest, 
or the South (Figure S).
Primary and Secondary Syphilis
The syphilis epidemic in the late 1980s
occurred primarily among heterosexual and
minority populations.3,4 During the 1990s,
the rate of P&S syphilis declined among all
racial and ethnic groups (Figure 36).
Between 2003 and 2007, the rate of P&S
syphilis increased among all racial and
ethnic groups.
Blacks — Between 2006 and 2007, the rate
of P&S syphilis among blacks increased
25.0% (from 11.2 to 14.0). In 2007, 46.0% of
all cases of P&S syphilis reported to CDC
were among blacks and 35.3% of all cases
were among non-Hispanic whites (Table 33A). 
Compared to whites, the overall 2007 rate for
blacks was 7.0 times higher. It was 5.9 times
higher in 2006 (Table 33B). In 2007, the P&S
rate among black men was more than 6.0
times higher than that among white men;
the rate among black women was 14 times
higher than that among white women. In
some age groups, particularly 15–19 year
old black men, disparities have increased
markedly in recent years as rates of disease 
have increased (Figure V).
Recent trends in young black men are of
particular concern given data indicating
high HIV incidence in this population.5
American Indian/Alaska Natives —
Between 2006 and 2007, the rate of P&S
syphilis among American Indian/Alaska
Natives increased 6.3% (from 3.2 to 3.4).
In 2007, 0.7% of all cases of P&S syphilis
reported to CDC were among American
Indian/Alaska Natives (Table 33A).
Compared to whites, the 2007 rate for
American Indian/Alaska Natives was 1.7
times higher (Table 33B).
Asian/Pacific Islanders — Between
2006 and 2007, the rate of P&S syphilis
among Asian/Pacific Islanders remained
unchanged (1.2 per 100,000 population).
In 2007, 1.2% of all cases of P&S syphilis
reported to CDC were among Asian/Pacific 
Islanders (Table 33A). The 2007 rate for
Asian/Pacific Islanders was 0.6 times the
rate for whites (Table 33B).
Hispanics — Between 2006 and 2007,
the rate of P&S syphilis among Hispanics
increased 22.9% (from 3.5 to 4.3). In
2007, 16.5% of all cases of P&S syphilis
reported to CDC were among Hispanics
(Table 33A). Compared to whites, the
2007 rate for Hispanics was 2.2 times
higher (Table 33B).
Congenital Syphilis
In 2007, the rate of congenital syphilis
(based on the mother’s race/ethnicity) was
32.3 cases per 100,000 live births among
blacks and 15.3 cases per 100,000 live
births among Hispanics. These rates are 14 
and 6.6 times higher, respectively, than the 
2007 rate among whites (2.3 cases per
100,000 live births) (Figure W, Table 40). 
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841.3 1906.0Black
211.7 753.3Hispanic
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Fig ure  O. Chlamydia — Rates by race/eth nic ity and sex: United States, 2007
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Fig ure  P. Chlamydia — Positivity among 15- to 24-year-old women screened in Indian
Health Service (IHS) clinics by HHS region, 2007
*Chlamydia positivity data not available. See Appendix for definitions of HHS Regions.
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Fig ure  Q. Gonorrhea — Rate ratios* by race/ethnicity: United States, 1998–2007
*Rate ratios are calculated as the gonorrhea rate per 100,000 population for a given racial or
ethnic minority population divided by the gonorrhea rate per 100,000 population for 
non-Hispanic whites. Any population with a lower rate of gonorrhea than the non-Hispanic white 
population will have a rate ratio less than 1:1.
 
†Y-axis is log scale.
Men Rate (per 100,000 population) Women
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69.5 143.4AI/AN
17.9 19.7Asian/PI
694.6 634.0Black
64.3 74.5Hispanic
26.6 42.6White
113.9 123.8Total
Fig ure  R. Gonorrhea — Rates by race/ethnicity and sex: United States, 2007
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Fig ure  S. Gonorrhea — Rate ratios* by race/ethnicity and region: United States, 2007
*Rate ratios are calculated as the gonorrhea rate per 100,000 population for a given racial or
ethnic minority population divided by the gonorrhea rate per 100,000 population for 
non-Hispanic whites. Any population with a lower rate of gonorrhea than the non-Hispanic white 
population will have a rate ratio less than 1:1.
 
†Y-axis is log scale.
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Fig ure  T. Pri mary and sec ond ary syph i lis — Rates by race/ethnicity and sex: United
States, 2007
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Fig ure  U. Pri mary and sec ond ary syph i lis — Rates among 15- to 19-year-old females by
race/eth nic ity: United States, 1998–2007
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Fig ure  V. Pri mary and sec ond ary syph i lis — Rates among 15- to 19-year-old males by
race/eth nic ity: United States, 1998–2007
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Fig ure  W. Con gen i tal syph i lis — Rates among in fants < 1 year of age by mother’s
race/eth nic ity: United States, 1998–2007
Note: The Healthy People 2010 target for congenital syphilis is 1.0 case per 100,000 live births.
Less than 5% of cases had missing maternal race/ethnicity information and were excluded.

STDs in Men Who Have Sex with
Men
Public Health Impact
Notifiable disease surveillance data on
syphilis and data from the Gonococcal
Isolate Surveillance Project (GISP) suggest
that an increasing number of MSM are
acquiring STDs.1,23,45,67 Data also suggest that an
increasing number of MSM engage in sexual 
behaviors that place them at risk for STDs
and HIV infection.8 Several factors may be
contributing to this change, including the
availability of highly active antiretroviral
therapy (HAART) for HIV infection.9
Because STDs and the behaviors associated 
with acquiring them increase the likelihood
of acquiring and transmitting HIV
infection,10 the rise in STDs among MSM
may be associated with an increase in HIV
diagnoses among MSM.11
With the exception of reported syphilis
cases, most nationally notifiable STD
surveillance data do not include information 
regarding sexual behaviors; national trends
in STDs among MSM in the United States
are not currently available. Data from
enhanced surveillance projects are
presented in this section to provide
information regarding STDs in MSM.
Monitoring Trends in Prevalence of
STDs, HIV and Risk Behaviors
among Men Who Have Sex with Men 
(MSM Prevalence Monitoring
Project), STD Clinics, 1999–2007
From 1999 through 2007, eight U.S. cities
participating in the MSM Prevalence
Monitoring Project submitted syphilis,
gonorrhea, chlamydia, and HIV test data to
CDC from 143,478 MSM visits to STD
clinics; data from 121,353 MSM visits were 
submitted from five public STD clinics
(Denver, New York City, Philadelphia, San
Francisco, and Seattle) and data from
22,125 MSM visits were submitted from
three STD clinics in community-based, gay 
men’s health clinics (Chicago, the District
of Columbia, and Houston).
Changes in testing technology for
gonorrhea and chlamydia have occurred
in recent years with the advent of nucleic
acid amplification tests (NAATs) which
achieve greater sensitivity than traditional
culture methods.12,13 The MSM Prevalence
Monitoring Project includes data from
culture and non-culture tests collected
during routine care and reflects testing
practices at participating clinics. Tests for
gonorrhea included culture, NAATs, or
nucleic acid hybridization tests (DNA
probes). Tests for chlamydia included
culture, NAATs, DNA probes, or direct
fluorescent antibody tests (DFAs).
Nontreponemal syphilis tests included the
Rapid Plasma Reagin (RPR) test and the
Venereal Disease Research Laboratory
(VDRL) test.
All statistics were based on data collected
from clinic visits and may reflect multiple
visits by a patient rather than unique
individuals. City-specific medians and
ranges were calculated for the proportion
of tests done and for STD and HIV test
positivity.
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Gon or rhea 
Between 1999 and 2007 the number of
gonorrhea tests for all anatomic sites
combined increased in all eight cities. The
trend in the number of positive gonorrhea
tests for all anatomic sites varied by city.
For all cities, the number of positive
gonorrhea tests in symptomatic men
accounted for the majority of the overall
positive tests (Figure X).
In 2007, 79% (range: 58–90%) of MSM
were tested for urethral gonorrhea, 37%
(range: 5–51%) were tested for rectal
gonorrhea, and 58% (range: 5–83%) were
tested for pharyngeal gonorrhea. 
In 2007, median clinic urethral gonorrhea 
positivity in MSM was 8% (range:
5–15%), median rectal gonorrhea
positivity was 7% (range: 3–11%), and
median pharyngeal gonorrhea positivity
was 6% (range: 1–13%).
Chlamydia 
In 2007, a median of 79% (range: 59–90%)
of MSM visiting participating STD clinics
were tested for urethral chlamydia,
compared to 65% (range: 57–68%) in 1999. 
In 2007, the median urethral chlamydia
positivity was 7% (range: 5–9%).
Syph i lis 
In 2007, 79% (range: 60–96%) of MSM
visiting participating STD clinics had a
nontreponemal serologic test for syphilis
(RPR or VDRL) performed, compared with
69% (range: 53–93%) in 1999 (Figure Y).
Overall, median seroreactivity among MSM
tested for syphilis increased from 4% (range: 
3–13%) in 1999 to 8% (range: 4–18%) in
2007.
Syphilis seroreactivity is used as a proxy for  
syphilis prevalence and has been correlated
with prevalence of P&S syphilis in this
population.14
HIV In fec tion 
Overall, the percent of MSM tested for HIV 
in STD clinics increased between 1999 and 
2007. In 2007, a median of 70% (range:
38–87%) of MSM visiting STD clinics who
were not previously known to be
HIV-positive were tested for HIV, while
44% (range: 23–55%) were tested in 1999. 
In 2007, median HIV positivity in MSM
was 4% (range: 2–5%) (Figure Z). 
In 2007, median HIV prevalence among
MSM, including persons previously known
to be HIV-positive and persons testing
HIV-positive at their current visit, was 13% 
(range: 7–15%).
HIV/STDs by Race/Eth nic ity 
HIV positivity among persons tested for
HIV during 2007 varied by race/ethnicity,
but was highest in black MSM. HIV
positivity was 2% (range: 2–3%) in whites,
8% (range: 2–10%) in blacks, and 5%
(range: 2–7%) in Hispanics (Figure AA).
HIV positivity was 9% (range: 6–15%) in
whites, 17% (range: 15–24%) in blacks,
and 14% (range: 6–16%) in Hispanics.
In 2007, urethral gonorrhea positivity was
6% (range: 5–14%) in whites, 15% (range: 
7–27) in blacks, and 6% (range: 4–14%) in 
Hispanics. Rectal gonorrhea positivity was
6% (range: 2–10%) in whites, 7%
(range: 2–11%) in blacks, and 5%
(range: 1–7%) in Hispanics. Pharyngeal
gonorrhea positivity was 6% (range:
1–15%) in whites, 6% (range: 1–13%) in 
blacks, and 5% (range: 1–10%) in
Hispanics (Figure AA).
Urethral chlamydia positivity was 6%
(range: 3–8%) in whites; 8% (range:
5–10%) in blacks, and 5% (range: 3–13%) 
in Hispanics (Figure AA). 
Median syphilis seroreactivity was 7%
(range: 4–12%) in whites; 14% (range:
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8–30%) in blacks, and 11% (range: 3–22%)
in Hispanics (Figure AA).
STDs by HIV Sta tus, STD Clin ics 
In 2007, urethral gonorrhea positivity was
11% (range: 8–16%) in HIV-positive MSM
and 7% (range: 5–15%) in MSM who were
HIV-negative or of unknown HIV status;
rectal gonorrhea positivity was 10% (range:
4–14%) in HIV-positive MSM and 4%
(range: 3–10%) in MSM who were
HIV-negative or of unknown HIV status;
pharyngeal gonorrhea positivity was 4%
(range: 2–12%) in HIV-positive MSM and
5% (range: 1–13%) in MSM who were
HIV-negative or of unknown HIV status.
Median urethral chlamydia positivity was
6% (range: 3–12%) in HIV-positive MSM
and 7% (range: 4–9%) in MSM who were
HIV-negative or of unknown HIV status.
Median syphilis seroreactivity was 32%
(range: 19–42%) in HIV-positive MSM and
6% (range: 3–13%) in MSM who were
HIV-negative or of unknown HIV status.
Nationally Notifiable Syphilis
Surveillance Data
P&S syphilis increased in the United States
between 2003 and 2007, with a 64.0%
increase in the number of P&S syphilis cases 
among men and a 39.0% increase in the
number of cases among women (Tables 26
and 27). In 2007, the rate of reported P&S
syphilis among men (6.6 cases per 100,000
males) was 6.0 times greater than the rate
among women (1.1 case per 100,000
females) (Tables 26 and 27). Higher rates
in men are observed for all racial and
ethnic groups.
In 2007, MSM accounted for 65% of P&S
syphilis cases in the United States. MSM
account for more cases than heterosexual
men or women for all racial and ethnic
groups. (Figure 38) Additional information
on syphilis can be found in the Syphilis
section (National Profile).
Gonococcal Isolate Surveillance
Project (GISP)
GISP is a national sentinel surveillance
system designed to monitor trends in
antimicrobial susceptibilities of strains of
Neisseria gonorrhoeae in the United
States.15,16
GISP also reports the percentage of N.
gonorrhoeae isolates obtained from MSM.
Overall, the proportion of isolates from
MSM in selected STD clinics from GISP
sentinel sites have increased steadily from
4% in 1988 to 22.4% in 2007 (Figure BB). 
Additionally, the proportion of isolates
coming from MSM varies geographically
with the largest percentage from the West
Coast (Figure CC).
Additional information on GISP may be
found in the Gonorrhea section (National 
Profile).
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Figure  X. MSM Prevalence Monitoring Project — Number of gonorrhea tests and number
of positive tests in men who have sex with men, STD clinics, 1999–2007 
*Data not reported in 2006 or 2007.
Note: The bars represent the number of total GC tests considering all anatomic sites (pharyngeal, 
rectal, and urethral) each year. The scales on the left and right axis differ. The bar graphs
use the scale on the left. The line graphs use the scale on the right.
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Figure  Y. MSM Prevalence Monitoring Project — Syphilis serologic reactivity among men
who have sex with men, STD clinics, 1999–2007
*Data not reported in 2006 or 2007. Titer data not reported in 2004 or 2005.
Note: Seroreactivity was based on nontreponemal tests results. All sites used the Rapid Plasma
Reagin (RPR) test, with the exception of San Francisco where the Venereal Disease
Research Laboratory (VDRL) test was used and Seattle where the type of test was
changed from VDRL to RPR in 2004.
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Fig ure  Z. MSM Prevalence Monitoring Project — City-specific median number of HIV tests 
and positivity among men who have sex with men, STD clinics, 1999–2007
*Excludes persons previously known to be HIV-positive.
Note: The bar graph uses the scale on the left. The line graph uses the scale on the right.
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with men, by race/ethnicity, STD clinics, 2007
*Excludes persons previously known to be HIV-positive.
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Fig ure BB. Gono coc cal Iso late Sur veil lance Pro ject (GISP)  — Per cent of urethral
Neisseria gonorrhoeae isolates obtained from men who have sex with men
attending STD clin ics, 1988–2007
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Fig ure CC. Gono coc cal Iso late Sur veil lance Pro ject (GISP)  — Per cent of urethral
Neisseria gonorrhoeae isolates obtained from men who have sex with men
attending STD clin ics by GISP site, 2004–2007
Note: Not all sites participated in GISP for the last 4 years. Sites include: ALB=Albuquerque, NM;  ATL=Atlanta, GA; BAL=Baltimore,
MD; BHM=Birmingham, AL; CHI=Chicago, IL; CIN=Cincinnati, OH; CLE=Cleveland, OH; DAL=Dallas, TX; DEN=Denver, CO;
DTR=Detroit, MI; GRB=Greensboro, NC; HON=Honolulu, HI; KCY=Kansas City, MO; LAX=Los Angeles, CA; LBC=Long Beach,
CA; LVG=Las Vegas, NV; MIA=Miami, FL; MIN=Minneapolis, MN;  NOR=New Orleans, LA; NYC=New York City, NY;
OKC=Oklahoma City, OK; ORA=Orange County, CA; PHI=Philadelphia, PA; PHX=Phoenix, AZ; POR=Portland, OR;
RIC=Richmond, VA; SDG=San Diego, CA; SEA=Seattle, WA; SFO=San Francisco, CA; and TRP=Tripler Army Medical Center, HI 
(does not provide sexual risk behavior data).
STDs in Persons Entering
Corrections Facilities 
Public Health Impact
Multiple studies and surveillance projects
have demonstrated a high prevalence of
STDs in persons entering jails and juvenile
corrections facilities.1,2,3,4 Prevalence rates for
chlamydia and gonorrhea in these settings
are consistently among the highest observed 
in any venue.4 Screening for chlamydia,
gonorrhea, and syphilis at intake offers an
opportunity to identify infections, prevent
complications, and reduce transmission in
the general community. For example, data
from one study in a locale with high syphilis
incidence suggested that screening and
treatment of women inmates for syphilis
may result in reduction of syphilis in the
general community.5 In some locations, a
substantial proportion of all early syphilis
cases are reported from corrections
facilities.6 
Description of Population 
In 2007, STD screening data from
corrections facilities were reported from 37
states and Puerto Rico for chlamydia, 33
states and Puerto Rico for gonorrhea, and
19 states for syphilis. The Infertility
Prevention Project (IPP) provided CDC with 
line-listed data for chlamydia and
gonorrhea. Aggregate syphilis data were
reported to CDC by local and state STD
prevention programs.
The figures and tables shown in this section
represent 47,042 chlamydia tests in women
and 115,014 in men; 37,243 gonorrhea
tests in women and 97,666 in men; and
50,666 syphilis serologic tests in women and 
200,064 in men entering corrections
facilities during 2007. 
Chlamydia 
Overall, chlamydia positivity was higher in
women than in men for all age groups. 
Adolescent Men — In adolescent men
entering 109 juvenile corrections facilities
in 2007, the median chlamydia positivity
by facility was 5.7% (range: 0.0% to
14.2%) (Table A). In men 12 to 18 years of 
age entering these facilities, the overall
chlamydia positivity was 6.4% (Figure
DD). Chlamydia positivity increased from
1.4% for adolescent men aged 12 years to
9.1% for those aged 18 years. 
Adolescent Women — In adolescent
women entering 73 juvenile corrections
facilities in 2007, median chlamydia
positivity by facility was 14.3% (range:
2.5% to 32.1%); positivity was greater
than 10% in almost all facilities reporting
data (Table A). In women 12 to18 years of
age entering these facilities, the overall
chlamydia positivity was 14.8% (Figure
DD). Positivity in women increased from
6.8% for those aged 12 years to 15.7% for 
those aged 14 years and, then remained
high for women aged 15 to 18 years. 
Men — In men entering 51 adult
corrections facilities in 2007, the median
chlamydia positivity by facility was 7.7%
(range: 0.5% to 25.3%) (Table D).
Positivity in young adult men aged less
than 25 years in these facilities (8.7%) was
higher than the overall prevalence
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observed in adolescent men entering
juvenile facilities (6.4%) (Figure EE).
Chlamydia positivity decreased with age
from 8.7% for those younger than 25 years
of age to 1.8% for those older than 34
years. Overall positivity among adult men
entering corrections facilities in 2007 was
6.2% 
Women — In women entering 37 adult
corrections facilities in 2007, median
positivity for chlamydia by facility was 6.4%
(range: 0.0% to 21.0%) (Table B). Overall,
in women entering these facilities, the
chlamydia positivity was 9.7% (Figure EE).
Chlamydia positivity decreased with age
from 18.6% for those younger than 20 years 
to 3.5% for those older than 34 years.
Overall chlamydia positivity in women
entering adult corrections facilities (9.7%)
was significantly lower than that in
adolescent women entering juvenile
corrections facilities (14.8%). However,
chlamydia positivity in women younger than 
20 years of age attending adult corrections
facilities was higher than that in women
attending juvenile corrections facilities.
Gonorrhea 
Overall, gonorrhea positivity in women was
uniformly higher than in men for all age
groups.
Adolescent Men — The median positivity
for gonorrhea by facility in adolescent men
entering 90 juvenile corrections facilities in
2007 was 1.0% (range: 0.0% to 4.5%)
(Table C). The overall positivity was 1.2% in 
men 12 to 18 years of age attending these
facilities. (Figure FF). Gonorrhea positivity
increased with age from 0.1% for those
aged 12 years to 2.1% for those aged 18
years.
Adolescent Women — The median
positivity for gonorrhea by facility in women 
entering 52 juvenile corrections facilities in
2007 was 5.3% (range: 0.0% to 13.9%)
(Table C). In women 12 to18 years of age
entering these, the overall gonorrhea
positivity was 5.6% (Figure FF). In 2007,
gonorrhea positivity increased with age
from 1.8% among 12-year-olds to 7.1%
among young women aged 18 years of
age. 
Men — In men entering 42 adult
corrections facilities in 2007, the median
gonorrhea positivity was 1.7% (range:
0.0% to 10.7%) (Table D). Overall
gonorrhea positivity for men attending
these facilities was 1.6% (Figure GG).
Gonorrhea positivity was highest in men
aged 20 to 24 years at 2.2%, declining
with age to 0.9% in men older than 34
years. Men aged younger than 20 years
attending adult facilities had higher
gonorrhea positivity than men attending
juvenile detention facilities. 
Women — In women entering 31 adult
corrections facilities in 2007, the median
gonorrhea positivity by facility was 2.9%
(range: 0.0% to 7.3%) (Table D). Overall,
in women entering these facilities, the
gonorrhea positivity was 3.7% (Figure
GG). Gonorrhea positivity decreased with
age from 6.5% for those younger than 20
years to 1.5% for those older than 34
years. Women younger than 20 years
attending adult facilities had higher
gonorrhea positivity than young women
attending juvenile detention facilities.
Syphilis
Adolescent Men — In 2007, the median
syphilis serologic positivity by facility was
0.1% (range: 0.0% to 0.9%) in adolescent
men entering eight juvenile corrections
facilities (Table E).
Adolescent Women — In 2007, the
median syphilis serologic positivity by
facility was 0.2% (range: 0.0% to 2.1%) in
adolescent women entering five juvenile
corrections facilities (Table E). 
Men — In men entering 60 adult
corrections facilities in 2007, the median
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syphilis serologic positivity by facility was
1.0% (range: 0.0% to 47.0%) (Table F). 
Women — In women entering 36 adult
corrections facilities in 2007, the median
serologic positivity by facility was 2.1%
(range: 0.0% to 28.0%) (Table F).
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Men Positivity Women
Age20 16 12 8 4 0 0 4 8 12 16 20
1.4 6.812
1.4 9.613
3.1 15.714
5.5 14.815
7.3 15.216
8.0 15.217
9.1 16.818
6.4 14.8Total
Fig ure DD. Chlamydia — Positivity by age and sex, juvenile cor rec tions fa cil i ties, 2007
Note: Percent positivity is presented from facilities reporting > 100 test results.
Men Positivity Women
Age20 16 12 8 4 0 0 4 8 12 16 20
8.7 18.6<20
8.7 13.620-24
5.5 9.725-29
5.6 7.130-34
1.8 3.5>=35
6.2 9.7Total
Fig ure EE. Chlamydia — Positivity by age group and sex, adult cor rec tions fa cil i ties, 2007
Note: Percent positivity is presented from facilities reporting > 100 test results.
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Men Positivity Women
Age20 16 12 8 4 0 0 4 8 12 16 20
0.1 1.812
0.4 3.613
0.5 5.214
0.9 5.715
1.4 5.716
1.7 6.217
2.1 7.118
1.2 5.6Total
Fig ure FF. Gon or rhea — Positivity by age and sex, ju ve nile cor rec tions fa cil i ties, 2007
Note: Percent positivity is presented from facilities reporting > 100 test results.
Men Positivity Women
Age20 16 12 8 4 0 0 4 8 12 16 20
2.1 6.5<20
2.2 4.420-24
1.5 3.825-29
1.1 3.730-34
0.9 1.5>=35
1.6 3.7Total
Fig ure GG. Gon or rhea — Positivity by age group and sex, adult cor rec tions fa cil i ties, 2007
Note: Percent positivity is presented from facilities reporting > 100 test results.
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Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)        
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)        
Alabama – – – 1 119 16.0
Arizona 6 5,375 5.4 (2.4-8.4) 5 1,503 16.1 (3.2-20.8)
California* 18 24,033 4.9 (0.0-10.6) 22 11,007 11.1 (2.5-27.0)
Colorado 1 236 7.6 – – –
Connecticut 2 726 3.2 (2.6-3.8) 2 257 11.3 (10.9-11.6)
Georgia 15 5,787 6.2 (1.7-11.0) 11 2,101 20.0 (13.5-27.7)
Hawaii 1 147 8.8 – – –
Idaho – – – 1 208 11.5
Illinois 5 4,705 7.8 (6.5-10.9) 1 396 17.9
Indiana 1 979 10.1 1 237 21.1
Kentucky 7 2,152 4.9 (2.3-9.8) 1 176 12.5
Maryland 4 1,731 5.9 (2.7-7.5) 2 408 15.1 (14.3-15.9)
Massachusetts 1 412 2.2 – – –
Michigan 8 5,096 10.1 (6.2-13.9) 4 1,378 17.0 (10.3-19.7)
Minnesota 1 306 11.8 – – –
Mississippi 1 465 9.0 1 106 15.1
Missouri 1 449 6.9 – – –
Nebraska 1 368 6.3 1 193 12.4
Nevada 2 1,388 8.9 (3.7-14.2) 2 278 23.0 (13.9-32.1)
New Jersey 3 2,786 7.9 (6.6-11.4) 1 169 18.3
New Mexico 2 638 5.7 (4.1-7.2) – – –
New York 7 4,616 4.2 (2.6-6.1) 5 1,086 14.6 (12.1-15.7)
North Dakota 1 132 6.8 – – –
Ohio 5 6,216 8.2 (5.0-11.2) 3 1,314 18.8 (7.6-20.4)
Oregon 3 1,442 4.5 (3.3-8.6) 3 423 7.6 (6.5-19.5)
Pennsylvania 1 127 3.1 – – –
Puerto Rico 2 354 4.1 (3.5-4.7) 1 107 20.6
Tennessee 1 1,911 4.3 1 825 12.4
Texas 1 832 9.4 1 199 16.6
Virginia 1 729 8.1 – – –
Washington 5 1,030 5.0 (2.7-13.4) 3 907 12.4 (3.5-21.0)
Wisconsin 2 576 5.6 (4.5-6.8) – – –
Total 109 75,744 5.7 (0.0-14.2) 73 23,397 14.3 (2.5-32.1)
Table A. Chlamydia — Po sitivity among men and women in juvenile corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results.
*Includes Los Angeles and San Francisco project areas.
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Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)        
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)         
Arizona 3 874 13.9 (11.5-15.7) 2 1,474 9.9 (4.7-15.2)
California* 5 4,338 4.2 (2.9-5.8) 4 9,316 11.2 (5.3-15.6)
Delaware 1 679 4.1 2 1,008 7.8 (5.1-10.4)
Hawaii – – – 2 288 12.3 (6.4-18.3)
Illinois 6 2,621 10.5 (5.9-14.8) 3 2,903 5.1 (3.3-5.7)
Indiana 1 1,209 6.7 2 1,433 10.1 (10.1-10.2)
Iowa 2 768 13.8 (8.1-19.4) 1 435 5.1
Maryland 1 633 6.0 – – –
Massachusetts 2 3,601 4.7 (4.7-4.8) 2 911 4.0 (3.6-4.3)
Michigan 1 154 25.3 1 240 10.4
Missouri 1 3,018 5.8 1 570 4.6
Montana – – – 1 106 0.0
Nebraska 4 1,585 8.2 (6.2-19.9) 1 225 11.6
Nevada 1 294 9.5 1 182 8.8
New Mexico 1 130 10.8 1 478 10.5
New York 2 7,054 7.0 (3.7-10.3) 1 249 5.2
North Dakota 1 469 5.5 1 101 5.9
Oregon 2 233 20.4 (18.4-22.3) 1 169 7.7
Pennsylvania 3 2,210 7.7 (4.3-10.3) 3 610 5.4 (4.9-6.9)
South Carolina 2 1,101 8.6 (7.9-9.3) 1 145 8.3
Texas 3 2,264 7.1 (0.5-16.6) 2 942 19.1 (17.3-21.0)
Utah 1 110 9.1 1 171 11.7
Washington – – – 1 801 6.1
West Virginia 4 1,510 2.9 (0.5-5.1) 1 151 0.7
Wisconsin 4 4,415 9.0 (5.6-13.5) 1 737 2.0
Total 51 39,270 7.7 (0.5-25.3) 37 23,645 6.4 (0.0-21.0)
Table B. Chlamydia — Po sitivity among men and women in adult corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results.
*Includes Los Angeles and San Francisco project areas.
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Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
Alabama – – – 1 120 10.8
Arizona 6 5,373 0.9 (0.0-1.4) 5 1,503 3.8 (0.9-5.6)
California* 6 16,309 0.5 (0.0-1.2) 6 4,426 4.2 (0.8-5.9)
Colorado 1 236 1.7 – – –
Connecticut 2 724 0.5 (0.0-1.1) 2 258 4.1 (1.7-6.5)
Georgia 15 5,781 1.8 (0.0-4.5) 11 2,098 8.3 (1.8-13.9)
Hawaii 1 147 0.0 – – –
Idaho – – – 1 208 0.0
Illinois 5 4,708 1.0 (0.0-2.3) 1 398 8.8
Indiana 1 979 3.8 1 237 7.2
Kentucky 7 2,151 1.2 (0.5-2.5) 1 176 3.4
Maryland 4 1,731 0.8 (0.0-1.1) 2 408 4.7 (4.7-4.7)
Michigan 8 4,979 1.9 (0.4-2.9) 4 1,353 6.7 (1.7-7.3)
Minnesota 1 307 4.2 – – –
Mississippi 1 464 1.1 1 106 5.7
Missouri 1 449 2.9 – – –
Nebraska 1 368 2.4 1 193 5.2
Nevada 2 1,389 0.8 (0.5-1.0) 2 278 2.7 (0.8-4.5)
New Jersey 3 2,787 2.0 (0.4-2.2) 1 169 5.3
New Mexico 2 638 0.3 (0.0-0.7) – – –
New York 6 4,085 0.5 (0.0-1.0) 4 962 3.4 (1.7-6.7)
Ohio 5 6,215 1.7 (0.0-1.8) 3 1,314 6.5 (3.5-6.6)
Pennsylvania 1 127 0.0 – – –
Puerto Rico 2 354 0.0 1 107 1.9
Tennessee 1 1,913 0.7 1 828 4.0
Texas 1 832 1.6 1 199 8.0
Virginia 1 729 0.5 – – –
Washington 4 649 0.0 (0.0-2.2) 2 723 5.8 (4.5-7.1)
Wisconsin 2 572 0.6 (0.0-1.3) – – –
Total 90 64,996 1.0 (0.0-4.5) 52 16,064 5.3 (0.0-13.9)
Table C. Gon or rhea — Po sitivity among men and women in juvenile corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results. *Includes Los Angeles and San Francisco project areas.
Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
Arizona 3 873 10.7 (9.6-10.7) 2 1,475 5.8 (5.3-6.2)
California* 5 4,340 1.2 (0.4-2.2) 4 9,310 4.2 (2.5-5.4)
Delaware 1 679 1.2 2 1,008 3.6 (2.9-4.3)
Hawaii – – – 2 290 3.3 (0.6-6.1)
Illinois 7 2,634 2.9 (0.6-5.5) 3 2,397 1.6 (1.6-2.9)
Indiana 1 1,209 2.7 2 1,433 7.1 (6.8-7.3)
Iowa 2 768 4.4 (0.8-7.9) 1 435 0.7 
Maryland 1 633 0.9 – – –
Michigan 1 154 7.1 1 240 2.9 
Missouri 1 3,020 1.2 1 570 1.9 
Montana – – – 1 106 0.0 
Nebraska 4 1,585 0.9 (0.0-8.2) 1 225 5.3 
Nevada 1 294 2.7 1 182 2.7 
New Mexico 1 131 2.3 1 477 2.1 
New York 1 6,373 0.5 – – –
Pennsylvania 3 2,210 1.7 (0.5-2.8) 3 610 2.4 (1.3-4.0)
South Carolina 2 991 1.7 (0.8-2.7) 1 133 4.5 
Texas 3 2,263 1.6 (0.0-5.1) 2 943 5.9 (5.3-6.6)
Utah 1 110 1.8 1 170 0.6 
Washington – – – 1 467 1.7 
Wisconsin 4 4,403 2.3 (0.7-6.1) 1 708 0.1 
Total 42 32,670 1.7 (0.0-10.7) 31 21,179 2.9 (0.0-7.3)
Table D. Gon or rhea — Po sitivity among men and women in adult corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results. *Includes Los Angeles and San Francisco project areas.
STD Surveillance 2007 Special Focus Profiles STDs in Persons Entering Corrections Facilities  97
Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
Arizona 2 2,345 0.3 (0.1-0.5) 1 478 0.2
Illinois 1 796 0.9 1 142 2.1
Mississippi 1 141 0.0 – – –
North Carolina 1 354 0.0 – – –
Texas 3 2,653 0.1 (0.0-0.8) 3 1,036 0.2 (0.0-1.6)
Total 8 6,289 0.1 (0.0-0.9) 5 1,656 0.2 (0.0-2.1)
Table E. Syphilis— Po sitivity among men and women in juvenile corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results. 
Men Women
State                                   
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
No. of  
Facilities
No. of
Tests
Median % Positivity
(Range)          
Arizona 1 27,629 2.0 1 6,310 4.3
Connecticut – – – 1 3,108 2.0
Illinois 3 575 0.7 (0.0-1.4) 1 111 3.6
Indiana 1 1,120 0.4 1 1,284 1.4
Kentucky 1 324 0.3 1 332 0.3
Louisiana – – – 1 1,003 28.0
Maryland 12 37,183 0.8 (0.3-3.7) 6 8,821 3.4 (0.8-8.5)
Massachusetts 16 17,546 1.1 (0.0-3.0) 4 3,883 0.9 (0.5-1.2)
Michigan 1 8,638 1.5 1 736 4.9
Mississippi 3 1,678 7.2 (4.0-12.6) – – –
Missouri 3 6,103 1.8 (1.1-47.0) 2 956 2.5 (1.1-4.0)
New Jersey 3 31,007 1.8 (0.7-3.8) 3 3,762 0.0 (0.0-8.9)
New York* 2 8,782 1.7 (1.1-2.4) 2 1,802 4.0 (2.3-5.7)
North Carolina 6 4,908 0.7 (0.0-0.8) 5 1,418 1.8 (0.0-3.5)
Oklahoma 1 1,402 0.0 1 2,019 0.0
Tennessee 1 8,027 3.3 1 5,322 9.4
Texas 4 31,096 3.0 (0.5-6.0) 4 6,643 7.7 (4.7-12.6)
Washington 1 7,270 4.0 1 1,500 0.0
Wisconsin 1 487 0.6 – – –
Total 60 193,775 1.0 (0.0-47.0) 36 49,010 2.1 (0.0-28.0)
Table F. Syphilis— Po sitivity among men and women in adult corrections facilities, 2007
Note: The percent positivity by facility is presented from facilities reporting > 100 test results.
*New York data is for confirmatory results.

SEL
B
AT
SEL
B
AT
STD Surveillance 2007   National Summary Tables  99
Syphilis
All Stages
Primary
and
Secondary
Early
Latent
Late and
Late Latent† Congenital‡ Chlamydia Gonorrhea
  
Chancroid
Year* Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate§ Cases Rate Cases Rate Cases Rate
1941 485,560 368.2 68,231 51.7 109,018 82.6 202,984 153.9 17,600 651.1 NR . 193,468 146.7 3,384 2.5
1942 479,601 363.4 75,312 57.0 116,245 88.0 202,064 153.1 16,918 566.0 NR . 212,403 160.9 5,477 4.1
1943 575,593 447.0 82,204 63.8 149,390 116.0 251,958 195.7 16,164 520.7 NR . 275,070 213.6 8,354 6.4
1944 467,755 367.9 78,443 61.6 123,038 96.7 202,848 159.6 13,578 462.0 NR . 300,676 236.5 7,878 6.1
1945 359,114 282.3 77,007 60.5 101,719 79.9 142,187 111.8 12,339 431.7 NR . 287,181 225.8 5,515 4.3
1946 363,647 271.7 94,957 70.9 107,924 80.6 125,248 93.6 12,106 354.9 NR . 368,020 275.0 7,091 5.2
1947 355,592 252.3 93,545 66.4 104,124 73.9 122,089 86.6 12,200 319.6 NR . 380,666 270.0 9,515 6.7
1948 314,313 218.2 68,174 47.3 90,598 62.9 123,312 85.6 13,931 383.0 NR . 345,501 239.8 7,661 5.3
1949 256,463 175.3 41,942 28.7 75,045 51.3 116,397 79.5 13,952 382.4 NR . 317,950 217.3 6,707 4.6
1950 217,558 146.0 23,939 16.7 59,256 39.7 113,569 70.2 13,377 368.3 NR . 286,746 192.5 4,977 3.3
1951 174,924 116.1 14,485 9.6 43,316 28.7 98,311 65.2 11,094 290.4 NR . 254,470 168.9 4,233 2.8
1952 167,762 110.2 10,449 6.9 36,454 24.0 105,238 69.1 8,553 218.8 NR . 244,957 160.8 3,738 2.5
1953 148,573 95.9 8,637 5.6 28,295 18.3 98,870 63.8 7,675 193.9 NR . 238,340 153.9 3,338 2.2
1954 130,687 82.9 7,147 4.5 23,861 15.1 89,123 56.5 6,676 164.0 NR . 242,050 153.5 3,003 1.9
1955 122,392 76.2 6,454 4.0 20,054 12.5 86,526 53.8 5,354 130.7 NR . 236,197 147.0 2,649 1.7
1956 130,201 78.7 6,392 3.9 19,783 12.0 95,097 57.5 5,491 130.4 NR . 224,346 135.7 2,135 1.3
1957 123,758 73.5 6,576 3.9 17,796 10.6 91,309 54.2 5,288 123.0 NR . 214,496 127.4 1,637 1.0
1958 113,884 66.4 7,176 4.2 16,556 9.7 83,027 48.4 4,866 114.6 NR . 232,386 135.6 1,595 0.9
1959 120,824 69.2 9,799 5.6 17,025 9.8 86,740 49.7 5,130 119.7 NR . 240,254 137.6 1,537 0.9
1960 122,538 68.8 16,145 9.1 18,017 10.1 81,798 45.9 4,416 103.7 NR . 258,933 145.4 1,680 0.9
1961 124,658 68.8 19,851 11.0 19,486 10.8 79,304 43.8 4,163 97.5 NR . 264,158 145.8 1,438 0.8
1962 126,245 68.7 21,067 11.5 19,585 10.7 79,533 43.3 4,070 97.7 NR . 263,714 143.6 1,344 0.7
1963 124,137 66.5 22,251 11.9 18,235 9.8 78,076 41.8 4,031 98.4 NR . 278,289 149.0 1,220 0.7
1964 114,325 60.4 22,969 12.1 17,781 9.4 68,629 36.3 3,516 87.3 NR . 300,666 158.9 1,247 0.7
1965 112,842 58.9 23,338 12.2 17,458 9.1 67,317 35.1 3,564 94.8 NR . 324,925 169.5 982 0.5
1966 105,159 54.2 21,414 11.0 15,950 8.2 63,541 32.7 3,170 87.9 NR . 351,738 181.2 838 0.4
1967 102,581 52.2 21,053 10.7 15,554 7.9 61,975 31.5 2,894 82.2 NR . 404,836 205.9 784 0.4
1968 96,271 48.4 19,019 9.6 15,150 7.6 58,564 29.4 2,381 68.0 NR . 464,543 233.4 845 0.4
1969 92,162 45.7 19,130 9.5 15,402 7.6 54,587 27.1 2,074 57.6 NR . 534,872 265.4 1,104 0.5
1970 91,382 44.8 21,982 10.8 16,311 8.0 50,348 24.7 1,953 52.3 NR . 600,072 294.2 1,416 0.7
1971 95,997 46.4 23,783 11.5 19,417 9.4 49,993 24.2 2,052 57.7 NR . 670,268 324.1 1,320 0.6
1972 91,149 43.6 24,429 11.7 20,784 9.9 43,456 20.8 1,758 54.0 NR . 767,215 366.6 1,414 0.7
1973 87,469 41.4 24,825 11.7 23,584 11.2 37,054 17.5 1,527 48.7 NR . 842,621 398.7 1,165 0.6
1974 83,771 39.3 25,385 11.9 25,124 11.8 31,854 14.9 1,138 36.0 NR . 906,121 424.7 945 0.4
1975 80,356 37.3 25,561 11.9 26,569 12.3 27,096 12.6 916 29.1 NR . 999,937 464.1 700 0.3
1976 71,761 33.0 23,731 10.9 25,363 11.7 21,905 10.1 626 19.8 NR . 1,001,994 460.6 628 0.3
1977 64,621 29.4 20,399 9.3 21,329 9.7 22,313 10.2 463 13.9 NR . 1,002,219 456.0 455 0.2
1978 64,875 29.2 21,656 9.8 19,628 8.8 23,038 10.4 434 13.0 NR . 1,013,436 456.3 521 0.2
1979 67,049 29.9 24,874 11.1 20,459 9.1 21,301 9.5 332 9.5 NR . 1,004,058 447.1 840 0.4
1980 68,832 30.3 27,204 12.0 20,297 8.9 20,979 9.2 277 7.7 NR . 1,004,029 442.1 788 0.3
1981 72,799 31.7 31,266 13.6 21,033 9.2 20,168 8.8 287 7.9 NR . 990,864 431.8 850 0.4
1982 75,579 32.6 33,613 14.5 21,894 9.5 19,799 8.5 259 7.0 NR . 960,633 414.7 1,392 0.6
1983 74,637 31.9 32,698 14.0 23,738 10.2 17,896 7.7 239 6.6 NR . 900,435 385.1 847 0.4
1984 69,872 29.6 28,607 12.1 23,131 9.8 17,829 7.6 305 8.3 7,594 6.5 878,556 372.5 665 0.3
1985 67,563 28.4 27,131 11.4 21,689 9.1 18,414 7.7 329 8.7 25,848 17.4 911,419 383.0 2,067 0.9
Table 1. Cases of sexually transmitted diseases reported by state health departments and rates per 100,000
population: United  States, 1941–2007 
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Syphilis
All Stages
Primary
and
Secondary
Early
Latent
Late and
Late Latent† Congenital‡ Chlamydia Gonorrhea
  
Chancroid
Year* Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate§ Cases Rate Cases Rate Cases Rate
1986 67,779 28.2 27,667 11.5 21,656 9.0 18,046 7.5 410 10.9 58,001 35.2 892,229 371.5 3,045 1.3
1987 87,286 36.0 35,585 14.7 28,233 11.7 22,988 9.5 480 12.6 91,913 50.8 787,532 325.0 4,986 2.1
1988 104,546 42.8 40,474 16.6 35,968 14.7 27,363 11.2 741 19.0 157,854 87.1 738,160 301.9 4,891 2.0
1989 115,089 46.6 45,826 18.6 45,394 18.4 22,032 8.9 1,837 45.5 200,904 102.5 733,294 297.1 4,697 1.9
1990 135,590 54.3 50,578 20.3 55,397 22.2 25,750 10.3 3,865 92.9 323,663 160.2 690,042 276.4 4,212 1.7
1991 128,719 50.9 42,950 17.0 53,855 21.3 27,490 10.9 4,424 107.6 381,228 179.7 621,918 245.8 3,476 1.4
1992 114,730 44.7 34,009 13.3 49,929 19.5 26,725 10.4 4,067 100.0 409,694 182.3 502,858 196.0 1,906 0.7
1993 102,612 39.5 26,527 10.2 41,919 16.1 30,746 11.8 3,420 85.5 405,332 178.0 444,649 171.1 1,292 0.5
1994 82,713 31.4 20,641 7.8 32,017 12.2 27,603 10.5 2,452 62.0 451,785 192.5 419,602 163.9 782 0.3
1995 69,359 26.0 16,543 6.2 26,657 10.0 24,296 9.1 1,863 47.8 478,577 187.8 392,651 147.5 607 0.2
1996 53,240 19.8 11,405 4.2 20,187 7.5 20,366 7.6 1,282 32.9 492,631 190.6 328,169 121.8 386 0.1
1997 46,715 17.1 8,556 3.1 16,631 6.1 20,447 7.5 1,081 27.9 537,904 205.5 327,665 120.2 246 0.1
1998 38,289 13.9 7,007 2.5 12,696 4.6 17,743 6.4 843 21.4 614,250 231.8 356,492 129.2 189 0.1
1999 35,385 12.7 6,617 2.4 11,534 4.1 16,655 6.0 579 14.6 662,647 247.2 360,813 129.3 110 0.0
2000 31,618 11.2 5,979 2.1 9,465 3.4 15,594 5.5 580 14.3 709,452 251.4 363,136 128.7 78 0.0
2001 32,284 11.3 6,103 2.1 8,701 3.0 16,976 5.9 504 12.5 783,242 274.5 361,705 126.8 38 0.0
2002 32,919 11.4 6,862 2.4 8,429 2.9 17,168 6.0 460 11.4 834,555 289.4 351,852 122.0 48 0.0
2003 34,289 11.8 7,177 2.5 8,361 2.9 18,319 6.3 432 10.6 877,478 301.7 335,104 115.2 54 0.0
2004 33,423 11.4 7,980 2.7 7,768 2.6 17,300 5.9 375 9.1 929,462 316.5 330,132 112.4 30 0.0
2005 33,288 11.2 8,724 2.9 8,176 2.8 16,049 5.4 339 8.2 976,445 329.4 339,593 114.6 17 0.0
2006 36,959 12.3 9,756 3.3 9,186 3.1 17,644 5.9 373 9.1 1,030,911 344.3 358,366 119.7 19 0.0
2007 40,920 13.7 11,466 3.8 10,768 3.6 18,256 6.1 430 10.5 1,108,374 370.2 355,991 118.9 23 0.0
Table 1. Cases of sexually transmitted diseases reported by state health departments and rates per 100,000
population: United  States, 1941–2007 (continued)
*For 1941–1946, data were re ported for the fed eral fis cal year end ing June 30 of the year in di cated. From 1947 to the pres ent, data were re ported for
the cal en dar year end ing De cem ber 31. For 1941–1958, data for Alaska and Ha waii were not in cluded.
 †Late and late latent syphilis includes late latent syphilis, latent syphilis of unknown duration, neurosyphilis, and late syphilis with clinical
manifestations other than neurosyphilis.
 ‡Rates include all cases of congenitally acquired syphilis per 100,000 live births. As of 1995, cases of con gen i tal syph i lis are ob tained in hardcopy or
elec tronic for mat based on case re port ing form CDC 73.126.
 Note: Ad just ments to the num ber of cases re ported from state health de part ments were made for hardcopy forms and for elec tronic data sub mis sions
through June 25, 2008 (see Ap pen dix). The num ber of cases and the rates shown here su per sede those pub lished in pre vi ous re ports. Cases and
rates shown in this ta ble exclude the outlying areas of Guam, Puerto Rico and Virgin Islands.
NR = No re port.
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1 Mississippi 21,686 745.1
2 Alaska 4,911 732.9
3 South Carolina 26,431 611.7
4 Alabama 25,153 546.9
5 New Mexico 9,460 484.0
6 Georgia 42,913 458.3
7 Louisiana 19,362 451.6
8 Tennessee 26,866 444.9
9 Hawaii 5,659 440.2
10 Illinois 55,470 432.3
11 New York 80,717 418.1
12 Ohio 47,434 413.3
13 Maryland 23,150 412.2
14 Delaware 3,479 407.6
15 Arizona 24,866 403.3
16 Missouri 23,308 398.9
17 California 141,928 389.3
18 Nevada 9,514 381.2
U.S. TOTAL† 1,108,374 370.2
19 Michigan 37,353 370.0
20 Texas 85,786 364.9
21 Colorado 17,186 361.6
22 Arkansas 9,954 354.1
23 Wisconsin 19,555 351.9
24 Oklahoma 12,529 350.0
25 North Carolina 30,611 345.6
26 Pennsylvania 42,469 341.4
27 South Dakota 2,620 335.1
28 Indiana 20,712 328.1
29 Connecticut 11,454 326.8
30 Virginia 24,579 321.6
31 Florida 57,575 318.3
32 Rhode Island 3,177 297.6
33 Kansas 8,180 295.9
34 Washington 18,784 293.7
35 Montana 2,748 290.9
36 Nebraska 5,132 290.2
37 Iowa 8,643 289.8
38 North Dakota 1,789 281.3
39 Oregon 9,849 266.1
40 Minnesota 13,413 259.6
41 Idaho 3,722 253.8
42 Massachusetts 16,145 250.8
43 New Jersey 21,536 246.8
44 Wyoming 1,197 232.4
45 Utah 5,721 224.3
46 Kentucky 8,798 209.2
47 Maine 2,541 192.3
48 West Virginia 3,168 174.2
49 Vermont 1,057 169.4
50 New Hampshire 2,055 156.3
Table 2. Chlamydia — Reported cases and rates by state, ranked by rates: United States, 2007
*States were ranked in descending order by rate, number of cases, and alphabetically by state.
†Total includes cases reported by the District of Columbia with 6,029 cases and a rate of 1036.7, but excludes outlying areas (Guam with 822 cases
and rate of 480.6, Puerto Rico with 7,909 cases and rate of 201.3, and Virgin Islands with 348 cases and rate of 320.4).
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State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 14,209 13,314 17,109 22,915 25,153 315.7 293.9 375.4 498.3 546.9
Alaska 3,900 3,954 4,355 4,525 4,911 601.1 603.3 656.2 675.3 732.9
Arizona 12,819 16,786 21,264 24,090 24,866 229.7 292.2 358.0 390.7 403.3
Arkansas 7,856 7,864 8,507 8,259 9,954 288.2 285.7 306.1 293.8 354.1
California 117,428 122,197 130,716 135,827 141,928 330.9 340.4 361.8 372.6 389.3
Colorado 13,039 14,151 15,432 16,313 17,186 286.5 307.5 330.8 343.2 361.6
Connecticut 9,393 9,552 11,039 10,946 11,454 269.7 272.6 314.5 312.3 326.8
Delaware 3,035 2,954 3,392 3,615 3,479 371.3 355.7 402.1 423.6 407.6
District of Columbia 3,168 3,493 3,678 3,368 6,029 561.4 631.0 668.1 579.2 1,036.7
Florida 42,382 42,554 43,372 48,955 57,575 249.0 244.6 243.8 270.6 318.3
Georgia 35,686 34,280 33,562 38,972 42,913 410.9 388.2 369.9 416.2 458.3
Hawaii 5,480 5,307 5,489 5,548 5,659 435.7 420.2 430.4 431.6 440.2
Idaho 2,366 2,784 2,799 3,345 3,722 173.2 199.8 195.9 228.1 253.8
Illinois 48,294 47,185 50,559 53,586 55,470 381.7 371.1 396.1 417.6 432.3
Indiana 17,075 18,440 20,063 19,859 20,712 275.6 295.6 319.9 314.5 328.1
Iowa 6,491 6,956 7,390 8,390 8,643 220.5 235.4 249.1 281.3 289.8
Kansas 7,249 7,493 7,419 7,829 8,180 266.2 273.9 270.3 283.2 295.9
Kentucky 7,981 6,470 8,351 8,940 8,798 193.8 156.1 200.1 212.5 209.2
Louisiana 20,970 21,837 17,227 17,885 19,362 466.4 483.6 380.8 417.1 451.6
Maine 2,030 2,113 2,254 2,306 2,541 155.5 160.4 170.6 174.5 192.3
Maryland 16,831 19,952 18,291 21,859 23,150 305.5 359.0 326.6 389.2 412.2
Massachusetts 11,301 13,242 14,411 15,394 16,145 175.7 206.4 225.2 239.1 250.8
Michigan 32,572 41,246 38,730 36,753 37,353 323.1 407.9 382.7 364.0 370.0
Minnesota 10,714 11,602 12,189 12,935 13,413 211.8 227.4 237.5 250.3 259.6
Mississippi 12,193 18,863 21,268 19,002 21,686 423.2 649.8 728.1 652.9 745.1
Missouri 18,570 21,319 22,371 22,982 23,308 325.5 370.5 385.7 393.3 398.9
Montana 2,547 2,608 2,400 2,650 2,748 277.6 281.4 256.5 280.5 290.9
Nebraska 4,739 5,238 5,098 5,428 5,132 272.5 299.8 289.9 307.0 290.2
Nevada 5,830 6,690 7,321 8,398 9,514 260.1 286.5 303.2 336.5 381.2
New Hampshire 1,616 1,736 1,842 1,997 2,055 125.5 133.6 140.6 151.9 156.3
New Jersey 16,169 17,448 19,152 20,194 21,536 187.2 200.6 219.7 231.5 246.8
New Mexico 7,480 9,035 8,456 9,829 9,460 399.0 474.7 438.5 502.9 484.0
New York 57,222 59,097 63,966 68,720 80,717 298.2 307.4 332.2 355.9 418.1
North Carolina 26,187 28,967 31,183 33,615 30,611 311.5 339.1 359.1 379.6 345.6
North Dakota 1,655 1,810 1,667 1,820 1,789 261.1 285.3 261.8 286.2 281.3
Ohio 42,522 39,379 43,806 40,106 47,434 371.8 343.7 382.1 349.4 413.3
Oklahoma 11,013 10,366 13,407 12,992 12,529 313.6 294.2 377.9 363.0 350.0
Oregon 7,688 8,690 9,018 9,577 9,849 216.0 241.8 247.7 258.8 266.1
Pennsylvania 37,291 38,025 37,261 39,487 42,469 301.6 306.5 299.8 317.4 341.4
Rhode Island 3,000 3,442 3,269 3,142 3,177 278.8 318.5 303.8 294.3 297.6
South Carolina 14,623 18,423 18,296 22,351 26,431 352.6 438.8 430.0 517.2 611.7
South Dakota 2,608 2,532 2,701 2,633 2,620 341.2 328.5 348.1 336.7 335.1
Tennessee 20,380 22,515 23,084 25,320 26,866 348.9 381.5 387.1 419.3 444.9
Texas 69,200 70,232 71,860 75,543 85,786 312.9 312.3 314.3 321.4 364.9
Utah 3,893 3,857 4,602 5,092 5,721 165.6 161.4 186.3 199.7 224.3
Vermont 1,060 1,137 957 1,191 1,057 171.2 183.0 153.6 190.9 169.4
Virginia 19,439 21,635 22,668 24,087 24,579 263.2 290.0 299.5 315.2 321.6
Washington 16,797 17,635 18,616 17,819 18,784 273.9 284.3 296.1 278.6 293.7
West Virginia 2,585 2,758 2,944 2,910 3,168 142.8 151.9 162.0 160.0 174.2
Wisconsin 17,942 19,217 20,461 20,190 19,555 327.9 348.8 369.6 363.4 351.9
Wyoming 960 1,082 1,173 1,422 1,197 191.5 213.6 230.3 276.1 232.4
U.S. TOTAL 877,478 929,462 976,445 1,030,911 1,108,374 301.7 316.5 329.4 344.3 370.2
Northeast 139,082 145,792 154,151 163,377 181,151 255.7 267.2 282.1 298.5 330.9
Midwest 210,431 222,417 232,454 232,511 243,609 321.7 338.4 352.4 351.1 367.9
South 327,738 346,477 358,199 390,588 428,069 313.5 327.0 333.2 358.1 392.4
West 200,227 214,776 231,641 244,435 255,545 301.2 318.6 339.2 352.4 368.5
Guam 554 748 807 832 822 338.6 450.4 478.7 486.5 480.6
Puerto Rico 2,746 3,588 3,714 5,102 7,909 70.8 92.1 94.9 129.9 201.3
Virgin Islands 416 303 235 203 348 382.3 278.6 216.2 186.9 320.4
OUTLYING AREAS 3,716 4,639 4,756 6,137 9,079 89.5 111.3 113.5 145.8 215.8
TOTAL 881,194 934,101 981,201 1,037,048 1,117,453 298.7 313.6 326.4 341.6 368.1
Table 3. Chlamydia — Reported cases and rates by state/area and region listed in alphabetical order: United
States and outlying areas, 2003–2007
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State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 12,977 11,685 14,532 17,915 19,186 559.0 500.6 619.4 756.0 809.7
Alaska 2,665 2,671 2,908 3,067 3,295 850.0 843.9 907.4 947.7 1,018.1
Arizona 10,043 12,896 16,201 18,485 18,794 360.1 449.3 546.2 600.1 610.1
Arkansas 6,284 6,252 6,823 6,604 7,893 451.5 445.3 481.8 460.8 550.7
California 85,967 88,439 93,646 97,170 101,175 483.7 491.9 517.8 532.9 554.9
Colorado 9,843 10,283 11,219 12,037 12,707 436.4 451.0 485.8 510.0 538.3
Connecticut 7,309 7,383 8,383 8,205 8,577 407.8 409.4 464.4 456.2 476.9
Delaware 2,155 2,140 2,493 2,625 2,554 513.9 502.7 576.8 597.6 581.5
District of Columbia 2,695 2,948 2,976 2,510 3,970 903.6 1,010.3 1,028.4 812.7 1,285.3
Florida 34,581 34,437 34,850 38,536 42,173 398.2 388.1 384.4 418.6 458.1
Georgia 28,992 27,656 26,317 30,546 31,827 659.2 619.5 574.0 642.7 669.6
Hawaii 4,113 4,019 4,093 4,161 4,228 655.9 635.1 640.1 648.0 658.4
Idaho 1,762 2,157 2,162 2,435 2,660 258.5 310.5 303.6 334.4 365.3
Illinois 36,284 35,996 37,672 39,705 41,733 563.1 556.3 580.3 609.5 640.6
Indiana 13,118 14,217 15,263 14,907 15,576 416.6 448.7 479.4 465.4 486.3
Iowa 4,915 5,208 5,400 6,157 6,310 328.5 347.1 358.7 407.9 418.1
Kansas 5,989 6,195 6,054 6,286 6,629 436.1 449.9 438.4 451.4 476.0
Kentucky 6,353 5,027 6,041 6,336 6,184 302.5 238.0 284.5 295.4 288.3
Louisiana 17,046 17,549 13,395 14,290 15,334 736.6 755.8 576.4 649.0 696.4
Maine 1,452 1,532 1,644 1,672 1,831 217.0 227.3 243.2 247.6 271.2
Maryland 13,746 16,108 14,653 17,339 18,230 483.5 561.8 507.5 598.1 628.9
Massachusetts 8,429 9,781 10,587 11,175 11,671 253.7 295.5 321.0 336.6 351.5
Michigan 25,903 32,624 30,079 27,915 28,341 505.1 634.2 584.6 544.6 552.9
Minnesota 7,866 8,521 8,820 9,243 9,681 308.4 331.7 341.3 355.7 372.6
Mississippi 10,536 15,097 16,684 14,853 16,718 709.5 1,010.4 1,110.4 989.4 1,113.6
Missouri 14,750 16,306 16,580 16,938 17,080 504.8 553.9 559.3 566.9 571.6
Montana 1,865 1,916 1,776 1,932 2,024 405.4 412.4 378.9 409.3 428.8
Nebraska 3,435 3,812 3,713 3,956 3,755 390.3 431.4 417.6 443.7 421.2
Nevada 4,268 4,857 5,362 6,185 7,044 388.3 423.8 452.3 504.2 574.3
New Hampshire 1,196 1,265 1,343 1,484 1,533 183.1 192.1 202.2 222.7 230.1
New Jersey 13,813 14,491 15,826 16,560 17,355 311.5 324.7 354.1 371.1 388.9
New Mexico 5,973 6,876 6,333 7,456 7,044 627.3 710.9 646.2 753.3 711.7
New York 43,907 44,975 45,391 48,568 56,590 442.9 453.3 457.2 488.1 568.7
North Carolina 21,807 23,916 25,702 27,301 25,110 509.9 550.8 582.6 604.6 556.1
North Dakota 1,087 1,206 1,091 1,231 1,194 342.8 379.6 342.1 389.0 377.3
Ohio 33,549 30,377 33,312 30,483 36,143 571.6 516.8 566.9 518.4 614.6
Oklahoma 8,990 8,237 10,608 9,678 9,130 505.0 461.9 591.1 533.3 503.1
Oregon 5,590 6,090 6,194 6,585 6,890 312.1 336.9 338.4 353.8 370.2
Pennsylvania 27,557 27,740 27,131 28,503 30,511 432.1 433.9 424.0 445.8 477.3
Rhode Island 2,232 2,502 2,396 2,175 2,282 400.2 447.3 430.7 394.5 413.9
South Carolina 12,745 15,925 15,694 19,055 20,793 598.8 739.7 719.6 859.3 937.7
South Dakota 1,864 1,824 1,924 1,923 1,894 484.9 470.5 492.9 491.4 484.0
Tennessee 14,669 16,237 16,453 18,352 19,604 490.7 538.6 540.8 594.3 634.9
Texas 57,549 57,470 58,668 60,327 67,966 518.0 509.1 511.4 511.5 576.3
Utah 2,787 2,720 3,081 3,457 3,926 238.0 228.6 250.6 272.7 309.7
Vermont 828 861 725 897 812 262.8 272.8 229.3 283.1 256.2
Virginia 15,535 16,578 16,805 17,682 18,136 413.8 437.6 437.2 455.0 466.7
Washington 12,341 12,835 13,471 13,021 13,793 401.4 412.8 427.8 406.1 430.2
West Virginia 2,102 2,105 2,272 2,208 2,423 226.6 226.8 244.9 238.0 261.1
Wisconsin 12,838 13,913 14,751 14,606 14,438 464.3 500.1 527.9 522.5 516.5
Wyoming 717 820 874 1,051 913 288.1 326.1 346.0 413.8 359.4
U.S. TOTAL 685,017 716,675 740,371 775,788 825,660 463.6 480.6 492.2 510.8 543.6
Northeast 106,723 110,530 113,426 119,239 131,162 380.7 393.4 403.5 423.8 466.2
Midwest 161,598 170,199 174,659 173,350 182,774 485.6 509.2 521.0 515.8 543.9
South 268,762 279,367 284,966 306,157 327,231 505.0 518.4 521.5 551.6 589.6
West 147,934 156,579 167,320 177,042 184,493 445.1 464.5 490.2 511.0 532.5
Guam 446 608 667 692 669 556.8 747.1 807.0 824.7 797.3
Puerto Rico 2,378 3,240 3,366 4,091 6,781 118.1 160.1 165.6 200.3 332.1
Virgin Islands 352 232 189 144 267 619.0 408.0 332.5 253.6 470.2
OUTLYING AREAS 3,176 4,080 4,222 4,927 7,717 147.6 188.8 194.4 225.7 353.6
TOTAL 688,193 720,755 744,593 780,715 833,377 459.0 476.4 488.0 506.7 540.9
Table 4. Chlamydia — Women – Reported cases and rates by state/area and region listed in alphabetical
order: United States and outlying areas, 2003–2007
Note: Cases reported with unknown sex are not included in this table.
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State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 1,201 1,603 2,507 4,985 5,955 55.1 73.0 113.4 223.6 267.1
Alaska 1,235 1,283 1,447 1,458 1,616 368.3 378.6 421.6 420.9 466.5
Arizona 2,772 3,884 5,058 5,588 6,055 99.3 135.2 170.1 181.1 196.2
Arkansas 1,567 1,612 1,684 1,655 2,060 117.5 119.5 123.6 120.1 149.5
California 31,238 33,323 36,449 38,003 40,213 176.4 186.0 202.0 208.5 220.7
Colorado 3,196 3,855 4,213 4,276 4,479 139.2 166.1 178.8 178.7 187.2
Connecticut 2,084 2,168 2,656 2,741 2,877 123.2 127.5 155.8 160.7 168.6
Delaware 880 814 899 990 925 221.0 201.1 218.6 239.0 223.3
District of Columbia 450 529 681 819 2,034 169.1 202.1 260.8 300.4 746.0
Florida 7,801 8,117 8,522 10,410 15,376 93.6 95.2 97.7 117.2 173.1
Georgia 6,509 6,411 6,793 8,089 10,808 151.8 146.9 151.4 175.4 234.4
Hawaii 1,367 1,288 1,396 1,384 1,431 216.8 204.4 219.6 215.1 222.4
Idaho 604 617 616 895 1,030 88.2 88.3 85.9 121.2 139.5
Illinois 12,009 11,187 12,886 13,881 13,736 193.4 179.2 205.5 219.7 217.4
Indiana 3,803 4,080 4,703 4,849 5,032 124.8 132.9 152.3 155.9 161.8
Iowa 1,561 1,743 1,990 2,233 2,333 107.8 119.9 136.2 151.6 158.4
Kansas 1,260 1,298 1,365 1,543 1,551 93.3 95.6 100.1 112.5 113.1
Kentucky 1,613 1,433 2,285 2,580 2,605 79.9 70.5 111.5 125.2 126.4
Louisiana 3,808 4,016 3,583 3,372 3,758 174.5 183.0 162.9 161.7 180.2
Maine 577 581 606 634 708 90.6 90.3 93.9 98.1 109.5
Maryland 3,068 3,841 3,627 4,439 4,907 115.1 142.7 133.7 163.4 180.6
Massachusetts 2,848 3,449 3,809 4,193 4,457 91.6 111.0 122.8 134.5 143.0
Michigan 6,669 8,622 8,525 8,724 8,845 134.7 173.5 171.3 175.5 178.0
Minnesota 2,848 3,081 3,369 3,692 3,732 113.5 121.7 132.2 143.7 145.3
Mississippi 1,657 3,766 4,584 4,149 4,968 118.7 267.3 323.1 294.4 352.5
Missouri 3,820 5,013 5,791 6,044 6,228 137.3 178.3 204.2 211.7 218.2
Montana 679 685 619 709 716 148.4 148.2 132.6 150.0 151.5
Nebraska 1,244 1,391 1,378 1,401 1,363 144.8 161.1 158.4 159.8 155.5
Nevada 1,552 1,821 1,955 2,211 2,460 135.9 153.2 159.0 174.2 193.9
New Hampshire 420 471 499 513 522 66.2 73.5 77.3 79.1 80.5
New Jersey 2,332 2,945 3,323 3,606 4,169 55.5 69.5 78.2 84.6 97.8
New Mexico 1,485 2,151 2,121 2,368 2,415 161.0 229.8 223.6 245.4 250.3
New York 13,106 14,031 18,547 20,148 24,045 141.3 150.8 198.9 215.4 257.0
North Carolina 4,379 5,051 5,481 6,314 5,493 106.0 120.3 128.3 145.4 126.5
North Dakota 567 601 574 588 594 179.0 189.8 180.6 184.1 186.0
Ohio 8,215 8,189 9,139 9,039 10,852 147.6 146.7 163.6 161.5 193.9
Oklahoma 2,023 2,129 2,799 3,314 3,399 116.8 122.3 159.6 187.8 192.6
Oregon 2,098 2,600 2,824 2,992 2,959 118.6 145.5 155.9 162.6 160.8
Pennsylvania 9,682 10,282 10,128 10,981 11,934 161.7 171.0 168.0 181.6 197.3
Rhode Island 768 936 868 962 892 148.1 179.6 167.0 186.4 172.8
South Carolina 1,813 2,456 2,572 3,272 5,549 89.8 120.1 124.0 155.5 263.8
South Dakota 742 708 774 709 725 195.3 184.7 200.7 181.5 185.6
Tennessee 5,711 6,278 6,619 6,968 7,262 200.2 217.5 226.6 236.1 246.1
Texas 11,594 12,619 13,138 15,178 17,687 105.3 112.7 115.4 129.6 151.0
Utah 1,103 1,137 1,521 1,635 1,795 93.4 94.8 122.6 127.5 140.0
Vermont 232 276 232 294 245 76.3 90.3 75.6 95.8 79.8
Virginia 3,868 5,024 5,823 6,384 6,433 106.5 136.8 156.4 169.9 171.2
Washington 4,456 4,800 5,145 4,798 4,991 145.8 155.1 163.9 150.4 156.5
West Virginia 472 649 671 698 744 53.5 73.1 75.5 78.4 83.5
Wisconsin 5,015 5,290 5,688 5,551 5,090 185.2 194.0 207.5 201.1 184.4
Wyoming 243 262 299 371 284 96.3 102.7 116.5 142.1 108.8
U.S. TOTAL 190,244 210,396 232,781 252,630 280,337 133.0 145.6 159.4 171.3 190.0
Northeast 32,049 35,139 40,668 44,072 49,849 121.6 132.7 153.3 165.6 187.4
Midwest 47,753 51,203 56,182 58,254 60,081 148.6 158.5 173.2 178.6 184.2
South 58,414 66,348 72,268 83,616 99,963 113.8 127.4 136.7 156.0 186.6
West 52,028 57,706 63,663 66,688 70,444 156.6 171.2 186.4 192.1 202.9
Guam 108 140 140 140 153 129.4 165.3 162.9 160.7 175.6
Puerto Rico 368 348 348 1,007 1,125 19.7 18.6 18.5 53.4 59.6
Virgin Islands 64 71 46 55 81 123.2 136.8 88.7 106.1 156.3
OUTLYING AREAS 540 559 534 1,202 1,359 27.0 27.8 26.5 59.3 67.1
TOTAL 190,784 210,955 233,315 253,832 281,696 131.5 144.0 157.6 169.7 188.4
Table 5. Chlamydia — Men – Reported cases and rates by state/area and region listed in alphabetical order:
United States and outlying areas, 2003–2007
Note: Cases reported with unknown sex are not included in this table.
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Atlanta-Sandy Springs-Marietta, GA 18,135 17,068 16,748 20,979 21,609 393.4 362.5 340.6 408.3 420.6
Austin-Round Rock, TX 4,456 4,580 5,103 7,325 6,814 323.5 324.3 351.3 484.0 450.2
Baltimore-Towson, MD 10,044 10,959 11,071 11,617 13,053 383.9 415.2 416.9 437.0 491.0
Birmingham-Hoover, AL 3,189 3,905 4,720 5,338 6,913 297.3 360.8 433.0 485.3 628.4
Boston-Cambridge-Quincy, MA-NH 7,831 9,006 9,368 9,918 10,697 176.4 203.5 212.3 222.6 240.1
Buffalo-Cheektowaga-Tonawanda, NY 3,513 4,865 5,013 4,992 5,078 303.0 421.4 436.8 438.8 446.4
Charlotte-Gastonia-Concord, NC-SC 4,619 4,832 5,830 5,076 4,216 321.3 327.7 383.2 320.7 266.3
Chicago-Naperville-Joliet, IL-IN-WI 37,017 35,953 38,966 41,521 41,403 396.6 382.8 412.6 436.8 435.6
Cincinnati-Middletown, OH-KY-IN 6,789 6,438 8,516 8,616 10,080 331.6 312.8 411.3 409.5 479.0
Cleveland-Elyria-Mentor, OH 8,489 7,867 8,181 7,462 9,351 396.8 368.1 384.7 353.0 442.3
Columbus, OH 5,758 5,167 5,902 5,843 7,157 343.8 305.0 345.4 338.6 414.8
Dallas-Fort Worth-Arlington, TX 16,828 15,744 18,005 17,035 22,292 301.1 276.2 309.4 283.7 371.3
Denver-Aurora, CO 7,039 7,774 8,534 7,934 9,539 305.9 333.6 361.6 329.4 396.0
Detroit-Warren-Livonia, MI 16,071 21,378 20,497 17,201 17,934 358.4 475.8 456.7 384.9 401.3
Hartford-West Hartford-East Hartford, CT 3,224 3,040 3,815 3,799 4,300 273.7 256.6 321.1 319.6 361.7
Houston-Baytown-Sugar Land, TX 13,530 14,796 13,476 14,641 17,196 266.6 285.6 255.2 264.3 310.4
Indianapolis, IN 7,304 6,922 8,226 7,780 8,173 457.8 426.9 501.4 467.0 490.6
Jacksonville, FL 5,200 5,017 5,246 5,582 6,501 432.3 409.4 420.2 436.8 508.7
Kansas City, MO-KS 7,105 8,003 7,900 7,825 8,358 373.0 415.7 405.6 397.7 424.8
Las Vegas-Paradise, NV 4,379 5,065 5,623 6,592 7,333 277.8 306.8 328.7 370.8 412.5
Los Angeles-Long Beach-Santa Ana, CA 46,342 46,202 50,703 50,913 52,352 361.2 357.5 392.3 393.1 404.3
Louisville, KY-IN 2,775 2,396 3,143 3,319 3,493 233.2 199.5 260.1 271.6 285.8
Memphis, TN-MS-AR 7,362 8,927 9,457 10,224 11,349 594.0 714.0 750.0 802.1 890.3
Miami-Fort Lauderdale-Miami Beach, FL 11,024 11,781 10,403 12,142 13,761 208.4 219.7 191.9 222.2 251.9
Milwaukee-Waukesha-West Allis, WI 9,320 10,070 10,368 10,498 10,150 615.5 664.4 685.3 695.2 672.2
Minneapolis-St. Paul-Bloomington, MN-WI 8,081 8,139 8,513 9,271 9,514 262.1 261.2 270.9 292.0 299.6
Nashville-Davidson-Murfreesboro, TN 3,981 4,243 4,538 4,910 4,972 290.3 304.0 319.0 337.4 341.7
New Orleans-Metairie-Kenner, LA 7,116 6,858 4,761 3,401 4,573 540.1 519.7 360.9 331.9 446.3
New York-Newark-Edison, NY-NJ-PA 51,614 52,266 58,134 62,334 74,071 276.9 279.4 310.1 331.2 393.6
Oklahoma City, OK 4,124 3,939 4,798 4,627 4,646 364.1 344.2 414.8 394.7 396.3
Orlando, FL 4,673 4,888 5,862 6,579 6,825 259.2 262.6 303.2 331.5 343.9
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 25,347 25,285 24,913 27,417 28,116 439.1 435.9 427.8 470.5 482.5
Phoenix-Mesa-Scottsdale, AZ 8,084 11,078 11,984 15,278 15,245 225.0 298.2 310.1 378.2 377.4
Pittsburgh, PA 5,499 5,539 5,880 5,789 6,616 228.1 230.6 246.4 244.2 279.1
Portland-Vancouver-Beaverton, OR-WA 4,703 5,256 5,636 5,654 5,970 230.5 254.6 268.9 264.5 279.3
Providence-New Bedford-Fall River, RI-MA 3,714 4,269 4,316 4,197 4,297 228.8 262.1 266.0 260.2 266.4
Richmond, VA 4,472 4,923 4,710 5,044 5,294 392.9 426.5 400.6 422.4 443.4
Riverside-San Bernardino-Ontario, CA 10,688 10,913 12,179 12,472 14,316 293.4 287.7 311.5 309.8 355.6
Rochester, NY 4,142 4,040 3,850 4,168 4,833 397.8 387.9 370.5 402.5 466.8
Sacramento-Arden-Arcade-Roseville, CA 6,240 7,294 8,175 9,094 8,770 316.0 361.7 400.3 439.9 424.3
Salt Lake City, UT 2,264 2,223 2,642 2,910 3,395 225.2 218.2 255.4 272.5 318.0
San Antonio, TX 7,212 7,645 8,049 8,338 8,727 396.1 412.3 425.9 429.3 449.3
San Diego-Carlsbad-San Marcos, CA 10,432 10,876 11,520 11,980 12,693 355.9 371.0 392.7 407.3 431.5
San Francisco-Oakland-Fremont, CA 12,774 13,580 13,988 15,565 16,710 307.3 326.9 336.8 372.4 399.8
San Jose-Sunnyvale-Santa Clara, CA 4,796 5,697 5,374 5,898 5,892 276.5 327.1 306.2 330.0 329.7
Seattle-Tacoma-Bellevue, WA 9,457 9,655 10,588 9,778 10,397 301.0 304.9 330.5 299.6 318.6
St. Louis, MO-IL 10,081 11,856 13,328 13,509 13,710 368.5 428.9 479.7 483.1 490.3
Tampa-St. Petersburg-Clearwater, FL 6,002 5,996 6,315 7,475 9,501 237.1 231.7 238.5 277.1 352.2
Virginia Beach-Norfolk-Newport News, VA-NC 6,668 7,601 8,414 9,139 9,383 407.3 462.3 510.8 554.1 568.9
Washington-Arlington-Alexandria, DC-VA-MD-WV 11,230 14,046 12,827 15,456 18,069 220.6 273.3 246.0 292.2 341.5
U.S. MSA TOTAL 500,737 525,860 556,108 584,455 635,637 320.5 333.0 348.7 362.3 394.0
Table 6. Chlamydia — Reported cases and rates in selected metropolitan statistical areas* (MSAs) listed in
alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 14,519 13,756 12,995 16,165 15,553 624.4 580.4 524.8 622.2 598.6
Austin-Round Rock, TX 3,418 3,405 3,720 5,170 4,753 506.4 492.5 522.7 699.1 642.7
Baltimore-Towson, MD 8,412 9,051 8,927 9,344 10,416 620.5 662.1 649.4 677.9 755.7
Birmingham-Hoover, AL 2,825 3,095 3,709 4,277 5,165 508.3 552.6 657.7 751.3 907.2
Boston-Cambridge-Quincy, MA-NH 5,715 6,549 6,663 7,140 7,721 249.8 287.6 293.8 311.7 337.1
Buffalo-Cheektowaga-Tonawanda, NY 2,677 3,698 3,849 3,762 3,818 444.3 616.7 646.3 637.8 647.3
Charlotte-Gastonia-Concord, NC-SC 3,915 4,059 4,878 4,189 3,430 536.5 541.9 631.9 520.7 426.3
Chicago-Naperville-Joliet, IL-IN-WI 27,419 27,271 28,860 30,600 31,134 576.5 570.2 600.4 633.8 644.9
Cincinnati-Middletown, OH-KY-IN 5,458 5,108 6,580 6,871 8,082 520.2 484.6 621.4 638.2 750.7
Cleveland-Elyria-Mentor, OH 6,548 5,909 6,066 5,458 7,023 588.0 531.6 548.7 497.2 639.8
Columbus, OH 4,525 4,058 4,445 4,549 5,428 532.1 472.8 513.4 520.7 621.3
Dallas-Fort Worth-Arlington, TX 13,633 12,536 14,641 13,466 17,251 488.3 440.7 504.7 450.4 577.0
Denver-Aurora, CO 5,225 5,558 6,122 5,827 7,020 455.8 479.3 521.7 485.8 585.2
Detroit-Warren-Livonia, MI 13,008 17,145 16,172 13,096 13,580 565.6 744.1 703.4 572.9 594.1
Hartford-West Hartford-East Hartford, CT 2,510 2,331 2,842 2,786 3,122 413.6 381.9 464.3 456.5 511.6
Houston-Baytown-Sugar Land, TX 11,325 12,258 11,539 12,178 14,170 446.0 473.1 437.0 439.8 511.8
Indianapolis, IN 5,337 5,167 5,949 5,596 5,808 656.5 625.9 712.5 660.3 685.4
Jacksonville, FL 4,051 3,759 4,021 4,273 4,627 658.1 600.4 630.6 654.9 709.2
Kansas City, MO-KS 5,434 5,993 5,930 5,791 6,231 559.4 611.3 598.8 578.2 622.1
Las Vegas-Paradise, NV 3,318 3,820 4,319 5,014 5,620 428.5 471.0 513.8 573.3 642.6
Los Angeles-Long Beach-Santa Ana, CA 33,124 32,903 36,044 35,826 36,520 511.9 504.6 552.9 549.2 559.8
Louisville, KY-IN 2,144 1,817 2,232 2,344 2,482 351.2 295.1 360.6 374.3 396.3
Memphis, TN-MS-AR 5,650 6,816 7,150 7,935 8,846 880.2 1,053.0 1,098.1 1,202.2 1,340.3
Miami-Fort Lauderdale-Miami Beach, FL 9,027 9,610 8,492 9,553 9,985 331.4 347.8 304.2 340.1 355.5
Milwaukee-Waukesha-West Allis, WI 6,756 7,358 7,558 7,761 7,653 868.3 945.2 973.0 1,004.8 990.8
Minneapolis-St. Paul-Bloomington, MN-WI 5,792 5,892 6,022 6,462 6,727 371.9 374.8 380.0 404.3 420.8
Nashville-Davidson-Murfreesboro, TN 2,834 3,018 3,122 3,413 3,445 406.9 426.5 433.4 462.7 467.1
New Orleans-Metairie-Kenner, LA 5,736 5,433 3,563 2,673 3,503 836.7 791.6 519.8 503.2 659.4
New York-Newark-Edison, NY-NJ-PA 40,956 41,039 42,214 45,007 52,815 423.7 423.4 435.0 462.7 543.0
Oklahoma City, OK 3,301 3,057 3,744 3,394 3,262 573.5 527.5 638.7 570.1 547.9
Orlando, FL 3,852 3,993 4,667 5,326 5,203 421.9 424.0 477.4 531.7 519.4
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 18,707 18,369 18,236 19,813 20,132 625.3 611.6 605.3 658.0 668.6
Phoenix-Mesa-Scottsdale, AZ 6,303 8,555 9,338 11,859 11,675 353.6 464.3 487.7 592.7 583.5
Pittsburgh, PA 4,191 4,185 4,398 4,267 4,870 333.7 334.6 354.2 346.5 395.5
Portland-Vancouver-Beaverton, OR-WA 3,332 3,555 3,816 3,769 4,109 325.2 343.2 363.1 351.7 383.4
Providence-New Bedford-Fall River, RI-MA 2,784 3,138 3,225 2,967 3,116 331.0 372.1 384.3 355.8 373.7
Richmond, VA 3,421 3,573 3,425 3,617 3,778 582.6 601.2 566.7 590.0 616.3
Riverside-San Bernardino-Ontario, CA 8,122 8,252 9,257 9,426 10,773 445.9 435.4 474.3 468.5 535.4
Rochester, NY 2,990 2,869 2,670 2,890 3,337 558.8 536.9 501.5 544.7 629.0
Sacramento-Arden-Arcade-Roseville, CA 4,603 5,326 5,890 6,614 6,310 458.6 519.5 567.4 629.1 600.2
Salt Lake City, UT 1,574 1,501 1,709 1,941 2,299 316.8 298.1 334.4 368.8 436.9
San Antonio, TX 5,985 6,182 6,105 6,232 6,567 644.1 653.1 633.1 628.0 661.8
San Diego-Carlsbad-San Marcos, CA 7,694 7,908 8,210 8,620 9,187 528.8 542.6 565.1 590.4 629.2
San Francisco-Oakland-Fremont, CA 8,824 9,151 9,217 10,418 11,118 420.4 436.4 439.6 495.3 528.5
San Jose-Sunnyvale-Santa Clara, CA 3,465 4,038 3,752 4,128 4,232 406.0 471.7 435.6 472.4 484.3
Seattle-Tacoma-Bellevue, WA 6,606 6,775 7,411 6,915 7,412 419.5 427.2 462.5 423.6 454.0
St. Louis, MO-IL 8,179 9,086 9,804 9,952 10,012 577.7 636.1 683.2 689.2 693.3
Tampa-St. Petersburg-Clearwater, FL 4,846 4,920 5,184 5,936 6,841 371.1 369.1 380.8 428.6 493.9
Virginia Beach-Norfolk-Newport News, VA-NC 5,378 5,862 6,016 6,651 6,884 648.6 704.2 720.5 789.6 817.2
Washington-Arlington-Alexandria, DC-VA-MD-WV 9,065 11,170 10,086 11,722 13,194 347.6 424.8 378.3 432.7 487.0
U.S. MSA TOTAL 384,513 399,877 414,784 432,983 466,239 483.1 497.5 511.3 528.1 568.7
Table 7. Chlamydia — Women – Reported cases and rates in selected metropolitan statistical areas* (MSAs)
listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 3,526 3,187 3,463 4,574 5,896 154.3 136.3 141.8 180.1 232.1
Austin-Round Rock, TX 1,026 1,093 1,357 2,147 2,053 146.0 151.6 183.2 277.4 265.2
Baltimore-Towson, MD 1,627 1,908 2,139 2,250 2,624 129.1 150.0 167.0 175.8 205.0
Birmingham-Hoover, AL 361 810 1,005 1,058 1,745 69.8 155.1 191.0 199.4 328.8
Boston-Cambridge-Quincy, MA-NH 2,097 2,449 2,697 2,762 2,966 97.4 114.0 125.8 127.6 137.0
Buffalo-Cheektowaga-Tonawanda, NY 836 1,167 1,164 1,229 1,260 150.1 210.4 210.8 224.4 230.1
Charlotte-Gastonia-Concord, NC-SC 700 770 951 887 786 98.9 106.1 126.9 113.9 101.0
Chicago-Naperville-Joliet, IL-IN-WI 9,542 8,602 10,075 10,905 10,259 208.5 186.7 217.3 233.1 219.3
Cincinnati-Middletown, OH-KY-IN 1,268 1,239 1,746 1,691 1,935 127.0 123.4 172.6 164.6 188.3
Cleveland-Elyria-Mentor, OH 1,875 1,904 1,986 1,953 2,285 182.8 185.7 194.6 192.2 224.8
Columbus, OH 1,174 1,058 1,377 1,272 1,706 142.5 126.6 163.4 149.3 200.3
Dallas-Fort Worth-Arlington, TX 3,179 3,192 3,346 3,558 4,987 113.6 111.8 114.6 118.0 165.5
Denver-Aurora, CO 1,814 2,210 2,412 2,107 2,519 157.1 188.8 203.3 174.2 208.3
Detroit-Warren-Livonia, MI 3,063 4,233 4,256 4,027 4,220 140.3 193.4 194.4 184.5 193.3
Hartford-West Hartford-East Hartford, CT 714 708 973 1,013 1,178 125.0 123.3 168.9 175.1 203.6
Houston-Baytown-Sugar Land, TX 2,185 2,504 1,930 2,449 2,963 86.1 96.7 73.1 88.4 106.9
Indianapolis, IN 1,906 1,744 2,242 2,167 2,340 243.6 219.1 278.3 264.7 285.9
Jacksonville, FL 1,149 1,258 1,225 1,309 1,873 195.6 209.9 200.6 209.3 299.4
Kansas City, MO-KS 1,671 2,010 1,970 2,034 2,127 179.0 212.7 205.8 210.6 220.2
Las Vegas-Paradise, NV 1,051 1,233 1,301 1,576 1,704 131.0 146.9 149.6 174.5 188.7
Los Angeles-Long Beach-Santa Ana, CA 13,161 13,208 14,585 14,921 15,639 207.0 206.2 227.7 232.2 243.3
Louisville, KY-IN 626 572 909 961 1,011 108.0 97.8 154.2 161.3 169.7
Memphis, TN-MS-AR 1,712 2,111 2,307 2,289 2,503 286.6 350.1 378.3 372.4 407.2
Miami-Fort Lauderdale-Miami Beach, FL 1,997 2,171 1,911 2,588 3,771 77.9 83.5 72.6 97.5 142.0
Milwaukee-Waukesha-West Allis, WI 2,486 2,711 2,804 2,720 2,473 337.7 367.7 380.9 368.8 335.3
Minneapolis-St. Paul-Bloomington, MN-WI 2,289 2,247 2,491 2,809 2,787 150.0 145.5 159.9 178.2 176.8
Nashville-Davidson-Murfreesboro, TN 1,147 1,225 1,415 1,497 1,527 170.0 178.0 201.5 208.6 212.8
New Orleans-Metairie-Kenner, LA 1,355 1,327 1,100 676 985 214.4 209.6 173.5 137.0 199.6
New York-Newark-Edison, NY-NJ-PA 10,437 11,125 15,890 17,301 21,165 116.3 123.4 175.7 190.3 232.8
Oklahoma City, OK 823 882 1,054 1,233 1,384 147.7 156.2 184.7 213.7 239.9
Orlando, FL 821 895 1,195 1,252 1,620 92.3 97.3 125.0 127.3 164.8
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 6,628 6,915 6,677 7,600 7,972 238.3 247.2 237.6 269.9 283.1
Phoenix-Mesa-Scottsdale, AZ 1,779 2,521 2,646 3,410 3,569 98.2 134.6 135.7 167.3 175.1
Pittsburgh, PA 1,296 1,353 1,482 1,522 1,745 112.3 117.6 129.5 133.6 153.2
Portland-Vancouver-Beaverton, OR-WA 1,371 1,701 1,820 1,885 1,861 135.0 165.4 174.2 176.9 174.6
Providence-New Bedford-Fall River, RI-MA 930 1,126 1,085 1,223 1,178 118.9 143.3 138.5 157.0 151.2
Richmond, VA 1,045 1,348 1,281 1,423 1,514 189.6 240.7 224.2 244.9 260.6
Riverside-San Bernardino-Ontario, CA 2,563 2,654 2,913 3,029 3,532 140.7 139.8 148.8 150.4 175.4
Rochester, NY 1,152 1,171 1,180 1,278 1,496 227.6 230.9 232.9 253.1 296.3
Sacramento-Arden-Arcade-Roseville, CA 1,588 1,901 2,220 2,431 2,387 163.5 191.7 221.1 239.3 235.0
Salt Lake City, UT 689 722 933 969 1,096 135.5 140.1 178.2 179.0 202.4
San Antonio, TX 1,225 1,460 1,942 2,104 2,160 137.4 160.9 209.8 221.5 227.4
San Diego-Carlsbad-San Marcos, CA 2,715 2,844 3,022 3,134 3,457 184.0 192.9 204.1 211.6 233.4
San Francisco-Oakland-Fremont, CA 3,908 4,370 4,686 5,058 5,465 189.9 212.4 227.9 243.6 263.2
San Jose-Sunnyvale-Santa Clara, CA 1,315 1,628 1,575 1,723 1,633 149.2 183.9 176.2 188.7 178.8
Seattle-Tacoma-Bellevue, WA 2,851 2,880 3,177 2,863 2,985 182.0 182.2 198.5 175.5 183.0
St. Louis, MO-IL 1,902 2,770 3,524 3,557 3,698 144.1 207.4 262.3 263.0 273.5
Tampa-St. Petersburg-Clearwater, FL 1,156 1,076 1,131 1,535 2,652 94.3 85.7 87.9 116.9 202.0
Virginia Beach-Norfolk-Newport News, VA-NC 1,276 1,724 2,375 2,481 2,494 157.9 212.4 292.4 307.4 309.0
Washington-Arlington-Alexandria, DC-VA-MD-WV 2,120 2,848 2,706 3,637 4,849 85.4 113.5 106.2 140.9 187.9
U.S. MSA TOTAL 115,127 124,765 139,651 150,077 168,034 150.2 160.9 178.2 189.2 211.8
Table 8. Chlamydia — Men – Reported cases and rates in selected metropolitan statistical areas* (MSAs)
listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Rank† County/Independent City   Cases     Rate per 100,000 Population     Cumulative Percent
1 Los Angeles County, CA 44,030 442.6 3
2 Cook County, IL 30,881 583.9 6
3 Philadelphia County, PA 17,029 1175.7 8
4 Kings County, NY 15,655 624.0 9
5 Bronx County, NY 14,572 1070.3 11
6 Maricopa County, AZ 14,542 385.9 12
7 Harris County, TX 13,387 344.5 13
8 San Diego County, CA 12,693 431.5 14
9 Wayne County, MI 12,403 629.0 15
10 Dallas County, TX 12,279 523.4 16
11 Queens County, NY 10,050 445.6 17
12 Milwaukee County, WI 9,637 1053.1 18
13 New York County, NY 9,605 596.0 19
14 Shelby County, TN 9,428 1034.4 20
15 Orange County, CA 8,322 277.2 21
16 Cuyahoga County, OH 8,219 625.4 21
17 San Bernardino County, CA 8,122 406.2 22
18 Bexar County, TX 8,055 517.8 23
19 Hamilton County, OH 7,404 900.1 24
20 Sacramento County, CA 7,372 536.3 24
21 Baltimore (City), MD 7,362 1166.0 25
22 Clark County, NV 7,333 412.5 26
23 Marion County, IN 7,157 826.9 26
24 Alameda County, CA 6,929 475.4 27
25 Franklin County, OH 6,336 578.3 27
26 Riverside County, CA 6,194 305.6 28
27 Tarrant County, TX 6,184 370.0 28
28 Jefferson County, AL 6,139 934.8 29
29 Washington, D.C. 6,029 1036.7 30
30 Miami-Dade County, FL 5,956 247.9 30
31 Santa Clara County, CA 5,740 331.5 31
32 Duval County, FL 5,509 657.4 31
33 Fulton County, GA 5,454 568.1 32
34 Broward County, FL 5,413 302.8 32
35 Fresno County, CA 5,362 601.3 33
36 King County, WA 5,308 290.6 33
37 DeKalb County, GA 5,202 718.9 34
38 Hillsborough County, FL 5,155 445.3 34
39 Jackson County, MO 5,032 757.7 34
40 St. Louis County, MO 4,894 489.2 35
41 Allegheny County, PA 4,893 399.9 35
42 Orange County, FL 4,862 465.9 36
43 Prince George’s County, MD 4,857 577.3 36
44 Essex County, NJ 4,851 617.1 37
45 Travis County, TX 4,844 525.9 37
46 Hennepin County, MN 4,742 422.6 38
47 Honolulu County, HI 4,497 494.3 38
48 Suffolk County, MA 4,459 648.5 38
49 Kern County, CA 4,433 568.2 39
50 St Louis (City), MO 4,392 1265.0 39
51 Erie County, NY 4,350 472.1 40
52 Monroe County, NY 4,224 578.0 40
53 Richland County, SC 4,211 1209.3 40
Table 9. Chlamydia — Counties and independent cities* ranked by number of reported cases: United States,
2007
*Accounting for 40% of reported chlamydia cases.
†Counties and independent cities were ranked in descending order by number of cases reported in 2007. 
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   Age
Group
Cases Rates
Year Total Male Female Total Male Female
2003
10–14 14,911 1,061 13,849 70.4 9.8 134.0
15–19 310,505 44,331 266,175 1,516.3 421.4 2,672.5
20–24 324,411 71,476 252,936 1,565.1 670.3 2,513.3
25–29 124,890 34,916 89,974 651.6 357.3 957.7
30–34 53,572 17,810 35,762 258.7 170.4 348.7
35–39 24,658 9,772 14,886 115.2 91.1 139.4
40–44 12,287 5,675 6,612 53.5 49.8 57.2
45–54 8,214 4,012 4,202 20.1 20.0 20.2
55–64 1,653 883 770 5.9 6.6 5.3
65+ 776 323 453 2.2 2.2 2.2
TO TAL 877,478 190,723 686,755 301.7 133.3 464.7
2004
10–14 14,817 1,172 13,646 70.1 10.8 132.3
15–19 323,246 48,209 275,036 1,559.3 453.3 2,724.6
20–24 344,159 79,410 264,749 1,641.1 735.1 2,603.7
25–29 137,041 39,374 97,667 700.6 393.9 1,021.0
30–34 56,759 19,353 37,406 277.3 187.1 369.3
35–39 26,486 10,647 15,839 125.8 100.7 151.1
40–44 13,626 6,397 7,229 59.1 55.8 62.4
45–54 9,251 4,602 4,649 22.2 22.5 22.0
55–64 1,885 993 892 6.5 7.1 5.9
65+ 755 335 420 2.1 2.2 2.0
TO TAL 929,462 210,935 718,527 316.5 145.9 481.9
2005
10–14 14,124 1,200 12,924 67.7 11.2 127.0
15–19 336,036 53,734 282,302 1,597.2 498.0 2,754.5
20–24 360,574 86,931 273,643 1,713.9 800.7 2,687.8
25–29 148,059 44,712 103,347 737.9 435.4 1,054.8
30–34 60,065 21,102 38,964 299.2 207.8 392.6
35–39 28,509 11,700 16,809 135.7 110.8 161.0
40–44 14,397 6,940 7,458 63.0 61.0 64.9
45–54 10,105 5,203 4,902 23.8 24.9 22.7
55–64 2,191 1,169 1,021 7.2 8.0 6.5
65+ 885 402 483 2.4 2.6 2.3
TO TAL 976,445 233,553 742,892 329.4 160.0 493.9
2006
10–14 13,601 1,238 12,364 65.9 11.7 122.8
15–19 352,212 58,820 293,392 1,651.7 537.9 2,824.0
20–24 377,798 93,035 284,763 1,789.6 852.7 2,791.5
25–29 161,178 49,369 111,809 778.3 466.4 1,104.3
30–34 63,810 22,558 41,252 323.8 226.0 424.1
35–39 30,947 12,763 18,184 146.1 119.8 172.6
40–44 15,329 7,410 7,919 68.2 66.2 70.2
45–54 11,351 5,818 5,533 26.2 27.3 25.2
55–64 2,411 1,334 1,077 7.6 8.8 6.6
65+ 894 424 469 2.4 2.7 2.2
TO TAL 1,030,911 253,236 777,675 344.3 171.7 512.0
2007
10–14 13,629 1,251 12,378 66.1 11.8 123.0
15–19 379,418 67,248 312,170 1,779.3 615.0 3,004.7
20–24 402,595 101,780 300,815 1,907.0 932.9 2,948.8
25–29 174,828 54,890 119,939 844.2 518.6 1,184.6
30–34 69,416 24,633 44,784 352.3 246.8 460.4
35–39 33,654 13,838 19,816 158.9 129.9 188.1
40–44 16,617 7,992 8,625 73.9 71.4 76.5
45–54 13,141 6,881 6,261 30.4 32.3 28.5
55–64 2,842 1,531 1,311 9.0 10.1 8.0
65+ 812 417 395 2.2 2.7 1.8
TO TAL 1,108,374 280,931 827,443 370.2 190.4 544.8
Table 10. Chlamydia — Reported cases and rates per 100,000 population by age group and sex: United
States, 2003–2007
 NOTE: This ta ble should be used only for age com par i sons. If age was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases
for which age was known. Dif fer ences be tween to tal cases from this ta ble and oth ers in the re port are due to dif fer ent re port ing formats. The 0 to 9
year age group is not shown  because some of these cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Age 
Group 
      White, Non-His panic           Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
3002
10–14 3,336 116 3,219 8,320 721 7,600 2,210 166 2,044 145 7 139 302 19 283
15–19 93,457 8,820 84,637 147,549 25,606 121,944 48,899 7,407 41,493 4,071 445 3,627 5,517 815 4,702
20–24 103,138 20,467 82,671 138,950 34,080 104,871 58,996 12,572 46,424 6,046 1,156 4,890 5,428 1,001 4,427
25–29 33,634 9,219 24,415 52,640 16,408 36,232 28,313 6,876 21,437 3,120 810 2,310 2,385 477 1,908
30–34 13,149 4,309 8,839 22,401 8,645 13,756 13,001 3,502 9,499 1,830 493 1,337 1,066 238 828
35–39 6,091 2,586 3,505 10,340 4,799 5,541 5,728 1,644 4,084 876 252 624 630 158 472
40–44 3,331 1,689 1,642 5,339 2,859 2,480 2,355 733 1,622 434 124 310 339 75 264
45–54 2,420 1,347 1,073 3,440 1,879 1,561 1,418 454 964 378 131 247 210 55 155
55–64 524 326 198 635 361 273 293 113 180 89 33 56 51 15 36
65+ 277 112 165 301 144 158 130 37 93 22 14 8 17 3 14
TO TAL 259,808 49,115 210,693 390,660 95,741 294,918 161,629 33,576 128,053 17,042 3,469 13,573 15,964 2,859 13,105
4002
10–14 3,199 122 3,076 8,504 759 7,745 2,152 222 1,929 135 5 130 266 31 236
15–19 95,195 9,468 85,727 157,398 28,143 129,255 49,457 7,769 41,688 3,900 485 3,415 5,551 776 4,774
20–24 109,590 22,268 87,322 149,743 38,420 111,322 59,885 13,482 46,403 6,232 1,291 4,941 5,820 1,176 4,644
25–29 37,871 10,560 27,311 58,590 18,657 39,933 29,424 7,409 22,014 3,159 802 2,357 2,614 549 2,065
30–34 13,869 4,596 9,273 24,171 9,671 14,499 13,326 3,572 9,754 1,863 502 1,361 1,209 287 922
35–39 6,553 2,748 3,806 11,323 5,277 6,047 5,927 1,777 4,150 967 324 643 646 161 486
40–44 3,815 1,947 1,868 5,900 3,148 2,753 2,532 829 1,703 499 164 335 332 90 242
45–54 2,543 1,360 1,182 4,190 2,322 1,868 1,416 501 915 471 178 294 265 82 183
55–64 593 363 231 790 444 346 292 118 174 88 26 62 40 8 33
65+ 253 116 137 281 140 140 118 37 81 27 9 17 19 7 12
TO TAL 273,854 53,669 220,186 421,608 107,202 314,407 164,762 35,786 128,976 17,358 3,791 13,568 16,787 3,174 13,613
5002
10–14 2,986 126 2,860 7,355 723 6,631 2,069 183 1,886 112 14 98 332 24 309
15–19 93,876 9,636 84,240 153,777 30,214 123,563 52,224 8,526 43,698 3,761 646 3,115 5,964 882 5,082
20–24 114,066 24,303 89,763 142,156 39,355 102,801 64,259 14,772 49,487 6,315 1,416 4,899 6,148 1,295 4,853
25–29 40,477 11,580 28,897 57,704 19,824 37,879 31,795 8,528 23,267 3,107 896 2,211 2,829 715 2,114
30–34 14,600 4,739 9,861 23,142 9,740 13,402 14,349 4,132 10,217 1,849 638 1,211 1,177 270 906
35–39 7,143 3,024 4,119 10,768 5,300 5,468 6,539 2,001 4,538 1,057 337 720 625 181 444
40–44 3,986 2,045 1,941 5,662 3,148 2,515 2,656 908 1,748 559 213 346 345 92 254
45–54 2,875 1,639 1,236 4,032 2,338 1,693 1,674 575 1,100 443 158 286 240 82 158
55–64 657 408 250 791 467 324 334 123 211 148 47 101 50 21 30
65+ 253 123 130 345 168 177 141 53 87 35 18 17 15 4 12
TO TAL 281,268 57,709 223,559 406,423 111,513 294,910 176,271 39,885 136,386 17,408 4,388 13,020 17,762 3,571 14,191
6002
10–14 2,732 84 2,648 8,187 891 7,296 2,088 233 1,856 98 3 95 309 18 290
15–19 97,442 10,379 87,063 180,893 36,692 144,201 58,312 9,483 48,829 3,387 413 2,974 6,259 1,016 5,243
20–24 120,835 26,260 94,575 164,045 45,448 118,597 71,991 16,675 55,316 5,836 1,129 4,707 6,646 1,309 5,337
25–29 46,643 13,506 33,137 67,691 23,107 44,584 36,568 9,968 26,600 3,206 826 2,381 3,103 708 2,395
30–34 16,327 5,518 10,809 26,296 11,044 15,253 16,281 4,596 11,685 1,876 523 1,354 1,421 329 1,092
35–39 8,102 3,265 4,837 12,686 6,367 6,319 7,570 2,319 5,251 998 292 706 709 171 538
40–44 4,253 2,131 2,122 6,436 3,639 2,797 3,211 1,157 2,054 633 197 437 413 106 307
45–54 3,296 1,792 1,504 5,049 2,901 2,148 1,938 695 1,242 486 190 296 271 82 189
55–64 796 474 322 943 588 355 392 157 234 133 47 86 64 16 48
65+ 285 147 139 337 177 161 176 56 119 26 14 12 28 6 22
TO TAL 301,064 63,675 237,389 473,235 131,077 342,159 198,783 45,432 153,351 16,701 3,640 13,061 19,267 3,773 15,493
7002
10–14 2,584 96 2,488 8,304 894 7,410 2,139 214 1,924 125 7 119 249 17 232
15–19 102,492 11,770 90,721 199,668 42,631 157,037 60,923 10,274 50,649 3,916 556 3,360 5,801 909 4,892
20–24 127,034 27,906 99,128 181,647 52,167 129,480 73,166 17,065 56,101 6,128 1,235 4,893 6,211 1,281 4,930
25–29 50,643 14,958 35,685 75,661 26,691 48,970 37,775 10,366 27,409 3,665 944 2,721 2,992 651 2,341
30–34 17,688 5,927 11,760 29,955 12,454 17,502 16,772 4,754 12,017 1,948 579 1,368 1,299 319 979
35–39 9,117 3,531 5,586 14,183 7,025 7,158 7,721 2,438 5,283 1,144 369 775 638 152 486
40–44 4,627 2,244 2,383 7,190 3,983 3,207 3,364 1,213 2,152 649 254 395 371 108 263
45–54 3,915 2,223 1,691 5,956 3,441 2,515 2,184 801 1,383 510 193 317 249 71 178
55–64 924 574 350 1,196 688 508 430 138 292 181 76 105 30 8 22
65+ 279 171 108 318 157 162 145 56 89 31 14 17 12 5 7
TO TAL 319,703 69,523 250,180 524,791 150,377 374,415 204,853 47,391 157,462 18,311 4,230 14,081 17,871 3,525 14,346
Table 11A. Chlamydia — Re ported cases by race/eth nic ity, age group and sex: United States, 2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 10 for age-spe cific cases and rates and Ta bles 3-5 for to tal and
sex-spe cific cases and rates. If age or race/eth nic ity was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these vari -
ables were spec i fied. For the fol low ing years the states listed did not re port age and/or race/eth nic ity for most cases and their case data and pop u la tion de -
nom i na tors were ex cluded: 2003 (CO, DC, NJ); 2004 (CO, DC, NJ); 2005 (CO, DC, GA, HI, NJ); 2006 (CO, HI); 2007 (CO, HI). Dif fer ences be tween to tal
cases from this ta ble and oth ers in the re port are due to dif fer ent re port ing for mats and above listed ex clu sions. The 0 to 9 year age group is not shown
 because some of these cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Age 
Group 
      White, Non-His panic          Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
10–14 26.8 1.8 53.1 257.1 43.8 477.2 63.5 9.3 120.3 18.1 1.6 35.6 132.8 16.1 252.4
2003
15–19 747.8 137.3 1,393.3 5,004.5 1,711.0 8,399.4 1,586.1 463.0 2,797.2 502.0 106.7 919.6 2,472.4 717.0 4,295.6
20–24 836.7 327.1 1,362.2 4,926.4 2,426.8 7,405.0 1,662.2 640.1 2,928.8 641.0 243.0 1,046.1 2,692.8 977.9 4,462.0
25–29 305.2 165.7 447.3 2,176.4 1,414.5 2,878.6 788.7 347.7 1,329.4 293.1 154.6 427.0 1,440.8 573.2 2,318.3
30–34 105.8 68.9 143.3 888.2 723.6 1,036.4 384.8 192.9 607.5 155.2 85.5 222.0 642.5 288.1 995.1
35–39 45.0 38.1 52.0 400.5 395.1 405.2 191.4 103.6 290.4 84.2 49.7 116.9 369.1 188.7 543.4
40–44 21.6 22.0 21.3 199.9 228.9 174.4 91.2 54.8 130.3 44.7 26.5 61.6 185.1 84.6 279.1
45–54 8.4 9.4 7.4 77.8 92.0 65.6 39.4 25.2 53.6 23.0 17.2 28.1 67.8 37.3 95.8
55–64 2.5 3.2 1.8 25.0 31.9 19.4 14.9 12.2 17.4 9.0 7.2 10.6 27.4 16.9 37.0
65+ 1.0 0.9 1.0 10.8 13.4 9.1 6.7 4.5 8.3 2.2 3.2 1.4 10.6 4.9 14.9
TO TAL 136.7 52.7 217.4 1,122.3 577.4 1,617.9 428.2 172.3 701.5 141.6 59.4 219.1 672.2 244.4 1,087.2
10–14 26.0 1.9 51.5 263.3 46.3 487.3 59.8 12.1 109.8 16.6 1.2 32.9 119.7 27.2 214.2
2004
15–19 757.4 146.7 1,402.3 5,217.4 1,840.6 8,687.4 1,562.2 474.9 2,725.0 475.0 114.9 856.3 2,467.3 677.8 4,323.7
20–24 878.2 350.5 1,425.4 5,215.0 2,673.0 7,762.9 1,677.8 686.3 2,891.6 658.5 269.6 1,056.5 2,790.5 1,113.2 4,512.3
25–29 337.6 186.4 491.8 2,351.1 1,553.3 3,093.3 794.8 361.4 1,332.5 294.5 152.1 432.4 1,541.8 641.3 2,459.7
30–34 114.9 75.6 154.7 963.4 813.6 1,098.2 381.1 189.7 604.4 153.2 84.3 219.2 734.2 350.3 1,115.4
35–39 49.9 41.7 58.2 447.4 442.3 452.0 191.9 108.1 287.2 89.7 61.7 116.4 389.7 196.4 578.0
40–44 24.9 25.5 24.4 219.1 249.9 192.0 93.0 58.5 130.3 49.4 33.7 64.1 180.0 100.9 254.4
45–54 8.7 9.4 8.0 92.2 110.6 76.4 37.3 26.3 48.4 27.7 22.3 32.4 83.8 54.0 111.0
55–64 2.7 3.4 2.1 29.6 37.3 23.4 14.0 11.8 15.9 8.3 5.2 11.0 20.5 8.0 31.9
65+ 0.9 1.0 0.8 9.9 12.9 8.0 5.8 4.3 6.8 2.5 2.1 2.9 11.1 9.9 11.9
TO TAL 143.6 57.4 226.7 1,196.6 638.4 1,704.8 421.4 177.1 682.4 139.8 62.9 212.3 699.9 268.8 1,117.9
10–14 25.6 2.1 50.5 251.4 48.7 460.9 57.2 9.9 106.8 14.8 3.6 26.7 157.4 22.1 295.9
2005
15–19 766.1 153.2 1,412.8 5,348.8 2,073.2 8,716.3 1,613.2 511.2 2,784.1 492.4 164.2 840.9 2,665.3 775.9 4,617.5
20–24 938.3 391.5 1,508.7 5,324.4 2,927.8 7,754.4 1,854.2 782.9 3,134.6 727.6 321.8 1,144.8 2,920.5 1,215.3 4,669.1
25–29 364.1 206.5 524.5 2,432.2 1,722.3 3,101.1 855.5 414.0 1,404.5 307.6 180.5 430.5 1,635.7 817.9 2,472.6
30–34 130.1 83.9 176.8 1,028.3 911.8 1,133.5 409.4 219.0 631.4 159.6 112.7 204.4 738.5 340.3 1,135.0
35–39 57.1 48.1 66.2 467.7 487.3 450.1 208.5 119.9 309.5 100.7 65.9 133.7 390.9 229.4 548.5
40–44 27.4 28.2 26.7 229.3 272.4 191.5 95.5 62.6 131.2 58.6 46.1 70.2 193.8 106.0 276.6
45–54 10.0 11.5 8.5 93.1 116.9 72.8 42.2 28.7 55.9 27.5 20.9 33.4 75.5 54.2 94.9
55–64 3.0 3.8 2.2 30.1 39.8 22.3 15.1 11.7 18.2 14.4 10.0 18.2 24.8 21.2 28.1
65+ 0.9 1.0 0.8 12.6 16.0 10.5 6.6 5.9 7.1 3.6 4.4 3.0 8.8 4.8 11.8
TO TAL 151.7 63.4 236.7 1,234.3 709.9 1,712.6 444.5 194.9 710.5 148.4 77.0 215.9 747.0 305.3 1,174.6
10–14 22.5 1.4 44.9 255.3 54.7 462.2 54.2 11.8 98.6 11.7 0.7 23.2 149.4 17.6 284.7
2006
15–19 748.9 155.4 1,374.9 5,483.0 2,195.4 8,858.2 1,646.6 519.5 2,845.8 402.3 95.2 729.3 2,748.8 879.6 4,672.9
20–24 940.2 398.9 1,508.7 5,435.0 2,980.0 7,942.6 1,964.5 838.3 3,301.5 627.9 238.5 1,032.1 3,066.6 1,187.9 5,008.6
25–29 385.5 221.9 550.9 2,425.6 1,705.6 3,105.1 900.9 440.4 1,481.2 288.6 151.1 421.5 1,696.7 767.3 2,642.2
30–34 142.2 95.6 189.4 1,046.0 926.6 1,153.6 424.6 220.7 666.9 146.1 83.3 206.2 889.7 411.4 1,368.0
35–39 61.0 49.0 73.1 482.4 514.6 453.7 219.1 125.8 325.9 82.5 49.5 113.9 434.9 211.8 653.6
40–44 28.5 28.6 28.4 231.8 280.4 189.1 105.0 72.1 141.3 58.7 37.5 78.8 232.5 121.8 338.0
45–54 10.7 11.7 9.7 101.4 126.3 80.1 43.9 31.1 57.0 26.8 22.3 30.8 81.9 52.3 108.8
55–64 3.3 4.1 2.6 30.3 42.5 20.6 15.8 13.2 18.1 11.2 8.6 13.5 29.7 15.5 42.6
65+ 1.0 1.2 0.8 10.9 14.8 8.4 7.5 5.6 8.8 2.4 3.0 2.0 14.9 7.4 20.7
TO TAL 152.8 65.9 236.6 1,261.3 733.3 1,741.8 459.2 203.0 733.6 127.2 57.0 193.6 790.1 314.5 1,250.8
10–14 21.3 1.5 42.2 258.9 54.9 469.4 55.5 10.9 102.3 14.9 1.5 28.9 120.4 16.4 227.1
2007
15–19 787.7 176.2 1,432.7 6,052.0 2,550.8 9,646.7 1,720.4 562.8 2,951.9 465.0 128.0 823.8 2,547.7 786.8 4,360.4
20–24 988.5 423.9 1,581.4 6,018.2 3,420.5 8,671.5 1,996.5 857.9 3,348.4 659.3 260.9 1,072.8 2,866.1 1,163.3 4,626.3
25–29 418.5 245.8 593.3 2,711.3 1,970.1 3,410.6 930.7 458.1 1,526.3 329.8 172.8 481.7 1,636.1 705.7 2,582.6
30–34 154.1 102.7 206.0 1,191.5 1,044.8 1,323.7 437.4 228.3 685.9 151.7 92.4 208.4 813.3 400.0 1,226.5
35–39 68.6 52.9 84.5 539.3 567.7 514.0 223.5 132.3 327.9 94.5 62.5 124.9 391.1 188.6 589.5
40–44 31.0 30.1 31.9 258.9 306.9 216.9 110.0 75.6 148.0 60.2 48.4 71.3 208.8 124.3 289.4
45–54 12.7 14.5 10.9 119.6 149.8 93.7 49.5 35.8 63.4 28.2 22.6 33.1 75.2 44.8 102.7
55–64 3.9 4.9 2.9 38.5 49.7 29.5 17.3 11.6 22.6 15.3 13.8 16.5 13.7 7.8 19.1
65+ 0.9 1.4 0.6 10.2 13.1 8.4 6.2 5.6 6.6 2.9 3.0 2.8 6.3 6.5 6.1
TO TAL 162.3 71.9 249.3 1,398.7 841.3 1,906.0 473.2 211.7 753.3 139.5 66.3 208.8 732.9 293.8 1,158.2
Ta ble 11B. Chlamydia — Rates per 100,000 pop u la tion by race/eth nic ity, age group and sex: United States,
2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 10 for age-spe cific cases and rates and Ta bles 3-5 for to tal and
sex-spe cific cases and rates. If age or race/eth nic ity was not specified, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these vari ables were
spec i fied. For the fol low ing years the states listed did not re port age and/or race/eth nic ity for most cases and their case data and pop u la tion de nom i na tors were ex -
cluded: 2003 (CO, DC, NJ); 2004 (CO, DC, NJ); 2005 (CO, DC, GA, HI, NJ); 2006 (CO, HI); 2007 (CO, HI). Dif fer ences be tween to tal rates from this ta ble and oth ers
in the re port are due to dif fer ent re port ing for mats and above listed ex clu sions. The 0 to 9 year age group is not shown  because some of these cases may not be due
to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Rank*    State                           Cases      Rate per 100,000 Population
1 Mississippi 8,314 285.7
2 Louisiana 11,137 259.7
3 South Carolina 10,326 239.0
4 Alabama 10,885 236.7
5 Georgia 17,835 190.5
6 North Carolina 16,666 188.2
7 Ohio 21,066 183.5
8 Missouri 9,876 169.0
9 Illinois 20,813 162.2
10 Tennessee 9,564 158.4
11 Michigan 15,482 153.4
12 Delaware 1,293 151.5
13 Arkansas 4,168 148.3
14 Indiana 8,790 139.2
15 Texas 32,073 136.4
16 Oklahoma 4,827 134.9
17 Florida 23,327 129.0
18 Wisconsin 6,752 121.5
19 Maryland 6,768 120.5
U.S. TOTAL† 355,991 118.9
20 Pennsylvania 12,706 102.1
21 Nevada 2,357 94.4
22 New Mexico 1,796 91.9
23 New York 17,697 91.7
24 Alaska 579 86.4
25 California 31,294 85.8
26 Kansas 2,282 82.6
27 Arizona 5,062 82.1
28 Virginia 6,269 82.0
29 Kentucky 3,449 82.0
30 Nebraska 1,434 81.1
31 Colorado 3,376 71.0
32 New Jersey 6,076 69.6
33 Minnesota 3,459 66.9
34 Connecticut 2,327 66.4
35 Iowa 1,928 64.7
36 Washington 3,653 57.1
37 Hawaii 659 51.3
38 West Virginia 930 51.1
39 Massachusetts 2,695 41.9
40 Rhode Island 402 37.7
41 Oregon 1,236 33.4
42 South Dakota 261 33.4
43 Utah 821 32.2
YEAR 2010 TARGET 19.0
44 Idaho 269 18.3
45 North Dakota 116 18.2
46 Wyoming 81 15.7
47 Montana 122 12.9
48 New Hampshire 138 10.5
49 Vermont 64 10.3
50 Maine 118 8.9
Table 12. Gonorrhea — Reported cases and rates by state, ranked by rates: United States, 2007
*States were ranked in descending order by rate, number of cases, and alphabetically by state.
†Total includes cases reported by the District of Columbia with 2,373 cases and a rate of 408.1, but excludes outlying areas (Guam with 141 cases
and rate of 82.4, Puerto Rico with 323 cases and rate of 8.2, and Virgin Islands with 69 cases and rate of 63.5).
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Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 9,303 8,206 9,406 10,665 10,885 206.7 181.1 206.4 231.9 236.7
Alaska 573 567 600 630 579 88.3 86.5 90.4 94.0 86.4
Arizona 3,580 4,065 4,951 5,949 5,062 64.1 70.8 83.4 96.5 82.1
Arkansas 4,251 4,137 4,476 4,306 4,168 156.0 150.3 161.1 153.2 148.3
California 25,963 30,155 34,338 33,740 31,294 73.2 84.0 95.0 92.5 85.8
Colorado 2,854 3,054 3,224 3,695 3,376 62.7 66.4 69.1 77.7 71.0
Connecticut 3,114 2,862 2,750 2,610 2,327 89.4 81.7 78.3 74.5 66.4
Delaware 1,128 894 913 1,485 1,293 138.0 107.7 108.2 174.0 151.5
District of Columbia 2,508 2,568 2,146 1,887 2,373 444.4 463.9 389.8 324.5 408.1
Florida 18,974 18,580 20,225 23,976 23,327 111.5 106.8 113.7 132.5 129.0
Georgia 17,686 15,783 15,860 19,669 17,835 203.6 178.8 174.8 210.1 190.5
Hawaii 1,263 1,193 1,024 885 659 100.4 94.5 80.3 68.8 51.3
Idaho 68 103 119 206 269 5.0 7.4 8.3 14.0 18.3
Illinois 21,817 20,597 20,019 20,186 20,813 172.4 162.0 156.8 157.3 162.2
Indiana 6,681 6,851 8,094 8,732 8,790 107.8 109.8 129.1 138.3 139.2
Iowa 1,554 1,249 1,606 1,966 1,928 52.8 42.3 54.1 65.9 64.7
Kansas 2,647 2,542 2,605 2,210 2,282 97.2 92.9 94.9 80.0 82.6
Kentucky 3,578 2,758 2,935 3,277 3,449 86.9 66.5 70.3 77.9 82.0
Louisiana 11,850 10,538 9,572 10,883 11,137 263.5 233.4 211.6 253.8 259.7
Maine 233 210 142 137 118 17.8 15.9 10.7 10.4 8.9
Maryland 8,032 8,297 7,035 7,328 6,768 145.8 149.3 125.6 130.5 120.5
Massachusetts 2,901 3,057 2,537 2,429 2,695 45.1 47.6 39.6 37.7 41.9
Michigan 13,965 17,376 17,684 15,677 15,482 138.5 171.8 174.7 155.3 153.4
Minnesota 3,202 2,957 3,482 3,303 3,459 63.3 58.0 67.8 63.9 66.9
Mississippi 6,328 7,163 7,171 7,511 8,314 219.6 246.7 245.5 258.1 285.7
Missouri 8,792 9,218 9,455 10,204 9,876 154.1 160.2 163.0 174.6 169.0
Montana 122 88 158 194 122 13.3 9.5 16.9 20.5 12.9
Nebraska 1,623 1,147 1,158 1,433 1,434 93.3 65.6 65.8 81.0 81.1
Nevada 2,221 3,078 2,880 2,791 2,357 99.1 131.8 119.3 111.8 94.4
New Hampshire 125 133 177 180 138 9.7 10.2 13.5 13.7 10.5
New Jersey 7,944 6,696 5,722 5,492 6,076 92.0 77.0 65.6 62.9 69.6
New Mexico 1,169 1,306 1,552 1,733 1,796 62.4 68.6 80.5 88.7 91.9
New York 22,166 18,737 17,717 17,459 17,697 115.5 97.5 92.0 90.4 91.7
North Carolina 15,116 15,194 15,072 17,312 16,666 179.8 177.9 173.6 195.5 188.2
North Dakota 103 110 128 153 116 16.3 17.3 20.1 24.1 18.2
Ohio 22,537 20,467 20,985 19,190 21,066 197.1 178.6 183.1 167.2 183.5
Oklahoma 4,552 4,453 5,228 4,951 4,827 129.6 126.4 147.4 138.3 134.9
Oregon 1,000 1,302 1,562 1,461 1,236 28.1 36.2 42.9 39.5 33.4
Pennsylvania 11,866 11,236 11,222 11,466 12,706 96.0 90.6 90.3 92.2 102.1
Rhode Island 973 816 438 508 402 90.4 75.5 40.7 47.6 37.7
South Carolina 8,518 9,171 8,561 10,320 10,326 205.4 218.5 201.2 238.8 239.0
South Dakota 226 304 351 367 261 29.6 39.4 45.2 46.9 33.4
Tennessee 8,519 8,475 8,605 9,694 9,564 145.8 143.6 144.3 160.5 158.4
Texas 24,595 24,371 26,110 30,449 32,073 111.2 108.4 114.2 129.5 136.4
Utah 412 603 727 888 821 17.5 25.2 29.4 34.8 32.2
Vermont 97 86 60 72 64 15.7 13.8 9.6 11.5 10.3
Virginia 9,066 8,565 8,346 6,476 6,269 122.7 114.8 110.3 84.7 82.0
Washington 2,753 2,810 3,739 4,231 3,653 44.9 45.3 59.5 66.2 57.1
West Virginia 847 892 770 953 930 46.8 49.1 42.4 52.4 51.1
Wisconsin 5,663 5,053 5,869 6,927 6,752 103.5 91.7 106.0 124.7 121.5
Wyoming 46 59 87 120 81 9.2 11.6 17.1 23.3 15.7
U.S. TOTAL 335,104 330,132 339,593 358,366 355,991 115.2 112.4 114.6 119.7 118.9
Northeast 49,419 43,833 40,765 40,353 42,223 90.8 80.3 74.6 73.7 77.1
Midwest 88,810 87,871 91,436 90,348 92,259 135.8 133.7 138.6 136.4 139.3
South 154,851 150,045 152,431 171,142 170,204 148.1 141.6 141.8 156.9 156.0
West 42,024 48,383 54,961 56,523 51,305 63.2 71.8 80.5 81.5 74.0
Guam 65 114 106 98 141 39.7 68.6 62.9 57.3 82.4
Puerto Rico 276 267 328 302 323 7.1 6.9 8.4 7.7 8.2
Virgin Islands 91 75 30 34 69 83.6 68.9 27.6 31.3 63.5
OUTLYING AREAS 432 456 464 434 533 10.4 10.9 11.1 10.3 12.7
TOTAL 335,536 330,588 340,057 358,800 356,524 113.8 111.0 113.1 118.2 117.4
Table 13. Gonorrhea —  Reported cases and rates by state/area and region listed in alphabetical order: United 
States and outlying areas, 2003–2007
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Alabama 4,583 3,673 4,494 5,983 6,095 197.4 157.4 191.5 252.5 257.2
Alaska 339 337 349 356 326 108.1 106.5 108.9 110.0 100.7
Arizona 1,636 1,787 2,338 2,847 2,342 58.7 62.3 78.8 92.4 76.0
Arkansas 2,108 2,032 2,252 2,182 2,275 151.5 144.7 159.0 152.3 158.7
California 11,912 13,620 15,827 15,688 14,533 67.0 75.8 87.5 86.0 79.7
Colorado 1,529 1,656 1,619 1,879 1,807 67.8 72.6 70.1 79.6 76.6
Connecticut 1,910 1,756 1,590 1,478 1,372 106.6 97.4 88.1 82.2 76.3
Delaware 602 508 515 829 699 143.5 119.3 119.2 188.7 159.1
District of Columbia 1,137 1,293 1,029 808 1,077 381.2 443.1 355.6 261.6 348.7
Florida 9,419 9,371 10,204 12,427 11,793 108.5 105.6 112.6 135.0 128.1
Georgia 9,137 8,119 7,819 10,002 9,334 207.8 181.9 170.5 210.4 196.4
Hawaii 723 680 619 476 295 115.3 107.5 96.8 74.1 45.9
Idaho 18 42 57 113 152 2.6 6.0 8.0 15.5 20.9
Illinois 11,624 11,510 10,998 10,926 11,312 180.4 177.9 169.4 167.7 173.6
Indiana 3,610 3,550 4,453 4,806 4,884 114.6 112.0 139.9 150.0 152.5
Iowa 869 736 885 1,179 1,121 58.1 49.1 58.8 78.1 74.3
Kansas 1,522 1,565 1,645 1,327 1,401 110.8 113.6 119.1 95.3 100.6
Kentucky 1,845 1,415 1,530 1,709 1,887 87.8 67.0 72.1 79.7 88.0
Louisiana 6,076 5,450 4,761 5,605 5,822 262.6 234.7 204.9 254.5 264.4
Maine 84 84 61 54 45 12.6 12.5 9.0 8.0 6.7
Maryland 4,166 4,327 3,620 3,850 3,529 146.5 150.9 125.4 132.8 121.7
Massachusetts 1,342 1,531 1,320 1,214 1,282 40.4 46.3 40.0 36.6 38.6
Michigan 7,823 9,614 10,161 8,900 8,984 152.5 186.9 197.5 173.6 175.3
Minnesota 1,784 1,712 1,909 1,814 1,930 70.0 66.6 73.9 69.8 74.3
Mississippi 3,757 4,362 4,234 4,400 4,901 253.0 291.9 281.8 293.1 326.5
Missouri 4,794 5,139 5,334 5,752 5,481 164.1 174.6 179.9 192.5 183.4
Montana 74 54 102 123 75 16.1 11.6 21.8 26.1 15.9
Nebraska 924 656 688 865 847 105.0 74.2 77.4 97.0 95.0
Nevada 1,062 1,417 1,343 1,257 1,066 96.6 123.7 113.3 102.5 86.9
New Hampshire 57 54 97 97 63 8.7 8.2 14.6 14.6 9.5
New Jersey 4,550 3,607 3,077 2,829 3,059 102.6 80.8 68.9 63.4 68.6
New Mexico 598 749 884 1,003 974 62.8 77.4 90.2 101.3 98.4
New York 11,296 9,720 9,031 8,479 8,324 113.9 98.0 91.0 85.2 83.6
North Carolina 7,383 7,384 7,545 8,718 8,941 172.6 170.0 171.0 193.1 198.0
North Dakota 59 72 76 86 66 18.6 22.7 23.8 27.2 20.9
Ohio 12,390 11,144 11,592 10,508 11,771 211.1 189.6 197.3 178.7 200.2
Oklahoma 2,562 2,471 3,018 2,780 2,606 143.9 138.6 168.2 153.2 143.6
Oregon 389 567 661 609 564 21.7 31.4 36.1 32.7 30.3
Pennsylvania 6,644 6,295 6,271 6,219 6,946 104.2 98.5 98.0 97.3 108.6
Rhode Island 517 478 227 273 169 92.7 85.4 40.8 49.5 30.6
South Carolina 4,369 5,007 4,601 5,406 5,640 205.3 232.6 211.0 243.8 254.3
South Dakota 133 178 196 215 153 34.6 45.9 50.2 54.9 39.1
Tennessee 4,263 4,327 4,395 5,104 5,247 142.6 143.5 144.5 165.3 169.9
Texas 12,643 12,433 13,827 15,619 16,192 113.8 110.1 120.5 132.4 137.3
Utah 153 266 319 369 345 13.1 22.4 25.9 29.1 27.2
Vermont 48 53 26 39 30 15.2 16.8 8.2 12.3 9.5
Virginia 4,809 4,650 4,402 3,287 3,369 128.1 122.7 114.5 84.6 86.7
Washington 1,167 1,229 1,622 1,938 1,858 38.0 39.5 51.5 60.4 58.0
West Virginia 464 470 427 488 504 50.0 50.6 46.0 52.6 54.3
Wisconsin 3,299 2,953 3,433 4,047 4,066 119.3 106.1 122.9 144.8 145.4
Wyoming 28 39 54 71 41 11.2 15.5 21.4 28.0 16.1
U.S. TOTAL 174,230 172,142 177,537 187,033 187,595 117.9 115.4 118.0 123.1 123.5
Northeast 26,448 23,578 21,700 20,682 21,290 94.3 83.9 77.2 73.5 75.7
Midwest 48,831 48,829 51,370 50,425 52,016 146.7 146.1 153.2 150.0 154.8
South 79,323 77,292 78,673 89,197 89,911 149.0 143.4 144.0 160.7 162.0
West 19,628 22,443 25,794 26,729 24,378 59.1 66.6 75.6 77.2 70.4
Guam 39 70 71 49 66 48.7 86.0 85.9 58.4 78.7
Puerto Rico 121 150 194 152 165 6.0 7.4 9.5 7.4 8.1
Virgin Islands 65 48 18 23 51 114.3 84.4 31.7 40.5 89.8
OUTLYING AREAS 225 268 283 224 282 10.5 12.4 13.0 10.3 12.9
TOTAL 174,455 172,410 177,820 187,257 187,877 116.4 114.0 116.5 121.5 121.9
Table 14. Gonorrhea —  Women –  Reported cases and rates by state/area and region listed in alphabetical
order: United States and outlying areas, 2003–2007
 NOTE: Cases reported with unknown sex are not included in this table.
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Alabama 4,705 4,526 4,892 4,678 4,786 215.9 206.1 221.2 209.8 214.7
Alaska 234 230 251 274 253 69.8 67.9 73.1 79.1 73.0
Arizona 1,942 2,274 2,610 3,097 2,718 69.6 79.1 87.8 100.4 88.1
Arkansas 2,141 2,104 2,223 2,122 1,890 160.5 156.0 163.1 154.0 137.2
California 13,965 16,440 18,348 17,856 16,632 78.8 91.8 101.7 98.0 91.3
Colorado 1,325 1,398 1,605 1,816 1,569 57.7 60.2 68.1 75.9 65.6
Connecticut 1,204 1,106 1,160 1,132 955 71.2 65.1 68.0 66.3 56.0
Delaware 526 386 398 656 594 132.1 95.4 96.8 158.4 143.4
District of Columbia 1,361 1,269 1,113 1,072 1,284 511.5 484.9 426.2 393.2 470.9
Florida 9,555 9,209 10,021 11,546 11,527 114.6 108.0 114.9 130.0 129.7
Georgia 8,487 7,596 7,885 9,510 8,401 198.0 174.0 175.7 206.2 182.2
Hawaii 540 513 405 409 364 85.6 81.4 63.7 63.6 56.6
Idaho 50 60 60 92 112 7.3 8.6 8.4 12.5 15.2
Illinois 10,192 9,087 9,020 9,260 9,501 164.1 145.5 143.8 146.6 150.4
Indiana 3,040 3,270 3,616 3,895 3,880 99.8 106.6 117.1 125.2 124.7
Iowa 680 511 721 787 807 47.0 35.1 49.4 53.4 54.8
Kansas 1,125 977 960 883 881 83.3 71.9 70.4 64.4 64.2
Kentucky 1,727 1,338 1,399 1,561 1,559 85.6 65.8 68.2 75.7 75.6
Louisiana 5,710 5,029 4,744 5,186 5,201 261.6 229.2 215.7 248.6 249.4
Maine 149 126 81 83 73 23.4 19.6 12.5 12.8 11.3
Maryland 3,858 3,969 3,410 3,461 3,238 144.7 147.5 125.7 127.4 119.2
Massachusetts 1,552 1,524 1,216 1,212 1,412 49.9 49.1 39.2 38.9 45.3
Michigan 6,141 7,762 7,468 6,738 6,447 124.0 156.2 150.1 135.6 129.7
Minnesota 1,418 1,245 1,573 1,489 1,529 56.5 49.2 61.7 58.0 59.5
Mississippi 2,571 2,801 2,937 3,111 3,413 184.1 198.8 207.0 220.7 242.2
Missouri 3,998 4,079 4,121 4,452 4,395 143.7 145.1 145.3 156.0 154.0
Montana 47 33 56 71 47 10.3 7.1 12.0 15.0 9.9
Nebraska 695 488 467 552 583 80.9 56.5 53.7 63.0 66.5
Nevada 1,158 1,658 1,535 1,533 1,291 101.4 139.5 124.9 120.8 101.7
New Hampshire 68 79 80 83 75 10.7 12.3 12.4 12.8 11.6
New Jersey 3,389 3,089 2,645 2,657 3,014 80.6 72.9 62.3 62.3 70.7
New Mexico 567 557 668 730 822 61.5 59.5 70.4 75.7 85.2
New York 10,813 8,985 8,680 8,976 9,363 116.6 96.6 93.1 95.9 100.1
North Carolina 7,733 7,810 7,527 8,594 7,725 187.2 186.0 176.2 198.0 177.9
North Dakota 44 38 52 67 50 13.9 12.0 16.4 21.0 15.7
Ohio 9,856 9,046 9,035 8,493 9,164 177.1 162.1 161.7 151.7 163.7
Oklahoma 1,990 1,982 2,210 2,171 2,221 114.9 113.9 126.0 123.0 125.9
Oregon 611 735 901 852 672 34.5 41.1 49.8 46.3 36.5
Pennsylvania 5,214 4,941 4,950 5,247 5,757 87.1 82.2 82.1 86.8 95.2
Rhode Island 456 338 211 235 232 88.0 64.8 40.6 45.5 44.9
South Carolina 4,118 4,136 3,925 4,899 4,665 204.0 202.2 189.2 232.9 221.8
South Dakota 93 126 155 152 107 24.5 32.9 40.2 38.9 27.4
Tennessee 4,256 4,148 4,209 4,590 4,317 149.2 143.7 144.1 155.5 146.3
Texas 11,932 11,902 12,269 14,812 15,819 108.4 106.3 107.7 126.4 135.0
Utah 259 337 408 519 476 21.9 28.1 32.9 40.5 37.1
Vermont 49 33 34 33 34 16.1 10.8 11.1 10.7 11.1
Virginia 4,237 3,904 3,939 3,187 2,895 116.7 106.3 105.8 84.8 77.1
Washington 1,586 1,581 2,117 2,293 1,795 51.9 51.1 67.4 71.9 56.3
West Virginia 380 421 343 465 426 43.0 47.4 38.6 52.2 47.8
Wisconsin 2,341 2,087 2,431 2,870 2,673 86.5 76.5 88.7 104.0 96.8
Wyoming 18 20 33 49 40 7.1 7.8 12.9 18.8 15.3
U.S. TOTAL 160,106 157,303 161,117 170,508 167,684 111.9 108.8 110.4 115.6 113.7
Northeast 22,894 20,221 19,057 19,658 20,915 86.8 76.4 71.8 73.9 78.6
Midwest 39,623 38,716 39,619 39,638 40,017 123.3 119.8 122.1 121.5 122.7
South 75,287 72,530 73,444 81,621 79,961 146.7 139.3 138.9 152.3 149.2
West 22,302 25,836 28,997 29,591 26,791 67.1 76.7 84.9 85.3 77.2
Guam 26 44 35 49 75 31.1 51.9 40.7 56.2 86.1
Puerto Rico 155 117 134 150 158 8.3 6.3 7.1 8.0 8.4
Virgin Islands 26 27 12 11 18 50.0 52.0 23.1 21.2 34.7
OUTLYING AREAS 207 188 181 210 251 10.3 9.4 9.0 10.4 12.4
TOTAL 160,313 157,491 161,298 170,718 167,935 110.5 107.5 109.0 114.2 112.3
Table 15. Gonorrhea — Men – Reported cases and rates by state/area and region listed in alphabetical order:
United States and outlying areas, 2003–2007
 NOTE: Cases reported with unknown sex are not included in this table.
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Atlanta-Sandy Springs-Marietta, GA 8,825 7,355 7,838 10,223 9,060 191.4 156.2 159.4 199.0 176.3
Austin-Round Rock, TX 1,458 1,472 1,706 2,446 2,075 105.8 104.2 117.5 161.6 137.1
Baltimore-Towson, MD 5,382 5,256 4,779 4,653 4,156 205.7 199.2 180.0 175.0 156.3
Birmingham-Hoover, AL 2,212 2,377 2,381 2,444 3,129 206.2 219.6 218.4 222.2 284.4
Boston-Cambridge-Quincy, MA-NH 1,818 1,998 1,684 1,542 1,770 40.9 45.2 38.2 34.6 39.7
Buffalo-Cheektowaga-Tonawanda, NY 1,809 1,670 1,926 2,068 2,289 156.0 144.7 167.8 181.8 201.2
Charlotte-Gastonia-Concord, NC-SC 3,130 2,998 3,330 3,388 2,388 217.8 203.3 218.9 214.0 150.9
Chicago-Naperville-Joliet, IL-IN-WI 17,080 15,684 14,857 15,127 14,979 183.0 167.0 157.3 159.1 157.6
Cincinnati-Middletown, OH-KY-IN 4,206 3,455 3,927 3,862 4,583 205.4 167.9 189.7 183.5 217.8
Cleveland-Elyria-Mentor, OH 5,338 4,472 4,641 4,663 4,286 249.5 209.3 218.3 220.6 202.7
Columbus, OH 2,963 3,004 3,445 3,303 4,136 176.9 177.3 201.6 191.4 239.7
Dallas-Fort Worth-Arlington, TX 7,570 7,119 8,416 8,365 10,064 135.4 124.9 144.6 139.3 167.6
Denver-Aurora, CO 2,136 2,232 2,147 2,253 2,238 92.8 95.8 91.0 93.5 92.9
Detroit-Warren-Livonia, MI 7,173 9,299 10,766 8,535 8,554 160.0 207.0 239.9 191.0 191.4
Hartford-West Hartford-East Hartford, CT 1,030 933 993 988 920 87.4 78.8 83.6 83.1 77.4
Houston-Baytown-Sugar Land, TX 5,191 5,525 5,213 7,318 7,757 102.3 106.7 98.7 132.1 140.0
Indianapolis, IN 3,349 3,510 4,142 4,410 4,543 209.9 216.5 252.5 264.7 272.7
Jacksonville, FL 2,574 2,197 2,578 2,954 3,113 214.0 179.3 206.5 231.1 243.6
Kansas City, MO-KS 3,694 3,832 3,769 3,822 3,683 193.9 199.0 193.5 194.3 187.2
Las Vegas-Paradise, NV 1,968 2,645 2,487 2,478 2,112 124.8 160.2 145.4 139.4 118.8
Los Angeles-Long Beach-Santa Ana, CA 9,753 11,103 12,697 12,210 11,059 76.0 85.9 98.2 94.3 85.4
Louisville, KY-IN 1,617 1,484 1,551 1,749 1,908 135.9 123.6 128.3 143.1 156.1
Memphis, TN-MS-AR 3,764 3,832 3,782 4,665 4,756 303.7 306.5 299.9 366.0 373.1
Miami-Fort Lauderdale-Miami Beach, FL 4,455 4,622 4,497 5,356 5,152 84.2 86.2 82.9 98.0 94.3
Milwaukee-Waukesha-West Allis, WI 3,998 3,311 4,031 5,006 4,960 264.0 218.4 266.4 331.5 328.5
Minneapolis-St. Paul-Bloomington, MN-WI 2,781 2,439 2,920 2,780 2,834 90.2 78.3 92.9 87.6 89.3
Nashville-Davidson-Murfreesboro, TN 1,888 1,602 1,474 1,734 1,692 137.7 114.8 103.6 119.2 116.3
New Orleans-Metairie-Kenner, LA 3,956 3,316 2,609 1,962 2,713 300.3 251.3 197.7 191.5 264.8
New York-Newark-Edison, NY-NJ-PA 20,480 16,915 15,533 14,949 15,396 109.9 90.4 82.9 79.4 81.8
Oklahoma City, OK 2,050 2,153 2,548 2,315 2,373 181.0 188.1 220.3 197.5 202.4
Orlando, FL 2,165 2,285 2,848 3,393 2,743 120.1 122.7 147.3 170.9 138.2
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 8,502 7,818 7,719 8,163 8,669 147.3 134.8 132.6 140.1 148.8
Phoenix-Mesa-Scottsdale, AZ 2,795 3,161 3,133 4,260 3,333 77.8 85.1 81.1 105.5 82.5
Pittsburgh, PA 2,035 1,799 2,157 2,057 2,599 84.4 74.9 90.4 86.8 109.6
Portland-Vancouver-Beaverton, OR-WA 858 1,173 1,393 1,128 1,053 42.1 56.8 66.5 52.8 49.3
Providence-New Bedford-Fall River, RI-MA 1,136 1,048 650 693 621 70.0 64.3 40.1 43.0 38.5
Richmond, VA 2,319 2,160 2,361 1,778 2,199 203.7 187.1 200.8 148.9 184.2
Riverside-San Bernardino-Ontario, CA 2,512 2,631 3,012 2,994 3,166 69.0 69.4 77.0 74.4 78.6
Rochester, NY 1,897 1,900 1,899 1,457 1,207 182.2 182.4 182.8 140.7 116.6
Sacramento-Arden-Arcade-Roseville, CA 1,859 2,066 2,450 2,235 2,315 94.1 102.4 120.0 108.1 112.0
Salt Lake City, UT 276 371 460 623 573 27.5 36.4 44.5 58.3 53.7
San Antonio, TX 2,333 2,183 2,300 2,701 2,601 128.1 117.7 121.7 139.1 133.9
San Diego-Carlsbad-San Marcos, CA 2,007 2,379 2,695 2,767 2,385 68.5 81.1 91.9 94.1 81.1
San Francisco-Oakland-Fremont, CA 4,394 4,967 5,713 6,029 5,695 105.7 119.6 137.6 144.2 136.2
San Jose-Sunnyvale-Santa Clara, CA 740 1,084 1,055 1,065 893 42.7 62.2 60.1 59.6 50.0
Seattle-Tacoma-Bellevue, WA 2,027 1,883 2,704 3,079 2,572 64.5 59.5 84.4 94.3 78.8
St. Louis, MO-IL 5,600 5,719 6,391 6,547 6,483 204.7 206.9 230.0 234.1 231.8
Tampa-St. Petersburg-Clearwater, FL 3,160 2,801 2,910 3,667 3,819 124.8 108.2 109.9 135.9 141.6
Virginia Beach-Norfolk-Newport News, VA-NC 4,201 3,812 3,355 2,544 2,504 256.6 231.8 203.7 154.2 151.8
Washington-Arlington-Alexandria, DC-VA-MD-WV 5,262 5,803 4,497 4,358 4,665 103.4 112.9 86.2 82.4 88.2
U.S. MSA TOTAL 199,726 194,853 202,369 209,106 208,773 127.8 123.4 126.9 129.6 129.4
Table 16. Gonorrhea —  Reported cases and rates in selected metropolitan statistical areas* (MSAs) listed in
alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Atlanta-Sandy Springs-Marietta, GA 4,177 3,563 3,567 5,026 4,515 179.6 150.3 144.1 193.5 173.8
Austin-Round Rock, TX 644 692 830 1,134 992 95.4 100.1 116.6 153.3 134.1
Baltimore-Towson, MD 2,793 2,710 2,426 2,470 2,179 206.0 198.2 176.5 179.2 158.1
Birmingham-Hoover, AL 1,100 1,060 1,133 1,511 1,761 197.9 189.2 200.9 265.4 309.3
Boston-Cambridge-Quincy, MA-NH 771 937 793 728 773 33.7 41.2 35.0 31.8 33.7
Buffalo-Cheektowaga-Tonawanda, NY 974 920 1,079 1,153 1,258 161.7 153.4 181.2 195.5 213.3
Charlotte-Gastonia-Concord, NC-SC 1,492 1,413 1,604 1,584 1,188 204.4 188.6 207.8 196.9 147.7
Chicago-Naperville-Joliet, IL-IN-WI 8,804 8,546 7,948 7,853 7,813 185.1 178.7 165.3 162.7 161.8
Cincinnati-Middletown, OH-KY-IN 2,371 2,038 2,274 2,465 2,884 226.0 193.3 214.8 229.0 267.9
Cleveland-Elyria-Mentor, OH 2,620 2,192 2,264 2,277 2,180 235.3 197.2 204.8 207.4 198.6
Columbus, OH 1,569 1,475 1,896 1,758 2,142 184.5 171.8 219.0 201.2 245.2
Dallas-Fort Worth-Arlington, TX 3,822 3,547 4,135 4,129 4,905 136.9 124.7 142.6 138.1 164.1
Denver-Aurora, CO 1,091 1,144 996 1,044 1,128 95.2 98.7 84.9 87.0 94.0
Detroit-Warren-Livonia, MI 3,807 4,850 6,079 4,613 4,721 165.5 210.5 264.4 201.8 206.5
Hartford-West Hartford-East Hartford, CT 614 533 520 521 522 101.2 87.3 85.0 85.4 85.5
Houston-Baytown-Sugar Land, TX 2,509 2,813 3,016 3,806 3,805 98.8 108.6 114.2 137.5 137.4
Indianapolis, IN 1,659 1,698 2,163 2,297 2,385 204.1 205.7 259.1 271.1 281.4
Jacksonville, FL 1,201 1,083 1,240 1,506 1,532 195.1 173.0 194.5 230.8 234.8
Kansas City, MO-KS 1,890 2,027 2,035 2,099 2,040 194.6 206.8 205.5 209.6 203.7
Las Vegas-Paradise, NV 931 1,206 1,163 1,123 954 120.2 148.7 138.4 128.4 109.1
Los Angeles-Long Beach-Santa Ana, CA 4,371 4,997 5,687 5,657 5,001 67.6 76.6 87.2 86.7 76.7
Louisville, KY-IN 767 720 740 887 1,026 125.6 116.9 119.6 141.6 163.8
Memphis, TN-MS-AR 1,860 1,926 1,990 2,548 2,789 289.8 297.6 305.6 386.0 422.6
Miami-Fort Lauderdale-Miami Beach, FL 2,114 2,307 2,317 2,708 2,444 77.6 83.5 83.0 96.4 87.0
Milwaukee-Waukesha-West Allis, WI 2,295 1,906 2,298 2,923 2,972 295.0 244.9 295.8 378.4 384.8
Minneapolis-St. Paul-Bloomington, MN-WI 1,508 1,373 1,548 1,486 1,500 96.8 87.3 97.7 93.0 93.8
Nashville-Davidson-Murfreesboro, TN 873 742 661 794 800 125.4 104.9 91.8 107.6 108.5
New Orleans-Metairie-Kenner, LA 1,961 1,606 1,287 965 1,322 286.0 234.0 187.8 181.7 248.9
New York-Newark-Edison, NY-NJ-PA 10,650 8,821 7,784 7,015 6,979 110.2 91.0 80.2 72.1 71.7
Oklahoma City, OK 1,138 1,181 1,486 1,275 1,202 197.7 203.8 253.5 214.2 201.9
Orlando, FL 1,039 1,063 1,286 1,688 1,377 113.8 112.9 131.6 168.5 137.5
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 4,593 4,189 4,219 4,257 4,416 153.5 139.5 140.0 141.4 146.7
Phoenix-Mesa-Scottsdale, AZ 1,254 1,373 1,456 2,014 1,497 70.3 74.5 76.0 100.7 74.8
Pittsburgh, PA 1,192 1,063 1,216 1,174 1,530 94.9 85.0 97.9 95.3 124.2
Portland-Vancouver-Beaverton, OR-WA 331 491 551 436 446 32.3 47.4 52.4 40.7 41.6
Providence-New Bedford-Fall River, RI-MA 603 607 365 374 282 71.7 72.0 43.5 44.9 33.8
Richmond, VA 1,260 1,187 1,256 824 1,122 214.6 199.7 207.8 134.4 183.0
Riverside-San Bernardino-Ontario, CA 1,289 1,323 1,572 1,602 1,705 70.8 69.8 80.5 79.6 84.7
Rochester, NY 982 919 1,006 748 608 183.5 172.0 188.9 141.0 114.6
Sacramento-Arden-Arcade-Roseville, CA 942 1,049 1,307 1,164 1,190 93.9 102.3 125.9 110.7 113.2
Salt Lake City, UT 91 143 183 246 229 18.3 28.4 35.8 46.7 43.5
San Antonio, TX 1,152 1,109 1,155 1,412 1,279 124.0 117.2 119.8 142.3 128.9
San Diego-Carlsbad-San Marcos, CA 739 936 1,108 1,158 961 50.8 64.2 76.3 79.3 65.8
San Francisco-Oakland-Fremont, CA 1,578 1,580 2,052 2,122 2,174 75.2 75.4 97.9 100.9 103.4
San Jose-Sunnyvale-Santa Clara, CA 328 467 457 488 385 38.4 54.6 53.1 55.8 44.1
Seattle-Tacoma-Bellevue, WA 732 717 1,060 1,300 1,205 46.5 45.2 66.1 79.6 73.8
St. Louis, MO-IL 3,037 3,213 3,638 3,718 3,539 214.5 225.0 253.5 257.5 245.1
Tampa-St. Petersburg-Clearwater, FL 1,498 1,474 1,542 2,064 1,973 114.7 110.6 113.3 149.0 142.5
Virginia Beach-Norfolk-Newport News, VA-NC 2,111 1,990 1,717 1,305 1,355 254.6 239.1 205.6 154.9 160.9
Washington-Arlington-Alexandria, DC-VA-MD-WV 2,520 2,973 2,269 2,048 2,268 96.6 113.1 85.1 75.6 83.7
U.S. MSA TOTAL 99,647 97,892 102,374 105,497 105,253 125.2 121.8 126.2 128.7 128.4
Table 17. Gonorrhea — Women – Reported cases and rates in selected metropolitan statistical areas* (MSAs)
listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 4,616 3,750 4,183 5,083 4,484 202.0 160.4 171.3 200.1 176.5
Austin-Round Rock, TX 811 768 870 1,310 1,081 115.4 106.5 117.4 169.2 139.7
Baltimore-Towson, MD 2,588 2,546 2,352 2,180 1,976 205.3 200.1 183.6 170.3 154.4
Birmingham-Hoover, AL 1,108 1,316 1,243 932 1,367 214.4 252.1 236.2 175.6 257.6
Boston-Cambridge-Quincy, MA-NH 1,045 1,060 890 812 996 48.6 49.4 41.5 37.5 46.0
Buffalo-Cheektowaga-Tonawanda, NY 835 750 847 913 1,031 149.9 135.2 153.4 166.7 188.3
Charlotte-Gastonia-Concord, NC-SC 1,638 1,583 1,726 1,804 1,199 231.5 218.1 230.4 231.7 154.0
Chicago-Naperville-Joliet, IL-IN-WI 8,265 7,122 6,900 7,267 7,161 180.6 154.5 148.8 155.4 153.1
Cincinnati-Middletown, OH-KY-IN 1,804 1,375 1,616 1,373 1,674 180.8 136.9 159.7 133.6 162.9
Cleveland-Elyria-Mentor, OH 2,683 2,236 2,329 2,366 2,091 261.5 218.0 228.2 232.8 205.7
Columbus, OH 1,380 1,509 1,531 1,537 1,985 167.4 180.6 181.6 180.4 233.0
Dallas-Fort Worth-Arlington, TX 3,742 3,560 4,276 4,230 5,123 133.7 124.7 146.5 140.3 170.0
Denver-Aurora, CO 1,045 1,088 1,151 1,209 1,110 90.5 92.9 97.0 100.0 91.8
Detroit-Warren-Livonia, MI 3,365 4,449 4,657 3,890 3,786 154.1 203.2 212.7 178.2 173.4
Hartford-West Hartford-East Hartford, CT 416 400 473 467 398 72.8 69.7 82.1 80.7 68.8
Houston-Baytown-Sugar Land, TX 2,672 2,707 2,194 3,504 3,930 105.3 104.5 83.1 126.4 141.8
Indianapolis, IN 1,680 1,808 1,972 2,106 2,150 214.7 227.1 244.8 257.3 262.6
Jacksonville, FL 1,373 1,114 1,338 1,448 1,581 233.8 185.9 219.1 231.5 252.7
Kansas City, MO-KS 1,804 1,805 1,734 1,723 1,643 193.3 191.0 181.1 178.4 170.1
Las Vegas-Paradise, NV 1,036 1,436 1,322 1,354 1,158 129.1 171.0 152.0 149.9 128.2
Los Angeles-Long Beach-Santa Ana, CA 5,364 6,084 6,985 6,505 6,023 84.4 95.0 109.1 101.2 93.7
Louisville, KY-IN 848 761 811 858 881 146.3 130.0 137.6 144.0 147.8
Memphis, TN-MS-AR 1,904 1,906 1,792 2,117 1,967 318.7 316.1 293.9 344.4 320.0
Miami-Fort Lauderdale-Miami Beach, FL 2,341 2,315 2,180 2,648 2,706 91.3 89.1 82.9 99.7 101.9
Milwaukee-Waukesha-West Allis, WI 1,682 1,405 1,731 2,080 1,975 228.5 190.6 235.2 282.0 267.8
Minneapolis-St. Paul-Bloomington, MN-WI 1,273 1,066 1,372 1,294 1,334 83.4 69.0 88.1 82.1 84.6
Nashville-Davidson-Murfreesboro, TN 1,015 860 813 940 892 150.4 125.0 115.8 131.0 124.3
New Orleans-Metairie-Kenner, LA 1,988 1,684 1,299 981 1,352 314.6 265.9 204.9 198.8 274.0
New York-Newark-Edison, NY-NJ-PA 9,769 8,063 7,744 7,929 8,406 108.9 89.4 85.6 87.2 92.5
Oklahoma City, OK 912 972 1,062 1,040 1,171 163.7 172.1 186.1 180.2 202.9
Orlando, FL 1,126 1,222 1,562 1,704 1,366 126.5 132.8 163.4 173.3 138.9
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 3,907 3,629 3,500 3,904 4,250 140.5 129.7 124.5 138.6 150.9
Phoenix-Mesa-Scottsdale, AZ 1,539 1,787 1,676 2,242 1,834 85.0 95.4 85.9 110.0 90.0
Pittsburgh, PA 841 736 941 883 1,069 72.8 63.9 82.2 77.5 93.8
Portland-Vancouver-Beaverton, OR-WA 527 682 842 692 607 51.9 66.3 80.6 64.9 57.0
Providence-New Bedford-Fall River, RI-MA 532 441 285 318 338 68.0 56.1 36.4 40.8 43.4
Richmond, VA 1,054 971 1,105 954 1,074 191.3 173.4 193.4 164.2 184.9
Riverside-San Bernardino-Ontario, CA 1,221 1,308 1,440 1,390 1,450 67.1 68.9 73.5 69.0 72.0
Rochester, NY 915 981 893 709 599 180.8 193.4 176.3 140.4 118.6
Sacramento-Arden-Arcade-Roseville, CA 897 1,002 1,123 1,046 1,098 92.4 101.1 111.8 103.0 108.1
Salt Lake City, UT 185 228 277 377 344 36.4 44.2 52.9 69.6 63.5
San Antonio, TX 1,181 1,073 1,145 1,289 1,322 132.5 118.2 123.7 135.7 139.2
San Diego-Carlsbad-San Marcos, CA 1,256 1,417 1,500 1,531 1,415 85.1 96.1 101.3 103.4 95.5
San Francisco-Oakland-Fremont, CA 2,797 3,367 3,644 3,882 3,493 135.9 163.7 177.2 186.9 168.2
San Jose-Sunnyvale-Santa Clara, CA 408 617 597 570 506 46.3 69.7 66.8 62.4 55.4
Seattle-Tacoma-Bellevue, WA 1,295 1,166 1,644 1,779 1,367 82.6 73.8 102.7 109.1 83.8
St. Louis, MO-IL 2,563 2,506 2,753 2,829 2,944 194.1 187.6 204.9 209.2 217.7
Tampa-St. Petersburg-Clearwater, FL 1,662 1,327 1,368 1,602 1,842 135.5 105.7 106.3 122.0 140.3
Virginia Beach-Norfolk-Newport News, VA-NC 2,077 1,816 1,636 1,237 1,148 257.0 223.7 201.4 153.3 142.2
Washington-Arlington-Alexandria, DC-VA-MD-WV 2,724 2,822 2,220 2,291 2,385 109.7 112.4 87.1 88.8 92.4
U.S. MSA TOTAL 99,709 96,596 99,544 103,129 103,082 130.1 124.6 127.0 130.0 129.9
Table 18. Gonorrhea — Men – Reported cases and rates in selected metropolitan statistical areas* (MSAs)
listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Rank† County/Independent City   Cases     Rate per 100,000 Population   Cumulative Percent
1 Cook County, IL 12,338 233.3 3
2 Los Angeles County, CA 10,063 101.2 6
3 Wayne County, MI 7,012 355.6 8
4 Harris County, TX 6,362 163.7 10
5 Dallas County, TX 6,180 263.4 11
6 Philadelphia County, PA 5,246 362.2 13
7 Milwaukee County, WI 4,882 533.5 14
8 Marion County, IN 4,286 495.2 15
9 Shelby County, TN 4,076 447.2 16
10 Cuyahoga County, OH 3,970 302.1 18
11 Franklin County, OH 3,909 356.8 19
12 Kings County, NY 3,802 151.5 20
13 Hamilton County, OH 3,781 459.6 21
14 Maricopa County, AZ 3,172 84.2 22
15 Fulton County, GA 3,083 321.1 23
16 Baltimore (City), MD 3,027 479.4 23
17 Jefferson County, AL 2,859 435.4 24
18 Duval County, FL 2,822 336.8 25
19 Tarrant County, TX 2,763 165.3 26
20 St Louis (City), MO 2,577 742.3 27
21 Jackson County, MO 2,558 385.2 27
22 DeKalb County, GA 2,504 346.0 28
23 Bexar County, TX 2,463 158.3 29
24 San Diego County, CA 2,385 81.1 29
25 Bronx County, NY 2,384 175.1 30
26 Washington, D.C. 2,373 408.1 31
27 Alameda County, CA 2,324 159.5 31
28 St. Louis County, MO 2,307 230.6 32
29 Broward County, FL 2,289 128.0 33
30 Allegheny County, PA 2,161 176.6 33
31 Sacramento County, CA 2,147 156.2 34
32 New York County, NY 2,137 132.6 34
33 Clark County, NV 2,112 118.8 35
34 Orange County, FL 2,090 200.3 36
35 Oklahoma County, OK 2,074 300.0 36
36 Hillsborough County, FL 2,064 178.3 37
37 Erie County, NY 2,026 219.9 37
38 San Francisco County, CA 2,007 269.7 38
39 Miami-Dade County, FL 1,988 82.8 38
40 San Bernardino County, CA 1,832 91.6 39
41 Queens County, NY 1,802 79.9 39
42 Essex County, NJ 1,786 227.2 40
43 Genesee County, MI 1,728 391.0 40
44 Guilford County, NC 1,703 376.8 41
45 Travis County, TX 1,682 182.6 41
46 Jefferson County, KY 1,652 235.5 42
47 Hennepin County, MN 1,651 147.1 42
48 Montgomery County, OH 1,645 303.4 43
49 Orleans County, LA 1,529 684.5 43
50 Pinellas County, FL 1,509 163.2 44
51 Caddo County, LA 1,496 591.0 44
52 Mobile County, AL 1,449 358.5 44
53 Montgomery County, AL 1,434 641.4 45
54 Hinds County, MS 1,429 573.9 45
55 Prince George’s County, MD 1,409 167.5 46
56 Richland County, SC 1,402 402.6 46
57 King County, WA 1,377 75.4 46
58 Riverside County, CA 1,334 65.8 47
59 Davidson County, TN 1,288 222.6 47
60 Cumberland County, NC 1,278 427.3 48
61 Charleston County, SC 1,252 377.2 48
62 East Baton Rouge County, LA 1,229 286.4 48
63 Wake County, NC 1,189 151.2 49
64 Richmond (City), VA 1,183 613.2 49
65 Mecklenburg County, NC 1,173 141.8 49
66 Denver County, CO 1,146 202.1 50
67 Monroe County, NY 1,133 155.0 50
68 Kent County, MI 1,120 186.8 50
69 Kern County, CA 1,111 142.4 50
Table 19. Gonorrhea — Counties and independent cities* ranked by number of reported cases:
United States, 2007
*Accounting for 50% of reported gonorrhea cases.
†Counties and independent cities were ranked in descending order by number of cases reported in 2007. 
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   Age
Group
Cases Rates
Year Total Male Female Total Male Female
2003
10–14 4,929 725 4,204 23.3 6.7 40.7
15–19 90,340 27,473 62,867 441.1 261.2 631.2
20–24 106,930 48,222 58,709 515.9 452.2 583.4
25–29 53,692 29,368 24,325 280.1 300.5 258.9
30–34 30,528 19,004 11,524 147.4 181.9 112.4
35–39 20,212 13,824 6,388 94.4 128.9 59.8
40–44 13,722 10,079 3,644 59.8 88.4 31.5
45–54 11,018 8,905 2,113 27.0 44.4 10.2
55–64 2,316 2,012 303 8.3 15.0 2.1
65+ 745 617 128 2.1 4.1 0.6
TO TAL 335,104 160,459 174,645 115.2 112.2 118.2
2004
10–14 4,447 630 3,817 21.0 5.8 37.0
15–19 87,454 26,607 60,847 421.9 250.2 602.8
20–24 103,187 45,917 57,269 492.0 425.0 563.2
25–29 54,857 29,520 25,337 280.4 295.4 264.9
30–34 30,372 18,664 11,708 148.4 180.5 115.6
35–39 19,793 13,350 6,443 94.0 126.3 61.5
40–44 14,026 10,220 3,806 60.8 89.2 32.8
45–54 12,078 9,645 2,433 29.0 47.2 11.5
55–64 2,653 2,286 367 9.1 16.3 2.4
65+ 745 615 130 2.1 4.1 0.6
TO TAL 330,132 157,623 172,509 112.4 109.1 115.7
2005
10–14 4,278 646 3,631 20.5 6.0 35.7
15–19 90,840 27,781 63,060 431.8 257.5 615.3
20–24 106,280 47,187 59,093 505.2 434.6 580.4
25–29 57,195 30,631 26,565 285.0 298.3 271.1
30–34 30,044 18,244 11,800 149.6 179.7 118.9
35–39 19,948 13,413 6,535 95.0 127.0 62.6
40–44 14,346 10,406 3,940 62.8 91.5 34.3
45–54 12,636 10,063 2,573 29.7 48.2 11.9
55–64 2,777 2,399 378 9.1 16.4 2.4
65+ 763 631 132 2.1 4.1 0.6
TO TAL 339,593 161,557 178,036 114.6 110.7 118.4
2006
10–14 4,250 675 3,574 20.6 6.4 35.5
15–19 96,524 30,119 66,405 452.6 275.4 639.2
20–24 110,969 49,304 61,665 525.6 451.9 604.5
25–29 61,843 32,946 28,897 298.6 311.3 285.4
30–34 31,313 18,858 12,455 158.9 188.9 128.1
35–39 20,674 13,813 6,861 97.6 129.7 65.1
40–44 14,534 10,636 3,898 64.6 95.0 34.6
45–54 13,847 11,064 2,782 32.0 52.0 12.7
55–64 3,137 2,686 451 9.9 17.6 2.8
65+ 800 648 152 2.1 4.1 0.7
TO TAL 358,366 170,902 187,464 119.7 115.9 123.4
10–14 3,958 623 3,335 19.2 5.9 33.1
2007
15–19 98,579 31,269 67,310 462.3 286.0 647.9
20–24 111,788 49,101 62,687 529.5 450.1 614.5
25–29 61,364 32,296 29,068 296.3 305.1 287.1
30–34 30,294 18,114 12,180 153.7 181.5 125.2
35–39 19,094 12,724 6,370 90.1 119.5 60.5
40–44 13,184 9,704 3,480 58.6 86.6 30.8
45–54 13,346 10,690 2,656 30.8 50.2 12.1
55–64 3,179 2,692 487 10.1 17.7 3.0
65+ 710 620 89 1.9 4.0 0.4
TO TAL 355,991 168,011 187,980 118.9 113.9 123.8
Table 20. Gonorrhea — Reported cases and rates per 100,000 population by age group and sex: United
States, 2003–2007
 NOTE: This ta ble should be used only for age com par i sons. If age was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases
for which age was known. Dif fer ences be tween to tal cases from this ta ble and oth ers in the re port are due to dif fer ent re port ing formats. The 0 to 9
year age group is not shown  because some of these cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
This page in ten tion ally left blank.
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Age 
Group 
      White, Non-His panic           Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
3002
10–14 789 51 739 3,662 594 3,068 390 71 320 31 3 28 55 7 49
15–19 15,541 2,532 13,009 66,553 22,572 43,980 7,011 2,086 4,924 533 116 417 700 163 537
20–24 19,132 6,097 13,035 77,129 37,552 39,577 9,080 4,085 4,994 840 270 570 767 229 539
25–29 9,891 4,159 5,732 38,142 22,275 15,866 4,787 2,544 2,243 499 250 249 375 146 229
30–34 6,648 3,512 3,136 20,459 13,498 6,961 2,821 1,704 1,117 381 206 175 214 83 131
35–39 5,126 3,314 1,812 12,840 9,130 3,710 1,823 1,160 663 244 139 105 174 80 94
40–44 3,835 2,634 1,201 8,642 6,626 2,016 981 654 327 145 95 49 118 70 48
45–54 2,917 2,169 748 7,268 6,172 1,096 660 467 192 105 64 41 66 32 33
55–64 713 588 125 1,439 1,301 138 123 98 25 31 19 13 8 7 2
65+ 239 196 43 443 379 64 44 29 15 11 7 4 8 6 2
TO TAL 64,961 25,288 39,673 237,038 120,266 116,771 27,793 12,922 14,872 2,823 1,171 1,652 2,489 823 1,666
4002
10–14 678 44 634 3,336 526 2,811 366 48 318 28 5 23 38 7 31
15–19 15,369 2,546 12,822 63,917 21,682 42,234 6,908 2,101 4,807 475 115 359 785 159 626
20–24 19,129 5,909 13,220 73,374 35,351 38,023 8,891 4,017 4,874 868 329 538 939 319 620
25–29 10,539 4,237 6,301 38,013 21,985 16,028 5,387 2,882 2,505 497 262 234 424 159 265
30–34 6,751 3,459 3,293 20,027 13,180 6,847 2,956 1,726 1,230 384 200 184 249 99 150
35–39 5,276 3,277 1,998 12,243 8,667 3,576 1,883 1,178 706 214 143 72 172 84 88
40–44 4,021 2,713 1,307 8,710 6,653 2,058 1,060 736 324 116 75 40 116 40 76
45–54 3,341 2,487 855 7,777 6,523 1,253 746 511 235 103 61 42 110 63 46
55–64 831 695 136 1,615 1,457 158 159 116 43 35 12 23 12 7 5
65+ 219 174 45 472 404 68 42 29 14 3 1 2 8 6 2
TO TAL 66,250 25,585 40,665 229,843 116,537 113,306 28,455 13,360 15,096 2,726 1,205 1,521 2,858 946 1,912
5002
10–14 691 35 655 3,154 549 2,604 355 52 304 25 1 23 45 8 37
15–19 15,758 2,679 13,079 66,165 22,563 43,602 7,299 2,134 5,165 606 176 430 845 196 650
20–24 20,892 6,509 14,383 73,365 35,373 37,991 9,742 4,438 5,303 960 418 542 1,012 344 668
25–29 11,681 4,667 7,013 38,213 22,200 16,013 5,915 3,126 2,790 633 341 293 569 216 353
30–34 6,790 3,405 3,385 19,172 12,540 6,632 3,248 1,830 1,418 405 281 124 314 137 177
35–39 5,384 3,256 2,127 12,004 8,570 3,433 2,009 1,270 739 268 180 88 193 97 97
40–44 4,255 2,863 1,392 8,606 6,593 2,012 1,153 776 377 146 93 53 119 44 75
45–54 3,535 2,668 867 7,993 6,667 1,325 831 561 270 118 79 39 93 46 46
55–64 853 721 132 1,653 1,490 163 191 134 57 44 28 16 24 17 6
65+ 242 203 39 452 386 66 55 36 19 8 4 4 3 1 2
TO TAL 70,209 27,050 43,159 231,076 117,025 114,050 30,845 14,374 16,471 3,214 1,602 1,612 3,225 1,112 2,113
6002
10–14 596 53 543 3,227 549 2,678 367 70 297 23 1 21 36 1 34
15–19 16,038 2,612 13,426 70,992 24,675 46,317 8,055 2,451 5,603 556 125 431 877 251 626
20–24 21,590 6,684 14,906 77,200 37,200 40,000 10,340 4,739 5,601 809 335 474 1,045 356 689
25–29 12,907 5,147 7,760 41,339 23,863 17,477 6,408 3,424 2,985 558 278 280 634 238 396
30–34 6,948 3,313 3,636 20,334 13,363 6,971 3,340 1,861 1,478 365 207 157 325 114 211
35–39 5,570 3,281 2,289 12,565 9,018 3,547 2,097 1,270 827 246 154 93 193 89 103
40–44 4,231 2,800 1,432 8,798 6,831 1,967 1,241 843 398 144 102 42 117 59 59
45–54 3,952 2,875 1,077 8,744 7,427 1,317 896 619 277 125 69 56 128 74 55
55–64 1,019 836 183 1,886 1,699 187 172 116 55 32 14 18 27 19 8
65+ 269 226 44 450 370 80 65 44 21 8 3 5 8 6 2
TO TAL 73,200 27,848 45,353 245,855 125,102 120,753 33,044 15,460 17,584 2,869 1,290 1,579 3,398 1,208 2,189
7002
10–14 475 20 454 3,068 537 2,531 364 64 300 22 0 22 30 3 27
15–19 15,635 2,700 12,935 74,237 25,856 48,380 7,538 2,442 5,096 498 122 376 666 147 519
20–24 20,830 6,346 14,484 79,555 37,665 41,890 9,761 4,544 5,218 767 297 470 884 256 628
25–29 12,482 4,994 7,488 42,000 23,645 18,355 5,880 3,188 2,692 519 285 234 485 186 299
30–34 6,515 3,005 3,510 20,078 12,995 7,083 3,120 1,822 1,297 354 207 146 227 85 143
35–39 4,983 2,778 2,206 11,916 8,578 3,338 1,843 1,171 673 187 120 67 164 78 86
40–44 3,680 2,451 1,229 8,238 6,433 1,804 1,049 710 339 119 82 37 98 28 70
45–54 3,788 2,809 978 8,539 7,174 1,365 824 594 230 114 64 50 81 48 33
55–64 1,010 833 177 1,908 1,680 228 196 133 63 49 33 16 15 13 2
65+ 274 243 31 367 319 49 50 44 6 13 10 3 4 4 0
TO TAL 69,767 26,207 43,559 250,245 125,006 125,238 30,680 14,733 15,947 2,643 1,221 1,422 2,657 850 1,808
Ta ble 21A. Gonorrhea — Re ported cases by race/eth nic ity, age group and sex: United States, 2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 20 for age-spe cific cases and rates and Ta bles 13-15 for to tal and
sex-spe cific cases and rates. If age or race/eth nic ity was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these vari ables were 
spec i fied. In 2005, HI did not re port age and/or race/eth nic ity for most cases and their case data and pop u la tion de nom i na tors were ex cluded. Dif fer ences be -
tween to tal cases from this ta ble and oth ers in the re port are due to  different re port ing formats. The 0 to 9 year age group is not shown be cause some of these
cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Age 
Group 
      White, Non-His panic          Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
10–14 6.0 0.8 11.6 108.3 34.6 184.4 10.7 3.8 17.9 3.7 0.6 6.9 23.9 5.7 42.7
2003
15–19 118.9 37.7 204.7 2,165.6 1,447.2 2,905.9 215.9 123.8 315.1 62.2 26.3 100.1 307.6 140.7 481.1
20–24 149.1 93.5 206.3 2,614.5 2,558.2 2,670.3 242.4 197.0 298.6 84.8 54.0 116.2 372.7 218.5 532.1
25–29 85.8 71.4 100.4 1,504.2 1,831.3 1,202.6 126.0 121.6 131.5 44.2 45.1 43.4 220.8 170.4 272.0
30–34 51.0 53.5 48.4 771.9 1,074.6 499.2 78.8 88.6 67.4 30.3 33.4 27.3 125.6 98.0 153.2
35–39 36.0 46.4 25.5 472.6 713.9 258.0 57.4 69.0 44.4 22.0 25.8 18.4 99.4 92.8 105.8
40–44 23.7 32.6 14.8 308.0 504.5 135.1 35.8 46.0 24.7 14.0 19.2 9.2 62.8 76.8 49.7
45–54 9.6 14.4 4.9 156.6 287.9 43.9 17.3 24.5 10.1 6.0 7.8 4.4 20.7 21.4 20.0
55–64 3.3 5.5 1.1 53.6 108.9 9.3 5.9 9.8 2.3 3.0 3.9 2.3 4.4 7.3 1.8
65+ 0.8 1.6 0.2 15.0 33.5 3.5 2.2 3.4 1.3 1.1 1.6 0.6 4.6 8.1 2.0
TO TAL 32.6 25.9 39.1 649.3 691.8 610.6 69.7 62.7 77.1 22.1 18.9 25.2 102.5 68.8 135.2
10–14 5.3 0.7 10.1 98.8 30.7 169.2 9.7 2.5 17.2 3.3 1.2 5.5 16.6 5.8 27.7
2004
15–19 116.8 37.7 200.4 2,032.9 1,360.8 2,723.6 207.3 122.0 298.4 54.7 25.8 85.3 342.3 136.3 556.1
20–24 147.1 89.3 207.1 2,449.7 2,357.1 2,542.6 236.2 193.8 288.0 87.2 65.4 109.4 440.7 295.1 590.4
25–29 89.9 71.6 108.6 1,457.9 1,748.9 1,187.0 137.6 132.9 143.4 43.7 47.0 40.5 243.5 180.3 308.0
30–34 53.3 54.2 52.3 761.0 1,056.8 494.6 79.9 86.6 72.0 29.5 31.4 27.7 147.4 117.7 177.0
35–39 38.2 47.3 29.1 460.3 690.9 254.4 57.6 67.7 46.1 18.6 25.4 12.1 101.3 100.0 102.5
40–44 25.0 33.8 16.2 308.0 502.7 136.7 36.7 49.1 23.3 10.7 14.5 7.2 61.5 44.2 77.7
45–54 10.9 16.3 5.5 163.2 296.5 48.9 18.5 25.3 11.7 5.7 7.2 4.3 33.8 40.8 27.3
55–64 3.7 6.3 1.2 57.4 116.2 10.1 7.2 11.0 3.7 3.1 2.3 3.9 5.7 6.8 4.7
65+ 0.7 1.4 0.3 15.7 35.1 3.7 2.0 3.1 1.1 0.3 0.3 0.3 4.4 7.6 2.0
TO TAL 33.2 26.1 40.0 622.5 662.5 586.2 68.9 62.6 75.6 20.7 18.8 22.4 116.5 78.3 153.6
10–14 5.5 0.5 10.7 95.5 32.8 160.2 9.2 2.6 16.1 3.0 0.3 5.8 20.9 7.4 34.7
2005
15–19 119.3 39.5 203.6 2,044.5 1,376.4 2,730.3 211.5 119.9 308.9 73.1 41.2 107.1 367.8 167.5 575.2
20–24 160.0 97.6 225.1 2,437.0 2,333.5 2,542.0 261.7 218.3 314.0 102.5 88.0 117.4 466.7 312.9 625.0
25–29 97.5 77.2 118.1 1,412.1 1,692.4 1,148.5 147.1 139.7 156.5 57.7 63.1 52.4 317.6 238.4 398.8
30–34 55.7 55.5 55.9 742.3 1,024.0 488.3 85.7 89.3 81.4 31.8 45.1 19.0 189.8 165.9 213.7
35–39 39.7 47.7 31.5 455.3 688.7 246.6 59.4 70.3 46.9 23.2 31.9 14.9 116.5 117.7 115.3
40–44 27.1 36.5 17.7 305.6 500.6 134.3 38.5 49.6 26.3 13.9 18.3 9.9 64.6 49.5 79.0
45–54 11.4 17.3 5.5 163.3 294.9 50.3 19.5 26.1 12.8 6.7 9.6 4.2 28.2 29.5 26.9
55–64 3.6 6.3 1.1 55.7 112.7 9.9 8.1 11.9 4.6 3.9 5.4 2.6 11.3 17.2 5.8
65+ 0.8 1.6 0.2 14.7 32.8 3.5 2.4 3.7 1.5 0.8 1.0 0.7 1.9 1.8 1.9
TO TAL 35.1 27.6 42.4 619.4 658.0 584.2 72.4 65.3 80.1 25.2 25.8 24.6 131.5 92.1 169.7
10–14 4.8 0.8 9.0 100.0 33.5 168.6 9.3 3.5 15.4 2.6 0.3 4.9 17.1 1.4 33.2
2006
15–19 121.0 38.4 208.3 2,139.5 1,467.6 2,829.6 222.3 131.3 319.2 61.8 27.0 98.7 379.0 214.1 548.9
20–24 164.6 99.4 233.2 2,540.8 2,421.0 2,663.3 275.6 232.6 326.7 82.1 66.8 97.9 473.3 317.3 634.8
25–29 104.3 82.7 126.2 1,471.2 1,748.0 1,209.6 153.9 147.5 162.1 47.5 48.1 46.9 339.5 252.5 428.2
30–34 59.2 56.1 62.4 803.0 1,111.7 524.0 85.0 87.2 82.4 27.0 31.5 22.8 199.1 139.7 258.6
35–39 41.1 48.2 33.9 474.4 722.8 253.2 59.4 67.3 50.2 19.3 24.7 14.2 115.7 108.4 123.0
40–44 27.8 36.8 18.8 314.8 522.4 132.3 39.7 51.4 26.8 12.5 18.3 7.1 64.7 66.2 63.3
45–54 12.6 18.4 6.8 174.6 321.3 48.8 19.8 27.1 12.4 6.4 7.5 5.5 38.0 45.9 30.9
55–64 4.2 7.0 1.5 60.4 122.1 10.8 6.8 9.6 4.2 2.5 2.3 2.6 12.4 18.2 7.0
65+ 0.9 1.8 0.2 14.4 30.8 4.2 2.7 4.3 1.5 0.6 0.6 0.7 4.3 7.2 2.1
TO TAL 36.5 28.3 44.4 651.2 695.1 611.3 74.6 67.4 82.2 20.4 18.9 21.9 136.9 98.9 173.7
10–14 3.8 0.3 7.6 95.1 32.7 159.4 9.2 3.2 15.6 2.4 0.0 4.9 14.2 2.6 26.1
2007
15–19 118.0 39.7 200.6 2,237.2 1,537.8 2,955.7 208.1 130.7 290.3 55.3 26.4 86.1 288.0 125.1 455.7
20–24 158.8 94.4 226.6 2,618.3 2,451.3 2,789.2 260.2 223.0 304.3 77.9 59.3 97.2 400.4 228.2 578.7
25–29 100.9 80.2 121.8 1,494.7 1,732.0 1,270.4 141.3 137.3 146.2 44.2 49.4 39.3 259.5 197.3 322.9
30–34 55.5 50.9 60.2 792.9 1,081.0 532.5 79.4 85.4 72.3 26.2 31.5 21.2 139.3 104.0 174.7
35–39 36.7 40.8 32.7 449.9 687.6 238.3 52.2 62.1 40.8 14.6 19.2 10.2 98.3 94.4 102.2
40–44 24.2 32.2 16.1 294.8 492.0 121.4 33.5 43.3 22.8 10.4 14.7 6.3 53.9 31.3 75.6
45–54 12.0 18.0 6.2 170.5 310.3 50.6 18.2 26.0 10.3 5.9 7.0 4.8 24.1 30.0 18.7
55–64 4.1 7.0 1.4 61.1 120.7 13.2 7.7 10.9 4.8 3.8 5.5 2.3 6.8 12.5 1.6
65+ 0.9 1.9 0.2 11.8 26.6 2.5 2.1 4.3 0.5 1.1 1.9 0.4 2.3 5.3 0.0
TO TAL 34.7 26.6 42.6 662.9 694.6 634.0 69.2 64.3 74.5 18.8 17.9 19.7 107.1 69.5 143.4
Ta ble 21B. Gon or rhea — Rates per 100,000 pop u la tion by race/eth nic ity, age group and sex: United States,
2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 20 for age-spe cific cases and rates and Ta bles 13-15 for to tal and
sex-spe cific cases and rates. If age or race/eth nic ity was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these vari ables
were spec i fied. In 2005, HI did not re port age and/or race/eth nic ity for most cases and their case data and pop u la tion de nom i na tors were ex cluded. Dif fer ences
be tween to tal rates from this ta ble and oth ers in the re port are due to  different re port ing for mats. The 0 to 9 year age group is not shown be cause some of these
cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 567 639 551 931 1,006 12.6 14.1 12.1 20.2 21.9
Alaska 8 15 22 25 16 1.2 2.3 3.3 3.7 2.4
Arizona 1,106 974 792 926 1,245 19.8 17.0 13.3 15.0 20.2
Arkansas 296 249 231 246 371 10.9 9.0 8.3 8.8 13.2
California 4,207 4,590 5,340 6,046 6,323 11.9 12.8 14.8 16.6 17.3
Colorado 144 179 144 182 157 3.2 3.9 3.1 3.8 3.3
Connecticut 207 169 166 197 148 5.9 4.8 4.7 5.6 4.2
Delaware 47 61 35 74 63 5.7 7.3 4.1 8.7 7.4
District of Columbia 330 357 365 314 416 58.5 64.5 66.3 54.0 71.5
Florida 3,283 2,964 2,888 2,945 3,918 19.3 17.0 16.2 16.3 21.7
Georgia 2,152 1,589 1,924 1,933 2,254 24.8 18.0 21.2 20.6 24.1
Hawaii 61 36 57 66 58 4.9 2.9 4.5 5.1 4.5
Idaho 45 78 54 12 14 3.3 5.6 3.8 0.8 1.0
Illinois 1,377 1,348 1,608 1,473 1,220 10.9 10.6 12.6 11.5 9.5
Indiana 367 273 288 250 217 5.9 4.4 4.6 4.0 3.4
Iowa 46 36 28 68 65 1.6 1.2 0.9 2.3 2.2
Kansas 77 87 88 87 97 2.8 3.2 3.2 3.1 3.5
Kentucky 160 151 129 188 153 3.9 3.6 3.1 4.5 3.6
Louisiana 1,581 1,646 1,239 1,390 1,807 35.2 36.5 27.4 32.4 42.1
Maine 21 7 6 22 21 1.6 0.5 0.5 1.7 1.6
Maryland 975 1,002 1,005 1,038 1,170 17.7 18.0 17.9 18.5 20.8
Massachusetts 644 517 398 378 399 10.0 8.1 6.2 5.9 6.2
Michigan 860 806 488 384 472 8.5 8.0 4.8 3.8 4.7
Minnesota 195 145 208 189 186 3.9 2.8 4.1 3.7 3.6
Mississippi 435 404 371 520 707 15.1 13.9 12.7 17.9 24.3
Missouri 207 269 372 430 484 3.6 4.7 6.4 7.4 8.3
Montana 0 4 7 2 8 0.0 0.4 0.7 0.2 0.8
Nebraska 27 15 18 34 30 1.6 0.9 1.0 1.9 1.7
Nevada 149 254 343 389 396 6.6 10.9 14.2 15.6 15.9
New Hampshire 37 26 33 35 52 2.9 2.0 2.5 2.7 4.0
New Jersey 1,089 826 813 799 926 12.6 9.5 9.3 9.2 10.6
New Mexico 205 251 183 237 180 10.9 13.2 9.5 12.1 9.2
New York 4,360 4,472 3,853 4,586 4,999 22.7 23.3 20.0 23.8 25.9
North Carolina 850 747 713 962 1,093 10.1 8.7 8.2 10.9 12.3
North Dakota 2 0 1 3 2 0.3 0.0 0.2 0.5 0.3
Ohio 481 571 502 491 549 4.2 5.0 4.4 4.3 4.8
Oklahoma 353 168 159 251 216 10.1 4.8 4.5 7.0 6.0
Oregon 118 108 109 99 59 3.3 3.0 3.0 2.7 1.6
Pennsylvania 706 574 712 889 844 5.7 4.6 5.7 7.1 6.8
Rhode Island 90 104 64 71 76 8.4 9.6 5.9 6.7 7.1
South Carolina 552 524 549 397 411 13.3 12.5 12.9 9.2 9.5
South Dakota 5 0 4 29 12 0.7 0.0 0.5 3.7 1.5
Tennessee 881 804 917 1,015 1,212 15.1 13.6 15.4 16.8 20.1
Texas 3,996 4,205 4,289 4,956 5,506 18.1 18.7 18.8 21.1 23.4
Utah 72 78 50 68 45 3.1 3.3 2.0 2.7 1.8
Vermont 1 3 1 7 11 0.2 0.5 0.2 1.1 1.8
Virginia 552 610 655 701 736 7.5 8.2 8.7 9.2 9.6
Washington 239 336 359 423 367 3.9 5.4 5.7 6.6 5.7
West Virginia 11 18 18 30 27 0.6 1.0 1.0 1.6 1.5
Wisconsin 111 128 138 170 170 2.0 2.3 2.5 3.1 3.1
Wyoming 4 6 1 1 6 0.8 1.2 0.2 0.2 1.2
U.S. TOTAL 34,289 33,423 33,288 36,959 40,920 11.8 11.4 11.2 12.3 13.7
Northeast 7,155 6,698 6,046 6,984 7,476 13.2 12.3 11.1 12.8 13.7
Midwest 3,755 3,678 3,743 3,608 3,504 5.7 5.6 5.7 5.4 5.3
South 17,021 16,138 16,038 17,891 21,066 16.3 15.2 14.9 16.4 19.3
West 6,358 6,909 7,461 8,476 8,874 9.6 10.2 10.9 12.2 12.8
Guam 16 13 19 13 37 9.8 7.8 11.3 7.6 21.6
Puerto Rico 1,357 1,154 1,223 1,068 1,267 35.0 29.6 31.3 27.2 32.3
Virgin Islands 14 17 13 5 5 12.9 15.6 12.0 4.6 4.6
OUTLYING AREAS 1,387 1,184 1,255 1,086 1,309 33.4 28.4 30.0 25.8 31.1
TOTAL 35,676 34,607 34,543 38,045 42,229 12.1 11.6 11.5 12.5 13.9
Table 22. All stages of syphilis*  — Reported cases and rates by state/area and region listed in alphabetical
order: United States and outlying areas, 2003–2007
*See Appendix (Syphilis Morbidity Reporting) for definition.
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Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 1,702 1,315 1,626 1,641 1,904 36.9 27.9 33.1 31.9 37.1
Austin-Round Rock, TX 152 200 193 212 234 11.0 14.2 13.3 14.0 15.5
Baltimore-Towson, MD 648 647 679 642 650 24.8 24.5 25.6 24.1 24.5
Birmingham-Hoover, AL 122 117 243 561 483 11.4 10.8 22.3 51.0 43.9
Boston-Cambridge-Quincy, MA-NH 568 410 339 329 324 12.8 9.3 7.7 7.4 7.3
Buffalo-Cheektowaga-Tonawanda, NY 11 24 14 42 26 0.9 2.1 1.2 3.7 2.3
Charlotte-Gastonia-Concord, NC-SC 167 154 235 303 301 11.6 10.4 15.4 19.1 19.0
Chicago-Naperville-Joliet, IL-IN-WI 1,341 1,296 1,541 1,386 1,117 14.4 13.8 16.3 14.6 11.8
Cincinnati-Middletown, OH-KY-IN 18 54 55 58 77 0.9 2.6 2.7 2.8 3.7
Cleveland-Elyria-Mentor, OH 62 84 52 53 83 2.9 3.9 2.4 2.5 3.9
Columbus, OH 266 254 227 229 222 15.9 15.0 13.3 13.3 12.9
Dallas-Fort Worth-Arlington, TX 1,505 1,374 1,495 1,678 1,643 26.9 24.1 25.7 27.9 27.4
Denver-Aurora, CO 116 135 111 141 120 5.0 5.8 4.7 5.9 5.0
Detroit-Warren-Livonia, MI 751 679 390 284 338 16.7 15.1 8.7 6.4 7.6
Hartford-West Hartford-East Hartford, CT 70 46 57 65 51 5.9 3.9 4.8 5.5 4.3
Houston-Baytown-Sugar Land, TX 1,256 1,289 1,188 1,570 2,048 24.7 24.9 22.5 28.3 37.0
Indianapolis, IN 142 128 134 121 95 8.9 7.9 8.2 7.3 5.7
Jacksonville, FL 135 218 151 165 198 11.2 17.8 12.1 12.9 15.5
Kansas City, MO-KS 118 101 193 228 268 6.2 5.2 9.9 11.6 13.6
Las Vegas-Paradise, NV 123 225 300 355 364 7.8 13.6 17.5 20.0 20.5
Los Angeles-Long Beach-Santa Ana, CA 2,166 2,483 3,159 3,594 3,581 16.9 19.2 24.4 27.8 27.7
Louisville, KY-IN 126 115 102 101 77 10.6 9.6 8.4 8.3 6.3
Memphis, TN-MS-AR 547 519 585 612 761 44.1 41.5 46.4 48.0 59.7
Miami-Fort Lauderdale-Miami Beach, FL 1,911 1,687 1,444 1,455 1,863 36.1 31.5 26.6 26.6 34.1
Milwaukee-Waukesha-West Allis, WI 74 85 77 100 127 4.9 5.6 5.1 6.6 8.4
Minneapolis-St. Paul-Bloomington, MN-WI 173 125 187 161 170 5.6 4.0 6.0 5.1 5.4
Nashville-Davidson-Murfreesboro, TN 220 194 189 194 240 16.0 13.9 13.3 13.3 16.5
New Orleans-Metairie-Kenner, LA 264 449 350 352 560 20.0 34.0 26.5 34.4 54.7
New York-Newark-Edison, NY-NJ-PA 5,101 4,918 4,318 4,924 5,503 27.4 26.3 23.0 26.2 29.2
Oklahoma City, OK 253 110 87 116 114 22.3 9.6 7.5 9.9 9.7
Orlando, FL 318 267 413 403 583 17.6 14.3 21.4 20.3 29.4
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 785 678 583 774 778 13.6 11.7 10.0 13.3 13.4
Phoenix-Mesa-Scottsdale, AZ 914 754 595 757 866 25.4 20.3 15.4 18.7 21.4
Pittsburgh, PA 57 32 112 152 122 2.4 1.3 4.7 6.4 5.1
Portland-Vancouver-Beaverton, OR-WA 103 84 94 74 51 5.0 4.1 4.5 3.5 2.4
Providence-New Bedford-Fall River, RI-MA 127 137 75 92 100 7.8 8.4 4.6 5.7 6.2
Richmond, VA 114 85 87 106 129 10.0 7.4 7.4 8.9 10.8
Riverside-San Bernardino-Ontario, CA 313 319 399 376 340 8.6 8.4 10.2 9.3 8.4
Rochester, NY 33 41 36 90 76 3.2 3.9 3.5 8.7 7.3
Sacramento-Arden-Arcade-Roseville, CA 35 64 39 136 117 1.8 3.2 1.9 6.6 5.7
Salt Lake City, UT 43 53 35 41 35 4.3 5.2 3.4 3.8 3.3
San Antonio, TX 231 361 458 473 420 12.7 19.5 24.2 24.4 21.6
San Diego-Carlsbad-San Marcos, CA 299 356 448 572 788 10.2 12.1 15.3 19.4 26.8
San Francisco-Oakland-Fremont, CA 901 917 719 741 783 21.7 22.1 17.3 17.7 18.7
San Jose-Sunnyvale-Santa Clara, CA 137 113 121 94 159 7.9 6.5 6.9 5.3 8.9
Seattle-Tacoma-Bellevue, WA 174 273 285 356 309 5.5 8.6 8.9 10.9 9.5
St. Louis, MO-IL 150 189 173 186 252 5.5 6.8 6.2 6.7 9.0
Tampa-St. Petersburg-Clearwater, FL 407 303 326 428 612 16.1 11.7 12.3 15.9 22.7
Virginia Beach-Norfolk-Newport News, VA-NC 148 198 246 245 232 9.0 12.0 14.9 14.9 14.1
Washington-Arlington-Alexandria, DC-VA-MD-WV 836 896 894 928 1,162 16.4 17.4 17.1 17.5 22.0
U.S. MSA TOTAL 26,233 25,555 25,859 28,696 31,456 16.8 16.2 16.2 17.8 19.5
Table 23. All stages of syphilis* — Reported cases and rates in selected metropolitan statistical areas†
(MSAs) listed in alphabetical order: United States, 2003–2007
*See Appendix (Syphilis Morbidity Reporting) for definition.
†MSAs selected based on largest population in 2000 U.S. census.
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Rank* State                                   Cases Rate per 100,000 Population
1 Louisiana 533 12.4
2 Alabama 380 8.3
3 Georgia 680 7.3
4 Maryland 345 6.1
5 Tennessee 367 6.1
6 California 2,038 5.6
7 New York 1,068 5.5
8 Florida 913 5.0
9 Texas 1,160 4.9
10 Arizona 296 4.8
11 Mississippi 133 4.6
12 Nevada 111 4.4
13 Arkansas 122 4.3
14 Missouri 239 4.1
U.S. TOTAL† 11,466 3.8
15 North Carolina 323 3.6
16 Illinois 464 3.6
17 Rhode Island 36 3.4
18 Virginia 230 3.0
19 New Jersey 227 2.6
20 Massachusetts 155 2.4
21 Washington 154 2.4
22 New Mexico 46 2.4
23 New Hampshire 30 2.3
24 Pennsylvania 263 2.1
25 Delaware 18 2.1
26 South Carolina 91 2.1
27 Oklahoma 65 1.8
28 Ohio 194 1.7
29 Vermont 10 1.6
30 Kentucky 56 1.3
31 Michigan 123 1.2
32 Colorado 57 1.2
33 Wisconsin 66 1.2
34 Minnesota 59 1.1
35 Connecticut 39 1.1
36 Alaska 7 1.0
37 Kansas 28 1.0
38 South Dakota 7 0.9
39 Indiana 54 0.9
40 Montana 8 0.8
41 Utah 20 0.8
42 Wyoming 4 0.8
43 Iowa 21 0.7
44 Hawaii 9 0.7
45 Maine 9 0.7
46 Oregon 18 0.5
47 West Virginia 6 0.3
48 Nebraska 4 0.2
YEAR 2010 TARGET 0.2
49 North Dakota 1 0.2
50 Idaho 1 0.1
Table 24. Primary and secondary syphilis — Reported cases and rates by state, ranked by rates:
United States, 2007
*States were ranked in descending order by rate, number of cases, and alphabetically by state.
†Total includes cases reported by the District of Columbia with 178 cases and a rate of 30.6, but excludes outlying areas (Guam with 8 cases and rate
of 4.7, Puerto Rico with 169 cases and rate of 4.3, and Virgin Islands with 0 case and rate of 0.0).
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Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 114 165 169 319 380 2.5 3.6 3.7 6.9 8.3
Alaska 1 8 9 11 7 0.2 1.2 1.4 1.6 1.0
Arizona 186 157 175 203 296 3.3 2.7 2.9 3.3 4.8
Arkansas 51 47 52 77 122 1.9 1.7 1.9 2.7 4.3
California 1,299 1,356 1,585 1,835 2,038 3.7 3.8 4.4 5.0 5.6
Colorado 39 63 46 69 57 0.9 1.4 1.0 1.5 1.2
Connecticut 30 45 58 64 39 0.9 1.3 1.7 1.8 1.1
Delaware 7 9 11 20 18 0.9 1.1 1.3 2.3 2.1
District of Columbia 48 69 114 116 178 8.5 12.5 20.7 19.9 30.6
Florida 658 728 724 719 913 3.9 4.2 4.1 4.0 5.0
Georgia 585 549 645 581 680 6.7 6.2 7.1 6.2 7.3
Hawaii 14 8 11 18 9 1.1 0.6 0.9 1.4 0.7
Idaho 15 24 20 3 1 1.1 1.7 1.4 0.2 0.1
Illinois 374 386 525 431 464 3.0 3.0 4.1 3.4 3.6
Indiana 50 60 62 93 54 0.8 1.0 1.0 1.5 0.9
Iowa 12 5 9 19 21 0.4 0.2 0.3 0.6 0.7
Kansas 25 24 19 27 28 0.9 0.9 0.7 1.0 1.0
Kentucky 33 47 52 73 56 0.8 1.1 1.2 1.7 1.3
Louisiana 183 332 278 342 533 4.1 7.4 6.1 8.0 12.4
Maine 8 2 1 9 9 0.6 0.2 0.1 0.7 0.7
Maryland 312 380 313 300 345 5.7 6.8 5.6 5.3 6.1
Massachusetts 133 114 125 124 155 2.1 1.8 2.0 1.9 2.4
Michigan 249 192 105 118 123 2.5 1.9 1.0 1.2 1.2
Minnesota 47 27 70 47 59 0.9 0.5 1.4 0.9 1.1
Mississippi 40 59 49 86 133 1.4 2.0 1.7 3.0 4.6
Missouri 61 94 147 168 239 1.1 1.6 2.5 2.9 4.1
Montana 0 4 7 1 8 0.0 0.4 0.7 0.1 0.8
Nebraska 10 7 4 7 4 0.6 0.4 0.2 0.4 0.2
Nevada 12 40 109 137 111 0.5 1.7 4.5 5.5 4.4
New Hampshire 19 5 16 13 30 1.5 0.4 1.2 1.0 2.3
New Jersey 170 150 133 173 227 2.0 1.7 1.5 2.0 2.6
New Mexico 71 82 56 79 46 3.8 4.3 2.9 4.0 2.4
New York 584 727 705 736 1,068 3.0 3.8 3.7 3.8 5.5
North Carolina 152 192 274 309 323 1.8 2.2 3.2 3.5 3.6
North Dakota 2 0 1 1 1 0.3 0.0 0.2 0.2 0.2
Ohio 197 237 211 184 194 1.7 2.1 1.8 1.6 1.7
Oklahoma 64 25 44 70 65 1.8 0.7 1.2 2.0 1.8
Oregon 48 29 41 29 18 1.3 0.8 1.1 0.8 0.5
Pennsylvania 159 118 199 264 263 1.3 1.0 1.6 2.1 2.1
Rhode Island 33 26 24 14 36 3.1 2.4 2.2 1.3 3.4
South Carolina 94 116 84 66 91 2.3 2.8 2.0 1.5 2.1
South Dakota 2 0 2 13 7 0.3 0.0 0.3 1.7 0.9
Tennessee 135 130 217 249 367 2.3 2.2 3.6 4.1 6.1
Texas 654 827 873 1,064 1,160 3.0 3.7 3.8 4.5 4.9
Utah 14 13 10 21 20 0.6 0.5 0.4 0.8 0.8
Vermont 1 1 1 3 10 0.2 0.2 0.2 0.5 1.6
Virginia 82 116 143 190 230 1.1 1.6 1.9 2.5 3.0
Washington 82 150 152 182 154 1.3 2.4 2.4 2.8 2.4
West Virginia 2 3 3 11 6 0.1 0.2 0.2 0.6 0.3
Wisconsin 16 29 41 68 66 0.3 0.5 0.7 1.2 1.2
Wyoming 0 3 0 0 4 0.0 0.6 0.0 0.0 0.8
U.S. TOTAL 7,177 7,980 8,724 9,756 11,466 2.5 2.7 2.9 3.3 3.8
Northeast 1,137 1,188 1,262 1,400 1,837 2.1 2.2 2.3 2.6 3.4
Midwest 1,045 1,061 1,196 1,176 1,260 1.6 1.6 1.8 1.8 1.9
South 3,214 3,794 4,045 4,592 5,600 3.1 3.6 3.8 4.2 5.1
West 1,781 1,937 2,221 2,588 2,769 2.7 2.9 3.3 3.7 4.0
Guam 1 0 2 3 8 0.6 0.0 1.2 1.8 4.7
Puerto Rico 202 182 224 150 169 5.2 4.7 5.7 3.8 4.3
Virgin Islands 3 5 1 1 0 2.8 4.6 0.9 0.9 0.0
OUTLYING AREAS 206 187 227 154 177 5.0 4.5 5.4 3.7 4.2
TOTAL 7,383 8,167 8,951 9,910 11,643 2.5 2.7 3.0 3.3 3.8
Table 25. Primary and secondary syphilis — Reported cases and rates by state/area and region listed in
alphabetical order: United States and outlying areas, 2003–2007
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State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 49 52 69 116 143 2.1 2.2 2.9 4.9 6.0
Alaska 0 0 1 2 1 0.0 0.0 0.3 0.6 0.3
Arizona 66 42 49 33 64 2.4 1.5 1.7 1.1 2.1
Arkansas 16 18 21 35 50 1.1 1.3 1.5 2.4 3.5
California 52 63 121 128 115 0.3 0.4 0.7 0.7 0.6
Colorado 5 7 2 5 2 0.2 0.3 0.1 0.2 0.1
Connecticut 3 3 2 2 2 0.2 0.2 0.1 0.1 0.1
Delaware 2 1 2 4 1 0.5 0.2 0.5 0.9 0.2
District of Columbia 3 4 11 6 5 1.0 1.4 3.8 1.9 1.6
Florida 73 98 100 98 153 0.8 1.1 1.1 1.1 1.7
Georgia 68 45 47 41 53 1.5 1.0 1.0 0.9 1.1
Hawaii 0 0 0 1 1 0.0 0.0 0.0 0.2 0.2
Idaho 5 11 6 2 1 0.7 1.6 0.8 0.3 0.1
Illinois 48 55 47 37 39 0.7 0.9 0.7 0.6 0.6
Indiana 16 6 10 10 8 0.5 0.2 0.3 0.3 0.2
Iowa 2 1 1 6 3 0.1 0.1 0.1 0.4 0.2
Kansas 13 7 2 2 6 0.9 0.5 0.1 0.1 0.4
Kentucky 13 6 3 7 9 0.6 0.3 0.1 0.3 0.4
Louisiana 79 123 112 123 209 3.4 5.3 4.8 5.6 9.5
Maine 0 0 0 2 0 0.0 0.0 0.0 0.3 0.0
Maryland 74 92 88 61 47 2.6 3.2 3.0 2.1 1.6
Massachusetts 3 5 4 7 10 0.1 0.2 0.1 0.2 0.3
Michigan 93 61 20 26 27 1.8 1.2 0.4 0.5 0.5
Minnesota 4 3 2 4 1 0.2 0.1 0.1 0.2 0.0
Mississippi 20 19 12 36 35 1.3 1.3 0.8 2.4 2.3
Missouri 14 12 12 19 27 0.5 0.4 0.4 0.6 0.9
Montana 0 1 1 0 2 0.0 0.2 0.2 0.0 0.4
Nebraska 1 4 0 1 0 0.1 0.5 0.0 0.1 0.0
Nevada 3 8 24 34 12 0.3 0.7 2.0 2.8 1.0
New Hampshire 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
New Jersey 49 38 17 12 16 1.1 0.9 0.4 0.3 0.4
New Mexico 23 36 16 22 15 2.4 3.7 1.6 2.2 1.5
New York 26 32 28 29 32 0.3 0.3 0.3 0.3 0.3
North Carolina 47 48 58 67 60 1.1 1.1 1.3 1.5 1.3
North Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Ohio 40 61 40 43 28 0.7 1.0 0.7 0.7 0.5
Oklahoma 20 9 17 19 24 1.1 0.5 0.9 1.0 1.3
Oregon 3 1 2 0 2 0.2 0.1 0.1 0.0 0.1
Pennsylvania 33 16 34 34 34 0.5 0.3 0.5 0.5 0.5
Rhode Island 8 10 6 0 2 1.4 1.8 1.1 0.0 0.4
South Carolina 24 25 17 11 10 1.1 1.2 0.8 0.5 0.5
South Dakota 0 0 0 5 2 0.0 0.0 0.0 1.3 0.5
Tennessee 40 34 64 73 113 1.3 1.1 2.1 2.4 3.7
Texas 162 179 243 261 297 1.5 1.6 2.1 2.2 2.5
Utah 3 3 1 3 0 0.3 0.3 0.1 0.2 0.0
Vermont 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Virginia 7 6 19 23 16 0.2 0.2 0.5 0.6 0.4
Washington 4 6 5 4 6 0.1 0.2 0.2 0.1 0.2
West Virginia 2 1 0 1 2 0.2 0.1 0.0 0.1 0.2
Wisconsin 1 2 3 3 6 0.0 0.1 0.1 0.1 0.2
Wyoming 0 1 0 0 1 0.0 0.4 0.0 0.0 0.4
U.S. TOTAL 1,217 1,255 1,339 1,458 1,692 0.8 0.8 0.9 1.0 1.1
Northeast 122 104 91 86 96 0.4 0.4 0.3 0.3 0.3
Midwest 232 212 137 156 147 0.7 0.6 0.4 0.5 0.4
South 699 760 883 982 1,227 1.3 1.4 1.6 1.8 2.2
West 164 179 228 234 222 0.5 0.5 0.7 0.7 0.6
Guam 0 0 1 1 4 0.0 0.0 1.2 1.2 4.8
Puerto Rico 93 62 81 46 56 4.6 3.1 4.0 2.3 2.7
Virgin Islands 2 3 0 0 0 3.5 5.3 0.0 0.0 0.0
OUTLYING AREAS 95 65 82 47 60 4.4 3.0 3.8 2.2 2.7
TOTAL 1,312 1,320 1,421 1,505 1,752 0.9 0.9 0.9 1.0 1.1
Table 26. Primary and secondary syphilis — Women – Reported cases and rates by state/area and region
listed in alphabetical order: United States and outlying areas, 2003–2007
 NOTE: Cases reported with unknown sex are not included in this table.
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State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 65 113 100 203 237 3.0 5.1 4.5 9.1 10.6
Alaska 1 8 8 9 6 0.3 2.4 2.3 2.6 1.7
Arizona 120 115 125 166 230 4.3 4.0 4.2 5.4 7.5
Arkansas 35 29 31 42 72 2.6 2.2 2.3 3.0 5.2
California 1,245 1,291 1,463 1,706 1,921 7.0 7.2 8.1 9.4 10.5
Colorado 34 56 44 64 55 1.5 2.4 1.9 2.7 2.3
Connecticut 27 42 56 62 37 1.6 2.5 3.3 3.6 2.2
Delaware 5 8 9 16 17 1.3 2.0 2.2 3.9 4.1
District of Columbia 45 65 103 110 173 16.9 24.8 39.4 40.3 63.4
Florida 585 630 624 621 760 7.0 7.4 7.2 7.0 8.6
Georgia 517 504 598 540 626 12.1 11.5 13.3 11.7 13.6
Hawaii 14 8 11 17 8 2.2 1.3 1.7 2.6 1.2
Idaho 10 13 14 1 0 1.5 1.9 2.0 0.1 0.0
Illinois 326 331 478 394 425 5.2 5.3 7.6 6.2 6.7
Indiana 34 54 52 83 46 1.1 1.8 1.7 2.7 1.5
Iowa 10 3 8 13 18 0.7 0.2 0.5 0.9 1.2
Kansas 12 17 17 25 22 0.9 1.3 1.2 1.8 1.6
Kentucky 19 41 49 66 47 0.9 2.0 2.4 3.2 2.3
Louisiana 104 209 166 219 324 4.8 9.5 7.5 10.5 15.5
Maine 8 2 1 7 9 1.3 0.3 0.2 1.1 1.4
Maryland 238 288 225 239 298 8.9 10.7 8.3 8.8 11.0
Massachusetts 129 109 121 117 145 4.1 3.5 3.9 3.8 4.7
Michigan 156 131 85 92 96 3.2 2.6 1.7 1.9 1.9
Minnesota 43 24 68 43 58 1.7 0.9 2.7 1.7 2.3
Mississippi 20 40 37 50 98 1.4 2.8 2.6 3.5 7.0
Missouri 47 82 135 149 212 1.7 2.9 4.8 5.2 7.4
Montana 0 3 6 1 6 0.0 0.6 1.3 0.2 1.3
Nebraska 9 3 4 6 4 1.0 0.3 0.5 0.7 0.5
Nevada 9 32 85 103 99 0.8 2.7 6.9 8.1 7.8
New Hampshire 19 5 16 13 30 3.0 0.8 2.5 2.0 4.6
New Jersey 121 112 116 161 211 2.9 2.6 2.7 3.8 5.0
New Mexico 48 46 40 57 31 5.2 4.9 4.2 5.9 3.2
New York 558 695 677 707 1,036 6.0 7.5 7.3 7.6 11.1
North Carolina 105 144 216 242 263 2.5 3.4 5.1 5.6 6.1
North Dakota 2 0 1 1 1 0.6 0.0 0.3 0.3 0.3
Ohio 157 176 171 141 166 2.8 3.2 3.1 2.5 3.0
Oklahoma 44 16 27 51 41 2.5 0.9 1.5 2.9 2.3
Oregon 45 28 39 29 16 2.5 1.6 2.2 1.6 0.9
Pennsylvania 126 102 165 230 229 2.1 1.7 2.7 3.8 3.8
Rhode Island 25 16 18 14 34 4.8 3.1 3.5 2.7 6.6
South Carolina 70 91 67 55 81 3.5 4.4 3.2 2.6 3.9
South Dakota 2 0 2 8 5 0.5 0.0 0.5 2.0 1.3
Tennessee 95 96 153 176 254 3.3 3.3 5.2 6.0 8.6
Texas 492 648 630 803 863 4.5 5.8 5.5 6.9 7.4
Utah 11 10 9 18 20 0.9 0.8 0.7 1.4 1.6
Vermont 1 1 1 3 10 0.3 0.3 0.3 1.0 3.3
Virginia 75 110 124 167 214 2.1 3.0 3.3 4.4 5.7
Washington 78 144 147 178 148 2.6 4.7 4.7 5.6 4.6
West Virginia 0 2 3 10 4 0.0 0.2 0.3 1.1 0.4
Wisconsin 15 27 38 65 60 0.6 1.0 1.4 2.4 2.2
Wyoming 0 2 0 0 3 0.0 0.8 0.0 0.0 1.1
U.S. TOTAL 5,956 6,722 7,383 8,293 9,769 4.2 4.7 5.1 5.6 6.6
Northeast 1,014 1,084 1,171 1,314 1,741 3.8 4.1 4.4 4.9 6.5
Midwest 813 848 1,059 1,020 1,113 2.5 2.6 3.3 3.1 3.4
South 2,514 3,034 3,162 3,610 4,372 4.9 5.8 6.0 6.7 8.2
West 1,615 1,756 1,991 2,349 2,543 4.9 5.2 5.8 6.8 7.3
Guam 1 0 1 2 4 1.2 0.0 1.2 2.3 4.6
Puerto Rico 109 120 143 104 113 5.8 6.4 7.6 5.5 6.0
Virgin Islands 1 2 1 1 0 1.9 3.9 1.9 1.9 0.0
OUTLYING AREAS 111 122 145 107 117 5.5 6.1 7.2 5.3 5.8
TOTAL 6,067 6,844 7,528 8,400 9,886 4.2 4.7 5.1 5.6 6.6
Table 27. Primary and secondary syphilis — Men – Reported cases and rates by state/area and region listed
in alphabetical order: United States and outlying areas, 2003–2007
 NOTE: Cases reported with unknown sex are not included in this table.
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Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 516 508 598 529 608 11.2 10.8 12.2 10.3 11.8
Austin-Round Rock, TX 31 56 44 84 74 2.3 4.0 3.0 5.5 4.9
Baltimore-Towson, MD 224 276 244 213 211 8.6 10.5 9.2 8.0 7.9
Birmingham-Hoover, AL 23 33 101 244 189 2.1 3.0 9.3 22.2 17.2
Boston-Cambridge-Quincy, MA-NH 121 84 106 117 131 2.7 1.9 2.4 2.6 2.9
Buffalo-Cheektowaga-Tonawanda, NY 2 9 7 18 11 0.2 0.8 0.6 1.6 1.0
Charlotte-Gastonia-Concord, NC-SC 23 46 103 121 103 1.6 3.1 6.8 7.6 6.5
Chicago-Naperville-Joliet, IL-IN-WI 346 373 510 416 427 3.7 4.0 5.4 4.4 4.5
Cincinnati-Middletown, OH-KY-IN 2 22 24 13 34 0.1 1.1 1.2 0.6 1.6
Cleveland-Elyria-Mentor, OH 32 40 22 18 29 1.5 1.9 1.0 0.9 1.4
Columbus, OH 120 109 109 107 76 7.2 6.4 6.4 6.2 4.4
Dallas-Fort Worth-Arlington, TX 265 279 305 320 265 4.7 4.9 5.2 5.3 4.4
Denver-Aurora, CO 32 55 38 56 46 1.4 2.4 1.6 2.3 1.9
Detroit-Warren-Livonia, MI 218 153 77 82 91 4.9 3.4 1.7 1.8 2.0
Hartford-West Hartford-East Hartford, CT 16 13 14 23 15 1.4 1.1 1.2 1.9 1.3
Houston-Baytown-Sugar Land, TX 227 235 279 396 501 4.5 4.5 5.3 7.1 9.0
Indianapolis, IN 25 34 35 47 26 1.6 2.1 2.1 2.8 1.6
Jacksonville, FL 21 72 50 41 44 1.7 5.9 4.0 3.2 3.4
Kansas City, MO-KS 43 35 89 112 149 2.3 1.8 4.6 5.7 7.6
Las Vegas-Paradise, NV 8 38 103 132 102 0.5 2.3 6.0 7.4 5.7
Los Angeles-Long Beach-Santa Ana, CA 562 551 806 945 1,061 4.4 4.3 6.2 7.3 8.2
Louisville, KY-IN 28 38 46 41 32 2.4 3.2 3.8 3.4 2.6
Memphis, TN-MS-AR 90 99 138 145 208 7.3 7.9 10.9 11.4 16.3
Miami-Fort Lauderdale-Miami Beach, FL 409 434 395 369 414 7.7 8.1 7.3 6.8 7.6
Milwaukee-Waukesha-West Allis, WI 11 19 22 38 53 0.7 1.3 1.5 2.5 3.5
Minneapolis-St. Paul-Bloomington, MN-WI 43 26 68 43 57 1.4 0.8 2.2 1.4 1.8
Nashville-Davidson-Murfreesboro, TN 26 17 34 40 84 1.9 1.2 2.4 2.7 5.8
New Orleans-Metairie-Kenner, LA 28 101 88 90 168 2.1 7.7 6.7 8.8 16.4
New York-Newark-Edison, NY-NJ-PA 709 816 773 811 1,208 3.8 4.4 4.1 4.3 6.4
Oklahoma City, OK 56 20 23 24 36 4.9 1.7 2.0 2.0 3.1
Orlando, FL 70 69 106 94 145 3.9 3.7 5.5 4.7 7.3
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 135 95 127 173 205 2.3 1.6 2.2 3.0 3.5
Phoenix-Mesa-Scottsdale, AZ 134 106 113 157 193 3.7 2.9 2.9 3.9 4.8
Pittsburgh, PA 38 22 69 91 60 1.6 0.9 2.9 3.8 2.5
Portland-Vancouver-Beaverton, OR-WA 47 26 39 25 11 2.3 1.3 1.9 1.2 0.5
Providence-New Bedford-Fall River, RI-MA 42 30 28 18 44 2.6 1.8 1.7 1.1 2.7
Richmond, VA 12 11 13 28 38 1.1 1.0 1.1 2.3 3.2
Riverside-San Bernardino-Ontario, CA 91 103 121 108 95 2.5 2.7 3.1 2.7 2.4
Rochester, NY 7 12 6 14 16 0.7 1.2 0.6 1.4 1.5
Sacramento-Arden-Arcade-Roseville, CA 19 19 16 32 59 1.0 0.9 0.8 1.5 2.9
Salt Lake City, UT 6 5 9 15 19 0.6 0.5 0.9 1.4 1.8
San Antonio, TX 52 116 129 136 157 2.9 6.3 6.8 7.0 8.1
San Diego-Carlsbad-San Marcos, CA 111 138 194 235 347 3.8 4.7 6.6 8.0 11.8
San Francisco-Oakland-Fremont, CA 406 422 331 363 308 9.8 10.2 8.0 8.7 7.4
San Jose-Sunnyvale-Santa Clara, CA 56 56 44 52 56 3.2 3.2 2.5 2.9 3.1
Seattle-Tacoma-Bellevue, WA 70 138 125 160 138 2.2 4.4 3.9 4.9 4.2
St. Louis, MO-IL 51 71 50 65 112 1.9 2.6 1.8 2.3 4.0
Tampa-St. Petersburg-Clearwater, FL 96 89 85 110 195 3.8 3.4 3.2 4.1 7.2
Virginia Beach-Norfolk-Newport News, VA-NC 23 50 60 84 88 1.4 3.0 3.6 5.1 5.3
Washington-Arlington-Alexandria, DC-VA-MD-WV 168 199 233 250 377 3.3 3.9 4.5 4.7 7.1
U.S. MSA TOTAL 5,891 6,368 7,149 7,845 9,116 3.8 4.0 4.5 4.9 5.7
Table 28. Primary and secondary syphilis — Reported cases and rates in selected metropolitan statistical
areas* (MSAs) listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 57 36 36 33 40 2.5 1.5 1.5 1.3 1.5
Austin-Round Rock, TX 2 3 3 11 12 0.3 0.4 0.4 1.5 1.6
Baltimore-Towson, MD 63 70 84 53 40 4.6 5.1 6.1 3.8 2.9
Birmingham-Hoover, AL 4 11 35 94 80 0.7 2.0 6.2 16.5 14.1
Boston-Cambridge-Quincy, MA-NH 2 5 1 7 10 0.1 0.2 0.0 0.3 0.4
Buffalo-Cheektowaga-Tonawanda, NY 1 1 0 2 0 0.2 0.2 0.0 0.3 0.0
Charlotte-Gastonia-Concord, NC-SC 3 12 20 28 20 0.4 1.6 2.6 3.5 2.5
Chicago-Naperville-Joliet, IL-IN-WI 44 55 50 43 31 0.9 1.1 1.0 0.9 0.6
Cincinnati-Middletown, OH-KY-IN 0 2 0 5 6 0.0 0.2 0.0 0.5 0.6
Cleveland-Elyria-Mentor, OH 13 3 1 2 5 1.2 0.3 0.1 0.2 0.5
Columbus, OH 17 31 22 30 11 2.0 3.6 2.5 3.4 1.3
Dallas-Fort Worth-Arlington, TX 99 73 100 112 93 3.5 2.6 3.4 3.7 3.1
Denver-Aurora, CO 3 6 1 3 1 0.3 0.5 0.1 0.3 0.1
Detroit-Warren-Livonia, MI 81 49 17 20 22 3.5 2.1 0.7 0.9 1.0
Hartford-West Hartford-East Hartford, CT 3 0 0 1 1 0.5 0.0 0.0 0.2 0.2
Houston-Baytown-Sugar Land, TX 26 39 61 65 108 1.0 1.5 2.3 2.3 3.9
Indianapolis, IN 7 2 4 1 3 0.9 0.2 0.5 0.1 0.4
Jacksonville, FL 9 32 20 11 11 1.5 5.1 3.1 1.7 1.7
Kansas City, MO-KS 20 5 5 17 25 2.1 0.5 0.5 1.7 2.5
Las Vegas-Paradise, NV 1 8 21 32 11 0.1 1.0 2.5 3.7 1.3
Los Angeles-Long Beach-Santa Ana, CA 28 40 63 72 58 0.4 0.6 1.0 1.1 0.9
Louisville, KY-IN 13 6 3 3 2 2.1 1.0 0.5 0.5 0.3
Memphis, TN-MS-AR 30 33 50 52 87 4.7 5.1 7.7 7.9 13.2
Miami-Fort Lauderdale-Miami Beach, FL 33 41 43 40 60 1.2 1.5 1.5 1.4 2.1
Milwaukee-Waukesha-West Allis, WI 1 1 1 2 5 0.1 0.1 0.1 0.3 0.6
Minneapolis-St. Paul-Bloomington, MN-WI 3 3 3 3 1 0.2 0.2 0.2 0.2 0.1
Nashville-Davidson-Murfreesboro, TN 6 2 2 2 13 0.9 0.3 0.3 0.3 1.8
New Orleans-Metairie-Kenner, LA 10 27 23 25 51 1.5 3.9 3.4 4.7 9.6
New York-Newark-Edison, NY-NJ-PA 65 58 37 31 42 0.7 0.6 0.4 0.3 0.4
Oklahoma City, OK 19 7 9 6 13 3.3 1.2 1.5 1.0 2.2
Orlando, FL 17 10 14 14 13 1.9 1.1 1.4 1.4 1.3
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 23 16 13 6 14 0.8 0.5 0.4 0.2 0.5
Phoenix-Mesa-Scottsdale, AZ 45 25 23 18 29 2.5 1.4 1.2 0.9 1.4
Pittsburgh, PA 17 7 25 28 25 1.4 0.6 2.0 2.3 2.0
Portland-Vancouver-Beaverton, OR-WA 2 0 0 0 1 0.2 0.0 0.0 0.0 0.1
Providence-New Bedford-Fall River, RI-MA 9 10 7 0 2 1.1 1.2 0.8 0.0 0.2
Richmond, VA 2 1 1 1 3 0.3 0.2 0.2 0.2 0.5
Riverside-San Bernardino-Ontario, CA 5 1 12 10 4 0.3 0.1 0.6 0.5 0.2
Rochester, NY 1 0 1 0 1 0.2 0.0 0.2 0.0 0.2
Sacramento-Arden-Arcade-Roseville, CA 1 0 0 3 2 0.1 0.0 0.0 0.3 0.2
Salt Lake City, UT 1 1 1 1 0 0.2 0.2 0.2 0.2 0.0
San Antonio, TX 6 20 34 32 35 0.6 2.1 3.5 3.2 3.5
San Diego-Carlsbad-San Marcos, CA 4 10 25 12 12 0.3 0.7 1.7 0.8 0.8
San Francisco-Oakland-Fremont, CA 4 2 8 7 12 0.2 0.1 0.4 0.3 0.6
San Jose-Sunnyvale-Santa Clara, CA 4 4 2 7 4 0.5 0.5 0.2 0.8 0.5
Seattle-Tacoma-Bellevue, WA 2 6 4 2 4 0.1 0.4 0.2 0.1 0.2
St. Louis, MO-IL 12 9 5 3 9 0.8 0.6 0.3 0.2 0.6
Tampa-St. Petersburg-Clearwater, FL 6 3 8 15 52 0.5 0.2 0.6 1.1 3.8
Virginia Beach-Norfolk-Newport News, VA-NC 3 4 15 18 10 0.4 0.5 1.8 2.1 1.2
Washington-Arlington-Alexandria, DC-VA-MD-WV 13 16 13 11 12 0.5 0.6 0.5 0.4 0.4
U.S. MSA TOTAL 840 806 926 994 1,106 1.1 1.0 1.1 1.2 1.3
Table 29. Primary and secondary syphilis — Women – Reported cases and rates in selected metropolitan
statistical areas* (MSAs) listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 459 472 562 496 567 20.1 20.2 23.0 19.5 22.3
Austin-Round Rock, TX 29 53 41 73 62 4.1 7.4 5.5 9.4 8.0
Baltimore-Towson, MD 161 206 160 160 171 12.8 16.2 12.5 12.5 13.4
Birmingham-Hoover, AL 19 22 66 150 109 3.7 4.2 12.5 28.3 20.5
Boston-Cambridge-Quincy, MA-NH 119 79 105 110 121 5.5 3.7 4.9 5.1 5.6
Buffalo-Cheektowaga-Tonawanda, NY 1 8 7 16 11 0.2 1.4 1.3 2.9 2.0
Charlotte-Gastonia-Concord, NC-SC 20 34 83 93 83 2.8 4.7 11.1 11.9 10.7
Chicago-Naperville-Joliet, IL-IN-WI 302 318 460 373 396 6.6 6.9 9.9 8.0 8.5
Cincinnati-Middletown, OH-KY-IN 2 20 24 8 28 0.2 2.0 2.4 0.8 2.7
Cleveland-Elyria-Mentor, OH 19 37 21 16 24 1.9 3.6 2.1 1.6 2.4
Columbus, OH 103 78 87 77 65 12.5 9.3 10.3 9.0 7.6
Dallas-Fort Worth-Arlington, TX 166 206 205 208 172 5.9 7.2 7.0 6.9 5.7
Denver-Aurora, CO 29 49 37 53 45 2.5 4.2 3.1 4.4 3.7
Detroit-Warren-Livonia, MI 137 104 60 62 69 6.3 4.8 2.7 2.8 3.2
Hartford-West Hartford-East Hartford, CT 13 13 14 22 14 2.3 2.3 2.4 3.8 2.4
Houston-Baytown-Sugar Land, TX 201 196 218 331 393 7.9 7.6 8.3 11.9 14.2
Indianapolis, IN 18 32 31 46 23 2.3 4.0 3.8 5.6 2.8
Jacksonville, FL 12 40 30 30 33 2.0 6.7 4.9 4.8 5.3
Kansas City, MO-KS 23 30 84 95 124 2.5 3.2 8.8 9.8 12.8
Las Vegas-Paradise, NV 7 30 82 100 91 0.9 3.6 9.4 11.1 10.1
Los Angeles-Long Beach-Santa Ana, CA 533 511 743 873 1,002 8.4 8.0 11.6 13.6 15.6
Louisville, KY-IN 14 32 43 38 30 2.4 5.5 7.3 6.4 5.0
Memphis, TN-MS-AR 60 66 88 93 121 10.0 10.9 14.4 15.1 19.7
Miami-Fort Lauderdale-Miami Beach, FL 376 393 352 329 354 14.7 15.1 13.4 12.4 13.3
Milwaukee-Waukesha-West Allis, WI 10 18 21 36 48 1.4 2.4 2.9 4.9 6.5
Minneapolis-St. Paul-Bloomington, MN-WI 40 23 65 40 56 2.6 1.5 4.2 2.5 3.6
Nashville-Davidson-Murfreesboro, TN 20 15 32 38 71 3.0 2.2 4.6 5.3 9.9
New Orleans-Metairie-Kenner, LA 18 74 65 65 117 2.8 11.7 10.3 13.2 23.7
New York-Newark-Edison, NY-NJ-PA 644 758 736 780 1,166 7.2 8.4 8.1 8.6 12.8
Oklahoma City, OK 37 13 14 18 23 6.6 2.3 2.5 3.1 4.0
Orlando, FL 53 59 92 80 132 6.0 6.4 9.6 8.1 13.4
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 112 79 114 167 191 4.0 2.8 4.1 5.9 6.8
Phoenix-Mesa-Scottsdale, AZ 89 81 89 136 162 4.9 4.3 4.6 6.7 7.9
Pittsburgh, PA 21 15 44 63 35 1.8 1.3 3.8 5.5 3.1
Portland-Vancouver-Beaverton, OR-WA 45 26 39 25 10 4.4 2.5 3.7 2.3 0.9
Providence-New Bedford-Fall River, RI-MA 33 20 21 18 42 4.2 2.5 2.7 2.3 5.4
Richmond, VA 10 10 12 27 35 1.8 1.8 2.1 4.6 6.0
Riverside-San Bernardino-Ontario, CA 86 102 108 98 90 4.7 5.4 5.5 4.9 4.5
Rochester, NY 6 12 5 14 15 1.2 2.4 1.0 2.8 3.0
Sacramento-Arden-Arcade-Roseville, CA 18 19 16 29 57 1.9 1.9 1.6 2.9 5.6
Salt Lake City, UT 5 4 8 14 19 1.0 0.8 1.5 2.6 3.5
San Antonio, TX 46 96 95 104 122 5.2 10.6 10.3 10.9 12.8
San Diego-Carlsbad-San Marcos, CA 107 128 169 223 335 7.3 8.7 11.4 15.1 22.6
San Francisco-Oakland-Fremont, CA 401 419 323 355 296 19.5 20.4 15.7 17.1 14.3
San Jose-Sunnyvale-Santa Clara, CA 52 52 42 45 52 5.9 5.9 4.7 4.9 5.7
Seattle-Tacoma-Bellevue, WA 68 132 121 158 134 4.3 8.3 7.6 9.7 8.2
St. Louis, MO-IL 39 62 45 62 103 3.0 4.6 3.3 4.6 7.6
Tampa-St. Petersburg-Clearwater, FL 90 86 77 95 143 7.3 6.9 6.0 7.2 10.9
Virginia Beach-Norfolk-Newport News, VA-NC 20 46 45 66 78 2.5 5.7 5.5 8.2 9.7
Washington-Arlington-Alexandria, DC-VA-MD-WV 155 183 220 239 365 6.2 7.3 8.6 9.3 14.1
U.S. MSA TOTAL 5,048 5,561 6,221 6,847 8,005 6.6 7.2 7.9 8.6 10.1
Table 30. Primary and secondary syphilis — Men – Reported cases and rates in selected metropolitan
statistical areas* (MSAs) listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Rank† County/Independent City   Cases   Rate per 100,000 Population Cumulative Percent
1 Los Angeles County, CA 919 9.2 8
2 Harris County, TX 454 11.7 11
3 New York County, NY 394 24.4 15
4 Cook County, IL 391 7.4 18
5 San Diego County, CA 347 11.8 21
6 Fulton County, GA 293 30.5 24
7 Kings County, NY 255 10.2 26
8 Miami-Dade County, FL 210 8.7 28
9 San Francisco County, CA 202 27.1 30
10 Shelby County, TN 191 21.0 31
11 Maricopa County, AZ 190 5.0 33
12 Washington, D.C. 178 30.6 35
13 Broward County, FL 178 10.0 36
14 Jefferson County, AL 166 25.3 38
15 Bexar County, TX 155 10.0 39
16 Dallas County, TX 152 6.5 40
17 DeKalb County, GA 142 19.6 42
18 Orange County, CA 142 4.7 43
19 Baltimore (City), MD 140 22.2 44
20 Queens County, NY 138 6.1 45
21 Philadelphia County, PA 136 9.4 46
22 Orange County, FL 119 11.4 47
23 Orleans County, LA 117 52.4 48
24 Bronx County, NY 116 8.5 49
25 Hillsborough County, FL 115 9.9 50
26 King County, WA 112 6.1 51
27 Jackson County, MO 107 16.1 52
28 Madison County, AL 104 34.2 53
29 Clark County, NV 102 5.7 54
30 Prince George’s County, MD 94 11.2 55
31 Mecklenburg County, NC 93 11.2 56
32 Tarrant County, TX 87 5.2 57
33 Wayne County, MI 85 4.3 57
34 Riverside County, CA 80 3.9 58
35 Pima County, AZ 78 8.2 59
36 Suffolk County, MA 73 10.6 59
37 Pinellas County, FL 72 7.8 60
38 East Baton Rouge County, LA 70 16.3 61
39 Davidson County, TN 70 12.1 61
40 Franklin County, OH 68 6.2 62
41 Travis County, TX 67 7.3 62
42 Essex County, NJ 64 8.1 63
43 Sacramento County, CA 59 4.3 63
44 Cobb County, GA 57 8.4 64
45 Lafayette County, LA 56 27.6 64
46 Santa Clara County, CA 55 3.2 65
47 Allegheny County, PA 54 4.4 65
48 St Louis (City), MO 51 14.7 66
49 Hudson County, NJ 49 8.2 66
50 Milwaukee County, WI 49 5.4 67
51 Alameda County, CA 49 3.4 67
52 Gwinnett County, GA 46 6.1 67
53 Tangipahoa County, LA 42 37.1 68
54 Hennepin County, MN 41 3.7 68
55 Duval County, FL 40 4.8 69
56 Jefferson County, TX 39 16.0 69
57 Knox County, TN 39 9.5 69
58 Clayton County, GA 37 13.6 70
59 Jefferson County, LA 36 8.3 70
60 Pulaski County, AR 35 9.5 70
61 St. Louis County, MO 35 3.5 70
Table 31. Primary and secondary syphilis — Counties and independent cities* ranked by number of reported
cases: United States, 2007
*Accounting for 70% of reported primary and secondary syphilis cases.
†Counties and independent cities were ranked in descending order by number of cases reported in 2007.
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   Age
Group
Cases Rates
Year Total Male Female Total Male Female
2003
10–14 11 1 10 0.1 0.0 0.1
15–19 322 150 172 1.6 1.4 1.7
20–24 860 620 240 4.2 5.8 2.4
25–29 941 760 181 4.9 7.8 1.9
30–34 1,187 1,023 164 5.7 9.8 1.6
35–39 1,460 1,290 170 6.8 12.0 1.6
40–44 1,157 1,021 136 5.0 8.9 1.2
45–54 991 871 119 2.4 4.3 0.6
55–64 205 187 18 0.7 1.4 0.1
65+ 42 36 6 0.1 0.2 0.0
TO TAL 7,177 5,959 1,218 2.5 4.2 0.8
2004
10–14 9 2 7 0.0 0.0 0.1
15–19 339 191 148 1.6 1.8 1.5
20–24 1,029 735 294 4.9 6.8 2.9
25–29 1,126 944 182 5.8 9.4 1.9
30–34 1,285 1,118 167 6.3 10.8 1.6
35–39 1,467 1,313 154 7.0 12.4 1.5
40–44 1,345 1,199 146 5.8 10.5 1.3
45–54 1,035 915 120 2.5 4.5 0.6
55–64 281 249 32 1.0 1.8 0.2
65+ 55 54 1 0.2 0.4 0.0
TO TAL 7,980 6,725 1,255 2.7 4.7 0.8
2005
10–14 10 2 8 0.0 0.0 0.1
15–19 443 251 192 2.1 2.3 1.9
20–24 1,181 875 306 5.6 8.1 3.0
25–29 1,214 1,008 206 6.0 9.8 2.1
30–34 1,329 1,178 150 6.6 11.6 1.5
35–39 1,574 1,394 179 7.5 13.2 1.7
40–44 1,418 1,253 164 6.2 11.0 1.4
45–54 1,192 1,080 111 2.8 5.2 0.5
55–64 304 284 20 1.0 1.9 0.1
65+ 59 57 2 0.2 0.4 0.0
TO TAL 8,724 7,385 1,339 2.9 5.1 0.9
2006
10–14 13 2 11 0.1 0.0 0.1
15–19 565 332 233 2.7 3.0 2.2
20–24 1,382 1,083 299 6.5 9.9 2.9
25–29 1,574 1,333 241 7.6 12.6 2.4
30–34 1,221 1,058 163 6.2 10.6 1.7
35–39 1,581 1,427 154 7.5 13.4 1.5
40–44 1,516 1,363 153 6.7 12.2 1.4
45–54 1,443 1,278 165 3.3 6.0 0.8
55–64 375 340 35 1.2 2.2 0.2
65+ 81 79 2 0.2 0.5 0.0
TO TAL 9,756 8,297 1,459 3.3 5.6 1.0
2007
10–14 13 5 8 0.1 0.0 0.1
15–19 664 416 248 3.1 3.8 2.4
20–24 1,818 1,462 356 8.6 13.4 3.5
25–29 1,841 1,576 265 8.9 14.9 2.6
30–34 1,500 1,306 193 7.6 13.1 2.0
35–39 1,721 1,530 191 8.1 14.4 1.8
40–44 1,745 1,553 192 7.8 13.9 1.7
45–54 1,664 1,464 200 3.8 6.9 0.9
55–64 409 379 30 1.3 2.5 0.2
65+ 91 82 9 0.2 0.5 0.0
TO TAL 11,466 9,773 1,693 3.8 6.6 1.1
Table 32. Primary and secondary syphilis — Reported cases and rates per 100,000 population by age group
and sex: United States, 2003–2007
 NOTE: This ta ble should be used only for age com par i sons. If age was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases
for which age was known. Dif fer ences be tween to tal cases from this ta ble and oth ers in the re port are due to dif fer ent re port ing formats. The 0 to 9
year age group is not shown  because some of these cases may not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
This page in ten tion ally left blank.
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Age 
Group 
      White, Non-His panic           Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
3002
10–14 0 0 0 5 1 4 5 0 5 0 0 0 1 0 1
15–19 48 24 24 205 93 112 63 28 35 6 5 1 0 0 0
20–24 195 154 41 471 309 161 178 142 36 13 11 2 3 3 0
25–29 301 265 36 408 293 115 195 173 23 28 25 3 8 4 4
30–34 524 485 39 416 316 100 213 190 23 20 20 0 14 12 2
35–39 743 703 40 451 335 116 222 211 11 28 28 0 16 14 2
40–44 588 563 26 382 288 94 158 146 12 20 19 1 9 5 3
45–54 489 472 17 373 287 86 107 97 9 10 8 1 13 6 6
55–64 104 100 4 81 68 13 13 12 1 2 2 0 4 4 0
65+ 17 16 1 18 16 2 5 2 3 0 0 0 1 1 0
TO TAL 3,010 2,783 227 2,811 2,005 805 1,160 1,001 159 127 119 8 69 50 19
4002
10–14 0 0 0 8 2 6 1 0 1 0 0 0 0 0 0
15–19 56 33 23 211 113 98 55 33 22 11 9 2 6 3 3
20–24 242 185 57 573 375 198 188 156 32 19 16 3 8 4 4
25–29 317 281 36 534 421 113 237 213 24 28 25 3 11 5 5
30–34 512 470 41 496 402 95 238 215 23 29 28 1 10 3 6
35–39 675 640 35 489 392 98 249 235 14 36 35 1 18 12 6
40–44 684 655 29 455 353 102 179 169 9 18 18 0 10 4 5
45–54 525 503 23 379 295 84 110 98 12 11 11 0 10 9 1
55–64 155 145 10 101 83 18 20 20 0 2 1 1 4 1 3
65+ 36 35 1 16 16 0 3 3 0 0 0 0 0 0 0
TO TAL 3,203 2,947 256 3,266 2,452 814 1,280 1,142 138 153 142 11 77 42 35
5002
10–14 0 0 0 9 1 8 1 1 0 0 0 0 0 0 0
15–19 67 36 30 304 173 131 62 36 26 5 4 1 5 1 4
20–24 281 230 51 660 459 201 216 167 49 15 11 4 8 7 1
25–29 331 299 32 612 480 132 236 198 38 27 25 2 8 6 2
30–34 491 456 35 554 455 99 230 216 14 43 42 1 12 10 2
35–39 761 712 49 518 415 103 268 244 24 19 19 0 8 4 4
40–44 741 700 40 446 350 97 193 172 21 26 24 2 12 7 4
45–54 660 631 29 385 320 65 126 111 14 15 14 1 6 4 2
55–64 167 162 5 102 90 13 30 28 2 4 4 0 0 0 0
65+ 26 26 0 23 21 2 8 8 0 2 2 0 0 0 0
TO TAL 3,524 3,254 270 3,615 2,764 850 1,370 1,182 188 156 145 11 60 40 20
6002
10–14 1 0 1 11 2 9 0 0 0 0 0 0 1 0 1
15–19 71 39 33 419 246 173 74 46 28 1 1 0 0 0 0
20–24 291 247 44 853 630 223 218 187 31 12 11 1 8 7 1
25–29 431 381 50 795 641 154 304 271 34 37 35 2 7 6 1
30–34 433 395 38 497 398 99 243 223 20 34 31 3 14 11 3
35–39 720 676 44 532 447 85 282 263 18 33 32 1 14 9 5
40–44 802 756 46 443 356 87 227 213 14 30 29 1 15 10 5
45–54 766 729 38 500 394 107 143 129 14 24 22 2 9 5 4
55–64 194 186 8 139 115 24 35 33 2 2 2 0 5 4 1
65+ 34 34 0 25 23 2 17 17 0 0 0 0 5 5 0
TO TAL 3,744 3,443 301 4,215 3,253 962 1,543 1,381 162 173 163 10 80 57 24
7002
10–14 0 0 0 13 5 8 0 0 0 0 0 0 0 0 0
15–19 95 49 46 470 299 171 91 66 26 0 0 0 7 2 5
20–24 338 271 67 1,124 883 240 328 289 40 15 12 2 13 6 7
25–29 487 432 54 953 783 170 352 319 33 35 34 1 15 7 7
30–34 506 455 51 612 504 108 325 298 27 38 35 3 19 15 4
35–39 699 650 49 683 559 125 293 280 12 31 31 0 15 10 5
40–44 841 783 58 605 486 119 265 254 11 27 26 1 6 4 2
45–54 824 773 51 620 488 132 187 171 16 23 23 0 10 7 2
55–64 213 210 3 154 130 24 41 38 3 2 2 0 0 0 0
65+ 47 45 2 38 31 7 5 5 0 1 1 0 0 0 0
TO TAL 4,050 3,669 381 5,273 4,169 1,104 1,887 1,719 167 171 164 7 85 52 33
Ta ble 33A. Pri mary and sec ond ary syph i lis — Re ported cases by race/eth nic ity, age group and sex: United States,
2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 32 for age-spe cific cases and rates and Ta bles 25-27 for to tal
and sex-spe cific cases and rates. If age or race/eth nic ity was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these
vari ables were spec i fied. In 2007, ID did not re port race/eth nic ity and their case data and pop u la tion de nom i na tors were ex cluded. Dif fer ences be tween to tal
cases from this ta ble and oth ers in the re port are due to  different re port ing for mats and above listed ex clu sion. The 0 to 9 year age group is not shown be -
cause some of these cases may not be due to sex ual trans mis sion; how ever, they are included in the to tals.
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Age 
Group 
      White, Non-His panic          Black, Non-His panic                     His panic                  Asian/Pa cific Is lander   
Amer i can In dian/
          Alaska Na tive           
To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male To tal Male Fe male
10–14 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.9
2003
15–19 0.4 0.4 0.4 6.7 5.9 7.4 1.9 1.7 2.2 0.7 1.2 0.2 0.0 0.0 0.0
20–24 1.5 2.4 0.6 16.0 21.1 10.9 4.8 6.8 2.2 1.4 2.3 0.4 1.5 3.0 0.0
25–29 2.6 4.6 0.6 16.1 24.1 8.7 5.1 8.3 1.3 2.5 4.4 0.5 4.9 5.0 4.9
30–34 4.0 7.4 0.6 15.7 25.2 7.2 5.9 9.9 1.4 1.6 3.3 0.0 8.1 13.8 2.4
35–39 5.2 9.8 0.6 16.6 26.2 8.1 7.0 12.5 0.8 2.6 5.3 0.0 9.0 15.9 2.3
40–44 3.6 7.0 0.3 13.6 21.9 6.3 5.8 10.3 0.9 1.9 3.7 0.2 4.5 6.0 3.2
45–54 1.6 3.1 0.1 8.0 13.4 3.4 2.8 5.1 0.5 0.5 1.0 0.1 4.0 4.2 3.8
55–64 0.5 0.9 0.0 3.0 5.7 0.9 0.6 1.2 0.1 0.2 0.5 0.0 2.3 4.8 0.0
65+ 0.1 0.1 0.0 0.6 1.4 0.1 0.3 0.3 0.3 0.0 0.0 0.0 0.7 1.5 0.0
TO TAL 1.5 2.8 0.2 7.7 11.5 4.2 2.9 4.9 0.8 1.0 1.9 0.1 2.8 4.2 1.5
10–14 0.0 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
2004
15–19 0.4 0.5 0.4 6.7 7.1 6.3 1.6 1.9 1.3 1.2 1.9 0.5 2.7 2.7 2.8
20–24 1.9 2.8 0.9 19.1 25.0 13.2 5.0 7.5 1.9 1.9 3.1 0.6 3.9 3.9 3.9
25–29 2.7 4.7 0.6 20.5 33.5 8.4 6.1 9.8 1.4 2.4 4.4 0.5 6.1 6.1 6.0
30–34 4.0 7.4 0.7 18.9 32.2 6.8 6.4 10.8 1.4 2.3 4.4 0.2 5.7 3.9 7.5
35–39 4.9 9.2 0.5 18.4 31.2 6.9 7.6 13.5 0.9 3.1 6.2 0.2 10.6 14.1 7.1
40–44 4.3 8.2 0.4 16.1 26.7 6.8 6.2 11.3 0.7 1.7 3.6 0.0 5.1 4.7 5.4
45–54 1.7 3.3 0.1 8.0 13.4 3.3 2.7 4.8 0.6 0.6 1.3 0.0 3.0 5.6 0.6
55–64 0.7 1.3 0.1 3.6 6.6 1.2 0.9 1.9 0.0 0.2 0.2 0.2 2.0 1.1 2.9
65+ 0.1 0.3 0.0 0.5 1.4 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0
TO TAL 1.6 3.0 0.3 8.8 13.9 4.2 3.1 5.4 0.7 1.2 2.2 0.2 3.1 3.5 2.8
10–14 0.0 0.0 0.0 0.3 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2005
15–19 0.5 0.5 0.5 9.4 10.6 8.2 1.8 2.0 1.6 0.6 0.9 0.2 2.3 0.9 3.7
20–24 2.1 3.4 0.8 21.9 30.2 13.5 5.8 8.2 2.9 1.6 2.3 0.8 3.8 6.6 0.9
25–29 2.8 4.9 0.5 22.6 36.5 9.5 5.8 8.8 2.1 2.4 4.5 0.4 4.6 6.6 2.6
30–34 4.0 7.4 0.6 21.4 37.1 7.3 6.0 10.5 0.8 3.2 6.5 0.2 7.1 11.6 2.5
35–39 5.6 10.4 0.7 19.6 33.3 7.4 7.9 13.5 1.5 1.5 3.2 0.0 5.1 5.3 4.9
40–44 4.7 8.9 0.5 15.8 26.5 6.4 6.4 11.0 1.5 2.3 4.4 0.4 6.2 8.3 4.3
45–54 2.1 4.1 0.2 7.9 14.1 2.5 2.9 5.2 0.7 0.8 1.6 0.1 1.9 2.7 1.2
55–64 0.7 1.4 0.0 3.5 6.8 0.8 1.3 2.5 0.2 0.3 0.7 0.0 0.0 0.0 0.0
65+ 0.1 0.2 0.0 0.7 1.8 0.1 0.4 0.9 0.0 0.2 0.4 0.0 0.0 0.0 0.0
TO TAL 1.8 3.3 0.3 9.7 15.5 4.4 3.2 5.4 0.9 1.1 2.2 0.2 2.4 3.3 1.6
10–14 0.0 0.0 0.0 0.3 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.0
2006
15–19 0.5 0.6 0.5 12.6 14.7 10.6 2.0 2.5 1.6 0.1 0.2 0.0 0.0 0.0 0.0
20–24 2.2 3.7 0.7 28.1 41.0 14.8 5.8 9.2 1.8 1.3 2.3 0.2 3.7 6.3 1.1
25–29 3.5 6.1 0.8 28.3 46.9 10.7 7.3 11.7 1.8 3.1 6.0 0.3 3.9 6.7 1.1
30–34 3.7 6.7 0.6 19.6 33.1 7.4 6.2 10.4 1.1 2.5 4.7 0.4 8.4 13.0 3.7
35–39 5.3 9.9 0.7 20.1 35.8 6.1 8.0 14.0 1.1 2.6 5.2 0.2 8.3 10.5 6.1
40–44 5.3 9.9 0.6 15.9 27.3 5.8 7.3 13.0 1.0 2.6 5.1 0.2 8.1 10.8 5.5
45–54 2.4 4.7 0.2 10.0 17.0 4.0 3.2 5.6 0.6 1.2 2.4 0.2 2.8 3.3 2.3
55–64 0.8 1.6 0.1 4.5 8.3 1.4 1.4 2.7 0.2 0.2 0.4 0.0 2.4 4.0 0.9
65+ 0.1 0.3 0.0 0.8 1.9 0.1 0.7 1.6 0.0 0.0 0.0 0.0 2.7 6.3 0.0
TO TAL 1.9 3.5 0.3 11.2 18.1 4.9 3.5 6.0 0.8 1.2 2.4 0.1 3.2 4.7 1.9
10–14 0.0 0.0 0.0 0.4 0.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2007
15–19 0.7 0.7 0.7 14.2 17.8 10.4 2.5 3.5 1.5 0.0 0.0 0.0 3.2 1.8 4.5
20–24 2.6 4.1 1.1 37.0 57.5 16.0 8.8 14.2 2.3 1.5 2.5 0.4 6.1 5.6 6.6
25–29 4.0 7.0 0.9 33.9 57.4 11.7 8.5 13.8 1.8 3.0 5.8 0.2 7.9 7.9 7.8
30–34 4.3 7.8 0.9 24.2 41.9 8.1 8.3 14.0 1.5 2.8 5.3 0.4 11.7 18.2 5.1
35–39 5.2 9.6 0.7 25.8 44.8 8.9 8.3 14.9 0.8 2.4 5.0 0.0 8.9 11.7 6.2
40–44 5.6 10.4 0.8 21.7 37.2 8.0 8.5 15.5 0.8 2.3 4.6 0.2 3.5 4.9 2.2
45–54 2.6 5.0 0.3 12.4 21.1 4.9 4.1 7.5 0.7 1.2 2.6 0.0 2.8 4.7 1.2
55–64 0.9 1.8 0.0 4.9 9.3 1.4 1.6 3.1 0.2 0.2 0.4 0.0 0.0 0.0 0.0
65+ 0.2 0.4 0.0 1.2 2.6 0.4 0.2 0.5 0.0 0.1 0.2 0.0 0.0 0.0 0.0
TO TAL 2.0 3.7 0.4 14.0 23.2 5.6 4.3 7.5 0.8 1.2 2.4 0.1 3.4 4.3 2.6
Ta ble 33B. Pri mary and sec ond ary syphilis — Rates per 100,000 population by race/eth nic ity, age group and sex:
United States, 2003–2007
NOTE: These ta bles should be used only for race/eth nic ity com par i sons. See Ta ble 32 for age-spe cific cases and rates and Ta bles 25-27 for to tal and
sex-spe cific cases and rates. If age or race/eth nic ity was not spec i fied, cases were pro rated ac cord ing to the dis tri bu tion of cases for which these vari ables were
spec i fied. In 2007, ID did not re port race/eth nic ity and their case data and pop u la tion de nom i na tors were ex cluded. Dif fer ences be tween to tal rates from this ta ble
and oth ers in the re port are due to  different re port ing for mats and above listed ex clu sion. The 0 to 9 year  age group is not shown be cause some of these cases may
not be due to sex ual trans mis sion; how ever, they are in cluded in the to tals.
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Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 140 231 184 341 363 3.1 5.1 4.0 7.4 7.9
Alaska 0 1 8 6 3 0.0 0.2 1.2 0.9 0.4
Arizona 232 219 134 186 269 4.2 3.8 2.3 3.0 4.4
Arkansas 71 56 48 67 115 2.6 2.0 1.7 2.4 4.1
California 820 873 1,153 1,369 1,421 2.3 2.4 3.2 3.8 3.9
Colorado 20 24 27 38 35 0.4 0.5 0.6 0.8 0.7
Connecticut 13 16 19 27 20 0.4 0.5 0.5 0.8 0.6
Delaware 11 25 9 16 14 1.3 3.0 1.1 1.9 1.6
District of Columbia 152 113 103 77 84 26.9 20.4 18.7 13.2 14.4
Florida 988 856 726 760 1,155 5.8 4.9 4.1 4.2 6.4
Georgia 720 333 380 366 423 8.3 3.8 4.2 3.9 4.5
Hawaii 6 3 4 2 11 0.5 0.2 0.3 0.2 0.9
Idaho 8 26 13 3 3 0.6 1.9 0.9 0.2 0.2
Illinois 350 322 397 267 224 2.8 2.5 3.1 2.1 1.7
Indiana 58 45 42 46 39 0.9 0.7 0.7 0.7 0.6
Iowa 5 12 6 6 6 0.2 0.4 0.2 0.2 0.2
Kansas 19 12 18 18 25 0.7 0.4 0.7 0.7 0.9
Kentucky 43 24 23 36 34 1.0 0.6 0.6 0.9 0.8
Louisiana 197 316 252 481 722 4.4 7.0 5.6 11.2 16.8
Maine 7 0 2 7 5 0.5 0.0 0.2 0.5 0.4
Maryland 211 213 289 193 320 3.8 3.8 5.2 3.4 5.7
Massachusetts 136 96 105 82 116 2.1 1.5 1.6 1.3 1.8
Michigan 122 121 69 43 73 1.2 1.2 0.7 0.4 0.7
Minnesota 45 21 46 58 55 0.9 0.4 0.9 1.1 1.1
Mississippi 173 130 162 197 269 6.0 4.5 5.5 6.8 9.2
Missouri 46 58 108 93 120 0.8 1.0 1.9 1.6 2.1
Montana 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Nebraska 1 0 2 1 3 0.1 0.0 0.1 0.1 0.2
Nevada 35 24 64 119 174 1.6 1.0 2.7 4.8 7.0
New Hampshire 4 0 0 2 13 0.3 0.0 0.0 0.2 1.0
New Jersey 326 344 289 314 343 3.8 4.0 3.3 3.6 3.9
New Mexico 53 69 53 85 66 2.8 3.6 2.7 4.3 3.4
New York 1,019 744 1,084 993 1,149 5.3 3.9 5.6 5.1 6.0
North Carolina 261 261 215 294 247 3.1 3.1 2.5 3.3 2.8
North Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Ohio 92 184 136 115 135 0.8 1.6 1.2 1.0 1.2
Oklahoma 77 62 64 121 115 2.2 1.8 1.8 3.4 3.2
Oregon 27 29 16 19 6 0.8 0.8 0.4 0.5 0.2
Pennsylvania 216 183 204 286 309 1.7 1.5 1.6 2.3 2.5
Rhode Island 7 15 5 6 10 0.7 1.4 0.5 0.6 0.9
South Carolina 180 204 222 174 143 4.3 4.9 5.2 4.0 3.3
South Dakota 3 0 0 6 4 0.4 0.0 0.0 0.8 0.5
Tennessee 228 206 203 233 304 3.9 3.5 3.4 3.9 5.0
Texas 1,065 1,069 1,013 1,312 1,467 4.8 4.8 4.4 5.6 6.2
Utah 7 5 7 7 2 0.3 0.2 0.3 0.3 0.1
Vermont 0 0 0 2 1 0.0 0.0 0.0 0.3 0.2
Virginia 74 108 148 165 177 1.0 1.4 2.0 2.2 2.3
Washington 36 51 63 81 76 0.6 0.8 1.0 1.3 1.2
West Virginia 2 9 3 6 9 0.1 0.5 0.2 0.3 0.5
Wisconsin 54 55 58 60 91 1.0 1.0 1.0 1.1 1.6
Wyoming 1 0 0 0 0 0.2 0.0 0.0 0.0 0.0
U.S. TOTAL 8,361 7,768 8,176 9,186 10,768 2.9 2.6 2.8 3.1 3.6
Northeast 1,728 1,398 1,708 1,719 1,966 3.2 2.6 3.1 3.1 3.6
Midwest 795 830 882 713 775 1.2 1.3 1.3 1.1 1.2
South 4,593 4,216 4,044 4,839 5,961 4.4 4.0 3.8 4.4 5.5
West 1,245 1,324 1,542 1,915 2,066 1.9 2.0 2.3 2.8 3.0
Guam 1 0 0 3 3 0.6 0.0 0.0 1.8 1.8
Puerto Rico 748 353 432 368 408 19.3 9.1 11.0 9.4 10.4
Virgin Islands 6 8 7 0 1 5.5 7.4 6.4 0.0 0.9
OUTLYING AREAS 755 361 439 371 412 18.2 8.7 10.5 8.8 9.8
TOTAL 9,116 8,129 8,615 9,557 11,180 3.1 2.7 2.9 3.1 3.7
Table 34. Early latent syphilis — Reported cases and rates by state/area and region listed in alphabetical
order: United States and outlying areas, 2003–2007
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Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 614 281 314 293 363 13.3 6.0 6.4 5.7 7.1
Austin-Round Rock, TX 42 59 59 51 66 3.0 4.2 4.1 3.4 4.4
Baltimore-Towson, MD 189 167 211 136 185 7.2 6.3 7.9 5.1 7.0
Birmingham-Hoover, AL 24 42 82 220 196 2.2 3.9 7.5 20.0 17.8
Boston-Cambridge-Quincy, MA-NH 117 70 84 65 95 2.6 1.6 1.9 1.5 2.1
Buffalo-Cheektowaga-Tonawanda, NY 2 4 3 14 6 0.2 0.3 0.3 1.2 0.5
Charlotte-Gastonia-Concord, NC-SC 51 58 71 98 63 3.5 3.9 4.7 6.2 4.0
Chicago-Naperville-Joliet, IL-IN-WI 344 322 395 269 209 3.7 3.4 4.2 2.8 2.2
Cincinnati-Middletown, OH-KY-IN 0 8 13 7 12 0.0 0.4 0.6 0.3 0.6
Cleveland-Elyria-Mentor, OH 7 33 21 11 21 0.3 1.5 1.0 0.5 1.0
Columbus, OH 44 72 41 55 47 2.6 4.3 2.4 3.2 2.7
Dallas-Fort Worth-Arlington, TX 488 380 381 532 468 8.7 6.7 6.5 8.9 7.8
Denver-Aurora, CO 17 22 22 32 30 0.7 0.9 0.9 1.3 1.2
Detroit-Warren-Livonia, MI 112 103 59 34 47 2.5 2.3 1.3 0.8 1.1
Hartford-West Hartford-East Hartford, CT 2 5 7 10 8 0.2 0.4 0.6 0.8 0.7
Houston-Baytown-Sugar Land, TX 237 246 207 291 468 4.7 4.7 3.9 5.3 8.4
Indianapolis, IN 23 24 19 18 20 1.4 1.5 1.2 1.1 1.2
Jacksonville, FL 40 75 56 56 51 3.3 6.1 4.5 4.4 4.0
Kansas City, MO-KS 31 23 51 41 70 1.6 1.2 2.6 2.1 3.6
Las Vegas-Paradise, NV 28 19 57 112 170 1.8 1.2 3.3 6.3 9.6
Los Angeles-Long Beach-Santa Ana, CA 434 445 666 851 893 3.4 3.4 5.2 6.6 6.9
Louisville, KY-IN 34 16 16 18 12 2.9 1.3 1.3 1.5 1.0
Memphis, TN-MS-AR 177 170 171 174 222 14.3 13.6 13.6 13.7 17.4
Miami-Fort Lauderdale-Miami Beach, FL 578 477 302 304 440 10.9 8.9 5.6 5.6 8.1
Milwaukee-Waukesha-West Allis, WI 41 37 36 46 65 2.7 2.4 2.4 3.0 4.3
Minneapolis-St. Paul-Bloomington, MN-WI 41 19 43 52 54 1.3 0.6 1.4 1.6 1.7
Nashville-Davidson-Murfreesboro, TN 31 30 29 42 56 2.3 2.1 2.0 2.9 3.8
New Orleans-Metairie-Kenner, LA 48 85 68 127 222 3.6 6.4 5.2 12.4 21.7
New York-Newark-Edison, NY-NJ-PA 1,259 1,012 1,281 1,178 1,360 6.8 5.4 6.8 6.3 7.2
Oklahoma City, OK 62 47 36 74 65 5.5 4.1 3.1 6.3 5.5
Orlando, FL 117 90 124 91 160 6.5 4.8 6.4 4.6 8.1
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 256 220 171 280 310 4.4 3.8 2.9 4.8 5.3
Phoenix-Mesa-Scottsdale, AZ 165 165 97 166 165 4.6 4.4 2.5 4.1 4.1
Pittsburgh, PA 11 8 28 43 45 0.5 0.3 1.2 1.8 1.9
Portland-Vancouver-Beaverton, OR-WA 22 23 12 9 5 1.1 1.1 0.6 0.4 0.2
Providence-New Bedford-Fall River, RI-MA 11 25 10 9 12 0.7 1.5 0.6 0.6 0.7
Richmond, VA 24 18 24 29 45 2.1 1.6 2.0 2.4 3.8
Riverside-San Bernardino-Ontario, CA 34 40 64 64 49 0.9 1.1 1.6 1.6 1.2
Rochester, NY 8 4 13 8 5 0.8 0.4 1.3 0.8 0.5
Sacramento-Arden-Arcade-Roseville, CA 5 11 11 23 16 0.3 0.5 0.5 1.1 0.8
Salt Lake City, UT 4 5 3 5 2 0.4 0.5 0.3 0.5 0.2
San Antonio, TX 66 79 144 172 115 3.6 4.3 7.6 8.9 5.9
San Diego-Carlsbad-San Marcos, CA 41 84 117 123 156 1.4 2.9 4.0 4.2 5.3
San Francisco-Oakland-Fremont, CA 230 235 220 220 200 5.5 5.7 5.3 5.3 4.8
San Jose-Sunnyvale-Santa Clara, CA 20 13 18 18 25 1.2 0.7 1.0 1.0 1.4
Seattle-Tacoma-Bellevue, WA 30 42 60 74 70 1.0 1.3 1.9 2.3 2.1
St. Louis, MO-IL 28 31 34 30 57 1.0 1.1 1.2 1.1 2.0
Tampa-St. Petersburg-Clearwater, FL 142 103 101 177 294 5.6 4.0 3.8 6.6 10.9
Virginia Beach-Norfolk-Newport News, VA-NC 21 45 78 74 54 1.3 2.7 4.7 4.5 3.3
Washington-Arlington-Alexandria, DC-VA-MD-WV 195 182 208 171 265 3.8 3.5 4.0 3.2 5.0
U.S. MSA TOTAL 6,547 5,774 6,338 6,997 8,034 4.2 3.7 4.0 4.3 5.0
Table 35. Early latent syphilis — Reported cases and rates in selected metropolitan statistical areas* (MSAs)
listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census.
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Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 309 232 193 262 254 6.9 5.1 4.2 5.7 5.5
Alaska 7 6 5 8 6 1.1 0.9 0.8 1.2 0.9
Arizona 659 572 455 521 650 11.8 10.0 7.7 8.4 10.5
Arkansas 172 142 124 92 122 6.3 5.2 4.5 3.3 4.3
California 2,024 2,293 2,527 2,773 2,777 5.7 6.4 7.0 7.6 7.6
Colorado 82 90 70 73 63 1.8 2.0 1.5 1.5 1.3
Connecticut 163 108 88 106 87 4.7 3.1 2.5 3.0 2.5
Delaware 29 26 15 38 31 3.5 3.1 1.8 4.5 3.6
District of Columbia 129 174 148 120 153 22.9 31.4 26.9 20.6 26.3
Florida 1,610 1,364 1,422 1,445 1,830 9.5 7.8 8.0 8.0 10.1
Georgia 836 701 898 977 1,142 9.6 7.9 9.9 10.4 12.2
Hawaii 39 25 42 46 38 3.1 2.0 3.3 3.6 3.0
Idaho 18 25 21 6 10 1.3 1.8 1.5 0.4 0.7
Illinois 633 614 663 760 522 5.0 4.8 5.2 5.9 4.1
Indiana 252 164 182 111 121 4.1 2.6 2.9 1.8 1.9
Iowa 29 19 13 43 37 1.0 0.6 0.4 1.4 1.2
Kansas 32 49 51 41 44 1.2 1.8 1.9 1.5 1.6
Kentucky 83 79 54 78 63 2.0 1.9 1.3 1.9 1.5
Louisiana 1,195 979 696 551 516 26.6 21.7 15.4 12.9 12.0
Maine 6 5 3 6 7 0.5 0.4 0.2 0.5 0.5
Maryland 443 399 387 526 482 8.0 7.2 6.9 9.4 8.6
Massachusetts 375 307 168 172 128 5.8 4.8 2.6 2.7 2.0
Michigan 451 470 297 210 262 4.5 4.6 2.9 2.1 2.6
Minnesota 103 96 89 83 72 2.0 1.9 1.7 1.6 1.4
Mississippi 220 212 160 237 305 7.6 7.3 5.5 8.1 10.5
Missouri 96 114 114 166 124 1.7 2.0 2.0 2.8 2.1
Montana 0 0 0 1 0 0.0 0.0 0.0 0.1 0.0
Nebraska 15 8 12 26 23 0.9 0.5 0.7 1.5 1.3
Nevada 102 189 169 117 104 4.6 8.1 7.0 4.7 4.2
New Hampshire 14 21 17 20 9 1.1 1.6 1.3 1.5 0.7
New Jersey 572 319 375 297 345 6.6 3.7 4.3 3.4 4.0
New Mexico 75 97 68 66 62 4.0 5.1 3.5 3.4 3.2
New York 2,715 2,979 2,054 2,833 2,766 14.1 15.5 10.7 14.7 14.3
North Carolina 417 285 213 352 516 5.0 3.3 2.5 4.0 5.8
North Dakota 0 0 0 2 1 0.0 0.0 0.0 0.3 0.2
Ohio 189 148 153 192 219 1.7 1.3 1.3 1.7 1.9
Oklahoma 211 79 50 58 33 6.0 2.2 1.4 1.6 0.9
Oregon 43 50 52 51 33 1.2 1.4 1.4 1.4 0.9
Pennsylvania 329 273 308 335 264 2.7 2.2 2.5 2.7 2.1
Rhode Island 50 62 35 51 30 4.6 5.7 3.3 4.8 2.8
South Carolina 263 194 239 155 176 6.3 4.6 5.6 3.6 4.1
South Dakota 0 0 2 10 1 0.0 0.0 0.3 1.3 0.1
Tennessee 511 459 493 527 537 8.7 7.8 8.3 8.7 8.9
Texas 2,200 2,244 2,336 2,501 2,780 9.9 10.0 10.2 10.6 11.8
Utah 51 59 33 38 23 2.2 2.5 1.3 1.5 0.9
Vermont 0 2 0 2 0 0.0 0.3 0.0 0.3 0.0
Virginia 395 380 361 343 328 5.3 5.1 4.8 4.5 4.3
Washington 121 135 144 160 135 2.0 2.2 2.3 2.5 2.1
West Virginia 7 6 12 13 11 0.4 0.3 0.7 0.7 0.6
Wisconsin 41 43 37 42 12 0.7 0.8 0.7 0.8 0.2
Wyoming 3 3 1 1 2 0.6 0.6 0.2 0.2 0.4
U.S. TOTAL 18,319 17,300 16,049 17,644 18,256 6.3 5.9 5.4 5.9 6.1
Northeast 4,224 4,076 3,048 3,822 3,636 7.8 7.5 5.6 7.0 6.6
Midwest 1,841 1,725 1,613 1,686 1,438 2.8 2.6 2.4 2.5 2.2
South 9,030 7,955 7,801 8,275 9,279 8.6 7.5 7.3 7.6 8.5
West 3,224 3,544 3,587 3,861 3,903 4.9 5.3 5.3 5.6 5.6
Guam 13 13 16 7 24 7.9 7.8 9.5 4.1 14.0
Puerto Rico 390 608 554 535 682 10.1 15.6 14.2 13.6 17.4
Virgin Islands 5 4 5 4 4 4.6 3.7 4.6 3.7 3.7
OUTLYING AREAS 408 625 575 546 710 9.8 15.0 13.7 13.0 16.9
TOTAL 18,727 17,925 16,624 18,190 18,966 6.3 6.0 5.5 6.0 6.2
Table 36. Late and late latent syphilis — Reported cases and rates by state/area and region listed in
alphabetical order: United States and outlying areas, 2003–2007
STD Surveillance 2007 Syphilis Tables  141
Cases Rates per 100,000 Population
Metropolitan Statistical Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Atlanta-Sandy Springs-Marietta, GA 566 522 714 814 929 12.3 11.1 14.5 15.8 18.1
Austin-Round Rock, TX 78 85 89 74 94 5.7 6.0 6.1 4.9 6.2
Baltimore-Towson, MD 229 195 209 283 236 8.8 7.4 7.9 10.6 8.9
Birmingham-Hoover, AL 74 40 57 94 93 6.9 3.7 5.2 8.5 8.5
Boston-Cambridge-Quincy, MA-NH 330 256 149 147 98 7.4 5.8 3.4 3.3 2.2
Buffalo-Cheektowaga-Tonawanda, NY 7 11 4 7 9 0.6 1.0 0.3 0.6 0.8
Charlotte-Gastonia-Concord, NC-SC 87 45 61 83 133 6.1 3.1 4.0 5.2 8.4
Chicago-Naperville-Joliet, IL-IN-WI 630 576 611 687 469 6.7 6.1 6.5 7.2 4.9
Cincinnati-Middletown, OH-KY-IN 16 24 18 37 31 0.8 1.2 0.9 1.8 1.5
Cleveland-Elyria-Mentor, OH 23 11 9 24 33 1.1 0.5 0.4 1.1 1.6
Columbus, OH 102 72 76 67 99 6.1 4.3 4.4 3.9 5.7
Dallas-Fort Worth-Arlington, TX 735 701 792 809 881 13.1 12.3 13.6 13.5 14.7
Denver-Aurora, CO 64 56 51 51 43 2.8 2.4 2.2 2.1 1.8
Detroit-Warren-Livonia, MI 383 400 238 155 187 8.5 8.9 5.3 3.5 4.2
Hartford-West Hartford-East Hartford, CT 52 28 35 32 27 4.4 2.4 2.9 2.7 2.3
Houston-Baytown-Sugar Land, TX 768 783 685 856 1,032 15.1 15.1 13.0 15.5 18.6
Indianapolis, IN 93 68 80 56 49 5.8 4.2 4.9 3.4 2.9
Jacksonville, FL 73 70 41 63 102 6.1 5.7 3.3 4.9 8.0
Kansas City, MO-KS 41 40 53 75 49 2.2 2.1 2.7 3.8 2.5
Las Vegas-Paradise, NV 87 167 139 95 85 5.5 10.1 8.1 5.3 4.8
Los Angeles-Long Beach-Santa Ana, CA 1,137 1,451 1,649 1,759 1,588 8.9 11.2 12.8 13.6 12.3
Louisville, KY-IN 63 60 40 42 33 5.3 5.0 3.3 3.4 2.7
Memphis, TN-MS-AR 278 242 272 287 326 22.4 19.4 21.6 22.5 25.6
Miami-Fort Lauderdale-Miami Beach, FL 909 769 742 773 997 17.2 14.3 13.7 14.1 18.2
Milwaukee-Waukesha-West Allis, WI 22 28 18 16 9 1.5 1.8 1.2 1.1 0.6
Minneapolis-St. Paul-Bloomington, MN-WI 89 79 74 65 59 2.9 2.5 2.4 2.0 1.9
Nashville-Davidson-Murfreesboro, TN 158 145 126 112 100 11.5 10.4 8.9 7.7 6.9
New Orleans-Metairie-Kenner, LA 187 259 190 133 157 14.2 19.6 14.4 13.0 15.3
New York-Newark-Edison, NY-NJ-PA 3,077 3,058 2,241 2,905 2,913 16.5 16.3 12.0 15.4 15.5
Oklahoma City, OK 135 42 28 18 12 11.9 3.7 2.4 1.5 1.0
Orlando, FL 129 106 183 217 277 7.2 5.7 9.5 10.9 14.0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 392 361 284 315 253 6.8 6.2 4.9 5.4 4.3
Phoenix-Mesa-Scottsdale, AZ 589 468 363 424 486 16.4 12.6 9.4 10.5 12.0
Pittsburgh, PA 8 2 15 18 17 0.3 0.1 0.6 0.8 0.7
Portland-Vancouver-Beaverton, OR-WA 34 35 43 40 34 1.7 1.7 2.1 1.9 1.6
Providence-New Bedford-Fall River, RI-MA 74 81 37 65 44 4.6 5.0 2.3 4.0 2.7
Richmond, VA 77 56 50 49 46 6.8 4.9 4.3 4.1 3.9
Riverside-San Bernardino-Ontario, CA 184 174 208 203 194 5.1 4.6 5.3 5.0 4.8
Rochester, NY 18 25 17 68 55 1.7 2.4 1.6 6.6 5.3
Sacramento-Arden-Arcade-Roseville, CA 11 33 8 78 40 0.6 1.6 0.4 3.8 1.9
Salt Lake City, UT 33 42 23 21 14 3.3 4.1 2.2 2.0 1.3
San Antonio, TX 109 164 178 156 142 6.0 8.8 9.4 8.0 7.3
San Diego-Carlsbad-San Marcos, CA 139 124 133 202 273 4.7 4.2 4.5 6.9 9.3
San Francisco-Oakland-Fremont, CA 260 258 165 156 263 6.3 6.2 4.0 3.7 6.3
San Jose-Sunnyvale-Santa Clara, CA 57 39 56 22 76 3.3 2.2 3.2 1.2 4.3
Seattle-Tacoma-Bellevue, WA 74 93 100 122 99 2.4 2.9 3.1 3.7 3.0
St. Louis, MO-IL 69 85 86 89 82 2.5 3.1 3.1 3.2 2.9
Tampa-St. Petersburg-Clearwater, FL 166 110 139 140 119 6.6 4.3 5.2 5.2 4.4
Virginia Beach-Norfolk-Newport News, VA-NC 104 100 105 85 89 6.4 6.1 6.4 5.2 5.4
Washington-Arlington-Alexandria, DC-VA-MD-WV 470 511 453 496 514 9.2 9.9 8.7 9.4 9.7
U.S. MSA TOTAL 13,490 13,150 12,137 13,585 13,990 8.6 8.3 7.6 8.4 8.7
Table 37. Late and late latent syphilis — Reported cases and rates in selected metropolitan statistical areas*
(MSAs) listed in alphabetical order: United States, 2003–2007
*MSAs selected based on largest population in 2000 U.S. census..
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     Rank*    State†                              Cases Rate per 100,000 Live Births
1 Louisiana 36 55.1
2 Arizona 30 32.0
3 Arkansas 12 31.1
4 Maryland 23 30.8
5 Texas 99 26.0
6 New Mexico 6 21.1
7 Nevada 7 19.9
8 California 87 16.0
9 Alabama 9 15.1
10 Michigan 14 10.8
U.S. TOTAL‡ 430 10.5
11 New Jersey 11 9.5
12 Florida 20 9.2
13 Georgia 9 6.5
14 New York 16 6.4
15 Oklahoma 3 5.8
16 North Carolina 7 5.8
17 Illinois 10 5.5
18 Pennsylvania 8 5.5
19 Tennessee 4 5.0
20 West Virginia 1 4.8
21 Connecticut 2 4.8
22 Oregon 2 4.4
23 Indiana 3 3.4
24 Colorado 2 2.9
25 Iowa 1 2.6
26 Washington 2 2.4
27 South Carolina 1 1.8
28 Wisconsin 1 1.4
29 Missouri 1 1.3
YEAR 2010 TARGET 1.0
30 Virginia 1 1.0
31 Ohio 1 0.7
Alaska 0 0.0
Delaware 0 0.0
Hawaii 0 0.0
Idaho 0 0.0
Kansas 0 0.0
Kentucky 0 0.0
Maine 0 0.0
Massachusetts 0 0.0
Minnesota 0 0.0
Mississippi 0 0.0
Montana 0 0.0
Nebraska 0 0.0
New Hampshire 0 0.0
North Dakota 0 0.0
Rhode Island 0 0.0
South Dakota 0 0.0
Utah 0 0.0
Vermont 0 0.0
Wyoming 0 0.0
Table 38. Congenital syphilis — Reported cases and rates in infants < 1 year of age by state, ranked
by rates: United States, 2007
*States were ranked in descending order by rate, number of cases, and alphabetically by state. States with no cases were not ranked.
†Mother’s state of residence used to assign case.
‡Total includes cases reported by the District of Columbia with 1 case and a rate of 12.6, but excludes outlying areas (Guam with 2 cases and rate of
58.6, Puerto Rico with 8 cases and rate of 15.6, and Virgin Islands with 0 cases and rate of 0.0).
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Cases Rates per 100,000 Live Births
State/Area* 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 4 11 5 9 9 6.7 18.5 8.4 15.1 15.1
Alaska 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Arizona 29 26 28 16 30 31.9 27.8 29.9 17.1 32.0
Arkansas 2 4 7 10 12 5.3 10.4 18.1 25.9 31.1
California 64 68 75 69 87 11.8 12.5 13.8 12.7 16.0
Colorado 3 2 1 2 2 4.3 2.9 1.5 2.9 2.9
Connecticut 1 0 1 0 2 2.3 0.0 2.4 0.0 4.8
Delaware 0 1 0 0 0 0.0 8.8 0.0 0.0 0.0
District of Columbia 1 1 0 1 1 13.1 12.6 0.0 12.6 12.6
Florida 27 16 16 21 20 12.7 7.3 7.3 9.6 9.2
Georgia 11 6 1 9 9 8.1 4.3 0.7 6.5 6.5
Hawaii 2 0 0 0 0 11.0 0.0 0.0 0.0 0.0
Idaho 4 3 0 0 0 18.3 13.3 0.0 0.0 0.0
Illinois 20 26 23 15 10 11.0 14.4 12.7 8.3 5.5
Indiana 7 4 2 0 3 8.1 4.6 2.3 0.0 3.4
Iowa 0 0 0 0 1 0.0 0.0 0.0 0.0 2.6
Kansas 1 2 0 1 0 2.5 5.0 0.0 2.5 0.0
Kentucky 1 1 0 1 0 1.8 1.8 0.0 1.8 0.0
Louisiana 6 19 13 16 36 9.2 29.1 19.9 24.5 55.1
Maine 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Maryland 9 10 16 19 23 12.0 13.4 21.4 25.5 30.8
Massachusetts 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Michigan 38 23 17 13 14 29.0 17.7 13.1 10.0 10.8
Minnesota 0 1 3 1 0 0.0 1.4 4.2 1.4 0.0
Mississippi 2 3 0 0 0 4.7 7.0 0.0 0.0 0.0
Missouri 4 3 3 3 1 5.2 3.9 3.9 3.9 1.3
Montana 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Nebraska 1 0 0 0 0 3.9 0.0 0.0 0.0 0.0
Nevada 0 1 1 16 7 0.0 2.8 2.8 45.5 19.9
New Hampshire 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
New Jersey 21 13 16 15 11 18.0 11.3 13.9 13.0 9.5
New Mexico 6 3 6 7 6 21.6 10.6 21.1 24.7 21.1
New York 42 22 10 24 16 16.6 8.8 4.0 9.6 6.4
North Carolina 20 9 11 7 7 16.9 7.5 9.2 5.8 5.8
North Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Ohio 3 2 2 0 1 2.0 1.3 1.3 0.0 0.7
Oklahoma 1 2 1 2 3 2.0 3.9 1.9 3.9 5.8
Oregon 0 0 0 0 2 0.0 0.0 0.0 0.0 4.4
Pennsylvania 2 0 1 4 8 1.4 0.0 0.7 2.8 5.5
Rhode Island 0 1 0 0 0 0.0 7.8 0.0 0.0 0.0
South Carolina 15 10 4 2 1 27.0 17.7 7.1 3.5 1.8
South Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Tennessee 7 9 4 6 4 8.9 11.3 5.0 7.5 5.0
Texas 77 65 67 79 99 20.4 17.0 17.6 20.7 26.0
Utah 0 1 0 2 0 0.0 2.0 0.0 3.9 0.0
Vermont 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Virginia 1 6 3 3 1 1.0 5.8 2.9 2.9 1.0
Washington 0 0 0 0 2 0.0 0.0 0.0 0.0 2.4
West Virginia 0 0 0 0 1 0.0 0.0 0.0 0.0 4.8
Wisconsin 0 1 2 0 1 0.0 1.4 2.9 0.0 1.4
Wyoming 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
U.S. TOTAL 432 375 339 373 430 10.6 9.1 8.2 9.1 10.5
Northeast 66 36 28 43 37 9.6 5.3 4.1 6.3 5.5
Midwest 74 62 52 33 31 8.3 7.0 5.8 3.7 3.5
South 184 173 148 185 226 12.2 11.3 9.7 12.1 14.8
West 108 104 111 112 136 10.7 10.2 10.9 11.0 13.4
Guam 1 0 1 0 2 30.5 0.0 29.3 0.0 58.6
Puerto Rico 17 11 13 15 8 33.5 21.5 25.4 29.3 15.6
Virgin Islands 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
OUTLYING AREAS 18 11 14 15 10 32.4 19.6 24.9 26.7 17.8
TOTAL 450 386 353 388 440 10.9 9.3 8.5 9.3 10.6
Table 39. Congenital syphilis — Reported cases and rates in infants < 1 year of age by state/area and region
listed in alphabetical order: United States and outlying areas, 2003–2007
*Mother’s state of residence used to assign case.
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       Year of Birth        Race/Ethnicity Cases Rate per 100,000 Live Births
2003
White, Non-Hispanic 35 1.5
Black, Non-Hispanic 201 34.7
Hispanic 166 18.2
Asian/Pacific Islander 14 6.5
American Indian/Alaska Native 2 5.1
Other 3 NA
Unknown 11 NA
Total 432 10.6
2004
White, Non-Hispanic 41 1.8
Black, Non-Hispanic 168 28.8
Hispanic 145 15.3
Asian/Pacific Islander 6 2.7
American Indian/Alaska Native 2 5.0
Other 1 NA
Unknown 12 NA
Total 375 9.1
2005
White, Non-Hispanic 31 1.3
Black, Non-Hispanic 156 26.8
Hispanic 124 13.1
Asian/Pacific Islander 15 6.8
American Indian/Alaska Native 5 12.4
Other 2 NA
Unknown 6 NA
Total 339 8.2
2006
White, Non-Hispanic 39 1.7
Black, Non-Hispanic 151 26.9
Hispanic 151 16.0
Asian/Pacific Islander 10 4.5
American Indian/Alaska Native 5 12.4
Other 5 NA
Unknown 12 NA
Total 373 9.1
2007
White, Non-Hispanic 54 2.3
Black, Non-Hispanic 188 32.3
Hispanic 145 15.3
Asian/Pacific Islander 19 8.6
American Indian/Alaska Native 8 19.9
Other 4 NA
Unknown 12 NA
Total 430 10.5
Table 40. Congenital syphilis — Reported cases and rates in infants < 1 year of age by race/ethnicity of
mother: United States, 2003–2007
NA = Not applicable
STD Surveillance 2007 Chancroid Tables  145
Cases Rates per 100,000 Population
State/Area 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Alabama 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Alaska 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Arizona 2 2 1 0 0 0.0 0.0 0.0 0.0 0.0
Arkansas 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
California 0 1 1 0 1 0.0 0.0 0.0 0.0 0.0
Colorado 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Connecticut 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Delaware 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
District of Columbia 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Florida 2 1 1 1 3 0.0 0.0 0.0 0.0 0.0
Georgia 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Hawaii 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Idaho 0 2 0 0 0 0.0 0.1 0.0 0.0 0.0
Illinois 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Indiana 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Iowa 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Kansas 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Kentucky 1 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Louisiana 0 2 4 1 4 0.0 0.0 0.1 0.0 0.1
Maine 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Maryland 1 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Massachusetts 3 3 1 0 1 0.0 0.0 0.0 0.0 0.0
Michigan 0 2 0 1 0 0.0 0.0 0.0 0.0 0.0
Minnesota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Mississippi 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Missouri 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Montana 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Nebraska 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Nevada 0 1 0 0 0 0.0 0.0 0.0 0.0 0.0
New Hampshire 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
New Jersey 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
New Mexico 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
New York 10 4 1 5 5 0.1 0.0 0.0 0.0 0.0
North Carolina 2 1 5 5 2 0.0 0.0 0.1 0.1 0.0
North Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Ohio 0 0 1 0 0 0.0 0.0 0.0 0.0 0.0
Oklahoma 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Oregon 2 1 0 0 0 0.1 0.0 0.0 0.0 0.0
Pennsylvania 1 1 0 0 0 0.0 0.0 0.0 0.0 0.0
Rhode Island 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
South Carolina 24 4 0 0 0 0.6 0.1 0.0 0.0 0.0
South Dakota 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Tennessee 0 1 0 0 0 0.0 0.0 0.0 0.0 0.0
Texas 3 3 1 5 5 0.0 0.0 0.0 0.0 0.0
Utah 2 1 0 0 0 0.1 0.0 0.0 0.0 0.0
Vermont 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Virginia 0 0 0 1 0 0.0 0.0 0.0 0.0 0.0
Washington 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
West Virginia 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Wisconsin 0 0 0 0 2 0.0 0.0 0.0 0.0 0.0
Wyoming 1 0 1 0 0 0.2 0.0 0.2 0.0 0.0
U.S. TOTAL 54 30 17 19 23 0.0 0.0 0.0 0.0 0.0
Guam 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
Puerto Rico 4 1 3 0 0 0.1 0.0 0.1 0.0 0.0
Virgin Islands 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0
OUTLYING AREAS 4 1 3 0 0 0.1 0.0 0.1 0.0 0.0
TOTAL 58 31 20 19 23 0.0 0.0 0.0 0.0 0.0
Table 41. Chancroid — Reported cases and rates by state/area listed in alphabetical order: United States and
outlying areas, 2003–2007
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Table 42. Selected STDs and complications — Initial visits to physicians' offices, National Disease and
Therapeutic Index: United States, 1966–2007
*Women only.
†Women 15-44 only.  NA = Not available.
NOTE: Standard errors for estimates under 100,000 are not available. The relative standard error for estimates 100,000-300,000 are between 20%
and 30%; 300,000–600,000 are between 16% and 20%; 600,000–1,000,000 are 13% and 15%; and 1,000,000–5,000,000 are between 9% and 13%.
SOURCE: National Disease and Therapeutic Index (IMS Health). See Appendix (Other Data Sources) for more information.
Year
Genital
Herpes
Genital
Warts 
Vaginal             
Trichomoniasis*      
Other   
Vaginitis*
Pelvic Inflammatory
Disease†        
1966 19,000 56,000 579,000 1,155,000 NA
1967 15,000 72,000 515,000 1,277,000 NA
1968 16,000 87,000 463,000 1,460,000 NA
1969 15,000 61,000 421,000 1,390,000 NA
1970 17,000 119,000 529,000 1,500,000 NA
1971 49,000 128,000 484,000 1,281,000 NA
1972 26,000 165,000 574,000 1,810,000 NA
1973 51,000 198,000 466,000 1,858,000 NA
1974 75,000 202,000 427,000 1,907,000 NA
1975 36,000 181,000 500,000 1,919,000 NA
1976 57,000 217,000 473,000 1,690,000 NA
1977 116,000 221,000 324,000 1,713,000 NA
1978 76,000 269,000 329,000 2,149,000 NA
1979 83,000 200,000 363,000 1,662,000 NA
1980 57,000 218,000 358,000 1,670,000 423,000
1981 133,000 191,000 369,000 1,742,000 283,000
1982 134,000 256,000 268,000 1,859,000 374,000
1983 106,000 203,000 424,000 1,932,000 424,000
1984 157,000 224,000 381,000 2,450,000 381,000
1985 124,000 263,000 291,000 2,728,000 425,000
1986 136,000 275,000 338,000 3,118,000 457,000
1987 102,000 351,000 293,000 3,087,000 403,000
1988 163,000 290,000 191,000 3,583,000 431,000
1989 148,000 220,000 165,000 3,374,000 413,000
1990 172,000 275,000 213,000 4,474,000 358,000
1991 235,000 282,000 198,000 3,822,000 377,000
1992 139,000 218,000 182,000 3,428,000 335,000
1993 172,000 167,000 207,000 3,755,000 407,000
1994 142,000 239,000 199,000 4,123,000 332,000
1995 160,000 253,000 141,000 3,927,000 262,000
1996 208,000 191,000 245,000 3,472,000 286,000
1997 176,000 145,000 176,000 3,100,000 260,000
1998 188,000 211,000 164,000 3,200,000 233,000
1999 224,000 240,000 171,000 3,077,000 250,000
2000 179,000 220,000 222,000 3,470,000 254,000
2001 157,000 233,000 210,000 3,365,000 244,000
2002 216,000 266,000 150,000 3,315,000 197,000
2003 203,000 264,000 179,000 3,516,000 123,000
2004 269,000 316,000 221,000 3,602,000 132,000
2005 266,000 357,000 165,000 4,071,000 176,000
2006 371,000 422,000 200,000 3,891,000 106,000
2007 317,000 312,000 205,000 3,723,000 146,000
XI
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Interpreting STD Surveillance Data
Sexually Transmitted Disease Surveillance,
2007 presents surveillance information
derived from the official statistics for the
reported occurrence of nationally notifiable
sexually transmitted diseases in the United
States, test positivity and prevalence data
from numerous prevalence monitoring
initiatives, sentinel surveillance of
gonococcal antimicrobial resistance, and 
national health care services surveys.
 Nationally Notifiable STD
Surveillance
Nationally notifiable STD surveillance data
are collected and compiled from reports
sent by the STD control programs and
health departments in the 50 states, the
District of Columbia, selected cities, U.S.
dependencies and possessions, and
independent nations in free association with 
the United States to the Division of STD
Prevention (DSTDP), National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Included among the dependencies,
possessions, and independent nations are
Guam, Puerto Rico, and the Virgin Islands.
These entities are identified as “outlying
areas” of the United States in selected
figures and tables.
Reporting Formats
STD morbidity data presented in this report 
are compiled from a combination of data
reported on standardized hardcopy report
forms and electronic data received via the
National Electronic Telecommunications
System for Surveillance (NETSS).
Summary Report Forms (hardcopy
format)
The following hardcopy forms were used to 
report national STD morbidity data:
1. FORM CDC 73.998: Monthly
Surveillance Report of Early Syphilis. This
monthly hardcopy reporting form was used 
from 1984 to 2002 to report summary data 
for P&S syphilis and early latent syphilis by
county and state.
2. FORM CDC 73.688: Sexually
Transmitted Disease Morbidity Report. This
quarterly hardcopy reporting form was
used from 1963 to 2002 to report summary 
data for all stages of syphilis, congenital
syphilis, gonorrhea, chancroid, chlamydia,
and other STDs by sex and source of report 
(private vs. public) for the 50 states,
Washington, D.C., and 64 selected cities
(including San Juan, Puerto Rico) and
outlying areas of the United States. Note:
genital chlamydial infection became a
nationally notifiable condition in 1996, and
the form was modified to support reporting
of chlamydia that year. Congenital syphilis
was dropped from this aggregate form in
1995 and replaced by the case-specific
CDC 73.126 form described below.
3. FORM CDC 73.2638: Report of Civilian
Cases of Primary & Secondary Syphilis,
Gonorrhea, and Chlamydia by Reporting
Source, Sex, Race/Ethnicity, and Age
Group. This annual hardcopy form was
used from 1981 to 2002 to report summary 
data for P&S syphilis, gonorrhea, and
chlamydia by age, race, sex and source
(public vs. private) for all states and seven
large cities (Baltimore, Chicago, New York
City, Los Angeles, Philadelphia, San
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Francisco, and Washington, D.C.), and
outlying areas of the United States. Note:
genital chlamydial infection became a
nationally notifiable condition in 1996 and
the form was modified to support reporting
of chlamydia that year.
4. FORM CDC 73.126: Congenital Syphilis 
(CS) Case Investigation and Report. This
case-specific hardcopy form was first used
in 1983 and continues to be used to report
detailed case-specific data for congenital
syphilis in some reporting areas.
National Electronic
Telecommunications System for
Surveillance (NETSS, electronic
format)
Notifiable STD data reported electronically
through NETSS comprise the nationally
notifiable disease information that is
published in the Morbidity and Mortality
Weekly Report (MMWR). 
As of December 31, 2003, all 50 states and
Washington, D.C. had converted from
summary hardcopy reporting to electronic
submission of line-listed (i.e., case-specific)
STD data via NETSS (41 reporting areas
are submitting congenital syphilis
surveillance data via NETSS). Puerto Rico
converted to electronic reporting in 2006.
Guam and the Virgin Islands continue to
report using summary hardcopy forms.
Jurisdictions differ in their ability to resolve
differences in total cases derived from
summary hardcopy monthly, quarterly, and 
annual reports (as well as electronically
submitted line-listed data). Thus,
depending on the database used, there
may be discrepancies in the total number of 
cases among the figures and tables for
earlier years. In most instances, these
discrepancies are less than 5% of total
reported cases and have minimal impact on 
national case totals and rates. However, for
a specific jurisdiction, the discrepancies
may be larger.
Surveillance data and updates sent to 
CDC on hardcopy forms and for
NETSS electronic data through June
25, 2008 have been included in this
report. Data received after this date
will appear in subsequent annual
Surveillance Reports. The data
presented in the figures and tables in
this document supersede those in all
earlier publications.
Population Denominators and Rate
Calculations
2000—2007 Rates and Population
The National Center for Health Statistics
released bridged race population counts for 
2000–2006 resident population based on
the Census 2000 counts. These estimates
resulted from bridging the 31 race
categories used in Census 2000, as
specified in the 1997 Office of Management 
and Budget (OMB) standards, to the five
race/ethnicity groups specified under the
1977 OMB standards.
Population estimates for Guam, Puerto
Rico, and the Virgin Islands were obtained
from the Bureau of Census web site: 
http://www.census.gov/ipc/www/idb/
tables.html. The 2006–2007 rates for
outlying areas were calculated using the
2006 population estimates.
Due to use of the updated population data, 
rates for the period 2000–2006 may be
different from prior Surveillance Reports.
1990—1999 Rates and Population
The population counts for 1990–1999
incorporated the bridged single-race
estimates of the April 1, 2000 resident
population. These files were prepared by
the U.S. Census Bureau with support from
the National Cancer Institute.
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1981—1989 Rates and Population
For the United States, rates were calculated
using Bureau of the Census population
estimates for 1981 through 1989 (Bureau
of the Census; United States Population
Estimates by Age, Sex and
Race:1980–1989 [Series P-25, No. 1045];
Washington: U.S. Government Printing
Office, 1990; and United States Population
Estimates by Age, Sex and Race: 1989
[Series P-25, No. 1057]; Washington: U.S.
Government Printing Office, 1990.
1941—1980 Rates and Population
Rates for 1941–1980 are based on
population estimates from the Bureau of
Census and currently maintained by the
Division of STD Prevention.
1941—2007 Congenital Syphilis Rates
and Live Births
Congenital syphilis (CS) data in Table 1 of
Sexually Transmitted Disease Surveillance
2007 represent the number of congenital
syphilis cases per 100,000 live births for all
years during the period 1941 through
2007. Previous publications presented
congenital syphilis rates per 100,000
population for 1941–1994 and rates for
cases diagnosed at < 1 year of age per
100,000 live births for 1995–2005. To
allow for trends in CS rates to be compared 
over the period 1941–2007, live births are
used as the denominator for CS and case
counts are no longer limited to those
diagnosed within the first year of life. CS
morbidity (i.e., case reports) is assigned by
year of birth. Rates of congenital syphilis for 
1963–1988 were calculated using published 
live birth data (NCHS; Vital Statistics
Report, United States, 1988
[Vol.1-Natality]). Congenital syphilis rates
for 1989–2003 were calculated using live
birth data based on information coded by
the States and provided to the National
Center for Health Statistics (NCHS)
through the Vital Statistics Cooperative
Program. Rates for 2004–2007 were
calculated using live birth data for 2004.
Reporting Practices
Although most areas generally adhere to
the national notifiable STD case definitions
collaboratively developed by the Council of 
State and Territorial Epidemiologists
(CSTE) and CDC, there may be differences 
in the policies and systems for collecting
surveillance data. Thus, comparisons of
case numbers and rates between
jurisdictions should be interpreted with
caution. However, since case definitions
and surveillance activities within a given
area remain relatively stable over time,
trends should be minimally affected by
these differences. In many areas, the
reporting from publicly supported
institutions (e.g., STD clinics) has been
more complete than from other sources
(e.g., private practitioners). Thus, trends
may not be representative of all segments
of the population.
Reporting of Metropolitan Statistical
Area-specific Surveillance Data
Sexually Transmitted Disease Surveillance,
2007 continues the presentation of STD
incidence data and rates for the fifty
Metropolitan Statistical Areas (MSAs) with
the largest populations based on 2000 U.S.
Census data. Sexually Transmitted Disease
Surveillance reports prior to 2005
presented data by selected cities which
estimated city-specific morbidity and were
derived from county data. Since county
data were used to estimate city-specific
morbidity and current STD project areas’
reporting practices do not support direct
identification of city-specific morbidity
reports, MSAs (described below) were
chosen as a geographic unit smaller than a
state or territory for presentation of STD
morbidity data.
Metropolitan Statistical Areas are defined
by the Office of Management and Budget
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to provide nationally consistent definitions
for collecting, tabulating, and publishing
federal statistics for a set of geographic
areas.1 An MSA is associated with at least
one urbanized area that has a population of 
at least 50,000. The MSA comprises the
central county or counties containing the
core, plus adjacent outlying counties having 
a high degree of social and economic
integration with the central county as
measured through commuting. The title of
an MSA includes the name of its principal
city with the largest Census 2000
population. If there are multiple principal
cities, the names of the second largest and
third largest principal cities appear in the
title in order of descending population size.
The MSA concept has been used as a
statistical representation of the social and
economic linkages between urban cores
and outlying, integrated areas. However,
MSAs do not equate to an urban-rural
classification; all counties included in MSAs
and many other counties contain both
urban and rural territory and populations.
Programs that treat all parts of an MSA as if 
they were as urban as the densely settled
core ignore the rural conditions that may
exist in some parts of the area. In short,
MSAs are not designed as a general
purpose geographic framework for
nonstatistical activities or for use in
program funding formulas.
For more information on MSA definitions
used in this report, please visit this web site: 
http://www.census.gov/population/
estimates/metro-city/03mfips.txt
Management of Unknown, Missing or
Invalid Age Group, Race/Ethnicity,
and Sex Data
The percentage of unknown, missing or
invalid data for age group, race/ethnicity,
and sex varies from year to year, state to
state, and by disease for reported STDs
(Table A1).
When the percentage of unknown, missing, 
or invalid data for the variables — age
group, race/ethnicity, and sex — exceeds
50% for any state, the state’s incidence
data and population data are excluded
from the tables presenting data stratified by
one or more of these variables. For those
states reporting > 50% valid data for these
variables, unknown, missing or invalid data 
are redistributed based on the state’s
distribution of known age group,
race/ethnicity, and sex data, respectively. As 
a result of this procedure, incidence and
rate data stratified by one or more of the
variables—age group, race/ethnicity, and
sex—may not accurately reflect total
national incidence or rates.
Classification of STD Morbidity
Reporting Sources
Prior to 1996, states classified the source of
case reports as either private source
(including private physicians, and private
hospitals and institutions) or public (clinic)
source (primarily STD clinics). As states
began reporting morbidity data
electronically in 1996, the classification
categories for source of case reports
expanded to include the following data
sources: STD clinics, HIV counseling and
testing sites, drug treatment clinics, family
planning clinics, prenatal/obstetrics clinics,
tuberculosis clinics, private
physicians/HMOs, hospitals (inpatient),
emergency rooms, correctional facilities,
laboratories, blood banks, National Job
Training Program, school-based clinics,
mental health providers, military, Indian
Health Service, and other unspecified
sources. Analysis of the data reported
electronically after 1996 confirmed that the
new STD clinic source of report data
corresponded to the earlier reporting source 
category, public (clinic) source. Therefore,
source of case report data for the period
1984–2007 are presented as STD clinic or
non-STD clinic only (Table A2).
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Definition of DHHS Regions
The ten U.S. Department of Health and
Human Services (DHHS) regions referred 
to in the text and figures include the
following jurisdictions: Region I =
Connecticut, Maine, Massachusetts, New
Hampshire, Rhode Island, and Vermont;
Region II = New Jersey, New York, Puerto
Rico, and U.S. Virgin Islands; Region III =
Delaware, District of Columbia, Maryland,
Pennsylvania, Virginia, and West Virginia;
Region IV = Alabama, Florida, Georgia,
Kentucky, Mississippi, North Carolina,
South Carolina, and Tennessee; Region V= 
Illinois, Indiana, Michigan, Minnesota,
Ohio, and Wisconsin; Region VI =
Arkansas, Louisiana, New Mexico,
Oklahoma, and Texas; Region VII = Iowa,
Kansas, Missouri, and Nebraska; Region
VIII = Colorado, Montana, North Dakota,
South Dakota, Utah, and Wyoming; Region 
IX = Arizona, California, Guam, Hawaii,
and Nevada; and Region X = Alaska,
Idaho, Oregon, and Washington.
Chlamydia Morbidity Reporting
Trends in chlamydia morbidity reporting
from many areas are more reflective of
changes in diagnosis, screening, and
reporting practices than of actual trends in
disease incidence. In particular, morbidity
trends are likely highly influenced by
changes in test technology, as areas
increase their usage of more sensitive
nucleic acid amplification tests. As areas
develop chlamydia prevention and control
programs, including improved surveillance
systems to monitor trends, the data should
improve and become more representative
of true trends in disease.
Syphilis Morbidity Reporting 
“Total syphilis” or “all stages of syphilis”
includes primary, secondary, latent
(including early latent, late latent, and latent 
syphilis of unknown duration), 
neurosyphilis, late (including late syphilis
with clinical manifestations other than
neurosyphilis), and congenital syphilis.
In 1996, the syphilis stage, “late syphilis
with clinical manifestations other than
neurosyphilis (late benign and
cardiovascular syphilis)”, was added to the
syphilis case definition (see STD Case
Definitions in this Appendix).
While neurosyphilis can occur at almost
any stage of syphilis, between 1996 and
2005, it was classified and reported as one
of several mutually exclusive stages of
syphilis. Beginning in 2005, neurosyphilis
was no longer classified or reported as a
distinct stage of syphilis. The Division of
STD Prevention is reviewing these data
collection and reporting changes to
determine their impact on syphilis
surveillance case definitions.
Congenital Syphilis Morbidity
Reporting
In 1988, the surveillance case definition for
congenital syphilis was changed. This case
definition has greater sensitivity than the
former definition.2 In addition, many areas
have greatly enhanced active case finding
for congenital syphilis since 1988. For these 
reasons, the number of reported cases
increased dramatically during 1989–1991.
All reporting areas had implemented the
new case definition for reporting congenital 
syphilis by January 1, 1992.
In addition to changing the case definition
for congenital syphilis, CDC introduced a
new data collection form (CDC 73.126) in
1990 (revised October 2003). Since 1995,
the data collected on this form have been
used for reporting congenital syphilis cases
and associated rates. This form is used to
collect individual case information which
allows more thorough analysis of case
characteristics. For the purpose of analyzing 
race/ethnicity, cases are classified by
race/ethnicity of the mother. Congenital
syphilis cases were reported by state and
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city of residence of the mother for the
period 1995 through 2007.
Congenital syphilis reporting may be
delayed as a result of case investigation and 
validation. Congenital syphilis cases for
prior years are added to CDC’s surveillance 
databases throughout the year. Congenital
syphilis data reported after publication of
the current annual Surveillance Report will
appear in subsequent surveillance reports
and are assigned by case patient’s year of
birth.
Chlamydia, Gonorrhea, and Syphilis
Prevalence Monitoring
Chlamydia and gonorrhea test positivity
and syphilis seroreactivity were calculated
for the following: women attending family
planning clinics and prenatal clinics, men
and women entering the National Job
Training Program, women attending Indian
Health Service clinics, men attending STD
clinics and primary care clinics participating 
in the MSM Prevalence Monitoring Project,
and men and women entering corrections
facilities. Positivity was calculated by
dividing the number of positive tests for
chlamydia, gonorrhea, or syphilis
(numerator) by the total number of positive 
and negative tests for each disease
(denominator) and was expressed as a
percentage. Except for the National Job
Training Program screening data, these
data sources may include more than one
test from the same individual if that person
was tested more than once during a year.
To increase the stability of the annual
National Job Training Program prevalence
estimates, chlamydia or gonorrhea
prevalence data are presented when valid
test results for 100 or more students per
year are available for the population
subgroup and state. The majority of the
National Job Training Program’s chlamydia 
screening tests are tested by a single
national contract laboratory, which
provides those data to CDC. Gonorrhea
screening tests for male and female students 
in many training centers are tested by local
laboratories; these data are not available to
CDC. To insure that state-specific
gonorrhea screening data presented here
are representative of all students entering
training centers, gonorrhea test results for
students at centers submitting specimens to
the national contract laboratory are
included only if the number of gonorrhea
tests submitted is greater than 90% of the
number of chlamydia tests submitted from
the same center for the same time period.
Various laboratory test methods were used
for all of these data sources. No
adjustments for laboratory test type and
sensitivity were made to any figures
presenting test positivity or prevalence data. 
For more details on chlamydia prevalence,
refer to the following annual publication:
Centers for Disease Control and
Prevention. Sexually Transmitted Disease
Surveillance 2007 Supplement: Chlamydia
Prevalence Monitoring Project Annual
Report 2007. Atlanta, GA: U.S. Department 
of Health and Human Services (available
first quarter 2009).
In the MSM Prevalence Monitoring Project,
the syphilis seroreactivity data in most
instances do not reflect confirmatory testing 
and thus biologic false positive test results
were not systematically excluded. The
extent to which these data reflect
prevalence of active syphilis infection varies 
by site. Similarly, in the Corrections
Prevalence Monitoring Project, syphilis
seroreactivity test results were not
confirmed. Only a few juvenile corrections
sites submitted data to CDC, making
overall interpretation difficult due to the
small sample size. Because only selected
corrections facilities participated in the
Corrections Prevalence Monitoring Project,
state-specific positivity for syphilis,
chlamydia, and gonorrhea may not be
representative of all corrections facilities in
the state.
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Prevalence data for region- and
state-specific figures were published with
permission from the Regional Infertility
Prevention Program, selected state STD
prevention programs, the National Job
Training Program, and the Indian Health
Service.
Gonococcal Isolate Surveillance
Project (GISP)
Data on antimicrobial susceptibility in
Neisseria gonorrhoeae were collected
through the Gonococcal Isolate
Surveillance Project (GISP), a sentinel
system of 30 STD clinics and five regional
laboratories located throughout the United
States. For more details on findings from
GISP gonorrhea surveillance activities, refer 
to the following annual publication: Centers 
for Disease Control and Prevention.
Sexually Transmitted Disease Surveillance
2007 Supplement: Gonococcal Isolate
Surveillance Project (GISP) Annual Report
2007 (available first quarter, 2009). Atlanta, 
GA: U.S. Department of Health and
Human Services, 2008.
Other Surveillance Data Sources
National Health and Nutrition 
Examination Survey (NHANES)
NHANES is composed of a series of
cross-sectional surveys designed to provide
national statistics on the health and
nutritional status of the general household
population through household interviews,
standardized physical examinations, and
the collection of biological samples in
special mobile examination centers. In
1999, NHANES became a continuous
survey with data released every 2 years.
The sampling plan of the survey is a
stratified, multistage, probability cluster
design that selects a sample representative
of the U.S. civilian noninstitutionalized
population.
National Disease and Therapeutic Index
(NDTI)
The information on the number of initial
visits to private physicians’ offices for
sexually transmitted diseases was based on
analysis of data from the National Disease
and Therapeutic Index (NDTI)
(machine-readable files or summary
statistics for the period 1966 through
2007).The NDTI is a probability sample
survey of private physicians’ clinical
management practices. For more
information on this database, contact IMS
Health, 660 W. Germantown Pike,
Plymouth Meeting, PA 19462; Telephone:
(800) 523-5333.
National Hospital Discharge Survey
(NHDS)
The information on patients hospitalized for 
pelvic inflammatory disease or ectopic
pregnancy was based on analysis of data
from the National Hospital Discharge
Survey (machine-readable files for years
1980–2006), an ongoing nationwide
sample survey of medical records of
patients discharged from acute care
hospitals in the United States, conducted by 
the National Center for Health Statistics.
For more information, see Graves EJ. 1988 
Summary: National Hospital Discharge
Survey; Advance data No. 185; Hyattsville
(MD): National Center for Health Statistics,
1990.
National Hospital Ambulatory Medical
Care Survey (NHAMCS-ER)
The National Hospital Ambulatory Medical
Care Survey (NHAMCS-ER)
(machine-readable files for 1995–2006)
was used to obtain estimates of the number 
of emergency room visits for pelvic
inflammatory disease among women ages
15 to 44 years. The estimates generated
using these data sources (NHDS and
NHAMCS-ER) are based on statistical
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surveys and therefore have sampling
variability associated with the estimates.
Healthy People 2010 Objectives
Healthy People 20103 (HP2010)is a set of
health objectives for the U.S. to achieve
over the first decade of the new century. It
is used by people, States, communities,
professional organizations, and others to
help develop programs to improve health.
HP2010 builds on initiatives pursued over
the past two decades. The 1979 Surgeon
General’s Report, Healthy People, and
Healthy People 2000: National Health
Promotion and Disease Prevention
Objectives established national health
objectives and served as the basis for the
development of State and community
plans. Like its predecessors, Healthy People 
2010 was developed through a broad
consultation process, built on the best
scientific knowledge and designed to
measure programs over time. Healthy
People 2010 is organized into 28 focus
areas, each with objectives and measures
designed to drive action that will support
two overarching goals: 1) increasing the
quality and years of healthy life and 2)
eliminating health disparities.
Focus area 25 of Healthy People 2010 —
Sexually Transmitted Diseases, — contains
objectives and measures related to STDs.
The baselines, HP2010 targets and annual
progress toward the targets are reported in
Table A3. The year 2010 targets for the
diseases addressed in this report are:
primary and secondary syphilis — 0.2 case
per 100,000 population; congenital syphilis 
— 1.0 case per 100,000 live births; and
gonorrhea — 19.0 cases per 100,000
population. An additional target established 
in the HP2010 objectives is to reduce the
Chlamydia trachomatis test positivity to 3%
among females aged 15 to 24 years who
attend family planning and STD clinics and
among males aged 15 to 24 who attend
STD clinics.
Government Performance and
Results Act of 1993 (GPRA) Goals
The Government Performance and
Results Act of 1993 (GPRA) was enacted
by Congress to increase the confidence of 
citizens in the capability of the federal
government, to increase the effectiveness
and accountability of federal programs, to 
improve service delivery, to provide
agencies a uniform tool for internal
management and to assist Congressional
decision making. GPRA requires each
agency to have a performance plan with
long-term outcomes and annual,
measurable performance goals and to
report on these plans annually,
comparing results with annual goals.
There are two STD GPRA goals: 1)
reduction in pelvic inflammatory disease
(PID) and 2) elimination of syphilis. Each
of these goals has measures. The
long-term goals and measures of progress 
are reported in Table A4.
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1 Of fice of Man age ment and Bud get. Stan dards
for De fin ing Met ro pol i tan and Micropolitan
Sta tis ti cal Ar eas: No tice Fed eral Reg is ter
De cem ber 27, 2000; 65(249):82228-38.
2 Kaufman RE, Jones OG, Blount JH, Wiesner
PJ. Ques tion naire sur vey of re ported early
con gen i tal syph i lis: prob lems in di ag no sis,
pre ven tion, and treat ment. Sex u ally Trans mit ted 
Dis eases 1977;4:135-9.
3 U.S. Department of Health and Human
Services. Healthy People 2010. 2nd ed. With
Understanding and Improving Health and
Objectives for Improving Health. 2 vols.
Washington, DC: U.S. Government Printing
Office, November 2000.
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Primary and Secondary Syphilis Gonorrhea Chlamydia
State                  
Percent
Unknown
Race/
Ethnicity
Percent
Unknown
Age
Percent
Unknown
Sex
Percent
Unknown
Sex of
Partners
Percent
Unknown
Race/
Ethnicity
Percent
Unknown
Age
Percent
Unknown
Sex
Percent
Unknown
Race/
Ethnicity
Percent
Unknown
Age
Percent
Unknown
Sex
Alabama 1.8 0.0 0.0 4.5 24.7 0.3 0.0 28.0 0.3 0.0
Alaska* 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
Arizona 22.6 0.0 0.7 80.1 27.9 0.0 0.0 34.8 0.0 0.1
Arkansas 2.5 0.0 0.0 40.2 5.2 0.4 0.1 5.9 0.2 0.0
California 2.4 0.1 0.1 9.7 33.0 0.5 0.4 33.7 0.5 0.4
Colorado 7.0 0.0 0.0 8.8 31.9 0.0 0.0 55.5 0.1 0.0
Connecticut 2.6 0.0 0.0 2.6 26.6 0.5 0.0 35.4 0.8 0.0
Delaware 5.6 0.0 0.0 100.0 1.8 0.0 0.0 3.1 0.0 0.0
District of Columbia 1.1 0.0 0.0 21.3 29.0 0.7 0.5 41.4 0.6 0.4
Florida 7.8 0.0 0.0 13.4 12.5 0.1 0.0 15.8 0.1 0.0
Georgia 2.4 0.1 0.1 20.0 37.1 0.9 0.6 43.9 0.9 0.6
Hawaii* 0.0 0.0 0.0 0.0 37.0 0.2 0.0 52.1 0.1 0.0
Idaho* 100.0 0.0 0.0 0.0 27.1 0.0 1.9 26.0 0.1 0.9
Illinois 4.1 0.0 0.0 8.4 8.9 0.0 0.0 12.3 0.0 0.0
Indiana 3.7 0.0 0.0 0.0 14.7 0.0 0.3 18.0 0.0 0.5
Iowa 4.8 0.0 0.0 9.5 7.5 0.1 0.0 11.8 0.2 0.0
Kansas 0.0 0.0 0.0 7.1 23.8 0.2 0.0 35.9 0.4 0.0
Kentucky 3.6 0.0 0.0 7.1 18.8 0.1 0.1 22.9 0.2 0.1
Louisiana 2.1 0.0 0.0 100.0 15.0 0.3 1.0 22.6 0.5 1.4
Maine* 0.0 0.0 0.0 11.1 7.6 0.8 0.0 21.1 0.4 0.1
Maryland 2.0 0.0 0.0 13.0 22.7 0.4 0.0 28.6 0.4 0.1
Massachusetts 7.1 0.0 0.0 9.7 31.0 0.7 0.0 40.1 0.8 0.1
Michigan 0.8 0.0 0.0 17.1 40.2 0.3 0.3 44.6 0.3 0.4
Minnesota 6.8 0.0 0.0 0.0 14.2 0.0 0.0 15.4 0.0 0.0
Mississippi 0.8 0.8 0.0 9.0 17.4 0.1 0.0 19.3 0.1 0.0
Missouri 0.0 0.0 0.0 2.5 15.9 0.1 0.0 21.7 0.1 0.0
Montana* 25.0 0.0 0.0 62.5 32.0 0.0 0.0 30.3 0.4 0.3
Nebraska* 25.0 0.0 0.0 0.0 23.3 0.0 0.3 28.7 0.1 0.3
Nevada 11.7 0.0 0.0 2.7 29.4 0.3 0.0 37.8 0.4 0.1
New Hampshire 0.0 0.0 0.0 3.3 8.0 0.0 0.0 14.3 0.0 0.0
New Jersey 0.9 0.0 0.0 17.6 34.0 0.6 0.0 47.4 0.7 0.1
New Mexico 10.9 0.0 0.0 4.3 16.0 0.2 0.0 11.8 0.3 0.0
New York 11.5 0.0 0.0 20.5 32.8 0.5 0.1 41.7 0.5 0.1
North Carolina 0.0 0.0 0.0 100.0 1.6 0.0 0.0 2.2 0.0 0.0
North Dakota* 0.0 0.0 0.0 0.0 10.3 0.0 0.0 11.1 0.3 0.1
Ohio 2.1 0.0 0.0 5.7 25.3 1.2 0.6 31.1 1.4 0.9
Oklahoma 0.0 0.0 0.0 15.4 1.6 0.0 0.0 2.2 0.0 0.0
Oregon 0.0 0.0 0.0 100.0 6.5 0.0 0.0 12.0 0.0 0.0
Pennsylvania 6.1 0.0 0.0 2.7 20.3 0.1 0.0 23.6 0.0 0.1
Rhode Island 2.8 0.0 0.0 0.0 11.2 0.0 0.2 20.3 0.2 0.1
South Carolina 0.0 0.0 0.0 3.3 26.7 0.6 0.2 29.3 0.3 0.3
South Dakota* 0.0 0.0 0.0 0.0 1.5 2.3 0.4 2.2 1.8 0.0
Tennessee 0.0 0.0 0.0 1.4 4.7 0.1 0.0 7.2 0.1 0.0
Texas 0.3 0.0 0.0 2.3 9.8 0.3 0.2 9.5 0.2 0.2
Utah 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0
Vermont 0.0 0.0 0.0 30.0 3.1 0.0 0.0 1.1 0.0 0.0
Virginia 0.0 0.0 0.0 3.5 6.0 0.1 0.1 11.8 0.1 0.0
Washington 8.4 0.0 0.0 23.4 21.1 1.1 0.0 20.7 1.2 0.0
West Virginia* 0.0 0.0 0.0 0.0 13.1 0.3 0.0 14.5 0.2 0.0
Wisconsin 0.0 0.0 0.0 4.5 26.1 0.0 0.2 28.7 0.0 0.1
Wyoming* 50.0 0.0 0.0 0.0 23.5 0.0 0.0 23.0 0.9 0.0
U.S. TOTAL 4.1 0.0 0.0 19.5 20.3 0.3 0.2 25.7 0.4 0.2
*Percentages for P&S syphilis are based on less than 10 cases.
NOTE: "Un known" in cludes un known, miss ing, or in valid data val ues.
Table A1. Selected STDs — Percentage of unknown, missing, or invalid values for selected variables by state
and by nationally notifiable STD, 2007
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Non-STD Clinic STD Clinic Total*
Disease Male Female Total Male Female Total Male Female Total
Chlamydia 165,128 658,503 825,160 92,906 98,382 191,495 280,337 825,660 1,108,374
Gonorrhea 90,669 137,261 228,359 62,320 32,495 94,891 167,684 187,595 355,991
Primary Syphilis 1,742 177 1,919 1,018 120 1,138 2,837 303 3,140
Secondary Syphilis 4,860 841 5,703 1,834 497 2,334 6,932 1,389 8,326
Early Latent Syphilis 5,092 1,886 6,982 2,265 995 3,260 7,751 3,013 10,768
Late and Late Latent Syphilis† 8,646 4,927 13,582 2,375 1,378 3,755 11,637 6,604 18,256
Chancroid 5 8 13 1 2 3 8 15 23
Table A2. Reported cases of sexually transmitted disease by reporting source and sex: United States, 2007
*Totals include unknown sex and reporting source.
†Late and late latent syphilis includes late latent syphilis, latent syphilis of unknown duration, neurosyphilis, and late syphilis with clinical
manifestations other than neurosyphilis.
See Appendix (Classification of STD Morbidity Reporting Sources).
STD Surveillance 2007 Appendix Healthy People 2010  157
HP 2010 Objectives
Baseline
Year Baseline 2003 2004 2005 2006 2007
 HP 2010
Target
25–1 Reduce the proportion of adolescents and young
adults with Chlamydia trachomatis infections
a. Females aged 15 to 24 years attending family
planning clinics
1997 5.0% 6.4%* 6.9%* 6.9%* 7.1%* 7.5%* 3.0%
b. Females aged 15 to 24 years attending STD clinics 1997 12.2% 14.1%* 15.3%* 15.4%* 14.8%* 15.3%* 3.0%
c. Males aged 15 to 24 years attending STD clinics 1997 15.7% 19.3%* 20.8%* 20.5%* 20.8%* 22.4%* 3.0%
d. Females aged 24 years or less enrolled in National
Job Training Program
2002 10.1% 9.9% 10.3% 9.2% 13.1% 13.2% 6.8%
25–2 Reduce the incidence of gonorrhea (new cases per
100,000 population)
a. Reduce gonorrhea incidence per 100,000 population 1997 123.0 115.2 112.4 114.6 119.7 118.9 19.0
b. Females aged 15 to 44 years 2002 279.0 270.0 267.0 275.0 290.0 290.0 42.0
25–3 Eliminate sustained domestic transmission of
primary and secondary syphilis (cases per 100,000
population)
1997 3.2 2.5 2.7 2.9 3.3 3.8 0.2
25–4 Reduce the proportion of adults aged 20 to 29 years
with genital herpes infection
1988–94 17.0% NA 10.0%† NA NA NA 14.0%
25–6 Reduce the proportion of females aged 15 to 44
years who have ever required treatment for pelvic
inflammatory disease (PID)
1995 8.0% 5.0%‡ NA NA NA NA 5.0%
25–7 Reduce the proportion of childless females with
fertility problems who have had a sexually
transmitted disease or who have required
treatment for pelvic inflammatory disease (PID)
1995 27.0% 22.0%‡ NA NA NA NA 15.0%
25–9 Reduce congenital syphilis (cases per 100,000 live
births)
1997 27.0 10.6 9.1 8.2 9.3 10.5 1.0
25–11 Adolescent sexual behavior (grades 9 through 12)
a. Increase the proportion of adolescents (grades 9
through 12) who abstain from sexual intercourse
or use condoms if currently sexually active
1999 50.0 53.0 NA 53.0 NA 52.0 56.0
b. Increase the proportion of adolescents (grades 9
through 12) who had sexual intercourse, but not in
the past 3 months
1999 27.0 26.0 NA 27.0 NA 27.0 30.0
c. Increase the proportion of adolescents (grades 9
through 12) who used condoms at last intercourse
1999 58.0 63.0 NA 63.0 NA 62.0 65.0
25–13 Increase the proportion of Tribal, state and local
sexually transmitted disease programs that
routinely offer hepatitis B vaccines to all STD
clients
1998 5.0 NA NA NA NA NA 90.0
25–16 Increase the proportion of sexually active females
aged 25 years and under who are screened
annually for genital chlamydia infections
a. Females aged 25 years and under enrolled in
commercial MCOs
2002 25.0 30.0 32.0 35.0 37.0 38.0 62.0
b. Females aged 25 years and under enrolled in
Medicaid MCOs
2002 41.0 45.0 47.0 51.0 52.0 52.0 62.0
Table A3. Healthy People 2010 Sexually Transmitted Diseases Objective Status
HP 2010 Ob jec tive Data Source
25–1 a, b, c
25–1 d
25–2 a, b
25–3
25–4
25–6
25–7
25–9
25–11 a, b, c
25–13
25–16 a, b
STD Surveillance Sys tem (STDSS), CDC, NCHHSTP.
Na tional Job Train ing Program.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
Na tional Health and Nu tri tion Ex am i na tion Sur vey (NHANES), CDC, NCHS.
Na tional Survey of Fam ily Growth (NSFG), CDC, NCHS.
Na tional Sur vey of Fam ily Growth (NSFG), CDC, NCHS.
STD Sur veil lance Sys tem, CDC, NCHHSTP, Na tional Vi tal Sta tis tics Sys tem- Na tal ity (NVSS-N), CDC, NCHS.
Youth Risk Be hav ior Sur veil lance Sys tem (YRBSS), CDC, NCCDPHP.
Sur vey of STD Pro grams, Na tional Co ali tion of STD Di rec tors (NCSD); IHS.
Healthcare Ef fec tive ness Data and In for ma tion Set (HEDIS), Na tional Com mit tee for Qual ity As sur ance (NCQA).
*Over all positivity not ad justed for changes in lab o ra tory test method and as so ci ated in creases in test sen si tiv ity.
†Data for years 1999–2004.
‡Data shown are for 2002, the most recent year these data were released. Be gin ning in 2009, data will be re leased ev ery 2 years. 
NOTE: Healthy Peo ple 2010 de vel op men tal ob jec tives are not ad dressed in this re port.
NA=Not avail able.
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GPRA Goals Baseline Actual Performance
Long-Term
 Goal  
2002 2006 2007 2010
Goal 1: Re duc tion in PID (as mea sured by ini tial vis its to phy si cians in women
15–44-years of age) 197,000 106,000 146,000 168,000
a.  Prevalence of Chlamydia in high-risk women ≤ 25 years 10.1%* 13.1%* 13.2%* 15.1%
b.  Prevalence of Chlamydia in women ≤ 25 years in family planning clinics 5.6%* 6.7%* 6.9%* 7.4%
c.  Incidence of Gonorrhea/100,000 population in women 15–44 years of age 279 290 290 296
Goal 2: Elimination of Syphilis (as measured by incidence of P&S
Syphilis/100,000 population) 2.4 3.3 3.8 2.2
a.  Incidence of P&S Syphilis/100,000 population - men 3.8 5.6 6.6 7.2
b.  Incidence of P&S Syphilis/100,000 population - women 1.1 1.0 1.1 1.2
c.  Incidence of Congenital Syphilis/100,000 live births 10.2 9.3 10.5 9.4 
d.  Black:white rate ratio of P&S Syphilis 8:1 5.9:1 7:1 6.7:1
GPRA Goals Data Source
1   
1–a
1–b
1–c
2  
2–a
2–b
2–c
2–d
Na tional Dis ease and Ther a peu tic In dex (IMS Health).
Na tional Job Train ing Pro gram.
Re gional In fer til ity Pre ven tion Pro jects (IPP).                                         
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
STD Sur veil lance Sys tem (STDSS), CDC, NCHHSTP.
*Me dian state-spe cific chlamydia prev a lence among women was not ad justed for changes in lab o ra tory test method and as so ci ated in creases in test
sen si tiv ity.
Table A4. Government Performance Results Act (GPRA) Sexually Transmitted Diseases Goals and Measures
STD Sur veil lance Case Def i ni tions
PART 1. CASE DEF I NI TIONS1 FOR NA TION ALLY NO TI FI ABLE IN FEC TIOUS DIS EASES
Chancroid (Re vised 9/96)
Clin i cal de scrip tion
A sex u ally trans mit ted dis ease char ac ter ized by pain ful gen i tal ul cer ation and in flam ma tory in -
gui nal adenopathy. The dis ease is caused by in fec tion with Haemophilus ducreyi.
Lab o ra tory cri te ria for di ag no sis
• Iso la tion of H. ducreyi from a clin i cal spec i men
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case with both a) no ev i dence of Treponema pallidum in fec tion by
darkfield mi cro scopic ex am i na tion of ul cer exudate or by a se ro logic test for syph i lis per formed ≥7
days af ter on set of ul cers and b) ei ther a clin i cal pre sen ta tion of the ul cer(s) not typ i cal of dis ease
caused by her pes sim plex vi rus (HSV) or a cul ture neg a tive for HSV.
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Chlamydia trachomatis, Gen i tal In fec tions (Re vised 9/96)
Clin i cal de scrip tion
In fec tion with Chlamydia trachomatis may re sult in ure thri tis, epididymitis, cervicitis, acute
salpingitis, or other syn dromes when sex u ally trans mit ted; how ever, the in fec tion is of ten asymp -
tom atic in women. Perinatal in fec tions may re sult in in clu sion con junc ti vi tis and pneu mo nia in new -
borns. Other syn dromes caused by C. trachomatis in clude lymphogranuloma venereum (see
Lymphogranuloma Venereum) and tra choma.
Lab o ra tory cri te ria for di ag no sis
• Iso la tion of C. trachomatis by cul ture or
• Dem on stra tion of C. trachomatis in a clin i cal spec i men by de tec tion of an ti gen or
nu cleic acid
Case clas si fi ca tion
Con firmed: a case that is lab o ra tory con firmed
Gon or rhea (Re vised 9/96)
Clin i cal de scrip tion
A sex u ally trans mit ted in fec tion com monly man i fested by ure thri tis, cervicitis, or salpingitis.
In fec tion may be asymp tom atic.
Lab o ra tory cri te ria for di ag no sis
• Iso la tion of typ i cal gram-neg a tive, oxidase-pos i tive diplococci (pre sump tive
Neisseria gonorrhoeae) from a clin i cal spec i men, or
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• Dem on stra tion of N. gonorrhoeae in a clin i cal spec i men by de tec tion of an ti gen or
nu cleic acid, or
• Ob ser va tion of gram-neg a tive intracellular diplococci in a ure thral smear ob tained
from a male
Case clas si fi ca tion
Prob a ble: a) dem on stra tion of gram-neg a tive intracellular diplococci in an endocervical smear ob -
tained from a fe male or b) a writ ten mor bid ity re port of gon or rhea sub mit ted by a phy si cian
Con firmed: a case that is lab o ra tory con firmed
Syph i lis (All Def i ni tions Re vised 9/96)
Syph i lis is a com plex sex u ally trans mit ted dis ease that has a highly vari able clin i cal course. Clas si -
fi ca tion by a cli ni cian with ex per tise in syph i lis may take pre ce dence over the fol low ing case def i ni -
tions de vel oped for sur veil lance pur poses.
Syph i lis, pri mary
Clin i cal de scrip tion
A stage of in fec tion with Treponema pallidum char ac ter ized by one or more chan cres (ul cers);
chan cres might dif fer con sid er ably in clin i cal ap pear ance.
Lab o ra tory cri te ria for di ag no sis
• Dem on stra tion of T. pallidum in clin i cal spec i mens by darkfield mi cros copy, di rect
flu o res cent an ti body (DFA-TP), or equiv a lent meth ods
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case with one or more ul cers (chan cres) con sis tent with pri mary
syph i lis and a re ac tive se ro logic test (nontreponemal: Ve ne real Dis ease Re search Lab o ra tory
[VDRL] or rapid plasma reagin [RPR]; treponemal: flu o res cent treponemal an ti body ab sorbed
[FTA-ABS] or microhemagglutination as say for an ti body to T. pallidum [MHA-TP])
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Syph i lis, sec ond ary
Clin i cal de scrip tion
A stage of in fec tion caused by T. pallidum and char ac ter ized by lo cal ized or dif fuse
mucocutaneous le sions, of ten with gen er al ized lymphadenopathy. The pri mary chan cre may still
be pres ent.
Lab o ra tory cri te ria for di ag no sis
• Dem on stra tion of T. pallidum in clin i cal spec i mens by darkfield mi cros copy, DFATP,
or equiv a lent meth ods
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case with a nontreponemal (VDRL or RPR) ti ter ≥4
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
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Syph i lis, la tent
Clin i cal de scrip tion
A stage of in fec tion caused by T. pallidum in which or gan isms per sist in the body of the in fected
per son with out caus ing symp toms or signs. La tent syph i lis is sub di vided into early, late, and un -
known cat e go ries based on the du ra tion of in fec tion.
Case clas si fi ca tion
Prob a ble: no clin i cal signs or symp toms of syph i lis and the pres ence of one of the fol low ing:
• No past di ag no sis of syph i lis, a re ac tive nontreponemal test (i.e., VDRL or RPR), and
a re ac tive treponemal test (i.e., FTA-ABS or MHA-TP)
• A past his tory of syph i lis ther apy and a cur rent nontreponemal test ti ter dem on strat ing 
four fold or greater in crease from the last nontreponemal test ti ter
Syph i lis, early la tent
Clin i cal de scrip tion
A sub cat e gory of la tent syph i lis. When ini tial in fec tion has oc curred within the pre vi ous 12
months, la tent syph i lis is clas si fied as early la tent.
Case clas si fi ca tion
Prob a ble: la tent syph i lis (see Syph i lis, la tent) in a per son who has ev i dence of hav ing ac quired the 
in fec tion within the pre vi ous 12 months based on one or more of the fol low ing cri te ria:
• Doc u mented seroconversion or four fold or greater in crease in ti ter of a
nontreponemal test dur ing the pre vi ous 12 months
• A his tory of symp toms con sis tent with pri mary or sec ond ary syph i lis dur ing the
pre vi ous 12 months
• A his tory of sex ual ex po sure to a part ner who had con firmed or prob a ble pri mary or
sec ond ary syph i lis or prob a ble early la tent syph i lis (doc u mented in de pend ently as
du ra tion < 1 year)
• Re ac tive nontreponemal and treponemal tests from a per son whose only pos si ble
ex po sure oc curred within the pre ced ing 12 months
Syph i lis, late la tent
Clin i cal de scrip tion
A sub cat e gory of la tent syph i lis. When ini tial in fec tion has oc curred > 1 year pre vi ously, la tent
syph i lis is clas si fied as late la tent.
Case clas si fi ca tion
Prob a ble: la tent syph i lis (see Syph i lis, la tent) in a pa tient who has no ev i dence of hav ing ac quired
the dis ease within the pre ced ing 12 months (see Syph i lis, early la tent) and whose age and ti ter do
not meet the cri te ria spec i fied for la tent syph i lis of un known du ra tion.
Syph i lis, la tent, of un known du ra tion
Clin i cal de scrip tion
A sub cat e gory of la tent syph i lis. When the date of ini tial in fec tion can not be es tab lished as hav ing
oc curred within the pre vi ous year and the pa tient’s age and ti ter meet cri te ria de scribed be low, la -
tent syph i lis is clas si fied as la tent syph i lis of un known du ra tion.
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Case clas si fi ca tion
Prob a ble: la tent syph i lis (see Syph i lis, la tent) that does not meet the cri te ria for early la tent syph i -
lis, and the pa tient is aged 13–35 years and has a nontreponemal ti ter ≥ 32
Neurosyphilis
Note
Since neurosyphilis can oc cur at al most any stage of syph i lis, be tween 1996 and 2005, it was clas -
si fied and re ported as one of sev eral mu tu ally ex clu sive stages of syph i lis. In 2005, the Di vi sion of
STD Pre ven tion re quested that STD con trol pro grams dis con tinue clas si fy ing and re port ing
neurosyphilis as a dis tinct stage of syph i lis. Since 2005, if the pa tient has con firmed or prob a bly
neurosyphilis, the case should be re ported as the ap pro pri ate state of syph i lis and neu ro log i cal
man i fes ta tions should be noted.
Clin i cal de scrip tion
Ev i dence of cen tral ner vous sys tem in fec tion with T. pallidum
Lab o ra tory cri te ria for di ag no sis
• A re ac tive se ro logic test for syph i lis and re ac tive VDRL in cerebrospinal fluid (CSF)
Case clas si fi ca tion
Prob a ble: syph i lis of any stage, a neg a tive VDRL in CSF, and both the fol low ing:
• El e vated CSF pro tein or leu ko cyte count in the ab sence of other known causes of
these ab nor mal i ties
• Clin i cal symp toms or signs con sis tent with neurosyphilis with out other known causes
for these clin i cal ab nor mal i ties
Con firmed: syph i lis of any stage that meets the lab o ra tory cri te ria for neurosyphilis
Syph i lis, late, with clin i cal man i fes ta tions other than neurosyphilis (late be nign syph i lis
and car dio vas cu lar syph i lis)
Clin i cal de scrip tion
Clin i cal man i fes ta tions of late syph i lis other than neurosyphilis may in clude in flam ma tory le sions
of the car dio vas cu lar sys tem, skin, and bone. Rarely, other struc tures (e.g., the up per and lower re -
spi ra tory tracts, mouth, eye, ab dom i nal or gans, re pro duc tive or gans, lymph nodes, and skel e tal
mus cle) may be in volved. Late syph i lis usu ally be comes clin i cally man i fest only af ter a pe riod of
15–30 years of un treated in fec tion.
Lab o ra tory cri te ria for di ag no sis
Dem on stra tion of T. pallidum in late le sions by flu o res cent an ti body or spe cial stains (al though or -
gan isms are rarely vi su al ized in late le sions)
Case clas si fi ca tion
Prob a ble: char ac ter is tic ab nor mal i ties or le sions of the car dio vas cu lar sys tem, skin, bone, or
other struc tures with a re ac tive treponemal test, in the ab sence of other known causes of these ab -
nor mal i ties, and with out CSF ab nor mal i ties and clin i cal symp toms or signs con sis tent with
neurosyphilis
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Com ment
Anal y sis of CSF for ev i dence of neurosyphilis is nec es sary in the eval u a tion of late syph i lis with
clin i cal man i fes ta tions.
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Syph i litic Still birth
Clin i cal de scrip tion
A fe tal death that oc curs af ter a 20-week ges ta tion or in which the fe tus weighs > 500 g and the
mother had un treated or in ad e quately treated* syph i lis at de liv ery
Com ment
For re port ing pur poses, syph i litic still births should be re ported as cases of con gen i tal syph i lis.
Syph i lis, Con gen i tal (Re vised 9/96)
Clin i cal de scrip tion
A con di tion caused by in fec tion in utero with Treponema pallidum. A wide spec trum of se ver ity
ex ists, and only se vere cases are clin i cally ap par ent at birth. An in fant or child (aged < 2 years) may
have signs such as hepatosplenomegaly, rash, condyloma lata, snuf fles, jaun dice (nonviral hep a ti -
tis), pseudoparalysis, ane mia, or edema (nephrotic syn drome and/or mal nu tri tion). An older child
may have stig mata (e.g., in ter sti tial keratitis, nerve deaf ness, an te rior bow ing of shins, fron tal boss -
ing, mul berry mo lars, Hutch in son teeth, sad dle nose, rhagades, or Clutton joints).
Lab o ra tory cri te ria for di ag no sis
Dem on stra tion of T. pallidum by darkfield mi cros copy, flu o res cent an ti body, or other spe cific
stains in spec i mens from le sions, pla centa, um bil i cal cord, or au topsy ma te rial
Case clas si fi ca tion
Prob a ble: a con di tion af fect ing an in fant whose mother had un treated or in ad e quately treated*
syph i lis at de liv ery, re gard less of signs in the in fant, or an in fant or child who has a re ac tive
treponemal test for syph i lis and any one of the fol low ing:
• Any ev i dence of con gen i tal syph i lis on phys i cal ex am i na tion
• Any ev i dence of con gen i tal syph i lis on ra dio graphs of long bones
• A re ac tive cerebrospinal fluid (CSF) ve ne real dis ease re search lab o ra tory (VDRL)
• An el e vated CSF cell count or pro tein (with out other cause)
• A re ac tive flu o res cent treponemal an ti body ab sorbed—19S-IgM an ti body test or IgM
en zyme-linked immunosorbent as say
Con firmed: a case that is lab o ra tory con firmed
Com ment
Con gen i tal and ac quired syph i lis may be dif fi cult to dis tin guish when a child is se ro pos i tive af ter
in fancy. Signs of con gen i tal syph i lis may not be ob vi ous, and stig mata may not yet have de vel oped.
Ab nor mal val ues for CSF VDRL, cell count, and pro tein, as well as IgM an ti bod ies, may be found in
ei ther con gen i tal or ac quired syph i lis. Find ings on ra dio graphs of long bones may help be cause ra -
dio graphic changes in the metaphysis and epiph y sis are con sid ered clas sic signs of con gen i tally ac -
quired syph i lis. The de ci sion may ul ti mately be based on ma ter nal his tory and clin i cal judg ment. In
a young child, the pos si bil ity of sex ual abuse should be con sid ered as a cause of ac quired rather
than con gen i tal syph i lis, de pend ing on the clin i cal pic ture. For re port ing pur poses, con gen i tal syph i -
lis in cludes cases of con gen i tally ac quired syph i lis among in fants and chil dren as well as syph i litic
still births.
*In ad e quate treat ment con sists of any nonpenicillin ther apy or pen i cil lin ad min is tered < 30 days be -
fore de liv ery.
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PART 2. CASE DEF I NI TIONS1 FOR NON-NO TI FI ABLE IN FEC TIOUS DIS EASES
Gen i tal Her pes (Her pes Sim plex Vi rus) (Re vised 9/96)
Clin i cal de scrip tion
A con di tion char ac ter ized by vis i ble, pain ful gen i tal or anal le sions
Lab o ra tory cri te ria for di ag no sis
• Iso la tion of her pes sim plex vi rus from cer vix, ure thra, or anogenital le sion, or
• Dem on stra tion of vi rus by an ti gen de tec tion tech nique in clin i cal spec i mens from
cer vix, ure thra, or anogenital le sion, or
• Dem on stra tion of multinucleated gi ant cells on a Tzanck smear of scrap ings from an
anogenital le sion
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case (in which pri mary and sec ond ary syph i lis have been ex -
cluded by ap pro pri ate se ro logic tests and darkfield mi cros copy, when avail able) with ei ther a di ag -
no sis of gen i tal her pes based on clin i cal pre sen ta tion (with out lab o ra tory con fir ma tion) or a his tory
of one or more pre vi ous ep i sodes of sim i lar gen i tal le sions
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Com ment
Gen i tal her pes should be re ported only once per pa tient. The first di ag no sis for a pa tient with no
pre vi ous di ag no sis should be re ported.
Gen i tal Warts (Re vised 9/96)
Clin i cal de scrip tion
An in fec tion char ac ter ized by the pres ence of vis i ble, exophytic (raised) growths on the in ter nal or 
ex ter nal gen i ta lia, per i neum, or perianal re gion
Lab o ra tory cri te ria for di ag no sis
• Histopathologic changes char ac ter is tic of hu man papillomavirus in fec tion in
spec i mens ob tained by bi opsy or exfoliative cy tol ogy or
• Dem on stra tion of vi rus by an ti gen or nu cleic acid de tec tion in a le sion bi opsy
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case with out histopathologic di ag no sis and with out mi cro scopic or 
se ro logic ev i dence that the growth is the re sult of sec ond ary syph i lis
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Com ment
Gen i tal warts should be re ported only once per pa tient. The first di ag no sis for a pa tient with no
pre vi ous di ag no sis should be re ported.
Granuloma Inguinale
Clin i cal de scrip tion
A slowly pro gres sive ul cer ative dis ease of the skin and lymphatics of the gen i tal and perianal area
caused by in fec tion with Calymmatobacterium granulomatis. A clin i cally com pat i ble case would
have one or more pain less or min i mally pain ful granulomatous le sions in the anogenital area.
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Lab o ra tory cri te ria for di ag no sis
• Dem on stra tion of intracytoplasmic Don o van bod ies in Wright or Giemsa-stained
smears or bi op sies of gran u la tion tis sue
Case clas si fi ca tion
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Lymphogranuloma Venereum
Clin i cal de scrip tion
In fec tion with L1, L2, or, L3 serovars of Chlamydia trachomatis may re sult in a dis ease char ac ter -
ized by gen i tal le sions, sup pu ra tive re gional lymphadenopathy, or hem or rhagic proctitis. The in fec -
tion is usu ally sex u ally trans mit ted.
Lab o ra tory cri te ria for di ag no sis
• Iso la tion of C. trachomatis, serotype L1, L2, or L3 from clin i cal spec i men, or
• Dem on stra tion by immunofluorescence of in clu sion bod ies in leu ko cytes of an
in gui nal lymph node (bubo) as pi rate, or
• Pos i tive microimmunofluorescent se ro logic test for a lymphogranuloma venereum
strain of C. trachomatis
Case clas si fi ca tion
Prob a ble: a clin i cally com pat i ble case with one or more ten der fluctuant in gui nal lymph nodes or
char ac ter is tic proctogenital le sions with sup port ive lab o ra tory find ings of a sin gle C. trachomatis
com ple ment fix a tion ti ter of > 64
Con firmed: a clin i cally com pat i ble case that is lab o ra tory con firmed
Mucopurulent Cervicitis (Re vised 9/96)
Clin i cal de scrip tion
Cer vi cal in flam ma tion that is not the re sult of in fec tion with Neisseria gonorrhoeae or
Trichomonas vaginalis. Cer vi cal in flam ma tion is de fined by the pres ence of one of the fol low ing
cri te ria:
• Mucopurulent se cre tion (from the endocervix) that is yel low or green when viewed on 
a white, cot ton-tipped swab (pos i tive swab test)
•  In duced endocervical bleed ing (bleed ing when the first swab is placed in the
endocervix)
Lab o ra tory cri te ria for di ag no sis
• No ev i dence of N. gonorrhoeae by cul ture, Gram stain, or an ti gen or nu cleic acid
de tec tion, and no ev i dence of T. vaginalis on wet mount
Case clas si fi ca tion
Con firmed: a clin i cally com pat i ble case in a fe male who does not have ei ther gon or rhea or
trichomoniasis
Com ment
Mucopurulent cervicitis (MPC) is a clin i cal di ag no sis of ex clu sion. The syn drome may re sult from
in fec tion with any of sev eral agents (see Chlamydia trachomatis, Gen i tal In fec tions). If gon or rhea,
trichomoniasis, and chlamydia are ex cluded, a clin i cally com pat i ble ill ness should be clas si fied as
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MPC. An ill ness in a fe male that meets the case def i ni tion of MPC and C. trachomatis in fec tion
should be clas si fied as chlamydia.
Nongonococcal Ure thri tis (Re vised 9/96)
Clin i cal de scrip tion
Ure thral in flam ma tion that is not the re sult of in fec tion with Neisseria gonorrhoeae. Ure thral in -
flam ma tion may be di ag nosed by the pres ence of one of the fol low ing cri te ria:
• A vis i ble ab nor mal ure thral dis charge, or
• A pos i tive leu ko cyte esterase test from a male aged < 60 years who does not have a
his tory of kid ney dis ease or blad der in fec tion, pros tate en large ment, uro gen i tal
an a tomic anom aly, or re cent uri nary tract in stru men ta tion, or
• Mi cro scopic ev i dence of ure thri tis (≥ 5 white blood cells per high-power field) on a
Gram stain of a ure thral smear
Lab o ra tory cri te ria for di ag no sis
• No ev i dence of N. gonorrhoeae in fec tion by cul ture, Gram stain, or an ti gen or nu cleic
acid de tec tion
Case clas si fi ca tion
Con firmed: a clin i cally com pat i ble case in a male in whom gon or rhea is not found, ei ther by cul ture, 
Gram stain, or an ti gen or nu cleic acid de tec tion
Com ment
Nongonococcal ure thri tis (NGU) is a clin i cal di ag no sis of ex clu sion. The syn drome may re sult
from in fec tion with any of sev eral agents (see Chlamydia trachomatis, Gen i tal In fec tion). If gon or -
rhea and chlamydia are ex cluded, a clin i cally com pat i ble ill ness should be clas si fied as NGU. An ill -
ness in a male that meets the case def i ni tion of NGU and C. trachomatis in fec tion should be
clas si fied as chlamydia.
Pel vic In flam ma tory Dis ease (Re vised 9/96)
Clin i cal case def i ni tion
A clin i cal syn drome re sult ing from the as cend ing spread of mi cro or gan isms from the va gina and
endocervix to the endometrium, fal lo pian tubes, and/or con tig u ous struc tures. In a fe male who has
lower ab dom i nal pain and who has not been di ag nosed as hav ing an es tab lished cause other than
pel vic in flam ma tory dis ease (PID) (e.g., ectopic preg nancy, acute ap pen di ci tis, and func tional
pain), all the fol low ing clin i cal cri te ria must be pres ent:
• Lower ab dom i nal ten der ness, and
• Ten der ness with mo tion of the cer vix, and
• Adnexal ten der ness
In ad di tion to the pre ced ing cri te ria, at least one of the fol low ing find ings must also be pres ent:
• Meets the sur veil lance case def i ni tion of C. trachomatis in fec tion or gon or rhea
• Tem per a ture > 100.4 F (> 38.0 C)
• Leukocytosis > 10,000 white blood cells/mm3
• Pu ru lent ma te rial in the peritoneal cav ity ob tained by culdocentesis or lap a ros copy
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• Pel vic ab scess or in flam ma tory com plex de tected by bimanual ex am i na tion or by
sonography
• Pa tient is a sex ual con tact of a per son known to have gon or rhea, chlamydia, or
nongonococcal ure thri tis
Case clas si fi ca tion
Con firmed: a case that meets the clin i cal case def i ni tion
Com ment
For re port ing pur poses, a cli ni cian’s re port of PID should be counted as a case.
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1 Centers for Disease Control and Prevention.
Case definitions for infectious conditions under
public health surveillance, 1997. MMWR
1997;46(No. RR-10;1).
STD Project Directors, STD Program Managers, State and Territorial Epidemiologists and Laboratory Directors
We grate fully ac knowl edge the con tri bu tions of state STD pro ject di rec tors, STD pro gram man ag ers, state and ter ri to rial
epidemiologists and laboratory directors. The per sons listed were in the po si tions shown as of November 4, 2008.
State/City/Outlying Area STD Project Directors STD Program Managers State Epidemiologists Laboratory Directors
Al a bama Charles Woernle Sandra Langston Charles Woernle William Callan
Alaska Mollie Rosier Donna Cecere Joe McLaughlin Bernard Jilly
Arizona Judy Norton Alfonso Urquidi Kenneth Komatsu Victor Waddell
Arkansas Kellye McCartney Mark Barnes Jim Phillips Glen Baker
California Gail Bolan Romni Neiman Gilberto Chavez Paul Kimsey
Los Angeles Peter Kerndt Mary Hayes Gilberto Chavez Sue Sabat
San Francisco Jeffrey Klausner Wendy Wolf Gilberto Chavez Sally Liska
Colorado Maureen Bush Ralph Wilmoth Ken Gershman David Butcher
Connecticut James Hadler Heidi Jenkins Matthew Cartter John Fontana
Delaware James Welch Catherine Mosley Ashley Love Jane Getchell
District of Columbia John Heath John Heath John Davies-Cole Maurice Knuckles
Florida Russell Eggert Karla Schmitt Richard Hopkins Max Salfinger
Georgia Vacant Russ Cantrell John Horan Elizabeth Franko
Hawaii Peter Whiticar Roy Ohye Sarah Park A. Christian Whelen
Idaho Richard Armstrong Kathy Cohen Christine G. Hahn Richard Hudson
Illinois Charlie Rabins Ed Renier Craig Conover (Acting) Tom Johnson
Chicago Will Wong John Paffel Craig Conover (Acting) Susan Gerber
Indiana Jerry Burkman Dawne Rekas James Howell Judith Lovchik
Iowa Mary Jones Karen Thompson Patricia Quinlisk Christopher Atchison
Kansas Brenda Walker Derek Coppedge Charles Hunt Patrick Williams
Kentucky Robert Brawley Sheri White Kraig Humbaugh Stephanie Gibson
Louisiana Lisa Ann Longfellow Lisa Ann Longfellow Raoult Ratard Stephen Martin
Maine Bob Woods Jennah Godo Kathleen Gensheimer John Krueger
Maryland Barbara Conrad Glen Oltoff David Blythe Jack DeBoy
Baltimore Laura Herrera Victoria Stovall David Blythe Jack DeBoy
Massachusetts Thomas Bertrand Thomas Bertrand Alfred DeMaria Mary Gilchrist
Michigan Mark Miller Mark Miller Corrine Miller Frances Downes
Minnesota Julia Ashley Julia Ashley Ruth Lynfield Joanne Bartkus
Mississippi Craig Thompson Craig Thompson Mary Currier K. Mills McNeill
Missouri Michael Herbert Michael Herbert Sarah Patrick Eric Blank
Montana Laurie Kops Lisa Underwood Steve Helgerson Anne Weber
Nebraska Phil Medina Phil Medina Thomas Safranek Steve Hinrichs
Nevada Richard Whitley Julia Spaulding Ishan Azzam L. Dee Brown
New Hampshire Denise Rondeau Drew Thomits Jose Montero Christine Bean
New Jersey Janet DeGraaf Patricia Masou Christina Tan Dennis Flynn
New Mexico Daryl Smith Daryl Smith C. Mack Sewell David Mills
New York F. Bruce Coles Dennis Murphy Perry Smith Lawrence Sturman
New York City Susan Blank Steve Rubin Perry Smith Sara Beatrice
North Carolina Evelyn Foust Evelyn Foust Jeffrey Engel Leslie Wolf
North Dakota Kimberly Weis Julie Goplin Kirby Kruger Myra Kosse
Ohio Bill Tiedemann Amy LaGesse Forrest Smith Tammy Bannerman
Oklahoma Michael Harmon Chang Lee Kristy Bradley Garry McKee
Oregon Vada Latin Doug Harger Melvin Kohn Michael Skeels
Pennsylvania Weston Ruhrig Steve Kowalewski Veronica Urdaneta S.I. Shahied
Philadelphia Caroline Johnson Melinda Salmon Veronica Urdaneta Kerry Buchs
Rhode Island Utpala Bandy Michael Gosciminski Utpala Bandy Ewa King
South Carolina Dorothy Waln (Acting) Vickie Boazman-Holmes (Acting) James Gibson Arthur Wozniak
South Dakota Laurie Gill David Morgan Lon Kightlinger Michael Smith
Tennessee Jeanece Seals Jane Russell Tim Jones David Smalley
Texas Felipe Rocha Jim Lee Vincent Fonseca Susan Neill
Utah Jennifer Brown Tim Lane Robert Rolfs Patrick Luedtke
Vermont Daniel Daltry Daniel Daltry Patsy Kelso Mary Celotti
Virginia Kathryn Hafford Kathryn Hafford (Acting) Carl Armstrong James Pearson
Washington Mark Aubin Mark Aubin Marcia Goldoft Romesh Gautom
West Virginia Caroline Williams Caroline Williams Loretta Haddy Andrea Labik
Wisconsin Sandra Breitborde Anthony Wade Jeffrey Davis Charles Brokopp
Wyoming Brownen Anderson Canyon Hardesty Tracy Murphy Richard Harris
American Samoa Utoofili Maga Sarona Maae Sharmain Edwards Utoofili Mago
Federated States of Micronesia Vita Skilling Johnny Hebel Nena Nena
Government of the Marshall Islands Justina Langidrik Zachraias Zachraias Paul Lalita
Northern Marianas (CNMI) Joseph Villagomz John Moreno James Hosfschneider Stephanie Hart-Gouleau
Guam Josie O'Mallan Bernadette Schumann Robert Haddock Josie O'Mallan
Puerto Rico Greduvel Duran-Guzman Trinidad Garcia Enid Garcia Francisco Toro
Republic of Palau Victor Yano Johana Ngiruchelbad Julie Erb-Alvarez Francis Permeteet
Virgin Islands Darlene Carty Taetia Phillips-Dorsett Darlene Carty Joseph Mark
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